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Abstract 
 
Osteoporosis is characterised by low bone mass, reduced bone mineral density and a deterioration 
of bone microarchitecture, resulting in increased susceptibility to fragility fractures. Oestrogen 
deficiency and thyrotoxicosis are established risk factors for osteoporosis.  Oestrogen and thyroid 
hormone have opposing actions on adult bone and I hypothesise that accelerated bone loss at the 
menopause is due to unopposed actions of thyroid hormone on the skeleton. 
To test this hypothesis, I investigated the effect of altered thyroid status on the skeleton in adult 
sham-operated and ovariectomised wild type and thyroid hormone receptor (TR) α and β knockout 
mice (TRα0/0 and TRβ-/-).  Skeletal phenotype analysis included determination of structural, 
densitometric, histomorphometric and biomechanical parameters. 
Skeletal phenotypes of euthyroid wild type mice were compared to hypothyroid and thyrotoxic wild 
type as well as TRα0/0and TRβ-/- mice.  Bone mass was elevated in TRα0/0and reduced in TRβ-/- mice 
despite similar bone formation rates.  These data suggest that the differences in bone mass are due 
to differing osteoclast activity. 
The skeletal phenotypes of TRα0/0 and TRβ-/- mice following manipulation of thyroid status were then 
described in detail.  TRβ-/- and wild type mice rendered hypothyroid, had significantly lower bone 
formation than hypothyroid TRα0/0 mice suggesting that, in the absence of thyroid hormone, TRα 
may inhibit bone formation.    
Finally, the effect of oestrogen withdrawal in each of these groups of mice was also investigated.  
These studies demonstrate oestrogen deficiency bone loss was greater in hypothyroid compared to 
hyperthyroid mice, indicating that accelerated bone loss following oestrogen withdrawal cannot 
result from unopposed actions of thyroid hormones.  Nevertheless, the studies contained in this 
thesis provide new insight regarding the roles of TRα and TRβ in bone maintenance and the effects 
of interactions between oestrogen and thyroid hormones on the regulation of bone mass. 
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The Thesis 
Characterisation of Oestrogen and Thyroid Hormone Interactions in the 
Regulation of Bone Mass 
 
Rationale for Investigation 
Osteoporosis is a worldwide public health priority that costs €32 billion per annum in Europe alone. 
Oestrogen deficiency is the major determinant of postmenopausal bone loss and thyrotoxicosis is an 
established risk factor for osteoporosis.  Clinical observations, epidemiological data, experimental 
evidence from mutant mice and our current understanding of the actions of oestrogen and T3 in 
bone cells, all support the concept that optimal adult bone mass and strength are maintained by 
balanced and opposing actions of oestrogen and thyroid hormones. 
 
Hypothesis 
I hypothesise that at the menopause, the actions of thyroid hormone on bone are unopposed 
following oestrogen withdrawal, leading to accelerated bone loss and fracture. 
To address this hypothesis, I will determine the skeletal responses to ovariectomy in adult TRα0/0 and 
TRβ-/- mice which have been maintained euthyroid, hypothyroid and hyperthyroid. 
 
Aims 
In order to investigate this hypothesis in a step by step and comprehensive manner, I aim to:  
 
1. Compare the bone phenotypes of TRα0/0 and TRβ-/- mice to hypothyroid and hyperthyroid 
wild type mice. 
2  Establish the effects of altered thyroid status on TRα0/0 and TRβ-/- mice. 
3  Characterise the effects of ovariectomy or sham operation on the bone phenotype of 
thyroid status manipulated wild type, TRα0/0 and TRβ-/- mice. 
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Chapter 1 
Introduction 
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1 INTRODUCTION 
1.1 BACKGROUND 
Osteoporotic fractures are a substantial public health burden, costing the NHS approximately £2.1 
billion per year and increasing as the ageing population increases (Dennison and Cooper, 2011).  
Oestrogen deficiency is the leading cause of postmenopausal bone loss and thyrotoxicosis is an 
established risk factor for osteoporosis (Bassett et al., 2007a).  The prevalence of postmenopausal 
osteoporosis increases with age and the lifetime incidence of fracture for a 50 year old woman in the 
UK is 40% (Sambrook and Cooper, 2006).  Although oestrogen withdrawal is widely recognised as the 
leading cause of osteoporosis, the contribution of excess thyroid hormone is also substantial.  More 
than 3% of 50 year old women receive thyroid hormone therapy, and over-treatment is common 
within the population (Parle et al., 1993), suggesting that thyroid abnormalities are underestimated 
contributors to the osteoporosis burden.  Understanding the regulation of bone mass is important 
for the prevention and treatment of osteoporosis.  Oestrogen and thyroid hormones have opposing 
actions on the skeleton, suggesting that optimal maintenance of bone mass is regulated by the 
balance of anabolic actions of oestrogen and catabolic actions of thyroid hormone.  The experiments 
in this thesis examine the role and interactions of oestrogen and thyroid hormone in the regulation 
of bone mass. 
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1.2 BONE PHYSIOLOGY 
To understand thyroid hormone and oestrogen action on the skeleton, it is important to have an 
understanding of normal bone physiology.  The skeleton provides mechanical strength and 
structure, protects vital organs and acts as a metabolic and endocrine organ.  Whilst being strong, it 
must also be light to enable locomotion.  In achieving all these functions, it is a dynamic, adaptive 
organ, able to respond to external and internal stimuli. 
 
1.2.1 STRUCTURE OF BONE 
Structurally, bones can be categorised into two main groups which have distinct developmental 
derivations: flat bones such as the ileum, skull and scapula and long bones such as the femur, tibia 
and humerus.  Some bones such as the vertebrae and small bones of the hands and feet do not fall 
into these distinct categories but have features of both. 
The gross anatomical structure of long bones can be subdivided into three main sections, as 
illustrated in Figure 1.1.  The diaphysis is the cylindrical section in the centre of the long bone, is 
composed of compact bone called the cortex and splays at each end to form the metaphysis.  The 
metaphysis commences at the growth plate, under which new bone is being accrued, and tapers 
down to the diaphysis.  At the ends of the long bone, beyond the growth plates, are the epiphyses.  
The external surface of the bone is enveloped by the periosteum, which during growth is a discrete 
entity and can be readily identified.  After the cessation of growth, the periosteum becomes a thin 
layer which lines the external bone.  The internal surface of the bone, the endosteal surface, 
includes the inside of the cortex (intramedullary cortical surface) and the trabecular surfaces.  The 
majority of the diaphysis of the long bone is filled with marrow, with little calcified bone, but directly 
under the growth plate and into the metaphysis, is found a lattice of trabecular or cancellous bone, 
which supports the growth plate (Baron, 1999). 
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Figure 1.1 Structure of long bones 
Backscattered electron-scanning electron microscopy (BSE-SEM) image of femur 
demonstrating the structure of long bones. 
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1.2.2 COMPOSITION OF BONE 
1.2.2.1 BONE CELLS 
1.2.2.1.1 Bone-forming osteoblasts 
Osteoblasts are cuboidal, matrix secreting cells found on bone surfaces.  They are derived from 
mesenchymal stem cells (MSCs).  MSCs can differentiate into osteoblasts, myocytes, chrondrocytes 
and adipocytes (see Figure 1.2). 
 
 
 
 
 
 
 
 
Figure 1.2 Mesenchymal progenitor differentiation 
 
Figure reproduced from Harada et al 2003 with permission (Harada and Rodan, 2003). 
Mesenchymal progenitor differentiation into osteoblasts, chondrocytes, adipocytes and 
myocytes is tightly regulated. 
 
Differentiation of osteoblasts requires Runx 2 (runt-related transcription factor 2), 
which is also involved in chondrocyte maturation.  Downstream from Runx 2, osterix 
(Osx) is also essential for osteoblast maturation, after which osteoblasts express specific 
markers such as osteocalcin (OC), bone sialoprotein (BSP) and collagen I (Col-1). 
 
Differentiation of mesenchymal progenitor cells into (i) myocytes is under the control of 
MRFs (myogenic regulatory factors) and MEF2 (myocytes enhancer factor 2), (ii) 
adipocytes is under the control of C/EBPa, b and d (CCAAT-enhancer-binding protein) 
and PPARγ (peroxisome proliferator activated receptor γ) and (iii) chondrocytes is under 
the control of Sox 5, 6, and 9 and STAT1 (signal transducers and activator of 
transcription 1) and express collagen X (Col-X). 
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Differentiation of mesenchymal progenitors into different cell types is tightly regulated by 
transcription factors and local growth factors (see Figure 1.2).  Mesenchymal progenitor cells 
differentiate initially into preosteoblasts (which can be identified by positive staining for alkaline 
phosphatise) but are unable to secrete mineral matrix.  Preosteoblasts mature into osteoblasts.  
Osteoblasts can be identified as cuboidal cells, found in clusters on the bone surface, stain strongly 
for ALP and secrete mineral matrix.  Osteoblasts secrete osteoid, containing type I collagen and 
noncollagenous proteins, such as osteocalcin and ALP.  These are important in the mineralisation of 
bone matrix.  Approximately 50-70% of osteoblasts undergo apoptosis with the remaining cells 
differentiating into osteocytes or bone lining cells (Bonewald, 2011). 
In addition to the production of new bone, osteoblasts secrete factors which are important in the 
regulation of mineralisation and osteoclast formation.  ALP is expressed by osteoblasts and is an 
important enzyme in the regulation of the mineralisation of bone (addressed in more detail in the 
section on bone mineralisation) as well as being commonly used as a marker of osteoblast activity.  
Osteoblasts also express free and cell surface receptor-activator of nuclear factor κB ligand (RANKL), 
which is essential for osteoclast maturation and express osteoprotegerin (OPG), which is a decoy 
receptor that inhibits RANKL binding to receptor-activator of nuclear factor κB (RANK) (this is 
addressed in more detail in the section on osteoclasts) (Takahashi et al., 1988).  By changing the 
ratio of RANKL to OPG expressed, osteoblasts are able to regulate osteoclast formation. 
Transcription and local growth factors important in osteoblasts 
Commitment into the osteoblast lineage occurs under the influence of transcription factors.  Two 
important transcription factors are runt-related transcription factor (Runx 2) and osterix. 
 
Runx 2 appears early on in the progenitor cells and is expressed until osteoblast maturity.  It is 
required for osteoblast differentiation and maturation and Runx 2 knockout mice have early 
arrested skeletal development with little cartilage or bone.  Due to its pivotal role in osteoblast 
function, Runx 2 is tightly regulated by co-repressors (Westendorf, 2006).  Runx 2 stimulates 
expression of RANKL and M-CSF (Geoffroy et al., 2002, Enomoto et al., 2003, Maruyama et al., 2007), 
promoting osteoblast driven osteoclastogenesis. 
 
Osterix is expressed by mature osteoblasts, is essential for osteoblast differentiation and regulates 
the expression of a number of osteoblast related genes, including type 1 Collagen.  Osterix knockout 
mice, similar to Runx 2 knockout mice, lack osteoblasts and have absent embryonic bone 
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development.  Osterix is expressed downstream of Runx 2 and osterix knockout mice express normal 
levels of Runx 2 and they do not have defects in hypertrophic chondrocytes (Peng et al., 2013). 
 
The number and function of osteoblasts are regulated by a number of extracellular signalling 
proteins and growth factors.  Although there are many signalling pathways which have been 
identified, there are a few factors that are of particular importance in osteoblasts: bone 
morphogenic proteins (BMPs), Fibroblast growth factors (FGFs) and Wnts (Miraoui and Marie, 2010). 
BMPs were first named because of their ability to induce bone formation and are a group of cytokine 
signalling molecules belonging to the transforming growth factor (TGF)-β superfamily, which bind to 
two classes of cell surface receptors, type I and type II.  BMPs are important in prenatal bone 
formation.  Binding of BMPs to their receptors activates SMAD and Ras to mitogen activated protein 
kinase (MAPK) signalling pathways.  SMAD 1, 5 and 8 in complex with SMAD 4, translocate into the 
nucleus and interact with a range of transcription factors such as Runx 2.  Clinically, gain of function 
mutation in BMP type I receptor, ACVR1, results in fibrodysplasia ossificans progressiva where there 
is dysregulation of bone deposition with extraskeletal ossification (Pignolo et al., 2011). 
FGFs and FGF receptors (FGFR) are present in the mesenchyme, chondrocytes and osteoblasts.  They 
are important for cell proliferation, differentiation and apoptosis.  Ligand, binding to the 
extracellular receptor domain, results in dimerisation and autophosphorylation of tyrosine residues 
in the cytoplasmic domains of the receptor.  This then activates downstream signalling cascades via 
one of three main pathways: phospholipase Cγ (PLCγ), signal transducers and activators of 
transcription (STATs) and MAPK.  Downstream signalling pathways may include (Extra cellular signal 
regulated kinase) ERK1/2, p38 MAPK, Ras-independent phophoinositide 3-kinase/Akt and Wnt.  
Many of the signalling pathways activated by FGFs result in an increased expression of genes 
involved in osteogenesis, such as Runx 2.  FGF signalling has been found to be important in the 
development of bone metastases associated with prostate cancers (Hideshima et al., 2001).  Genetic 
mutations in FGFR result in skeletal dysplasias such as achondroplasia (activating FGFR3 mutation) 
and craniosynostosis (mutation in FGFR1 or 2) (Miraoui and Marie, 2010). 
The canonical Wnt pathway is activated by the binding of Wnt to a cell-surface co-receptor 
comprising Frizzled (Frz) and a low-density lipoprotein receptor-related protein (Lrp5/6).  Wnt 
inhibits a complex that includes axin, glycogen synthase kinase 3 (GSK3) and adenomatous 
polyposis coli protein (APC).  When Wnt is absent, this complex phosphorylates β-catenin and 
promotes its degradation by the proteasome.  After Wnt binding, axin/GSK3/APC is inhibited and β-
catenin translocates to the nucleus where it acts with Tcf/Lef to promote gene transcription 
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(Johnson and Kamel, 2007).  The pathway is subject to feedback inhibition - secreted Frz-related 
proteins act as decoy Wnt receptors, whilst Dickkopf (Dkk) inactivates signalling from Lrp co-
receptors (Glass and Karsenty, 2007, Hartmann, 2006).  Sclerostin, produced by osteocytes, binds to 
Lrp5/6 and is an inhibitor of Wnt signalling.  Wnt stimulates osteoblast proliferation and inhibits 
apoptosis in vivo, and -catenin is required for terminal osteoblast differentiation (Day et al., 2005, 
Hens et al., 2005, Ducy et al., 2000).  The canonical pathway also stimulates expression of OPG 
(Holmen et al., 2005), a decoy receptor for RANKL that inhibits osteoclast differentiation (Glass and 
Karsenty, 2007).  Wnt inhibition therefore leads to reduced -catenin activity and high bone 
turnover osteoporosis (Hartmann, 2006).  Gain of function mutations in LRP5 cause high bone mass 
whilst loss of function mutations cause osteoporosis pseudoglioma syndrome. 
 
In summary, osteoblasts are the cells responsible for the production of new bone.  They also play 
important roles in the regulation of both mineralisation and osteoclast function. 
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1.2.2.1.2 Bone resorbing osteoclasts 
 
 
 
 
 
 
Osteoclasts are multinucleated cells derived from the monocyte macrophage lineage (Krause, 2008).  
They are specialised cells that adhere to the mineral surface and secrete acid and enzymes into the 
extracellular space to resorb mineralised matrix (Figure 1.3).  They are found both on the endosteal 
surface and at the metaphyseal periosteum.  Osteoclasts migrate from the bone marrow and 
become located on the bone surface.  They anchor themselves onto the bone surface by foot-like 
processes known as podosomes and migrate via membrane protrusions called lamellipodia.  During 
the migration phase, the osteoclasts have flattened structures; however, at the resorption site, the 
cytoskeleton becomes polarised and dome shaped.  The cytoplasmic actin becomes organised into a 
circular structure known as the actin ring.  An area of bone, known as the sealing zone, is isolated via 
attachment of the actin ring by integrin αvβ3, in preparation for acidic resorption (see Figure 1.4).  
The membrane of the osteoclast within the sealing ring, known as the ruffled border, is where HCl 
and acidic proteases such as cathepsin K and matrix metalloproteinases (MMP) are secreted.  HCl 
breaks down the mineral component of bone (hydroxyapatite) into Ca+, HPO42- and H2O.  This 
exposes the organic matrix, composed of collagen and other proteins, which can then be degraded 
by proteases.  Degradation products are exocytosed into the surrounding extracellular matrix (Boyle 
et al., 2003). 
 
Figure 1.3 Histology image of osteoclast (Oc) resorbing bone and BSE-SEM image of resorbed 
bone surface. 
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Figure 1.4 Diagram of resorbing osteoclast 
 
Figure reproduced with permission from Bruzzaniti A et al. 2006 (Bruzzaniti and Baron, 
2006). 
 
Osteoclasts attach to the bone surface via integrins, creating a sealing zone around the 
ruffled border.  Osteoclast maturation is stimulated by binding of RANKL and M-CSF to 
their receptors on the cell surface.  Osteoclast differentiation is inhibited by binding of 
calcitonin ligand to its receptors.  Carbonic anhydrase converts CO2 to H+ and HCO3- .  
Chloride enters and bicarbonate leaves the cell via the chloride-bicarbonate exchanger.  
Hydrochloric acid and acidic proteases are secreted onto the surface of the bone where 
resorption takes place.  
PKA - Protein kinase A, PKC - Protein kinase C, TRAP - Tartrate resistant acid phosphatase, 
MMP-9 - Matrix metalloproteinase 9. 
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Transcription and local growth factors important in osteoclasts 
Osteoclasts are formed by the fusion of macrophage precursors.  Commitment to the osteoclast 
lineage requires two key cytokines - RANKL and M-CSF. 
RANK-RANKL-OPG: In 1998, RANK, a member of the tumour necrosis factor superfamily (also known 
as tumour necrosis factor ligand superfamily member 11), was shown to be essential for osteoclast 
formation.  RANK is a transmembrane molecule found on the surface of osteoclasts and their 
precursors.  Binding of RANK by RANKL results in the commitment of monocytes to the osteoclast 
lineage and maturation of the osteoclast.  RANKL is expressed by many cells in the bone 
environment, including osteocytes, osteoblasts, T-cells, growth plate chondrocytes and endothelial 
cells.  It can be expressed on cell surfaces or excreted extracellularly.  Osteoclasts at the growth 
plate derive their source of RANKL primarily from chondrocytes, whilst osteoclasts on cancellous 
bone do so primarily from osteocytes (Nakashima et al., 2011). As a result, chondrocyte and 
osteocyte defects can adversely affect osteoclastic resorption. 
Activation of RANK transduces signals via the TNF receptor-associated factor (TRAF) family of 
proteins which leads to activation of a cascade of signalling pathways involving NF-κB, MAPK and 
phosphoinositide 3 kinase (PI3K), resulting in osteoclast proliferation, cytoskeletal re-organisation, 
differentiation and cell survival.  The binding of RANK to RANKL is inhibited by OPG, a soluble decoy 
receptor secreted by osteoblasts, which competes with RANKL for the binding to RANK. 
The key role of RANKL is highlighted by human mutations in the TNFSF11 gene (encoding RANKL) 
which results in autosomal recessive osteopetrosis.  This is often a lethal disease characterised by a 
depletion of osteoclasts and an arrest of skeletal modelling and remodelling.  Osteopetrotic Rankl-/- 
mice, treated with RANKL have an improved bone phenotype (Lo Iacono et al., 2012).  In humans, 
autoantibodies to OPG have been reported to result in osteoporosis (Riches et al., 2009), whilst 
conversely, monoclonal antibodies against RANKL are currently used in the treatment of 
osteoporosis (Silva-Fernandez et al., 2013). 
 
M-CSF: M-CSF is produced by osteoblasts and stromal cells.  M-CSF binds to its receptor colony-
stimulating factor-1 receptor (c-fms) in early osteoclast precursors, promoting survival, proliferation 
and differentiation.  Signalling via M-CSF occurs through multiple pathways but experiments in 
primary macrophages (Ross, 2006) indicate that ERK1/2 and PI3K are the key mediators of signalling.  
PI3K is important in regulating cell proliferation via the GSK3β and Forkhead box (FOXO) family of 
transcription factors.  Mice lacking M-CSF or c-fms have an osteopetrotic phenotype and in humans, 
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mutations in M-CSF can be found in patients with myelodysplastic syndromes and myeloid 
leukaemia (Rauner et al., 2013). 
In summary, osteoclasts are the cells responsible for bone resorption.  They respond to signals from 
osteoblasts, osteocytes and the surrounding bone marrow environment, to direct the timing and 
direction of bone removal. 
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1.2.2.1.3 Bone-orchestrating osteocytes 
 
 
 
 
 
 
Osteocytes make up 90-95% of bone cells and are derived from the MSC lineage via osteoblasts 
which have become entombed in bone.  They differ from osteoblasts morphologically by having long 
dendritic processes which contact cells on the surface of bone and other embedded osteocytes.  
They become polarised towards the direction of the mineralising surface. 
Osteocytes respond to mechanical strain and send signals through dendritic processes to alter 
resorption or formation.  These signals can negatively regulate osteoblast function and/or activate 
osteoclastogenesis (Turner and Pavalko, 1998).  Osteocytes are the primary source of RANKL for 
osteoclasts in bone remodelling (Nakashima et al., Xiong et al., 2011).  They also highly express DKK1 
and sclerostin, which are negative regulators of the Wnt pathway (Moriishi et al., 2012).  Mechanical 
loading reduces sclerostin expression (Robling et al., 2008). 
Osteocytic apoptosis occurs with mechanical damage, such as fracture or microcracks.  Hypoxia, 
oestrogen withdrawal, immobilisation and glucocorticoid treatment also promote osteocyte 
apoptosis (Weinstein et al., 2000, Dodd et al., 1999, Tomkinson et al., 1997, Emerton et al., 2010).  
Figure 1.5 Osteocyte lacunae and dendritic processes in cortical bone 
BSE-SEM image of acid-etched plastic-embedded murine cortical bone.  The dendritic 
processes are clearly identified, as are the osteocytic lacunae. 
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Apoptosed osteocytes result in the release of chemotactic factors (such as RANKL) which are 
involved in recruiting osteoclasts and initiating resorption. 
More recently, it has become clear that osteocytes are important regulators of bone mineralisation 
and phosphate metabolism.  Osteocytes highly express molecules phosphate-regulating neutral 
endopeptidase, X-linked (PHEX), FGF23 and DMP1, all of which are important in phosphate 
regulation. 
Mutations in osteocyte specific DMP1 result in autosomal recessive hypophosphatemic rickets, 
patients affected with PHEX mutations have X linked dominant hypophosphatemic rickets and 
mutations in FGF23 result in autosomal dominant hypophosphatemic rickets (Bergwitz and Juppner, 
2010). 
In summary, osteocytes are important regulators of bone homeostasis.  They are involved in co-
ordinating the activity of osteoclasts and osteoblasts through the release of factors such as RANKL 
and sclerostin.  Osteocytes are also key cells involved in phosphate regulation and, subsequently, 
bone mineralisation. 
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1.2.2.1.4 Other cells 
Within the bone marrow niche, bone cells are in close proximity to immune cells such as 
lymphocytes (T-cells and B-cells), granulocytes, monocytes/macrophages, mast cells and 
megakaryocytes/platelets.  Some of these cells have also been shown to modulate the skeleton via 
cross talk with bone cells. 
T-Cells: T-cells express RANKL and so are able to activate RANK on osteoclast precursors.  T-cells also 
produce cytokines such as TNF-α and IL-17, which upregulate RANKL and MMPs in osteoblasts.  In 
contrast, T-helper cells can produce IFN-γ and IL-4, both of which suppress osteoclastogenesis via 
direct action on osteoclast precursors (Gao et al., 2007b, Bendixen et al., 2001).  T-cell deficient mice 
demonstrate resistance to ovariectomy induced bone loss and further studies suggested that T-cell 
derived TNF-α is important in bone loss, secondary to ovariectomy (Pacifici, 2007).  Consistent with 
these findings, women with postmenopausal osteoporosis have a greater density of membranous 
RANKL in marrow T-cells, with greater activation of T-cells. These findings suggests that T-cells play 
an important role in postmenopausal osteoporosis (Eghbali-Fatourechi et al., 2003). 
Osteomacs: Osteomacs have been relatively recently described and is a term used for resident tissue 
macrophages which lie in close proximity to periosteal or endosteal surfaces (Kular et al., 2012) 
(Chang et al., 2008).  Osteomacs, often in association with bone lining cells, form a canopy over 
mature osteoblasts in bone modelling and also above the bone remodelling unit (BRU) (see later 
section on BRU).  They are thought to help regulate bone mineralisation as depletion of osteomacs 
results in decreased mineralisation.  Osteomacs secrete cytokines TGFβ and Ephrin B2, which 
activate osteoclasts and this is potentially one mechanism by which osteomacs help regulate bone 
remodelling (Pettit et al., 2008). 
 
1.2.2.2 BONE MATRIX AND MINERALISATION 
1.2.2.2.1 Bone matrix deposition 
Bone is formed when osteoblasts secrete osteoid, which subsequently becomes mineralised by 
active (primary ossification) and passive (secondary ossification) mechanisms.  Osteoid is an organic 
matrix composed of type I collagen, SIBLING (small integrin-binding ligand, N-linked glycoprotein) 
proteins (such as osteopointin and bone sialoprotein) and osteocalcin.  Type I collagen is a triple 
helix molecule consisting of two α1 chains and one α2 chain. 
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Figure 1.6 Synthesis and structural organisation of type 1 collagen 
Figure reproduced with permission Baum, J 1999 (Baum and Brodsky, 1999).  
Type I collagen molecules are synthesised in the endoplasmic reticulum (ER) 
of osteoblasts, and after post translational modification (PTM), a triple helix, 
procollagen, is formed.  Procollagen is excreted from the cell, after which the 
N and C terminals are cleaved before assembly into collagen strands with 
cross linking of fibrils. Hyp-Hydroxyproline; Gly-Glycine; Pro-Proline; Hyl-
Hydroxylysine, Lys- Lysyl. 
Reproduced with permission from J Baum 1999 
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Type I collagen is initially formed at the endoplasmic reticulum as procollagen, which then 
undergoes several post translational modifications: hydroxylation of prolyl and lysyl residues, 
glycosylation of hydroxylysyl, terminal propeptide phosphorylation/glycosylation and formation of 
covalent cross links between the three strands.  After post translational modification, a procollagen 
triple helix is formed and secreted into the extracellular space.  Cleavage of the C and N propeptide 
terminals of procollagen are removed by proteases, after which the collagen molecules aggregate 
and cross link to other collagen fibrils (see Figure 1.6).  The molecules of collagen are arranged in 
sheets of unidirectional fibres with each subsequent sheet at a different angle.  This allows tight 
packing of the collagen and also gives the bone tensile strength.  These layers give the bone a 
lamellar structure (see Figure 1.7). 
 
1.2.2.2.2 Matrix mineralisation 
The mineral component of bone, hydroxylapatite (Ca10(PO4)5(OH)2), is deposited into the spaces in 
between the organic bone matrix.  Mineralisation of matrix is tightly regulated.  Osteoblasts 
maintain a high extracellular concentration of calcium and phosphate via calcium and phosphate 
pumps, so that the matrix is primed to incorporate mineral.  Mineralisation is, however, inhibited by 
the presence of inorganic pyrophosphate (POP) and it is the ratio of phosphate and POP which 
regulates the rate of mineralisation.  Matrix vesicles bud off the cell membranes of osteoblasts and 
are released into the premineralised matrix.  These vesicles are rich in enzymes such as Nucleotide 
pyrophosphates phophodiesterase1 (NPP1) and tissue nonspecific alkaline phosphatase (TNAP).  
NPP1 increases extracellular POP concentration and TNAP decreases POP whilst increasing 
phosphate concentration.  The regulation of mineralisation is tightly controlled as excessive 
mineralisation results in stiff, brittle bones (seen in patients with osteopetrosis) and insufficient 
mineralisation results in soft, malleable bones (seen in patients with hypophosphataemic rickets). 
Mineralisation of matrix in humans initially occurs between 5-10 days after matrix deposition.  This is 
termed ‘primary mineralisation’.  After this, a slow ‘secondary mineralisation’ phase takes place 
which may last up to 30 months and involves up to 50% increased mineral deposition with an 
increase and augmentation of crystal size (Boivin and Meunier, 2002).  Mineral density distribution 
(also termed material density) can be determined by quantitative backscattered electron microscopy 
(qBSE-SEM) (Roschger et al., 1998).  The degree of bone mineralisation can give some indication of 
the bone remodelling rate (Boivin and Meunier, 2002), with high turnover bone having a low mineral 
density distribution and low turnover bone having a high mineral density on qBSE-SEM.  
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1.2.3 EMBRYONIC DERIVATION OF BONE 
Embryonically, the skeleton is derived from mesenchymal progenitor cells which aggregate at the 
site of the future skeleton.  Skeletal patterning is tightly controlled by temporo-spatial expression of 
genes such as those in the canonical Wnt and Notch pathways (Dequeant et al., 2006).  Ossification 
occurs by two major mechanisms - the flat bones of the body are formed by intramembranous 
ossification and the long bones are formed by endochondral ossification. 
1.2.3.1 INTRAMEMBRANOUS OSSIFICATION 
The aggregation of MSCs, known as the ossification centre, becomes highly vascularised and MSCs 
differentiate into preosteoblasts and then osteoblasts.  Osteoblasts secrete an organic mineral 
matrix which mineralises to form an irregular and disorganised type of bone known as woven bone.  
Woven bone is then removed and replaced by a highly organised structure known as lamellar bone.  
Flat bones formed by this mechanism include skull bones, the scapula, mandible and the ilium 
(Baron, 1999). 
 
 
 
 
Figure 1.7 Collagen fibrils in woven bone and lamellar bone 
Mineralised collagen fibrils are arranged in a random manner in woven bone (A).  Woven bone 
is resorbed and replaced by fibrils arranged in parallel sheets known as lamellar bone (B). 
Adapted with permission from Weiner S 1998 (Weiner and Wagner, 1998). 
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1.2.3.2 ENDOCHONDRAL OSSIFICATION 
The majority of long bones in the body are formed by endochondral ossification.  Embryonic MSCs 
condense and form a cartilage template (see Figure 1.8).  The MSCs differentiate into chondrocytes, 
which proliferate, release extra cellular matrix (ECM) factors and finally hypertrophy and apoptose. 
Ossification of the long bone begins in the middle of the cartilaginous template, where invading 
blood vessels, and bone marrow containing bone resorbing osteoclasts and bone forming 
osteoblasts, remove cartilaginous ECM and deposit new bone.  From the centre, new bone 
formation proceeds distally and expands to the distal ends of the cartilaginous template (see Figure 
1.8). 
 
 
 
 
 
  
Figure 1.8 Diagram showing the different steps in endochondral 
ossification. 
See text for details 
Adapted with permission from Gilbert 2006 (Gilbert, 2006). 
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At a later stage of development, a secondary centre of ossification commences at the distal ends of 
the long bones, forming the epiphysis.  Where the primary and secondary ossification centres meet, 
the cartilaginous growth plate remains and is active until the cessation of growth.  New bone is 
formed under the growth plate and in this manner, elongation of long bones occurs (Mackie et al., 
2011). 
At the epiphyseal end of the growth plate, MSCs differentiate into chondrocytes.  Growth plate 
chondrocytes have a tightly regulated spatial arrangement of columns that lie parallel to the 
longitudinal axis of the bone (see Figure 1.9).  In the distal resting zone, the cells are small and have 
a low rate of proliferation and matrix secretion.  When the chondrocytes enter the proliferative zone 
(PZ), the cells become ordered into columns, proliferate profusely and express ColII.  The 
chondrocytes mature and hypertrophy and express ColX, appearing large and round before 
undergoing apoptosis (Figure 1.11).  Before entering the hypotrophic zone, the prehypertrophic 
chondrocytes produce Indian Hedgehog protein (Ihh).  This both increases chondrocyte proliferation 
and activates the expression of parathyroid related protein (PTHrP) in articular and periarticular 
chondrocytes.  PTHrP, via the G-protein coupled receptor (PTH/PTHrP receptor) PPR, maintains 
proliferating chondrocytes in the proliferative pool, thereby inhibiting chondrocyte hypertrophy and 
the production of Ihh (see Figure 1.10).  This negative feedback loop regulates the rate of 
proliferation and hypertrophy of chondrocytes and can be modified by interactions with other 
signalling molecules such as BMP and FGFs.  BMP signalling from hypertrophic chondrocytes 
promotes Ihh expression and chondrocyte proliferation.  Conditional knockout of BmpRIA and 
BmpRIB (BMP receptors) in differentiated chondrocytes leads to reduced Ihh expression and 
reduced chondrocyte proliferation (Kronenberg, 2003).  FGFs are highly expressed in the growth 
plate and, of particular note; FGFR3 inhibits chondrocyte proliferation and hypertrophy through 
both MAPK signalling pathways and via interactions with the Ihh-PTHrP-BMP pathways.  Wnt 
signalling pathways stimulate chondrocyte terminal differentiation (Wang et al., 2007) (Figure 1.17). 
Hypertrophic chondrocytes secrete large quantities of matrix proteins and matrix vesicles.  Matrix 
vesicles contain calcium, phosphates, hydroxyapatite and MMP, all of which function to mineralise 
the surrounding matrix.  Following apoptosis of the chondrocytes, angiogenic factors promote the 
invasion of blood vessels, which bring osteoblasts and osteoclast progenitors, and the remaining 
calcified cartilage becomes a scaffold for new bone formation. 
Chondrocytes are an important source of the cytokine receptor activator RANKL, which is essential 
for osteoclast formation and function in the primary spongiosum (Xiong et al., 2011). 
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Figure 1.9 Growth plate 
Image of tibial growth plate of wild type mouse stained with van Gieson (red for collagen) and alcian blue 
(blue for cartilage).  The growth plate is found between the epiphysis and metaphysis.  It consists of matrix 
embedded chondrocytes arranged in distinct zones.  The resting zone chondrocytes are quiescent before 
becoming organised into columns undergoing proliferation (proliferative zone), differentiation, maturation 
(hypertrophic zone) and finally undergoing apoptosis. 
Slide stained by Y. Liu and raw image taken Dr J. Logan 
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Figure 1.10 Growth plate signalling  
Reproduced with permission from Kronenberg Nature 2003 (Kronenberg, 2003). 
Chondrocyte proliferation and hypertrophy is regulated by parathyroid related protein (PTHrP) 
and Ihh.  Perichondral cells at the distal end of the bone produce PTHrP, which acts via receptors 
on proliferating chondrocytes to keep chondrocytes in the proliferative stage (1).  When the 
chondrocytes are far away enough from the source of PTHrP, they differentiate into hypertrophic 
chondrocytes, which express Ihh (2).  Ihh acts to stimulate the production of PTHrP (3) and delay 
hypertrophy of chondrocytes.  Ihh also acts to stimulate the production of osteoblasts in the 
perichondral cells (4). 
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1.2.4 REGULATION OF BONE: MODELLING AND REMODELLING 
Bone deposition does not occur in a haphazard manner, instead it is directed and shaped during 
growth (a process known as modelling) and after cessation of growth, bone is continually renewed, 
replaced and repaired (a process known as remodelling). 
 
1.2.4.1 BONE MODELLING 
Long bones increase longitudinally by deposition of bone under the growth plate and increase in 
diameter by bone deposition under the periosteum.  At the metaphysis, bone is removed on the 
periosteal cortical surface by bone resorbing osteoclasts, resulting in a slender diaphysis.  This 
modelling process is termed metaphyseal inwasting and can be seen to be disrupted when 
inappropriate doses of osteoclast disrupting bisphosphonates are given during growth, resulting in 
club shaped bones and in disorders of osteoclasts, such as in osteopetrosis. 
Bone is deposited under the periosteum, increasing the external circumference of the diaphysis, 
whilst bone is also resorbed from the intramedullary cortex.  An indication of periosteal bone 
formation can therefore be gained by assessing the mid shaft diameter of long bones.  The cortical 
thickness of bone results from the difference between periosteal deposition and intramedullary 
cortical resorption (bone removal). 
Disruption of osteoclast function during development would not only result in a decrease in the 
amount of bone being removed by the BRU, but also in a modelling defect, resulting in club shaped 
bones.  The diameter of the intramedullary cavity and cortical width can also give an indication of 
osteoclast function. 
1.2.4.2 BONE REMODELLING 
Bone is renewed and repaired by the BRU, which consists of coordinated teams of osteoclasts and 
osteoblasts.  About 10% of the human adult skeleton is replaced per year with millions of BRUs 
active at any one time. 
The balance of resorption versus deposition determines bone mass and thus is important in bone 
strength.  To maintain the correct balance of bone mass, a tightly regulated process couples the 
activities of osteoclasts and osteoblasts and disorders in this process result in too little bone 
(osteopenia, osteoporosis) or excess bone (osteopetrosis, osteosclerosis).  In cortical bone, 
remodelling occurs by osteoclasts removing a cutting zone which is then filled in by layers of bone 
laid down by invading teams of thousands of osteoblasts.  In cortical bone, these BRUs are known as 
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osteons.  In trabecular bone, BRUs are known as hemiosteons, where osteoclasts carve out pits 
which are then re-filled with bone by invading osteoblasts (Raggatt and Partridge, 2010).  The bone 
remodelling cycle can be divided into several phases (see Figure 1.11) as set out below. 
 
1.2.4.2.1 Activation/Resorption phase 
The activation phase is thought to be initiated by the release of local chemotactic factors by 
osteocytic death (Martin and Burr, 1982) and by signalling by osteocytes in response to mechanical 
strain (Smit et al., 2002).  Hormones such as parathyroid hormone (PTH) also act on osteoblasts and 
osteocytes to inhibit sclerostin production, and oestrogen (E2) reduces activation of osteoclasts.  
When the activation phase commences, the lining cells are disrupted, and in preparation for 
resorption, collagenases and MMPs are produced (Meikle et al., 1992).  In addition, osteocytes, 
lining cells and osteoblasts produce osteoclastogenic factors such as RANKL and M-CSF, which lead 
to osteoclast precursors being recruited to the site.  The osteoclast precursors are recruited either 
from the bone marrow or via the vasculature which is within the BRU.  Osteoclasts bind to the 
surface of the bone and form an actin ring sealing zone and release HCl and matrix removing 
enzymes to resorb bone.  The activation phase is thought to last about 10 days, after which 
osteoclasts apoptose and the reversal phase commences. 
 
1.2.4.2.2 Reversal/Formation phase 
The activation phase is followed by the reversal phase, where there is inactivation of the osteoclasts 
which apoptose, and invasion of teams of co-ordinated osteoblasts which differentiate and lay down 
new bone.  Between inactivation of the osteoclasts and the invasion of osteoblasts, a mononuclear 
reversal cell of undetermined lineage, removes the collagen remnants in preparation for the 
invasion of osteoblasts.  The migration of osteoblast precursors to the site of resorption is likely to 
be mediated via factors (such as TGFβ and insulin like growth factor 1 (IGF1)) which are released 
when the matrix of bone is broken down.  Once they reach the site of newly exposed bone, they lay 
down layers of osteoid and new bone is formed.  The precise mechanism of coupling of breakdown 
and formation is still unclear but it is likely that osteoclasts produce coupling factors that regulate 
osteoblasts (Kular et al., 2012). 
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1.2.4.2.3 Termination phase 
The final and longest phase is the termination phase, where osteoblasts lay down matrix and 
mineralise bone.  Osteoblasts secrete type I collagen and non collagenous proteins such as 
osteocalcin (OCN), osteopontin (OPN), BSP, osteonectin (OSN) and proteoglycans.  Primary and 
secondary mineralisation, as previously described, occurs.  Osteoblasts then undergo terminal 
differentiation and either apoptose, become quiescent lining cells or become buried into bone as 
osteocytes.  The mechanisms by which bone formation is terminated are still unclear, but signalling 
from the osteocytes via production of sclerostin, may be a mechanism of regulation.  This formation 
phase may last up to 3 months and the bone becomes quiescent until the next BRU is activated. 
 
 
 
 
 
 
 
Figure 1.11 Remodelling cycle  
Adapted from Raggett 2010 with permission (Raggatt and Partridge, 2010). 
During the activation phase, osteoclasts are recruited, attach to bone and mature, leading to 
resorption of bone.  This is followed by the reversal phase where teams of coordinated osteoblasts 
are recruited and lay down new bone in orderly sheets.  Osteoblasts either apoptose, become 
quiescent lining cells or become buried and mature into osteocytes that act as mechanosensory 
regulators, coordinating and directing bone remodelling.  As well as osteocytes, cells present in the 
bone marrow niche such as T and B lymphocytes are also involved in cross communication between 
osteoblasts and osteoclasts. 
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1.2.4.3 OTHER MECHANISMS OF REGULATION OF SKELETAL MASS 
1.2.4.3.1 Autonomic control 
Both the sympathetic (SNS) and parasympathetic (PNS) nervous systems have been shown to 
influence bone mass.  The SNS has been shown to be a negative regulator of bone mass by inhibiting 
osteoblast proliferation and increasing RANKL expression (Karsenty, 2006), whilst in contrast, the 
PNS is a positive regulator of bone mass.  
Leptin is a neurotransmitter produced by adipocytes, which acts on the hypothalamus to suppress 
appetite.  Recently, it has also been proposed as a key regulator of bone mass, acting via two 
mechanisms (Ducy et al., 2000).  First, leptin acts on the central nervous system, inhibiting the 
synthesis and release of serotonin, which in turn leads to a decrease in signalling via the 
hypothalamus, resulting in increased sympathetic output.  Sympathetic signals to osteoblasts via 
adrenergic receptors result in decreased osteoblast proliferation.  Second, leptin acts via the 
hypothalamus to increase expression of a gene called CART (cocaine and amphetamine-regulated 
transcript).  CART decreases RANKL production from osteoblasts, thus inhibiting bone resorption 
(Elefteriou et al., 2005).  Although these seem to have opposing actions, the combined effect of 
leptin is the prevention of bone mass accrual via the actions of the SNS and CART. 
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1.3 OSTEOPOROSIS 
Osteoporosis is characterised by reduced bone mass, low bone mineral density (BMD), deterioration 
of bone microarchitecture and an increased susceptibility to fragility fracture.  Adult bone mass is 
determined by the maximum acquisition of bone during growth and the net balance of bone 
deposition (bone formation) versus bone loss (resorption) thereafter (Seeman and Delmas, 2006). 
Established osteoporosis in adults is defined by the World Health Organisation (WHO) as individuals 
having a BMD measured by dual energy X-ray absorptiometry (DXA) which is more than 2.5 standard 
deviations below that of a sex-matched young adult (T-score). 
Fractures occur when the skeleton is not able to withstand the demands of mechanical stress and is 
dependent on multiple factors such as bone structure, bone mass and bone quality as well as the 
stress placed upon the bone.  The most common sites of osteoporotic fracture are at the hip, spine 
and wrist (Seeley et al., 1991). 
Estimates for the number of postmenopausal women in the UK with osteoporosis have been 
predicted to rise from 1.8 million in 2010 to 2.1 million in 2020 (Gauthier et al., 2011).  In the UK, the 
ten year risk of fracture in woman aged 50 years is 0.3% and increases to 8.7% for those aged 80 
years.  In 50 year old men, the ten year risk of fracture is 0.2%, increasing to 2.9% for those aged 80 
years (Karaguzel and Holick, 2010, Harvey et al., 2010).  Some estimates state that half of women 
and a fifth of men over the age of 50 will suffer a fracture.  This would equate to over 60,000 hip, 
50,000 wrist and over 120,000 vertebral fractures each year in the UK (Harvey et al., 2010). 
 
1.3.1 RISK FACTORS FOR OSTEOPOROSIS 
Identifying risk factors has helped medical professionals to diagnose, prevent and treat osteoporosis.  
Many factors are intrinsic but due to the significant financial burden of osteoporotic fractures, much 
focus has been placed on the modifiable risk factors. 
Age: In adults, age and bone mass are inversely related irrespective of gender (Kanis et al., 2005a).  
A decline in trabecular bone mass begins around the third decade (Manolagas and Parfitt, 2010, 
Khosla et al., 2011).  Ageing is associated with many disease processes and hormonal changes which 
together adversely affect bone quality and mass.  An increase in reactive oxidative stress (ROS) has 
been identified as an important mechanism of age related bone loss.  This increase in ROS affects 
both bone forming osteoblasts and bone regulating osteocytes.  Increased ROS leads to reduced 
bone formation by reducing osteoblast lifespan and redirecting progenitors to the adipocyte lineage.  
  
 
49 
 
ROS also increases osteocytic apoptosis by reducing autophagy and compromising osteocytic nuclear 
pore structures (Manolagas, 2010). 
Female gender: Women are at greater risk of osteoporosis due to their relatively smaller size and 
lower total bone mass.  Accelerated bone loss after the menopause and comparative longevity 
increases women’s risk of osteoporosis in comparison to men (Khosla et al., 2011). 
Family history: A family history of osteoporosis which may include kyphosis or low trauma fractures 
after the age of 50, is a risk factor for osteoporosis (Soroko et al., 1994).  Monozygotic and dizygotic 
twins studies show a high level of heritability, accounting for 60-80% of variability in BMD and a 
modest but significant heritability of fracture risk (Dequeker et al., 1987, Pocock et al., 1987).  A 
recent meta-analysis of genome wide association (GWAS) studies has identified 56 loci which are 
associated with BMD variation susceptibility and 14 that are associated with fragility fractures 
(Estrada et al., 2012).  Further GWAS studies have tried to identify loci associated with trabecular (1 
loci identified) versus cortical (4 loci identified) determinants (Paternoster et al., 2013). 
Ethnicity: Caucasian women have a 2.5 times greater increased risk of osteoporosis than Afro-
Caribbean women (Snelling et al., 2001).  This is likely to be due to genetic factors resulting in Afro-
Caribbean women having a higher average BMD at all ages and a decreased rate of age related bone 
loss (Aloia et al., 1996). 
Modifiable risk factors: Several studies have shown that body mass index (BMI) is positively 
associated with BMD and thus low BMI may be a risk factor for osteoporosis (Soroko et al., 1994, 
Ravn et al., 1999).  Other factors have been shown to correlate but it is not clear if these associations 
are causative. 
Smoking is associated with low BMD and increased fracture risk (Kanis et al., 2005b).  A meta-
analysis of 29 cross sectional studies showed that smokers have a greater rate of post-menopausal 
bone loss than non-smokers and have a 17% greater risk of fracture at 60 years, 41% at 70 years, 
71% at 80 years and 108% at 90 years (Law and Hackshaw, 1997). 
Current physical activity levels and physical activity in adolescence have been shown to have a 
positive correlation with BMD (Rubin et al., 1999); individuals who currently have a sedentary 
lifestyle and particularly those who were sedentary in adolescence could be at greater risk of 
osteoporosis.  Studies assessing correlation between physical activity and BMD in adults have been 
conflicting.  A study of 580 post-menopausal women in the UK found that brisk walking and stair 
climbing had a positive correlation with BMD (Coupland et al., 1999).  In contrast, an Australian 
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study of 1075 women and 690 men showed an initially positive correlation between BMD and 
physical exercise but significance was lost on adjustment for age, BMI, calcium intake and 
quadriceps strength (Nguyen et al., 2000). 
Secondary causes of osteoporosis: Osteoporosis can be secondary to a large number of clinical 
conditions such as thyrotoxicosis, anorexia nervosa, chronic liver disease, hyperparathyroidism, 
inflammatory bowel disease, male hypogonadism, renal disease, rheumatological diseases and 
vitamin D deficiency (Kanis et al., 2005a).  Iatrogenic causes include some diuretics, anticonvulsants 
and corticosteroids (Rizzoli et al., 2012). 
Further study of how thyroid and oestrogen hormones interact to maintain bone health is important 
in understanding how to prevent osteoporosis and fragility fractures. 
The next two sections of this Introduction will give background information on thyroid hormone and 
oestrogen action and what is currently known about their action on bone. 
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1.4 THYROID HORMONE 
In children, thyroid hormone excess (thyrotoxicosis) accelerates growth and advances bone 
maturation, whereas thyroid hormone deficiency (hypothyroidism) causes growth arrest with 
delayed skeletal development (Rivkees et al., 1988).  Normal thyroid status is essential for 
acquisition of peak bone mass.  In adults, untreated thyrotoxicosis accelerates bone loss and causes 
osteoporosis (Bassett et al., 2007b).  Prospective clinical studies have revealed that even minor or 
transient disturbances of thyroid status can increase hip and vertebral fracture risk by up to 4-fold 
(Sambrook and Cooper, 2006, Parle et al., 1993, Murphy and Williams, 2004). 
 
1.4.1 HOMEOSTATIC CONTROL OF THYROID HORMONE  
Circulating levels of thyroid hormone are tightly regulated by a classical negative feedback loop in 
the hypothalamic-pituitary-thyroid (HPT) axis (see Figure 1.12). 
Thyrotrophin releasing hormone (TRH) is a peptide hormone which is synthesised by neurons in the 
hypothalamic paraventricular nucleus (Abel et al., 2001).  TRH binding to cell surface TRH receptors 
on anterior pituitary thyrotrophs stimulates the synthesis and release of the glycoprotein thyroid 
stimulating hormone (TSH).  TSH binding to TSHR, a G protein coupled receptor on the plasma 
membrane of the thyroid follicular cell, stimulates thyroid hormone production and secretion in the 
thyroid gland.  Transcription of TRH is suppressed by the binding of T3 to thyroid hormone receptor 
β2 which binds to a negative thyroid response element (TRE) in the promoter region of the TRH 
gene.  T3 binding to TRβ2 in the hypothalamus similarly leads to rapidly decreased transcription of 
TSH (Forrest et al., 1996). 
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Figure 1.12 Homeostatic control of thyroid hormone 
Circulating levels of thyroxine (T4), the prohormone, are converted to 3,5,3’-L-triiodothyronine (T3) 
by the action of deiodinase 2 (D2) in the hypothalamus and pituitary.  The active hormone, T3, 
inhibits the hypothalamic production of thyroid releasing hormone (TRH) and anterior pituitary 
production of thyroid stimulating hormone (TSH), via a negative feedback loop.   Thus the HPT axis 
senses circulating levels of mainly T4.  Peripherally, T4 is converted to T3 via deiodinase 1 (D1) 
expressed in the kidney and liver. 
Entry into cells is regulated by the transporters MCT8/10 and OATP1C1 on the cell surface.  
Intracellular T3 is also regulated by deiodinase type 3, which inactivates T4 and T3 to rT3 and T2 
respectively and D2, which converts T4 to T3. 
PVN - paraventricular nucleus; TRH - thyrotrophin-releasing hormone; TSH - thyroid-stimulating 
hormone; DIO1, DIO2 and DIO3, type 1, 2 and 3 deiodinases; MCT8 and MCT10, OATP1C1 - 
organic acid transporter protein-1C1; TR, thyroid hormone receptor; TRb2, thyroid hormone 
receptor b2; RXR, retinoid X receptor; T4 - thyroxine; T3 – 3,3’,5-triiodothyronine; rT3 - 3,3’,5’-
triiodothyronine; T2 - 3,3’-diiodothyronine. 
Reproduced from Nicholls 2012 with permission (Nicholls et al., 2012) 
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1.4.2 THYROID HORMONE SYNTHESIS  
The thyroid gland synthesises the prohormone 3,5,3’,5’-L-tetraiodothyronine (thyroxine -T4)  and a 
small amount of T3.  Iodide is actively taken up and concentrated in the thyroid gland by Na
+/I- 
symporters (NIS).  Once intracellular, iodide is transported into the lumen of the follicle by a 
transporter located on the apical surface called pendrin (see Figure 1.13). 
Intra luminal iodide is oxidised and incorporated into the tyrosine residues of a large glycoprotein 
called thyroglobulin (Tg) by the apical membrane enzyme, thyroid peroxidase (TPO).  Dual oxidase 2 
(DUOX2) is a glycoprotein on the apical membrane and in the presence of the maturation factor dual 
oxidase maturation factor 2 (DUOXA2), catalyses oxidation of Nicotinamide adenine dinucleotide 
phosphate (NADPH) from the cytoplasm and releases H2O2 into the follicular lumen. 
TPO catalyses iodination of specific tyrosine residues on Tg, forming mono-iodotyrosine (MIT) and 
di-iodotyrosine (DIT) residues.  TPO also enzymatically couples MIT and DIT in the presence of H2O2.  
T3 and T4 still attached to the Tg backbone is formed and stored in the colloid of the lumen of the 
thyroid follicle.  Secretion of the hormones into the circulation occurs by macropinocytosis and 
micropinocytosis of vesicles at the apical membranes.  Proteolysis by lysosomes releases T4 and T3 
from Tg into the circulation.  Iodotyrosines are rapidly deiodinated by dehalogenase1 in the 
endoplasmic reticulum and released iodine is recycled.  The process of thyroid hormone synthesis 
and release are stimulated by TSH. 
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Figure 1.13 Thyroid hormone synthesis  
Reproduced with permission from Bizhanova (Bizhanova and Kopp, 2009). 
At the basolateral membrane of thyroid follicular cells, NIS transports iodide into thyrocytes 
after which pendrin further transports the iodide into the follicule lumen.  Thyroid follicular 
cells line the lumen filled with colloid.  H2O2 is produced in the luman by DUOX2 in the 
presence of DUOXA2.  H2O2 is needed for the oxidisation by iodide by TPO.  Thyroglobulin is 
secreted into the follicular lumen and MIT and DIT are formed on its tyrosine residues.  TPO 
couples MIT and DIT to form either T3 or T4 and are stored in the follicule until required. 
When required, thyroglobin is internalised by pinocytosis. T3 and T4 are released into the 
bloodstream after thyroglobulin is digested by lysosomes.  Any remaining MIT and DIT are 
deiodinated (by DHAL1) and the iodide recycled.  
Na+/I- symporters (NIS), pendrin (PDS/SLC26A4), Thyroglobulin (TG), iodotyrosine 
dehalogenase 1 (DEHAL1),  
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1.4.3 LOCAL CONTROL OF THYROID HORMONE CONCENTRATIONS 
Tissue bioavailability of thyroid hormone is dependent on several modulating factors - serum levels 
of T3 and T4, transport into the cells, intracellular conversion of prohormone to active hormone, 
intracellular receptor availability and intracellular inactivation of T3. 
 
1.4.3.1 Serum concentrations of thyroid hormone 
 
The prohormone, T4, is secreted at concentrations approximately 15 times greater than that of the 
active hormone T3 (130 nmol/l of T4 to 9 nmol of T3).  Both hormones are lipophilic and are over 
95% protein bound.  Free T3 and T4 levels are therefore dependent on the concentration and 
saturation of transporter proteins, namely thyroxine binding globulin (TBG), transthyretin (TTR) and 
albumin.  75% of T4 is bound to TBG, 15% bound to albumin and 10% bound to TTR, leaving only 
about 0.02% non protein bound.  Due to higher binding affinities of T4 to transport proteins 
compared to T3, the circulating free T4 concentration is four-fold greater than free T3.  The majority 
of circulating active T3 hormone (80%) is derived from T4 mono deiodination of its outer ring and is 
catalysed by the selenocysteine containing deiodinase enzyme type 1 (D1) and deiodinease enzyme 
type 2 (D2)  (Bianco and Kim, 2006). 
 
1.4.3.2 Active transport of thyroid hormones into cells 
 
Despite the lipophilic properties of thyroid hormones, entry to cells by passive diffusion is minimal.  
Active transporters increase the uptake of tissues by tenfold and regulate intracellular availability.  
Energy dependent, membrane bound thyroid hormone transporter proteins include 
monocarboxylate transporter 8 (MCT8), MCT10, organic anion-transporting-polypepetide 1c1 
(OATP1c1, OATP14) and non-specific amino acid transporters such as L-type amino acid transporters 
1 and 2 (LAT1, LAT2) (Heuer and Visser, 2012, Bianco and Kim, 2006). 
1.4.3.3 Intracellular modulation of T3 availability 
 
Intracellular availability of T3 is tightly regulated by deiodinases, a group of selenocysteine 
containing enzymes. Deiodinase 2 (D2), which has a 700 fold greater catalytic efficiency than D1, 
converts T4 to T3 in the endoplasmic reticulum near the nucleus.  The high catalytic efficiency of D2 
is important in protecting the cell against hypothyroidism.  D2 is also important in thyroid hormone 
feedback regulation of TRH and TSH, converting circulating T4 to T3 so that appropriate negative 
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feedback can take place in proportion to circulating serum levels of thyroid hormone.  D2 can be 
inactivated by ubiquitination, which is triggered by deiodination of T4 (St Germain et al., 2009).  
Deiodination of T4 exposes lysine residues on D2, which become conjugated to ubiquitin.  This 
complex can be deubiquitinated and reactivated to continue deiodination or can become degraded 
(Bianco and Kim, 2006, Waung et al., 2012). 
 
Inactivation of T3 and T4 occurs by D3 deiodination to 3, 3’-diioeothyronine (T2) and T4 to 3,3’,5’-
triiodothyronine (rT3), respectively.  Thus, the intracellular availability of thyroid hormone can be 
fine tuned independently of circulating thyroid levels (see Figure 1.14). 
 
 
 
 
 
 Figure 1.14 Deiodinase activation and inactivation of thyroid hormone 
 Prohormone T4 is monodeiodinated to either the active hormone T3 or inactive metabolite 
rT3 by the action of iodothyronine deiodinase 1 and 2 (D1 and D2) or D1 and D3 respectively.  
T3 or rT3 can be further monodeiodinated to inactive metabolite 3,3’-diiodothyronine (T2). 
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1.4.4 MOLECULAR MECHANISMS OF THYROID HORMONE ACTION 
The principal action of thyroid hormone is via the two nuclear thyroid receptors, thyroid hormone 
receptor alpha (TRα) and thyroid hormone receptor beta (TRβ).  Three functional mRNA isoforms 
exist: TRα1, TRβ1 and TRβ2 (Cheng, 2000). 
Gothe et al compared mice devoid of TRα1 and all TRβ receptors with controls and found that these 
mice had a phenotype which was more severe (hyperactive pituitary-thyroid axis, poor female 
fertility, retarded growth and bone maturation) than mice lacking TRα1 or TRβ individually.  They 
concluded that the absence of either TR could be substituted, to a degree, by the other.  They also 
rendered TRα1-/- and TRβ
-/- mice hypothyroid with no detectable change in weight, in contrast to the 
control mice that lost 7.8% of their weight in 3 weeks.  This suggested that TRα1 and TRβ provide the 
principal means by which thyroid hormone action is mediated (Gothe et al., 1999). 
 
1.4.4.1 Thyroid hormone receptors 
Thyroid hormone receptors belong to the nuclear receptor superfamily (Williams and Franklyn, 
1994).  Other members of this group include sex steroids, adrenal steroids, vitamin D3 and retinoid 
receptors.  These receptors specifically regulate target genes involved in metabolism, development 
and reproduction.  Nuclear receptors are ligand inducible transcription factors which, when bound 
to hormones, mediate transcriptional response in target genes by binding to hormone response 
elements in the promoter region of responsive genes.  Nuclear receptors have a similar structure 
consisting of a series of functional domains (Cheng et al., 2010). 
The functional domains consist of: 
1. Amino-terminal A/B domain which varies highly between isoforms.  This is where the N-terminal 
activation function1 domain (AF) is located. 
2. The C domain contains the central DNA binding domain (DBD) which is highly conserved and has 
two zinc finger subdomains which bind to TREs.  This domain also contains motifs important in homo 
and hetero dimerisation. 
3. The hinge domain which contains a nuclear localisation signal, which is involved in transporting 
the receptor into the nucleus. 
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4. The E/F domain contains the carboxyl-terminal ligand-binding domain (LBD) which can bind to 
thyroid hormones, corepressors and coactivators.  The E domain contains the AF2 and another 
nuclear localisation signal. 
TRs bind to TREs in DNA both as homodimers and more frequently as heterodimers with retinoid X 
receptor (RXR). TREs commonly consist of either two half-site sequences (AGGTCA) or a repeat of 
the half site sequence separated by zero, four or six nucleotides (Lazar, 1993).  Binding of the homo 
or heterodimer is via specific grooves in the two ‘zinc fingers’ of the DBD.   Cofactors and 
corepressors are recruited and interact with the TR and transcriptional machinery to either result in 
activation or repression of gene transcription. 
 
 
 
 
 
 
 
  
Figure 1.15 Structure of steroid hormone and TR isoforms 
(A) The structure of steroid hormone receptors classically has an A/B 
domain which is the N-terminal and AF1, the C domain, which is 
involved in DNA binding, D domain is the hinge domain and E/F domain 
contains the C-terminal and AF2 and which is important in thyroid 
hormone binding and co activator and co repressor binding. 
(B) The different isoforms of the receptors are shown with a summary of 
whether each is a functional receptor, its T3 binding properties, DNA 
binding and whether it forms heterodimers. 
Taken from Bassett 2003 (Bassett and Williams, 2003). 
(C)  
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1.4.4.2 Thyroid receptors are differentially temporally and spatially expressed 
Thra and Thrb genes on chromosomes 17 and 3 respectively, transcribe three functional mRNA 
isoforms: TRα1, TRβ1 and TRβ2 (Cheng et al., 2010). 
The TRα locus also encodes TRα2, TRΔα1 and TRΔα2, which lacks the DNA binding domain of TRα1.  
TRα1 binds T3 and is the predominant thyroid receptor expressed in the brain, heart and bone 
(Forrest et al., 1990).  The delta isoforms TRΔα1 and TRΔα2 are driven by a promoter in intron 7 and 
lack both a DNA binding domain and part of the ligand binding domain (LBD) (Chassande et al., 
1997).  They inhibit the actions of TRs in vitro (Gauthier et al., 2001) but their role in vivo is still 
uncertain (see Figure 1.15). 
TRβ1 is the major receptor in the liver, skeletal muscle, kidney and fat whilst TRβ2 is the 
predominant receptor expressed in the pituitary, hypothalamus, retina and cochlea.  The TRβ locus 
also encodes for TRβ3 and TRΔβ3 (Williams, 2000); their roles in vivo remain unclearly defined. 
TRs heterodimerise with RXR and bind to DNA sequences TREs.  Heterodimerisation with RXR 
increases binding of TRs to TRE thus increasing transcriptional activation (Zhang and Kahl, 1993, 
Cheng, 2000). 
 
1.4.4.3 Coactivators and corepressors 
In the absence of T3, unliganded TR/RXR dimers are known as aporeceptors and are bound to DNA 
along with complexes of co repressors.  Co repressors include nuclear receptor co repressor (NCOR) 
and silencing mediator of retinoid and thyroid hormone receptors (SMRT), which bind to the TR via 
the C-terminal LBD (see Figure 1.15).  Corepressors have chromatin deacetylase activity, which 
maintains the chromatin in a compact repressed state, thereby blocking access to basal 
transcriptional machinery (see Figure 1.16).  In the absence of T3, aporeceptors therefore mediate 
repression or silencing of the basal transcription of target genes (Cheng et al., 2010, Chatterjee et al., 
1989, Glass et al., 1989). 
Liganded TR are known as holoreceptors and in the presence of T3, there is a conformational change 
in the TR/RXR complex leading to release of co repressors and recruitment of complexes of 
coactivators such as steroid receptor coactivator-1 (SRC1) and cAMP response element binding 
protein.  Many co-activators belong to the SRC/p160 family, which share approximately 40% 
homology and have functional properties including DNA binding and dimerisation interaction 
regions.  Other complexes are also present, such as the TR-associated protein, which have 
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chromatin-free transcriptional enhancing properties and interact with TR in response to T3 (Harvey 
and Williams, 2002).  Coactivators directly or indirectly result in basal transcriptional machinery 
activation which promotes transcription and histone acetylation.  This leads to an open chromatin 
structure and allows transcriptional activation by nuclear receptors. 
The proportion of apo versus holo TRs may be a mechanism of control of T3 action.  Furthermore, 
the repressive effects of apo versus holo TRs serve to augment the amplitude of the transcriptional 
response to thyroid hormone. 
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Figure 1.16 TR control of gene expression.  
Diagram taken from J. Bernal 2007 with permission (Bernal, 2007). 
TR, usually as heterodimers with RXR but also as homodimers, bind to TRE in the regulatory region of target genes.   
In the absence of hormone binding, the unliganded receptor recruits corepressors such as NCoR and SMRT and 
histone deacetylases, which maintain the chromatin in a compact repressed state. 
(A) In the presence of T3 there is a release of corepressors and recruitment of coactivators such as SRC-1, 
histone acetylases (CBP, p300 and pCAF) and other mediators such as TRAP and DRIP, which facilitate 
transcriptional machinery access to the promoter. 
(B) In the absence of TR, there is lack of repression and the receptor may facilitate transcription of other 
transcription factors (basal transcription). 
(C) In the presence of a mutation in the hormone binding domain which blocks T3 binding but with intact DNA 
binding, a repressed chromatin state remains. 
CBP-CREB-binding protein; DRIP- vitamin D receptor-interacting protein; HDAC- histone deacetylase; NCoR- nuclear 
receptor corepressor; pCAF- mammalian homologue of the yeast transcriptional activator GCN5; RNA Pol II- RNA 
polymerase II; RXR- 9-cis retinoic acid receptor; SRC-1- steroid receptor coactivator 1; SMRT- silencing mediator for 
retinoic and thyroid receptor; TAF- transcription initiation factor; TBP- TATA box binding protein; TFIIA- transcription 
initiation factor IIA; TR- thyroid hormone receptor; TRE- thyroid hormone response element; TRAP- thyroid-
hormone-receptor-associated protein. 
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1.4.5 THE EFFECTS OF CIRCULATING THYROID HORMONE LEVELS ON THE SKELETON 
1.4.5.1 Hypothyroidism in humans 
The skeletal effects of hypothyroidism during childhood are characterised by delayed bone age, 
failure to close fontenelles, epiphyseal dysgenesis and growth arrest.  Treatment results in catch up 
growth with acceleration of bone age and rapid linear growth but may result in compromise of final 
height (Rivkees et al., 1988).  Histomorphometric studies in hypothyroid adults showed reduced 
osteoid apposition suggesting impaired osteoblast activity, a prolonged period of secondary bone 
mineralisation and decreased resorption parameters.  Despite a reduction in bone remodelling, 
there is a net positive bone balance resulting in an increased BMD (Eriksen et al., 1986).  Population 
studies suggest that patients with a prior history of hypothyroidism have a 2-3 times increase in 
relative fracture risk up to 10 years after diagnosis (Vestergaard et al., 2005). 
1.4.5.2 Animal models of hypothyroidism 
Different animal models have been used to study the effects of hypothyroidism on bone. 
1.4.5.2.1 Wild type animals rendered hypothyroid 
Several groups have induced hypothyroidism by thyroidectomy (Lanham et al., 2011) or via the 
administration of drugs such as Propylthiouracil (PTU), methimazole or potassium perchlorate (Allain 
et al., 1995, Conti et al., 2009). 
Adult animals with hypothyroidism develop an increased bone mass.  This was demonstrated by an 
elevated bone volume per tissue volume (BV/TV) (Allain et al., 1995), a higher ash calcium content 
(Conti et al., 2009) and increased BMD when compared with euthyroid controls. 
Histomorphometric parameters were assessed in 18 week old rats which were rendered hypothyroid 
for 12 weeks (Allain et al., 1995).  This resulted in elevated BV/TV accompanied by a marked 
decrease in osteoid, mineral apposition (MA) and eroded surface per bone surface (BS).  These 
results suggest that the increase in bone was secondary to decreased osteoclast resorption. 
Conti at al rendered juvenile 13 week old rats hypothyroid for 10 weeks which resulted in growth 
retardation with decreased weight and length.  They were found to have higher calcium 
concentration when ashed and higher femoral bone mass.  Mechanical properties were assessed 
and femoral stiffness (elastic modulus) but no other biomechanical parameters of hypothyroid 
animals were greater than controls (Conti et al., 2009).  Lanham et al assessed structural and 
mechanical properties in ovine foetuses post thyroidectomy and found that there was no change in 
cortical thickness compared to controls but a decrease in cortical diameter.  The trabecular bone had 
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thicker, more closely spaced trabeculae, despite having a lower BMD.  Serum bone markers showed 
decreased osteocalcin but C-terminal cross-linked telopeptide of type I collagen (CTX) was no 
different to controls, suggesting that hypothyroidism in utero affects bone formation to a greater 
extent than resorption.  Mechanical testing of hypothyroid foetal femurs compared to controls did 
not show significant differences in parameters.  However, mechanical testing of trabecular bone in 
hypothyroid animals resulted in a failure at a higher maximum load and higher stiffness and stress 
than controls (Lanham et al., 2011).  Capelo et al rendered pregnant mice hypothyroid and examined 
the bone development and growth plates of foetal tissue. Their findings suggested that up to 
embryonic day 16.5, thyroid hormone signalling was kept to a minimum, with little differences 
compared to controls.  Low thyroid hormone signalling was maintained by elevated levels of D3.  
After this stage, by embryonic day 18.5, D2 expression, which was previously low, was markedly 
increased (Capelo et al., 2008). 
 
1.4.5.2.2 Pax8-/- , Hyt/hyt and Duoxa-/- mice 
The skeletal phenotype of some knockout mice with mutations resulting in severe hypothyroidism 
has been described in detail in the literature. 
Pax8-/- mice lack a transcription factor essential for the development of the thyroid gland and have a 
complete absence of thyroid follicular cells, with a consequent lack of thyroid hormone in post natal 
life.  These mice die at weaning unless treated for a short period with thyroid hormone (Flamant et 
al., 2002, Mansouri et al., 1998).  Pax8-/- mice have a skeletal phenotype typical of severe 
hypothyroidism, including severe delay in growth and ossification, more coarse and plate-like 
trabeculae and increased connectivity with retention of mineralised calcified cartilage, suggestive of 
a bone remodelling defect (Bassett et al., 2008). 
Hyt/hyt mice have a non functional TSHR and are grossly hypothyroid, exhibiting a skeletal 
phenotype very similar to that of Pax8 mice. They exhibit delayed ossification, reduced cortical bone, 
a trabecular bone remodelling defect and decreased bone mineralisation (Bassett et al., 2008). 
Duoxa-/- mice lack DUOX protein (which is critical for the generation of thyroid H2O2), have 
undetectable serum thyroid levels and grossly elevated TSH levels.  These mice died if weaned at 
P21 but if they were weaned at P30, then some of them survived into adulthood.  Although the 
skeletal phenotype for these mice has not been described in detail, mice at P13 exhibit impaired 
long bone growth, delayed ossification and reduced bone mineralisation (Grasberger et al., 2012). 
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In summary, animal models of hypothyroidism have similar skeletal findings to those found in 
human data (Eriksen et al., 1986), indicating that in the hypothyroid mature skeleton, there is an 
increase in bone mass, which is secondary to decreased osteoclast resorption.  Hypothyroidism also 
depresses osteoblast function, resulting in reduced MA and reduced presence of osteoid.  There is 
also a suggestion that osteocytes may be affected as there is a decrease in secondary mineralisation.  
Biomechanical animal data suggests that hypothyroidism may result in stronger (higher maximum 
load) but more stiff bones. 
 
1.4.5.3 Thyrotoxicosis in humans 
Hyperthyroidism in childhood results in accelerated growth and bone age, and premature fusion of 
growth plates leading to short stature and craniosynostosis (Segni et al., 1999). 
Thyroid disease occurs 10-fold more frequently in women and its prevalence increases with age.  As 
a result, 3% of the 12 million women over the age of 50 in the UK receive thyroxine (T4) for either 
primary hypothyroidism or the consequences of surgical or radioiodine treatment for thyrotoxicosis, 
and more than 20% of them are over-treated (Parle et al., 1993). 
In adults, thyrotoxicosis results in osteoporosis and an increased fracture risk (Vestergaard and 
Mosekilde, 2003).  Large population studies in patients with a history of hyperthyroidism have 
shown a reduced BMD, increased serum bone turnover markers and increased fracture rates 
(Cheung et al., 2011). 
Histomorphometric studies in thyrotoxic patients reveal high bone turnover osteoporosis stemming 
from increased activation frequency of remodelling units.  The reduced duration of the bone 
remodelling cycle coupled with increased bone resorption parameters results in a net negative bone 
balance (Eriksen, 1986, Mosekilde and Melsen, 1978). 
1.4.5.4 Animal models of hyperthyroidism 
1.4.5.4.1 Wild type animals rendered thyrotoxic 
Adult mice with hyperthyroidism have decreased bone mass although some studies suggest that this 
is site specific only.  Ongphiphadhanaku et al reported that three weeks of treatment with T4 in rats 
reduced femoral but not vertebral BMD (Ongphiphadhanakul et al., 1992). No decrease in BV/TV 
was noted at the vertebral body (Balena et al., 1993, Yamamoto et al., 1993). 
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Histomorphometric evaluation of adult rats treated with T4 for 3 weeks resulted in a 45% decrease 
in BV/TV compared to controls, which exhibited a 32% reduction in trabecular number (Tb.N) and a 
modest but not significant decrease in trabecular thickness (Tb.Th) in the tibia (Balena et al., 1993).  
This loss in bone mass was secondary to a high turnover osteoporosis.  Osteoclast surface (Oc.S) per 
BS was increased by 40% in the T4 treated tibias.  An increase in mineral apposition rate (MAR) and 
mineral formation rate per BS in thyrotoxic mice compared to controls was reported by Allain et al, 
with a slight increase in eroded surfaces (Allain et al., 1992). 
Mechanical properties of bones from thyrotoxic animals have not been reported in the literature. 
In summary, studies in humans and animals demonstrate that thyrotoxicosis results in a high 
turnover osteoporosis, the effect of which is site specific. 
 
1.4.6 THE ROLE OF THYROID HORMONE TRANSPORTERS AND DEIODINASES IN THE SKELETON 
Mutations in genes controlling thyroid hormone transporters and deiodinases provide key 
information on what role these proteins play in the skeleton. 
1.4.6.1 Thyroid hormone transporters 
Inactivating mutations in MCT8 lead to a lack of thyroid hormone transport into cells and results in 
Allan Herndon Dudley Syndrome.  Although patients with this syndrome suffer severe global 
developmental delay (Heuer and Visser, 2012) due to a lack of thyroid hormone transport into 
neurons, growth in these patients is reportedly unaffected.  Based on these observations, Abe et al 
examined the mRNA expression of several different thyroid hormone transporters in ATDC 5 
chondrocyte cell lines and found that MCT10 was the most highly expressed.  MCT10 was also found 
to be highly expressed in the resting growth plate zone, whilst MCT8 and OAT1c1 were minimally 
expressed (Abe et al., 2012).  Capelo et al showed that osteoblasts and MC3T3 osteoblast-like cell 
lines expressed MCT8, LAT1 and LAT2, but not OATP1 and NTCP.  These transporters were up 
regulated in hypothyroidism and down regulated on treatment with T3.  They did not, however, 
examine the expression of the MCT10 transporter (Capelo et al., 2008).  The current data suggests 
that thyroid hormone transporters are cell type specific, and that in the growth plate, MCT10 is the 
principal transporter, unlike in neurons, where MCT8 is the most significant thyroid hormone 
transporter. 
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1.4.6.2 Thyroid hormone transporter deficient mice 
The role of thyroid hormone transporters in bone development has yet to be comprehensively 
studied but of the published knockout mice that do exist, only growth parameters have been 
reported.  Mice lacking MCT8 (Trajkovic et al., 2007) were noted to have similar growth to that of 
wild type controls.  MCT8 is expressed in ATDC5 and MC3T3 cell lines, primary osteoblasts and 
primary osteoclasts.  In vitro studies show that silencing MCT10 in ATDC5 cells reduces the 
proliferative effects of thyroid hormone (Abe et al., 2012) but studies of mice lacking MCT10 have 
not been published.  Mice deficient in the thyroid hormone transporters Lat2 and Oatp1c1 have 
reportedly normal growth but full skeletal phenotyping is awaited (Braun et al., 2011, Mayerl et al., 
2012).  Growth preservation in these knockout mice gives us limited information but suggests a 
degree of compensation within skeletal tissue, with consequent preservation of growth. 
 
1.4.6.3 Deiodinases 
In mice, high D3 levels during early foetal bone development results in minimal thyroid hormone 
signalling.  Towards the end of gestation, there is a steep rise in D2 and a decrease in D3, resulting in 
an acceleration in bone development (Capelo et al., 2008).  In adult mice, D2 is present in whole 
bone and osteoblasts but is absent in chondrocytes and osteoclasts, D3 is present in chondrocytes, 
osteoblasts and osteoclasts, but D1 is not detectable in any bone cells (Williams and Bassett, 2011, 
Bassett et al., 2010). 
1.4.6.3.1 Deiodinase deficient mice 
The role of deiodinase enzymes in the skeleton has been extensively studied in knockout mice.  Mice 
deficient in D2, have a decreased intracellular availability of T3 and affected cells have decreased 
thyroid signalling, despite normal circulating thyroid hormone status.  Growth and development 
were normal in these mice but adult D2KO mice bones had reduced toughness and were brittle.  
Bone formation was decreased due to local deficiency of T3 in osteoblasts (Bassett et al., 2010), 
indicating that D2 in osteoblasts is essential in adult skeletal homeostasis.  Studies of D1/D2 double 
knockout mice have been published and although their skeletal phenotype has not been 
comprehensively analysed, the weight of the adult mice was lower than controls (Galton et al., 
2009).  D3 knockout mice have a 35% reduction in body weight at weaning with persistence of 
severe growth retardation.  These global knockout mice have neonatal thyrotoxicosis followed by 
central hypothyroidism that persists in later life.  This extreme thyroid function derangement makes 
interpretation of the skeletal response complicated (Hernandez et al., 2006). 
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1.4.7 THE ROLE OF TRS IN THYROID HORMONE SIGNALLING IN THE SKELETON  
Changes in TRα and TRβ, both in humans and in animal models, provide evidence for the complex 
interactions of thyroid receptors in the tissue specific regulation of thyroid hormone signalling. 
In the skeleton, TRα is expressed in ten-fold greater concentrations than TRβ (Bookout et al., 2006, 
O'Shea et al., 2003).  Osteoblasts express TRα1, TRα2 and TRβ1 as do reserve and proliferative 
chondrocytes (Bassett and Williams, 2009).  It is not known which receptors are expressed in 
osteocytes or osteoclasts. 
1.4.7.1 Thyroid hormone receptor alpha mutations in humans 
Analysis of 19,195 Caucasians did not reveal any associations between a set of 14 polymorphisms in 
THRA and either BMD or fracture risk (Medici et al., 2012).  However, heterozygous human 
mutations in THRA have been reported in a 6 year old (Bochukova et al., 2012) and a father and 
daughter, all of whom showed classical features of hypothyroidism (van Mullem et al., 2012, 
Bochukova et al., 2012).  Serum measurements of thyroid hormones showed T4 in the low normal 
range, elevated T3 and TSH in the normal range.  Serum IGF1 levels were reduced.  Skeletal 
radiographs demonstrated patent cranial fontanelles with delayed closure of cranial sutures, 
multiple wormian bones, delayed tooth eruption, femoral epiphyseal dysgenesis and delayed bone 
age. 
 
1.4.7.2 TRα knockout mice 
Chassande et al generated a TRα knockout mouse (TRα-/-) but as a result, a previously unknown 
promoter within intron 7 was discovered, resulting in production of the truncated isoforms Δα1 and 
Δα2 (Chassande et al., 1997).  Consequently, full TRα knockout mice (TRα0/0) were generated which 
lack all TRα isoforms (Gauthier et al., 2001, Macchia et al., 2001, Pelletier et al., 2008). 
During growth, TRα0/0 mice have normal circulating thyroid hormone levels.  Skeletal phenotyping 
during growth and in adulthood shows divergence.  During growth, TRα0/0 mice have a reduced 
cortical bone diameter compared to wild type mice at P21, delayed endochondral ossification and 
reduced mineralisation. As adults, TRα0/0 mice have similar cortical bone diameters compared to 
controls and are osteosclerotic, with increased bone fraction and reduced bone resorption - a 
phenotype very similar to that of hypothyroid mice (Bassett et al., 2007a). 
Accordingly, skeletal expression of the T3 target genes FGFRs 1 and 3 was reduced (Barnard et al., 
2005, O'Shea et al., 2003, Stevens et al., 2003), suggesting that skeletal thyroid hormone signalling 
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was reduced in TRα0/0 mice.  As TRα is the predominant receptor in bone, it has been proposed that 
skeletal thyroid signalling is reduced in TRα0/0 mice (Bassett and Williams, 2009).  Although bone 
formation parameters in TRα0/0 mice have not been published, one would expect them to be 
reduced, as with hypothyroid mice. 
 
1.4.7.3 Other TRα mutant mouse models 
Several dominant negative mutations of TRα have been generated (Kaneshige et al., 2001, Liu et al., 
2003, O'Shea et al., 2003, Quignodon et al., 2007, Tinnikov et al., 2002).  The different mutations, 
depending on the location of the mutation, result in varying degrees of dominant negative TR 
activities.  This is clearly evident in the mutant mice and is also likely to be the case in affected 
humans with mutations in TRs.  Mutations in TRα1PV/+ mice (dominant-negative PV mutation was 
identified based on a mutation in a patient with known severe resistance to thyroid hormone) 
resulted in severely delayed growth and bone maturation, diminished trabecular mineralisation and 
reduced cortical thickness.  Adult mice have a severe phenotype, with osteosclerosis and greatly 
increased mineralisation.  Dynamic bone formation has not been reported in these mice but 
osteoclastic bone resorption is decreased (O'Shea et al., 2005).  TRα1+/m mice harbour a milder 
resistance to thyroid hormone (RTH) mutation than TRα1PV/+ mice, the latter also displaying a 
transient period of hypothyroidism between P10 and P35.  During growth, these mice had delayed 
endochondral ossification, reduced cortical width and abnormal bone modelling, which remained 
after the cessation of growth.  Trabecular bone was similar to controls during development but 
increased as adults, where there was increased mineralisation with retention of calcified cartilage.  
Adult mice had reduced resorption in both cortical and trabecular compartments but dynamic bone 
formation parameters have not been reported.  The skeletal abnormalities seen in these mice were 
rescued when they were crossed with TRβ-/- mice as the elevated thyroid hormone levels allowed 
TRα1+/m to bind to thyroid hormone and activate target genes (Bassett and Williams, 2009). 
 
1.4.7.4 RTH in humans 
Dominant negative mutations in TRβ genes result in a loss in negative feedback in the hypothalamus 
and pituitary gland, giving rise to the clinical syndrome RTH (Refetoff, 1993).  RTH is characterised by 
an end organ RTH, leading to elevated levels of T4 or T3, with inappropriately normal or slightly 
increased serum TSH responsiveness to TRH stimulation.  Diagnosis is confirmed on characteristic 
serum thyroid function tests and a lack of suppression of TSH responsiveness in the presence of 
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elevated T3.  The signs and symptoms of patients with RTH vary widely, with some tissues suggestive 
of hypothyroidism whilst others suggestive of thyrotoxicosis (Weiss and Refetoff, 2000).  The skeletal 
phenotype of patients with RTH can vary widely.  Some may be severely affected, having short 
stature, advanced bone age, increased bone turnover, osteoporosis, craniofacial abnormalities, 
osteoporosis and fractures, whilst other patients can have normal stature and development (Weiss 
and Refetoff, 1996). 
Patients with RTH have a disruption of the HPT axis due to tissue insensitivity, resulting in elevated 
serum thyroid levels but end organ responsiveness in the skeleton and, consequently, increased 
signalling in the skeleton.  Although the skeletal phenotype of these patients has been quite 
variable, animal models have allowed closer investigation of the role of TRβ and its effects on the 
skeleton. 
 
1.4.7.5 TRβ Knockout mice 
Two TRβ-/- mice lacking all TRβ isoforms have been generated (Forrest et al., 1996, Gauthier et al., 
2001, Ng et al., 2001).  Heterozygous animals are unaffected but due to the lack of negative 
feedback on the HPT axis, TRβ-/- mice have elevated circulating TSH and serum T3 and T4 levels.  
During growth, TRβ-/- mice show advanced skeletal maturation with accelerated chondrocyte 
differentiation, endochondral ossification and short stature due to premature growth plate 
quiescence.  In maturity, these mice are osteoporotic with reduced micro-mineralisation.  Bone 
resorption is increased as shown by increased osteoclast resorption surfaces and increased number 
of osteoclasts per BS (Bassett et al., 2007b).  Dynamic bone formation parameters and mechanical 
properties have not been published (Bassett and Williams, 2009). 
 
1.4.7.6 Other TRβ mutant mouse models 
Mouse models have been generated with dominant negative mutations in TRβ, based on a mutation 
in a patient with known severe RTH (Hashimoto et al., 2001, Kaneshige et al., 2000).  These mice 
have a severe RTH phenotype with 400-fold elevation of TSH and a 15-fold elevation of circulating 
T4.  TRβ PV/PV mice have accelerated in utero ossification and growth.  The juvenile mice show a 
premature cessation of growth, advanced endochondral ossification and increased mineralisation 
(Bassett et al., 2007a).  There is early quiescence of the growth plate by 3 weeks, resulting in 
shortened bone length and persistent growth retardation.  The adult mice have reduced final length 
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with reduced tibia and ulna length.  The complete adult skeletal phenotype has not yet been 
published. 
 
1.4.7.7 What studies of TR0/0 and TR-/- mice have revealed about the roles of TRs in thyroid 
signalling 
TR0/0 and TR1PV dominant-negative mutant mice are euthyroid but have delayed ossification and 
reduced bone mineralisation.  These changes are consistent with decreased thyroid hormone 
signalling in the skeleton (Bassett et al., 2007b, Bassett and Williams, 2009).  By contrast, TR-/- 
knockout and TRPV mutant mice have elevated circulating thyroid hormone levels, and display 
advanced ossification with increased bone mineralisation, features which are consistent with 
increased thyroid signalling in the skeleton (O'Shea et al., 2003, Bassett and Williams, 2009 , 
Kaneshige et al., 2000).  It has been proposed that these opposing phenotypes arise because the 
pituitary is TR-responsive, whereas bone is predominantly TR-responsive.  Disrupted TR function 
leads to impaired feedback inhibition of TSH in the pituitary (Bassett et al., 2007a, Waung et al.), 
resulting in elevated T4 and T3 levels, which act via TR in bone to induce increased thyroid 
signalling in the skeleton.  By contrast, decreased thyroid signalling in the skeleton in TR mutants 
may result from impaired TR function in bone (Bassett and Williams, 2009).  Analysis of adult 
TR0/0 and TR-/- mice is consistent with these findings.  Adult trabecular bone in TR0/0 mice is 
increased, whereas TR-/- mice are osteoporotic.  These findings in TR0/0 mice are also seen in 
TRα1PV dominant-negative mice (Kaneshige et al., 2001, Tinnikov et al., 2002).  Thus, deletion or 
mutation of TR causes an increase in trabecular bone mass in adult mice, suggesting that TR 
regulates bone maintenance in adults as well as regulating bone formation and mineralisation during 
growth.  Additionally, the finding that increased TR activity in adult TR-/- mice causes osteoporosis 
indicates that the level of TR activity determines acquisition of peak bone mass during growth as 
well as the efficiency of adult bone maintenance. 
 
1.4.7.8 Double thyroid receptor knockout mice 
Mice with absent TRα or TRβ transcripts were generated by crossing TRα0/0 with TRβ-/- mice (Gothe 
et al., 1999, Flamant et al., 2002).  Although these mice were viable, they had severely delayed 
growth, delayed endochondral ossification, impaired chondrocyte differentiation and reduced 
mineralisation.  No dynamic bone formation or osteoclast parameters have been reported in adult 
TRα0/0TRβ-/- mice. 
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1.4.7.9 The role of aporeceptors 
Dominant negative mutations in TRα result in a more severely affected skeletal phenotype than in 
the absence of TRα alone.  The mechanism for this was recently explored by Fozzatti et al when they 
crossed TRα1PV/+ mice with NCOR1ΔID/ ΔID mice; the latter globally express a mutant NCOR protein 
leading to an inability to interact with TR or with the PV mutant.  NCOR is a protein which mediates 
transcriptional repression when recruited by unliganded TRs.  NCOR1ΔID/ ΔID mice have increased 
sensitivity to thyroid hormone and have reduced levels of T3 and T4 but normal levels of TSH.  
Although the skeletal phenotype of these mice was not comprehensively described, the reduced 
IGF1 levels in TRα1PV/+ mice were normalised in TRα1PV/+ NCOR1ΔID/ ΔID mice and the length of femurs 
was also partially rescued, suggesting that the dominant negative actions of TRα1PV are in part due 
to a defective ability of the mutant TR to release the corepressor NCOR1 (Fozzatti et al., 2013). 
The most detrimental effects of hypothyroidism are in mice with defects of thyroid gland agenesis 
such as in Pax8-/- mice, where they do not survive beyond weaning, and is more severe than in the 
absence of TRα alone or dominant negative models such as TRα1PV/PV.  Flamant et al reported that 
the severe phenotype of Pax8-/- mice can be partially rescued by eliminating TRα, suggesting that 
unliganded TRα (apo TRα) was responsible for the severe phenotype.  This suggestion was 
challenged by Mittag et al who generated Pax8-/-TRα1-/-  compound mutants, which similar to Pax8-/- 
mice, die shortly after weaning (Flamant et al., 2002, Mittag et al., 2005).  This may suggest a role for 
TRα2 which is non DNA binding and has unknown function. 
 
1.4.8 IMPORTANT SIGNALLING PATHWAYS INVOLVED IN THYROID ACTION IN THE SKELETON 
The growth plate is extremely sensitive to thyroid hormone dysregulation during growth.  
Hypothyroidism results in delayed bone age, however this delayed maturation accelerates and 
corrects on treatment with thyroid hormone if treated early enough but can result in compromised 
final height (Rivkees et al., 1988).  Conversely, thyrotoxicosis results in advanced bone age with 
premature fusion of the growth plate. 
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In 1955, Fell and Mellanby established that thyroid hormone has the direct effect of stimulating 
chondrocyte maturation in vitro by studying the bones of embryonic chicks.  Burch et al also 
demonstrated that porcine scapula and pelvic growth plate cartilage had increased growth and 
maturation on stimulation with thyroxine in vitro (Fell and Mellanby, 1955, Burch and Van Wyk, 
1987).  Other in vitro work looking at markers of chondrocyte differentiation, such as synthesis of 
type X collagen, AP and cellular hypertrophy, have shown similar effects of thyroid hormone (Burch 
and Van Wyk, 1987, Ballock and Reddi, 1994, Ohlsson et al., 1992, Quarto et al., 1992). 
The relationship between thyroid hormone and the growth hormone/insulin-like growth factor-1 
(GH/IGF1) axis was studied using mice with a dominant-negative TRα (TRα1pv/+) and mice with a 
dominant-negative TRβ (TRβpv/pv).  TRα is the predominant isoform in bone and TRα1pv/+ mice have 
decreased thyroid signalling in the skeleton whereas TRβ is the predominant isoform in the HPT axis 
and TRβpv/pv mice have elevated circulating serum thyroid hormone resulting in increased signalling 
via intact TRα in the skeleton.  O’Shea et al demonstrated normal GH production but reduced 
growth plate chondrocyte GH receptor (GHR) and IGF1 expression in TRα1pv/+ mice.  They also 
demonstrated decreased GH production and increased GHR and IGF1 expression in TRβpv/pv mice, 
suggesting that thyroid hormone has a role in the regulation of the GH/IGF1 axis (O'Shea et al., 
2006). 
The mechanism by which thyroid hormone alters the rate of growth plate maturation is in part via 
the Ihh/PTHrP axis in the growth plate.  PTHrP acts on its receptors in the prehypertrophic 
Figure 1.17 Key signalling pathways in the growth plate 
This diagram illustrates some of the key signalling pathways in the growth plate.  GH 
and thyroid hormone act on factors secreted by chondrocytes to modify chondrocyte 
proliferation and hypertrophy. See text for more details. 
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chondrocytes to maintain cells in a proliferative state and prevents maturation of cells into 
hypertrophic chondrocytes and is therefore important in the Ihh/PTHrP feedback loop (see previous 
section on chondrocytes).  Hypothyroid animals have increased PTHrP mRNA expression in the 
growth plate (Stevens et al., 2000).  Thus, the growth impairment seen in hypothyroidism is likely to 
be a result of increased expression of PTHrP in the growth plate.  In contrast, growth plates of 
thyrotoxic animals have undetectable expression of mRNA PTHrP receptors.  This results in elevated 
chondrocyte differentiation, thereby resulting in accelerated maturation and early fusion of growth 
plates (Mackie et al., 2011, Dentice et al., 2005, Stevens et al., 2000). 
T3 also acts via FGFRs and there is increased expression of FGFR1 and FGFR3 mRNA and enhanced 
FGFR2 activation.  FGFR3 activation in humans results in acceleration of chondrocyte maturation and 
achondroplasia.  In TRα0/0 mice with decreased skeletal thyroid hormone signalling, there is reduced 
expression of FGFR3, whilst in TRβ-/- mice with increased skeletal thyroid hormone signalling, there is 
increased FGFR3 expression, suggesting that FGFR3 may be mediating the action of thyroid hormone 
on chondrocyte proliferation (Barnard et al., 2005). 
In osteoblasts, T3 stimulates cell proliferation, differentiation and apoptosis.  Treatment with T3 
enhances expression of collagen I, osteocalcin, ALP, MMP9 and MMP13 (Gouveia et al., 2001, 
Pereira et al., 1999, Varga et al., 2010).  In vitro osteoblast studies have demonstrated that T3 signals 
indirectly through the FGFR1 pathway.  FGFR1 dependent FGF2 signalling stimulates MAPK in 
osteoblasts via TRα.  Accordingly, Stevens et al showed decreased thyroid hormone signalling in 
TRα0/0 mice, with osteoblasts and osteocytes having reduced FGFR1 mRNA expression and an 
absence of T3 stimulated increase in FGFR1 response (Stevens et al., 2003). 
Although thyroid hormone clearly increases resorption in vivo, the mechanism by which TH acts in 
osteoclasts is unclear.  Osteoclasts express TRα and TRβ mRNA but it is unclear if TR proteins are 
expressed (Abu et al., 2000, Robson et al., 2000).  Identifying TR protein expression in skeletal cells is 
unreliable because available antibodies cannot detect low levels of endogenous TRs expressed in 
target tissues, even though they are specific and reliable for measurement of TR over-expression in 
vitro or following transfection (Abu et al., 2000, Kanatani et al., 2004, Robson et al., 2000, Stevens et 
al., 2000, Williams and Franklyn, 1994, Bassett and Williams, 2003, Saraiva et al., 2008).  
Experimental data as to whether thyroid hormone acts directly or via a secondary cell such as 
osteoblasts, is conflicting in the literature.  Kanatani et al demonstrated that T3 directly stimulates 
spleen derived osteoclast formation (Kanatani et al., 2004).  By contrast, Allain et al reported that 
the resorptive activity of calvarial derived osteoclasts did not increase with T3, corroborating 
findings by Miura et al suggesting that thyroid hormone stimulation of osteoclast activity is 
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secondary to action in osteoblasts (Allain et al., 1992, Miura et al., 2002, Harvey and Williams, 2002).  
Currently, it is not known if TRs are expressed in osteocytes and further studies are needed to detail 
the cell specificity and temporal expression of TR. 
To summarise, thyroid hormones are essential in the normal development and maintenance of the 
healthy skeleton.  T3 availability is finely controlled on a systemic and cellular level.  Disruption to 
thyroid signalling can result in compromise to skeletal health. 
 
1.4.9 THYROID STIMULATING HORMONE 
The catabolic effects of thyrotoxicosis have mostly been attributed to increased genomic action of 
liganded skeletal thyroid receptors.  However, one group proposed that thyrotoxic changes were 
instead due to a lack of the osteoprotective effects of TSH.  Mice with absent TSH receptors (TSHR) 
and congenital hypothyroidism were treated with thyroid hormone and were found to have high 
turnover osteoporosis.  This finding was interpreted to be due to the lack of TSHR action and was 
supported with in vitro studies showing that TSH inhibits both osteoclast and osteoblast activity (Abe 
et al., 2003).  This data conflicts with clinical data in which patients with TSH antibodies – Graves’ 
disease, for example - have a high turnover osteoporosis and patients with RTH (where there is a 
mutation in TRβ, which gives rise to high circulating TSH and thyroid levels) also have a high turnover 
osteoporosis.  To investigate this relationship, the skeletal phenotypes of two mice with congenital 
hypothyroidism were compared.  Pax8 mice, with a mutation resulting in thyroid follicular cell 
agenesis, hypothyroidism and 2000-fold elevated TSH were compared with hyt/hyt mice, which 
lacked all TSHR signalling but exhibited hypothyroidism and 2000-fold elevated TSH (Bassett et al., 
2007b).  Both of these mice types therefore had elevated TSH and hypothyroidism but Pax8 mice 
had maximum TSH signalling whereas hyt/hyt mice had no TSH signalling.  The findings of similar 
skeletal phenotypes indicate that the major HPT axis regulator of skeletal development is thyroid 
hormone and not TSH.  TSH could have a minor role in modulating the skeleton and low doses of TSH 
were found to prevent ovariectomy induced bone loss (Sun et al., 2008, Sampath et al., 2007). 
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1.5 OESTROGEN 
In adults, oestrogen is important for reproduction, cardiovascular and bone health, and cognition.  
Oestrogen levels are low prepubertally, when a large proportion of growth takes place indicating 
that oestrogen is not essential during this phase of development.  However, after puberty, oestrogen 
becomes integral to the maintenance of skeletal integrity.  Oestrogen withdrawal in women at the 
menopause, or earlier where due to ovarian failure, results in an increased turnover and accelerated 
loss of bone (Clarke and Khosla, 2010a). 
Studies have also shown that up to 70% of effects of sex steroids on bone in men are accounted for 
by oestrogen (Falahati-Nini et al., 2000).  Oestrogen deficiency in men can be as a result of 
aromatase deficiency which leads to diminished oestrogen production or due to a non functional 
oestrogen receptor (ER) (Khosla et al., 1998, Adler, 2011, Smith et al., 1994). 
 
1.5.1 OESTROGEN SYNTHESIS 
Oestrogen is a steroid hormone which is synthesised from cholesterol.  There are three main 
physiological oestrogens: 17β-estradiol (E2); estrone (E1) and estriol.  During the reproductive years, 
E2 is the major physiological oestrogen.  Oestrogens are present in males and females and are 
synthesised from cholesterol via androgens produced in principal by the ovaries in females, the 
testes in males but also from the adrenal glands in both sexes.  Androgens are converted to 
oestrogens via aromatase, an enzyme in the cytochrome P450 family.  The relative production of 
oestrogen is target tissue dependent.  The ovaries express large amounts of aromatase enzyme and 
95% of E2 is therefore secreted by the ovaries in premenopausal women.  Post menopause, the 
majority of oestrogen is derived from the peripheral conversion of adrenal androgens to oestrogens. 
 
1.5.2 HOMEOSTATIC CONTROL OF OESTROGEN 
Circulating oestrogen serum concentrations are low in childhood, rise with the onset of puberty 
(usually around 12.8 y) and decline after the menopause.  Premenarchal children have low levels of 
gonadotrophin releasing hormone (GnRH), luteinising hormone (LH), follicle stimulating hormone 
(FSH) and E2 but as they approach puberty, the ovaries respond to pulsatile release of FSH and LH 
from the anterior pituitary gland to begin production of E2.  Premenopausal women have a tightly 
regulated cycle of events leading to ovulation, on average every 28-32 days.  Decreased ovarian 
function in postmenopausal women leads to a decrease in serum E2 levels by 85-90%. 
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Serum oestrogen levels are regulated by a classical negative feedback loop in the hypothalamic-
pituitary-ovarian axis.  The menstrual cycle is divided into two phases: the follicular or proliferative 
phase and the luteal or secretary phase.  Ovulation and menstruation separates these two phases 
(see Figure 1.18). 
In premenopausal women, pulsatile GnRH from the hypothalamus stimulates the pituitary to release 
gonadotrophins FSH and LH, which act by specific membrane receptors in the ovaries to induce 
oestrogen secretion.  At lower concentrations, oestrogen levels negatively feed back to the 
hypothalamus and pituitary gland to decrease gonadotrophin release.  Feedback also occurs via 
other hormones that are produced by the ovaries such as inhibins, which down regulate FSH 
synthesis and secretion, and activins, which stimulate FSH synthesis and secretion.  Inhibin A begins 
to be produced in early and mid follicular phase and reaches a peak in the luteal phase.  Inhibin B 
peaks during the follicular phase in response to rising FSH levels and inhibits FSH, resulting in a 
plateau in the FSH levels in the mid follicular phase. 
When concentrations of oestrogen have reached a peak, negative inhibition of GnRH and 
gonadotrophins reverses and positive feedback results in a surge of GnRH secretion, coupled with an 
increased responsiveness of the pituitary gland to GnRH.  The resultant rise in FSH and LH 
concentrations induces ovulation.  After ovulation, oestrogen levels fall as hypothalamic-pituitary 
feedback again becomes negative.  Progesterone levels, produced by the ovaries, are low during the 
follicular phase and start to rise and peak just after the FSH/LH peak.  The levels then fall, unless the 
ovum is fertilised. 
At the menopause, there is reduced gonadal function with decreased oestrogen secretion, which 
results in a loss of negative feedback and results in elevation of GnRH, FSH and LH (Clarke and 
Khosla). 
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Figure 1.18 Serum hormone concentrations and follicular growth 
during the menstrual cycle 
Taken from Broekmans FJ 2009 with permission (Broekmans et al., 
2009). 
See text for detail. 
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1.5.3 LOCAL CONTROL OF OESTROGEN LEVELS 
Oestrogen is predominantly bound to sex-hormone-binding globulin (SHBG) and with less affinity to 
albumin, with 2-3% of the active hormone in the free state.  Conversion of androgens to oestrogen is 
effected via aromatase.  Androgens in males are predominantly produced in the testes, the most 
important being testosterone, however the adrenal cortices also secrete large amounts of 
dehydroepiandronsterone (DHEA), DHEA sulphate and androstenedione.  These androgens can be 
metabolised to E1, 5α-dihydrotestosterone (DHT) or testosterone.  In the skeleton, enzymes 
important in the synthesis of oestrogens such as aromatase and biologically active androgens are 
present, which may contribute to a degree of local control of hormone availability.  Currently, there 
are no known transmembrane transporters of oestrogen and it is thought that oestrogen passively 
diffuses into cells (Miller, 1979, De Ryck et al., 1985, Muller and Wotiz, 1979). 
 
1.5.4 MOLECULAR MECHANISMS OF OESTROGEN ACTION 
The biological effects of oestrogen are mediated via genomic and non genomic pathways.  Genomic 
action involves the binding of oestrogen to ERs and can activate gene transcription either by direct 
binding to DNA at specific, inverted palindromic sequences known as oestrogen response elements 
(EREs) or indirectly by associating with transcription factors involved in DNA binding.  ERs can also be 
found bound to the membrane and from there mediate non genomic signalling. 
 
1.5.4.1 Oestrogen receptors 
Oestrogen binds to two nuclear receptors: oestrogen receptor alpha (ERα) and oestrogen receptor 
beta (ERβ), mapped to chromosomes 6q25.1 and 14q23-24 respectively.  G protein-coupled receptor 
(GPCR) was reported to be a membrane associated ER, however the status still remains unclear as 
some studies suggest that it may not be an ER at all (Filardo and Thomas, 2012, Langer et al., 2010, 
Levin, 2009).  ERs like TRs belong to the nuclear hormone receptor family and share a similar 
structure (see Figure 1.12).  They are found in the cytoplasm and nucleus and can shuttle in between 
the two.  They are complexed, in the absence of ligand, to heat shock proteins (eg hsp56, hsp90) 
which are then released on binding to oestrogen.  The liganded ERs bind to DNA hormone response 
elements as homodimers or Erα-Erβ heterodimers (Pettersson et al., 1997, Klinge, 2001).  This differs 
from thyroid receptors which principally bind as heterodimers with RXR. 
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In animals, there have been several isoforms of ERs described.  In healthy humans, there have been 
six characterised alternative splice variants.  They all produce a common human Erα protein that is 
66 kDa in size (Flouriot et al., 1998).  A further, smaller 46kDa Erα protein which does not possess an 
A/B region had also been identified, which is generated by alternative splicing of the Erα gene and 
acts as a competitive inhibitor for AF-1 (Flouriot et al., 2000).  Other human ER isoform variants have 
been described in the literature but have been mainly isolated from human cancer cell lines 
(Vladusic et al., 1998, Pfeffer et al., 1996, Karas et al., 1995).  No alternative isoforms of human Erβ 
have been described as yet. 
Similar to TRs, ERs have six domains A-F (see Figure 1.19).  The N terminus contains a weak ligand-
independent transcription activating function-1 (AF-1).  The C domain or DNA binding domain 
contains zinc finger-like motifs that are involved in binding to the EREs.  This is the most highly 
conserved area (>95%) (Pace et al., 1997) between the two receptors and means that Erα and Erβ 
bind to the same DNA sequences.  The hinge domain (D region) is important in receptor dimerisation 
and for binding to heat-shock proteins.  The C terminus, containing the LBD and activating function-2 
(AF-2), is not well conserved, suggesting that the different isoforms may bind different ER specific 
ligands. 
Figure 1.19 ER isoforms  
Illustration of the different isoforms of ERα and β and whether they are found in rats (r), mice (m) 
or humans (h).  
Reproduced with permission from Deroo, B 2006 (Deroo and Korach, 2006). 
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Erα has five times the affinity for binding to E2 than Erβ (Kuiper et al., 1997).  Ligand bound ERs 
undergo conformational change and dimerise as homodimers or Erα-Erβ heterodimers.  Gene 
transcription occurs via binding of receptors to EREs in promoter regions of genes.  Binding of AF-1 
and AF-2 to cofactors results in association with the basal transcriptional machinery to promote 
gene transcription (Imai et al., 2009). 
 
1.5.4.2 Coactivators and corepressors 
Similar to TRs, liganded ER interacts with co-activators to promote gene transcription.  Coactivators 
such as acetyltransferases enable an open chromatin structure and allow transcriptional machinery 
to access DNA (Klinge et al., 2004). 
Unlike TRs, ERs do not typically repress transcription in the absence of hormones, but may have 
certain repressive functions by interacting with corepressors such as NCOR and SMRT when bound 
to hormone antagonists such as tamoxifen (Varlakhanova et al., 2010). 
 
1.5.5 THE EFFECTS OF REDUCED OESTROGEN SIGNALLING IN THE SKELETON 
1.5.5.1 Postmenopausal osteoporosis 
Age related bone loss in women is most pronounced during oestrogen withdrawal at the 
menopause.  Cross sectional and longitudinal population studies have shown a period of rapid bone 
loss which lasts for about 10 years after the menopause, after which the rate of bone loss becomes 
similar to that of men (see Figure 1.20) (Clarke and Khosla, 2010a).  Bone resorption markers 
increase by 90% after the menopause but this is only accompanied by a 45% increase in bone 
formation markers. 
Oestrogen withdrawal has the greatest detrimental effect on cortical bone, with density remaining 
fairly consistent in adults until the menopause.  Subsequently, there is an increase in distal forearm 
fractures around the time of menopause, which plateaus about 15 years after the menopause 
(Cooper and Melton, 1992).  Trabecular bone loss commences at the third decade and continues 
throughout life with a small acceleration at the menopause (Khosla et al., 2006).  There is therefore 
an increase in the number of vertebral compression fractures at the menopause, a factor which 
continues to increase throughout the woman’s lifespan. 
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1.5.5.2 Ovariectomy in animal models 
The effects of postmenopausal oestrogen withdrawal on the skeleton cannot be adequately 
recapitulated by ER knockouts (see next section), with these animal models still undergoing 
ovariectomy induced bone loss.  Currently, ovariectomy in rodents is the most widely used model to 
study the skeletal effects of postmenopausal oestrogen deficiency (Jee and Yao, 2001).  Following 
ovariectomy, rapid loss of cancellous mass consisting of decreased Tb.N and thickness, increase in 
bone formation, increased resorption and reduction in biomechanical strength recapitulates human 
menopause or oophorectomy (Egermann et al., 2005). The rat is the established animal model of 
OVX induced oestrogen deficiency, but the ovariectomised (OVX) mouse model has been the most 
widely used to understand physiological mechanisms for diseases such as osteoporosis (Iwaniec et 
al., 2006).  Despite widespread use of ovariectomy as a model of oestrogen deficiency, there are 
various shortcomings of this model.  For example, site specific and magnitude responses to 
ovariectomy are strain/background dependent (Iwaniec et al., 2006).  Additionally, small rodents 
lack osteonal remodelling of cortices, so changes in cortical bone inadequately reflect human 
responses (Bouxsein et al., 2005, Iwaniec et al., 2006). 
 
1.5.5.3 Aromatase deficiency in humans 
Androgens in males and females exert an anabolic effect on bone directly via androgen receptors in 
bone cells and indirectly via aromatisation to oestrogens.  Men with aromatase deficiency such as 
those with mutations in the CYP19 gene (Bouillon et al., 2004, Gennari et al., 2004, Lanfranco et al., 
Figure 1.20 Decline in BMD in men and women 
Post-menopausal decline in BMD is accelerated for about a decade, after which the 
rate of bone loss becomes similar to that of men. The dashed lines represent 
trabecular bone whilst the solid lines represent cortical bone. 
Reproduced from Clarke 2010 (Clarke and Khosla, 2010b). 
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2008, Rochira et al., 2007) also have reduced bone mass which improves on treatment with 
oestrogen therapy but not androgen treatment (Carani et al., 1997).  Treatment of children by the 
use of aromatase inhibitors or GnRh analogues can lead to reduced bone mass (Hero et al., 2005). 
 
1.5.4.4 Aromatase knockout mice 
Two different groups, Miyaura et al and Oz et al, studied the effects of targeted disruption of the 
aromatase gene.  These animals had both in vivo evidence of oestrogen insufficiency with uterine 
atrophy and elevated circulating testosterone levels.  Female ArKO mice had increased bone 
turnover and osteopenia, a bone phenotype similar to postmenopausal osteoporosis in humans.  
The results for males, however, conflicted between the two groups, with Oz et al reporting a 
decrease in formation and resorption parameters and Miyaura et al reporting elevated formation 
and resorption parameters.  It is evident however that there is a sexually dimorphic response to 
oestrogen (Miyaura et al., 2001, Oz et al., 2000).  Although aromatase knockout mice are oestrogen 
insufficient, they do not recapitulate the bone phenotype of postmenopausal bone loss as closely as 
ovariectomy. 
 
1.5.5.5 Oestrogen resistance in humans due to ER mutation 
The importance of oestrogen in men’s skeletal health was first noted in a report of osteoporosis and 
delayed bone maturation with unfused growth plates in a 28 year old man with Erα mutation (Smith 
et al., 1994).  Recently, an 18 year old female with a mutation in Erα was reported to have a low 
bone mass with a Z score of -2.4, a delayed bone age and open epiphyses.  She also had elevated 
osteocalcin, bone ALP and serum C-telopeptide levels, consistent with a high turnover osteoporosis 
(Quaynor et al., 2013).  No patients with Erβ have yet been described. 
 
1.5.5.6 ER animal knockout models 
Knockout mice of Erα, Erβ and of both receptors have been generated.  The skeletal phenotypes are 
not in line with oestrogen deficiency bone loss and are dissimilar to the recently described female 
patient with an Erα mutation, but they have still provided insights into the molecular role of these 
receptors in oestrogen signalling. 
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1.5.5.7 Erα and Erβ knockout mice 
Global ERα knockout mice (ERαKO) that had no detectable mRNA for Erα were found to be infertile 
and had elevated circulating levels of oestrogen and androgen (Dupont et al., 2000).  Unexpectedly, 
these mice had decreased, rather than increased, bone turnover.  These mice also had increased 
cortical bone thickness and elevated BMD and trabecular bone volume.  Ovariectomy-induced bone 
loss occurs in ERαKO mice and this can be partially rescued with oestrogen treatment, resulting in an 
increase in BMD in the trabecular but not cortical compartment (Sims et al., 2003, Windahl et al., 
2002). 
Two complete ErβKO mice were generated and were shown to have no detectable Erβ protein on 
analysis by immunohistochemistry (Krege et al., 1998, Dupont et al., 2000).  Males and females had 
differing responses to deletion of Erβ.  Males were unaffected by the deletion whilst females had 
decreased bone resorption and increased trabecular bone volume but no change in cortical bone 
thickness (Sims et al., 2002).  Circulating oestrogen and androgens were not elevated in ErβKO mice 
and such mice were not protected against gonadectomy induced bone loss, but similarly to ErαKO 
mice, could be rescued with oestrogen therapy (Lindberg et al., 2002). 
A double knockout of Erα and Erβ was generated by crossing ErαKO and ErβKO mice.  These mice did 
not have elevated testosterone or oestrogen levels.  Female mice had decreased trabecular bone, 
associated with a decrease in bone turnover (McCauley et al., 2003, Sims et al., 2002).  Ovariectomy 
in these osteoporotic mice is less clear in the literature, with one group showing no further bone loss 
(Sims et al., 2002) and another demonstrating OVX induced bone loss (Windahl et al., 2002). 
These knockout mouse models were informative as they indicated that in the absence of either ER, 
the other could at least partially compensate and that the skeletal phenotype was more severe in 
the double knockout mice. 
The literature shows that both ErαKO and ErβKO mouse models were not protected against 
gonadectomy induced bone loss.  Studies also showed that the double knockout mouse model 
underwent ovariectomy induced bone loss, which suggests one of the following mechanisms was in 
effect: oestrogen acts via non genomic actions, there is some low affinity binding of oestrogen to 
other nuclear receptors or bone loss may be indirect such as oestrogen having an effect on the liver 
or pituitary gland. 
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Treatment with oestrogen rescued trabecular BMD in wild type and ErβKO ovariectomised mice, but 
not in ErαKO mice, demonstrating that oestrogen signalling in the trabecular compartment is Erα 
dependent. 
To clarify the effects of oestrogen in osteoclasts, Erα was specifically deleted in these cells by two 
research groups using cre-lox recombination technology.  ER mutant mice have a floxed allele of Erα 
and deletion occurs following exposure to cre-recombinase, which excises by cutting DNA at loxP 
sites and recombining the cut loxP sites.  Thus, depending on the cre-recombinase used, cell specific 
gene deletion can be generated. 
Nakamura (Nakamura et al., 2007) created a mouse model where cre-recombinase was inserted into 
the gene locus of Cathepsin K (a gene expressed in mature osteoclasts) and crossed these mice with 
floxed Erα mice to produce animals which had excised Erα only in differentiated osteoclasts 
(ErαΔoc/Δoc).  Likewise, Martin-Millan et al (Martin-Millan et al., 2010) generated a mouse model with 
restricted Erα in osteoclasts but used a cre recombinase under the control of the promoter of the 
LysM gene, which is expressed in early osteoclast precursors (ErαlysM
-/-).  Both osteoclast specific 
deletions of Erα resulted in a loss of trabecular bone mass compared to controls, with an increase in 
osteoclast indices in females.  Ovariectomy in these conditional knockout mice did not show the 
expected increases in trabecular osteoclast indices or a reduction in bone density, but in the ErαlysM
-/-  
mice, there was a loss of cortical bone.  Taken together, these results suggest that the 
osteoprotective action of E2 in the trabecular compartment was via Erα in osteoclasts, whereas this 
did not appear to be the case in the cortical compartment.  Nakamura et al also identified that the 
proapoptotic effect of oestrogen on osteoclasts was mediated by FasL, which was later confirmed by 
Krum et al (Krum et al., 2008). 
Martin-Millan further created a mouse model with an osteoclast specific knockin of Erα, which 
prevents binding to DNA (ErαNERKI/-), thus leaving any nongenomic actions of Erα intact.  These mice 
responded to ovariectomy in a similar manner to controls, suggesting that the non genomic 
mechanisms of Erα in osteoclasts are important. 
  
  
 
85 
 
 
 ErαKO ErβKO ErαβKO OcERαKO OVX 
Trabecular 
BMD 
↑ ↑ → ↓ ↓ 
Cortical BMD ↓ → ↓ → ↓ 
BV/TV ↑ ↑ ↓ ↓ ↓ 
Bone formation ↓ → ↓ ↑ ↑ 
Bone 
resorption 
↓ ↓ → ↑ ↑ 
 
 
 
 
In summary, the data from the knockout mice suggest that Erα and Erβ are able to compensate for 
each other but that Erα is the predominant receptor in bone. The bone phenotype of ER knockout 
mice was less severe than that from ovariectomy induced oestrogen deficient mice, which suggests 
that the non genomic effects of oestrogen are important in the maintenance of bone health.  Whilst 
these knockout mice provide important insights into the roles of specific ERs, ovariectomy is a more 
representative animal model of postmenopausal bone loss. 
 
1.5.6 IMPORTANT SIGNALLING PATHWAYS INVOLVED IN OESTROGEN ACTION IN THE SKELETON 
Whereas the growth plate is extremely sensitive to thyroid hormone status during growth, the 
serum levels of oestrogen during growth are minimal, suggesting that during this phase, 
chondrocyte proliferation and maturation is oestrogen independent.  Oestrogen is, however, 
important during the growth spurt and for the final fusion of the growth plate. 
Table 1.1 Bone phenotype of ER deficient mice 
Summary of oestrogen receptor (ER) α, β, αβ and osteoclast (Oc) specific 
knockout (KO) bone phenotypes compared to ovariectomy in female 
mice. ↓ decrease, ↑ increase, → no difference. 
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Erα and Erβ have been shown to be expressed in all bone cells - osteoblasts, osteocytes and 
osteoclasts (Bord et al., 2001, Braidman et al., 2001).  The relative role of oestrogen on each 
different cell type in the control of bone mass is not yet completely understood but the effect on 
osteoclasts has been extensively studied.  In contrast to TRs, where the presence of receptors in 
osteoclasts has not been conclusively established, ERs have been shown to be present in osteoclasts, 
and studies of osteoclast specific deletions of Erα have demonstrated a decrease in trabecular bone 
mass (Martin-Millan et al., 2010, Nakamura et al., 2007). 
The predominant effects of oestrogen on bone are inhibition of new osteoclast formation, increase 
in osteoclast apoptosis and inhibition of osteoblast and osteocyte apoptosis (Nakamura et al., 2007).  
Conversely, oestrogen deficiency results in high bone turnover with increased osteoclast activity, 
leading to accelerated bone loss and an increased risk of osteoporosis and fracture.  In humans, 
bisphosphonates, with their potent inhibition of osteoclastic bone resorption, are the most 
commonly used treatment for postmenopausal osteoporosis (Bock and Felsenberg, 2008). 
Although there is extensive literature on the downstream pathways important in oestrogen 
signalling in osteoclasts, it is clear that RANK-RANKL-OPG is a key pathway.  In vivo and in vitro 
studies have shown that RANKL production is suppressed by E2 in osteoblasts, T lymphocytes and B 
lymphocytes (Eghbali-Fatourechi et al., 2003, Clowes et al., 2005, Hsu et al., 1999, Kimble et al., 
1996, Onal et al., Pacifici, 2007).  E2 increases OPG and TNFβ production in osteoblasts (Hofbauer et 
al., 1999, Shevde et al., 2000), whilst suppressing the production of bone-resorbing cytokines such as 
IL1, IL6, TNFalpha, Macrophage colony stimulating factor (M-CSF) and prostaglandins (Riggs, 2002, 
Lorenzo et al., 1998, Poli et al., 1994).  Direct effects of oestrogen attenuate the RANKL pathway via 
reduction of c-jun and TRAF6, resulting in decreased NF-κβ activation (Huber et al., 2001, Shevde et 
al., 2000, Srivastava et al., 2001, Robinson et al., 2009). 
In osteoblasts, oestrogen deficiency was shown to result in an increase in NF-κB activity in 
osteoblasts and inhibition of this activity mitigated ovariectomy induced bone loss (Chang, 1966).  
Erα is important in osteoblasts for the nuclear translocation of β-catenin in response to strain 
(Zaman et al., 2000).  Studies in premenopausal women and mice suggest that oestrogen deficiency 
results in a four-fold increase in osteocyte apoptosis (Tomkinson et al., 1997).  In vitro studies also 
confirm that oestrogen can prevent induced apoptosis in an osteocyte like cell line (Emerton et al., 
2010).  In contrast, a study using osteocyte specific DMP1 cre mice, where Erα had been deleted, 
failed to show any increase in osteocytic apoptosis (Khosla et al., 2012). 
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1.5.7 FOLLICLE STIMULATING HORMONE 
FSH stimulates the ovarian follicles to release oestrogen, which negatively feeds back on the 
hypothalamic pituitary axis to reduce the production of FSH.  Just prior to the menopause, FSH 
becomes elevated to maintain normal oestrogen levels and bone loss begins.  During the 
perimenopausal phase and prior to complete ovarian dysfunction, oestrogen levels begin to fall.  
Studies have shown that bone turnover markers correlate more closely to serum FSH levels than to 
oestrogen levels.  Additionally, changes in hip and spine BMD correlated better with longitudinal FSH 
levels than androgen or oestrogen levels (Ebeling et al., 1996, Sowers et al., 2006).  Due to the 
clinical evidence and the reciprocal relationship between FSH and oestrogen, it was proposed that 
menopausal related bone loss was secondary to high levels of FSH rather than loss of oestrogen (Sun 
et al., 2006, Zhu et al.).  FSH receptor null (FORKO) mice with gonadal dysfunction had normal bone 
mass and it was found that FSH but not LH could induce osteoclast formation and function in vitro.  
Furthermore, a FSH blocking antibody injected into ovariectomised FORKO mice inhibited osteoclast 
resorption and increased bone formation (Sun et al., 2006, Zhu et al.).  These results seem to confirm 
the hypothesis that increases in FSH, and not loss of oestrogen, is the principal hormone implicated 
in postmenopausal bone loss.  However, additional studies showed that androgen levels were 
elevated in FORKO mice and it was suggested that this factor had led to normal BMD rather than the 
lack of FSH signalling.  When bilateral ovariectomy was performed on these animals, and there was a 
fall in androgen levels, there was a consequent decrease in bone mass (Gao et al., 2007a). 
Clinical studies also examined the hypothesis that rising FSH levels lead to bone loss - 
postmenopausal women were administered a GnRH agonist to suppress circulating FSH levels and 
the results were compared to controls.  An aromatase inhibitor was also given to both groups to 
prevent the effects of any oestrogen production from androgen.  The results showed that despite 
the treatment group having low FSH and the control group having very high FSH, there was no 
difference in bone resorption markers CTX and TRAP5b (Drake et al., 2010) and so concluded that in 
humans, lack of oestrogen and not elevated FSH was the major contributor to postmenopausal bone 
loss.  There is a degree of controversy surrounding the role of FSH in the skeleton and like TSH, there 
may be a minor role that FSH contributes to skeletal physiology. 
  
  
 
88 
 
1.6 SIMILARITIES OF OESTROGEN AND THYROID HORMONE ACTION ON BONE 
The actions of oestrogen and thyroid hormone are essential for the optimal maintenance of bone 
mass.  Both hormones act via receptors that belong to the nuclear receptor superfamily.  Both 
circulating hormone levels are controlled by negative feedback mechanisms involving the 
hypothalamic pituitary axis and are transported in the circulation via binding proteins.  They bind to 
hormone specific receptors which act as ligand inducible transcription factors and these receptors 
bind to hormone response elements on DNA to induce transcription of key genes.  Both oestrogen 
and thyroid hormone receptors dimerise and bind with coactivators.  The actions of oestrogen and 
thyroid hormone have opposing effects on bone.  Oestrogen deficiency and thyrotoxicosis both 
result in a high turnover osteoporosis.  A comparison of oestrogen and thyroid hormone actions on 
bone are summarised in Table 1.2.  Based on the evidence demonstrating the similarities in the way 
oestrogen and thyroid hormone act on bone with balanced but opposing effects, I hypothesised that 
at the menopause, the actions of thyroid hormone on bone are unopposed following oestrogen 
withdrawal, leading to accelerated bone loss and fracture. 
Table 1.2 Comparison between the actions of thyroid hormone and oestrogen in the skeleton 
  Thyroid Hormone Oestrogen 
Control of circulating serum levels Negative feedback to pituitary 
and hypothalamus 
Negative feedback to pituitary 
and hypothalamus 
Binding proteins TGB, TTR and Albumin SHBG, Albumin 
Main Receptors TRα and TRβ ERα and ERβ 
Dimerisation Predominantly with RXR but 
heterodimers or homodimers 
Heterodimers with ERα and ERβ 
or homodimers. 
Transport into cells Active via transporters such as 
MCT8 and 10, LAT1 and 2 
Passive 
Intracellular modification Activation or inactivation by 
deiodinases 
Binding to hsp, which is released 
upon binding to ER 
Co regulatory molecules Co activator and co repressor Co activator 
Repression in absence of hormone Yes No 
Action on skeleton during growth Essential and anabolic Only after puberty 
Action  on mature skeleton Catabolic Anabolic 
High turnover osteoporosis Excess Deficiency 
 
  
  
 
89 
 
1.7 EXPERIMENTAL DESIGN 
1.7.1 Hypothesis 
 
I hypothesise that at the menopause, the actions of thyroid hormone on bone are unopposed 
following oestrogen withdrawal, leading to accelerated bone loss and fracture. 
1.7.2 Aims 
 
I aim to: 
1. Compare the bone phenotypes of TRα0/0 and TRβ-/- mice to hypothyroid and hyperthyroid 
wild type mice. 
2  Establish the effects of altered thyroid status on TRα0/0 and TRβ-/- mice. 
3 Characterise the effects of ovariectomy or sham operation on the bone phenotype of 
thyroid status manipulated wild type, TRα0/0 and TRβ-/- mice. 
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Chapter 2 
Materials and methods 
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2 MATERIAL AND METHODS 
2.1 GENETICALLY MODIFIED MICE 
All strains of mice are housed in the registered CBS facility at Imperial College.  Breeding, handling 
and experimental procedures have been followed in accordance with Home Office guidance. 
Project Licence 70/7188. 
2.1.1 TRα0/0 MICE 
TRα0/0 mice were obtained from Professor J. Samarut of Ecole Normale Supérieure, 46 allée d'Italie, 
69364 Lyon, France.  These mice were generated using TRα gene inactivated blastocysts from 129SV 
mice which were implanted into C57 black6 mothers.  The mutant TRα allele contains a deletion 
extending from the middle part of intron 4 to the beginning of exon 8.  These mice are devoid of all 
known TRα isoforms produced by the TRα locus (Gauthier et al., 2001).  
2.1.2 TRβ-/- MICE 
TRβ-/- mice were also obtained from Professor J. Samarut.  These mice were generated using TRβ 
gene inactivated blastocysts from 129SV mice which were implanted into C57 black6 mothers.  The 
TRβ gene was inactivated by targeted insertion of a recombination cassette downstream of exon 3 
(Gauthier et al., 1999).  TRβ-/- mice are devoid of all known Thrb isoforms. 
 
2.2 GENOTYPING OF MOUSE STRAINS 
2.2.1 DNA EXTRACTION 
Genomic DNA was extracted for genotyping using mouse ear-clip samples using the REDExtract-N-
Amp Tissue PCR Kit (Sigma Aldrich, UK). 50μl extraction buffer and 12.5μl tissue preparation 
solutions were added to the samples in 1.5ml microtubes and incubated for 15 minutes at 37oC.  
Samples were then incubated at 95-98oC for 3 minutes and 50μl neutralisation solution added prior 
to removal of remaining tissue and storage at 4oC.  
2.2.2 POLYMERASE CHAIN REACTION (PCR) 
Genotyping PCR was performed using 2μl of DNA solution as template (see Appendix for PCR mix).  
PCR primers and conditions were: 
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Thra 
TRα wild type allele 
Forward Primer: GAGGAGGCGAAAGGAGGAG  
Reverse Primer: TGCCCTGGGCGTTAGTGCTG  
TRα mutant allele 
Forward primer: ATCGCCTTCTATCGCCTTCTTGACG  
Reverse primer: TTCAGGAGGATGATCTGGTCTTCGCAAG  
PCR conditions:  
950C for 7 mins then 5 cycles of 940C  for 20 secs (denaturing), 600C for 20 secs (annealing), 720C for 
60 secs (extending) followed by 27 cycles of 940C  for 20 secs (denaturing), 560C for 20 secs 
(annealing), 720C for 60 secs (extending) followed by a final extension at 720C for  10 mins. 
 
Thrb 
TRβ wild type allele 
Forward primer: TGGTGCTGGATGACAGCAAG  
Reverse primer: CAGGAATTTCCGCTTCTGCTT  
TRβ mutant allele 
Forward primer: GCCAGAACAATTGCTCTTATTC  
Reverse primer: CCTCTTCGCTATTACGCCAG  
PCR conditions: 
950C for 7 mins followed by 35 cycles of 940C for 30 secs (denaturing), 600C for 30 secs (annealing) 
and 720C for 30 secs (extending) followed by a final extension at 720C for 10 mins. 
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134
1 2 3 4 5 6 8 97
11,283 2,469 747 3,852 697 994 461 490
349 68 101 148 206 147 259 834
3’UTRTRα1
Exon 6
115bp
TRAWTF TRAWTR
134 349 68 101 259 834
1 2 3 4 8 9
11,283 2,469 747 490
3’UTRTRα0/0 LacZ Neo
660bp
TRAKOF TRAKOR
Exon 8Neo gene
 
Figure 2.1 Primer locations for identification of wild type and mutant TRα alleles 
TRα0/0 is constructed from a deletion from intron 4 to 8.  Exons are shown as rectangles 
with the number of base pairs in numerals above.  Figures above indicate the position 
of the primers for the wild type (TRα1) and mutant TRα allele (TRα0/0) and the resultant 
PCR product size.  Illustrations by Dr T. Galliford. 
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325/XXX
1 2 3 4 5 6 7
20,326 5,940 2,348 15,366 3,359 3,023
101 148 206 147 259 242
3’UTRTRβ
Exon 4
206bp
TRBWTF TRBWTR
325/XXX
1 2 3 6 7
20,326 5,940 3,023
101 148 259 242
3’UTRTRβ
LacZ gene
210bp
Betai 3.2 Lacz
LacZ Neo
Intron 3
 
 
 
 
 
Figure 2.2 Primer locations for identification of wild type and 
mutant TRβ alleles 
The TRβ gene was inactivated by targeted insertion of a 
recombination cassette downstream of exon 3.  Exons are shown as 
rectangles with the number of base pairs in numerals above. Figures 
indicate the position of the primers for the wild type and mutant TRβ 
allele and the resultant PCR product size. Illustrations by Dr T. 
Galliford. 
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Agarose gel electrophoresis: PCR products were visualised using a UV transilluminator (Bio-Rad 
Laboratories Ltd, UK) following electrophoresis in an agarose gel stained with ethidium bromide. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.3 Example of PCR gel used for identifying wild type and mutant TRα PCR 
products 
Examples of PCR products run on a 1.5% agarose gel used to identify the genotype of the 
mice.  Mice were categorised into wild type, heterozygous TRα0/-or homozygous TRα0/0 
dependent on the presence or absence of PCR products. Mouse numbers 383-387 and 390 
have both the wild type and mutant PCR products, so are TRα0/-(heterozygous for mutant 
TRα allele) whilst mice 389 and 391 only show the presence of the mutant PCR product 
and no wild type PCR product, indicating they are TRα0/0 (homozygous for mutant TRα 
allele).  The remaining mice only have wild type PCR products, indicating they are wild type 
mice.  DNA molecular weight marker Hyper II ladder (Bioline reagents Ltd, UK) was used to 
verify product size; 115 base pairs for wild type and 660 base pairs for mutant TRα PCR 
products. 
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Figure 2.4 Example of PCR gel used for identifying wild type and mutant TRβ PCR 
products 
Examples of PCR products run on a 1.5% agarose gel used to identify the genotype of TRβ-/-
mice.  Mouse numbers 679, 683, 685 687 and 688 are wild type mice. Mouse numbers 
678, 684 and 686 are TRβ+/- (heterozygous for mutant allele) and mice 677, 680 and 682 
are TRβ-/- (homozygous for mutant TRβ allele).  DNA molecular weight marker Hyper II 
ladder (Bioline reagents Ltd, UK) was used to verify product size; 206 base pairs for wild 
type and 210 base pairs for mutant TRβ allele. 
  
 
97 
 
2.3 OESTROGEN AND THYROID HORMONE MANIPULATION 
The effects of altered thyroid status and oestrogen deficiency on adult bone structure and 
mineralisation was determined in wild-type, TRα0/0 and TRβ-/- female mice. At the time of cessation 
of growth, post-natal day 70 mice were ovariectomised (OVX) or sham operated and maintained in 
three groups of 12 mice: (i) euthyroid (n=6 OVX, n=6 sham), (ii) hypothyroid (n=6 OVX, n=6 sham) 
and (iii) hyperthyroid (n=6 OVX, n=6 sham). Mice were sacrificed and their skeletal phenotypes 
analysed 6 weeks later at P112. The total number of mice required was 108 (n=3 genotypes, n=3 
groups of altered thyroid status, n=12 mice per group). 
 
2.3.1 WILD TYPE AND TRα0/0 MICE  
Euthyroid mice were fed a standard diet. Hypothyroid animals were fed a low I2 diet containing 
0.15% w/v of the anti-thyroid drug PTU (TD95125 Harlan laboratories, Indianapolis, USA). 
Hyperthyroid mice were obtained by supplementing their diet with TSH-suppressive doses of T4 
(1.2μg/ml in drinking water T1775, Sigma Aldrich, UK - see Appendix for solution). Water was 
changed every three days as T4 slowly degrades following exposure to light.  As the mice became 
thyrotoxic, they drank more and so the concentration of supplemented T4 was adjusted according to 
intake, in two week cycles, to ensure that the mice did not become markedly thyrotoxic.  
 
2.3.2 TRβ-/- MICE 
Euthyroid group: untreated TRβ-/- mice have elevated circulating thyroid hormone concentration so 
euthyroid status was achieved by a low I2 diet containing PTU and co-administering a physiological 
replacement dose of T3 (0.05μg/ml T2877 Sigma Aldrich, UK - see Appendix for solution) in the 
drinking water. Treatment with T3 rather than T4 was required because PTU inhibits activity of the 
D1 which converts T4 to T3. Hypothyroid animals were fed a low I2 diet containing PTU. 
Hyperthyroid group: TRβ-/- mice have elevated circulating thyroid hormone concentration and were 
fed a standard diet. 
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Genotype Thyroid status Treatment 
 
Hyperthyroid T4 (1.2μg/ml of drinking water) 
Wild Type Euthyroid No treatment 
 
Hypothyroid Low iodine diet with 0.15% PTU 
   
 
Hyperthyroid T4 (1.2μg/ml of drinking water) 
TRα0/0 Euthyroid No treatment 
 
Hypothyroid Low iodine diet with 0.15% PTU 
   
 
Hyperthyroid No treatment 
TRβ-/- Euthyroid 
Low iodine diet with 0.15% PTU and T3 (0.05μg/ml of 
drinking water) 
 
Hypothyroid Low iodine diet with 0.15% PTU 
 
 
 
2.4 CALCEIN LABELLING 
All mice were labelled with 2.5mg/kg of calcein (Sigma CO875), administered by intravenous 
injection at P107 and P109 prior to sacrifice at P112. 
 
2.5 GROWTH PARAMETERS 
Mice were weighed at sacrifice (P112).  Tail length was measured immediately prior to sacrifice.   
  
Table 2.1 Summary of drugs administered to manipulate 
circulating thyroid status in each group. PTU – propylthiouracil. 
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2.6 SERUM SAMPLES 
Mice were fasted for 12 hours before sacrifice and blood obtained by cardiac puncture (1ml syringe, 
25G needle, Becton Dickinson, UK). Blood samples were incubated at room temperature to allow for 
coagulation, then spun at 16,000 rpm for 10 mins at 4οC.  The pellet was discarded, and the serum 
supernatant was removed and stored at -80οC. 
 
2.6.1 THYROID HORMONE AND BONE TURNOVER MARKERS 
Free T4 and fT3 were measured in chemiluminescence assays (Vitros ECI Immunodiagnostic 
Systems).  Bone formation marker N-terminal propeptide of type 1 procollagen (P1NP) and bone 
resorption marker CTX concentrations, were determined by enzyme immunoassay using 
Immunodiagnostic systems (IDS) kit AC-33F1 and AC-06F1.  Both assays were carried out in 
accordance with the manufacturer’s instructions (briefly outlined below). 
 
2.6.1.1 P1NP assay IDS AC-33F1 
50µl of calibration, control or 5μl of serum sample with 45µl of sample dilutant, were added to 
antibody coated plate wells.  50µl of P1NP biotin was then added to each of the wells.  The plate was 
placed on a microplate shaker at 500-700 rpm at room temperature, for 1 hour. 
The wells were then rinsed with wash solution three times before adding 150μl of enzyme conjugate 
to each well and incubated for 30 minutes.  The wells were then rinsed three times with wash 
solution and 150µl of TMB solution was added and incubated for 30 minutes.  50µl of HCl was added 
to all the wells to stop the reactions and the absorbance of each well was measured at 450nm using 
a microplate reader.  
The results of the standards were plotted, creating a standard curve from which sample absorbance 
values could be read, to determine the serum concentration of P1NP.  
 
 
2.6.1.2 CTX assay IDS AC-06F1 
100μl of biotinylated RatLaps Antigen was added to wells and incubated at room temperature for 30 
minutes.  The immune strips were washed 5 times with 300μl washing solution.  20 μl of standards, 
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controls and serum samples were added to each well followed by 100μl of primary antibody. The 
wells were then sealed and incubated overnight at 4 οC.  The following day, the strips were washed 5 
times in washing solution and then 100μl of peroxidise conjugated Goat anti-Rabbit IgG Antibody 
was added to each well and further incubated at 6 mins at room temperature.  The wells were again 
washed 5 times as before and then 100μl of substrate solution was added and incubated for 15 mins 
in darkness.  100μl of stop solution was added to each well and the absorbance was measured at 
450nm.  The results of the standards were plotted creating a standard curve and checked against the 
control.  The serum CTX concentration was then determined by reading corresponding absorbance 
values of samples. 
 
2.7 DISSECTION, FIXATION AND STORAGE OF THE SKELETON 
The skeletons of P112 mice were dissected out and all soft tissue removed.   The left lower limb, 
right femur and proximal tail vertebrae were placed in 70% ethanol.  The right tibia, lumbar 
vertebrae and mandible were fixed in 2.5% glutaraldehyde in 0.15M sodium cacodylate buffer (see 
Appendix for solution) for 18 hours, before storage in 70% ethanol.  The left upper limb was fixed in 
neutral buffered formalin for 18 hours and stored in 70% ethanol.  All samples were stored at 4οC. 
 
2.8 BONE IMAGING 
2.8.1 FAXITRON POINT PROJECTION MICRORADIOGRAPHIC ANALYSIS 
Left lower limb and proximal tail vertebrae digital x-ray images were recorded at 10-μm pixel 
resolution, using a Qados Faxitron MX20 variable kV point projection x-ray source and digital image 
system, operating at 26 kV and 5× magnification (Cross Technologies plc). Magnifications were 
calibrated by imaging a digital micrometre at 15mm.  The relative mineral content of calcified tissues 
was determined by comparison between groups.  Each image taken was adjusted according to the 
following standards included in each image frame: a 1-mm thick steel plate, a 1-mm diameter 
spectrographically pure aluminium wire, and a 1-mm diameter polyester fibre. 16-bit (2368 × 2340) 
DICOM images were converted to 8-bit Tiff images using ImageJ, and the histogram stretched from 
the polyester (grey level 0) to the steel (grey level 255) standards. Decreasing gradations of 
mineralisation density were represented in 16 equal intervals by a pseudocolor scheme for 
presentation of digital images.  Images of the bones were montaged according to type of bone, 
genotype and treatment groups.  Statistical analyses was performed in an excel spread sheet using 
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the Kolmogorov-Smirnov test between the grey level distribution of each montage on the 
cumulative frequencies (CF).  The Kolmogorov-Smirnov test is described by Demidenko 
(http://www.springerlink.com/content/wpc6c4aw8mpup66g/). 
 
Femur and tibial lengths were determined on faxitron images using ImageJ 1.41 software 
(http://rsb.info.nih.gov/ij/).   Cortical bone thickness and diameter were determined at the mid 
diaphysis in the mediolateral projection position.  A 100 pixel grey box was inserted over the mid 
diaphysis using Photoshop CSI 5 software.  10 measurements were taken: five between the 
periosteal surfaces and five between endosteal surfaces (see Figure 2.6).  From these 
measurements, the average cortical thickness was calculated for each bone. 
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Figure 2.5 Image processing used for determining BMC 
A: Faxitron DICOM image of caudal vertebrae and lower limb.  Standards: 1-mm thick 
steel plate (s), a 1-mm diameter spectrographically pure aluminium wire (a), and a 1-mm 
diameter polyester fibre (p) were imaged with each set of bones. B: The images were 
standardised by stretching the grey scale histogram from the polyester (grey level 0) to 
the steel (grey level 255).  C: The varying gradations of mineral densities were split into 
16 equal intervals and pseudocoloured. 
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Figure 2.6 Determining cortical thicknesses 
Cortical bone thickness was determined by 10 measurements across the mid 
diaphysis.  To optimise accuracy, cortical thickness was determined by 
measurements of diameter of the external diaphysis (between the white 
arrows) minus the distance between the internal cortices (between the black 
arrows).    The double headed arrow illustrates measurement of femoral 
lengths.  
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2.8.2 MICRO COMPUTED TOMOGRAPHY (CT) ANALYSIS 
Femurs were analysed by Skyscan 1172a micro CT at 50kV and 200μA using a 0.5mm Al filter and a 
detection pixel size of 4.3 μm². Images were taken every 0.7° through 180° rotation of each bone. 
Reconstruction of scanned images created using Skyscan NRecon software. A 1mm³ volume of 
trabecular bone, 0.2mm from the growth plate, was selected as the region of interest.  
Trabecular bone volume as a proportion of tissue volume (BV/TV), trabecular separation (Tb.Sp, 
mm), Tb.N, mm-1, Tb.Th, mm and structure model index (SMI) were determined.  Images and 
processing were undertaken by Miss Holly Evans in collaboration with Professor P. Croucher at 
Sheffield University.   
 
 
 
 
 
 
  
Figure 2.7 Micro CT images of a femur 
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2.8.3 qBSE-SEM 
The distribution of bone micro-mineralisation densities was analysed by qBSE-SEM at cubic micron 
voxel resolution.  Bones were fixed in 2.5% glutaraldehyde in 0.15M sodium cacodylate buffer (see 
Appendix for solution) and stored in 70% ethanol prior to being embedded in poly-methyl-
methacrylate (PMMA). Midline block faces were polished, coated with carbon and analysed using a 
Zeiss DSM962 digital SEM. Mineralisation densities were determined by comparison with 
halogenated dimethylacrylate standards: C22H25O10Br (BSE coefficient = 0.1159) to C22H25O10I (BSE 
coefficient = 0.1519). Increasing gradations of mineralisation density were represented in 8 equal 
intervals by a pseudocolour scheme for presentation of digital images.  Statistical analyses between 
the distribution of grey levels of each montage were performed on the cumulative frequencies using 
the Kolmogorov-Smirnov test in an excel spread sheet.  Embedding was performed by Maureen 
Arora and images were taken by Professor Alan Boyde at the Queen Mary, University of London 
(QMUL).   Analysis of images was undertaken by the author. 
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Figure 2.8 Image of lumbar vertebra taken by qBSE 
Increasing gradations of mineralisation density were represented in 8 equal 
intervals by a pseudocolour scheme for presentation of digital images. This 
image shows the different grey levels represented into 8 equal intervals by a 
pseudocolour scheme. 
Figure 2.9 Different densities represented in different colours 
High density is shown in white and low density in yellow and red.  
Scale bar is 100 microns.  Calcified cartilage is highly mineralised 
and shown in the areas near the growth plate.  New bone is of a 
lower density where remodelling has occurred. 
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2.8.4 BSE-SEM 
Femurs were opened longitudinally along anatomical curvatures using a fine tungsten carbide milling 
tool to remove half the cortical bone and medullary trabecular elements. Samples were cleared of 
cell remnants by maceration with an alkaline bacterial pronase, which also removed unmineralised 
cartilage. Samples were carbon-coated and imaged using backscattered electrons at 20kV beam 
potential. The resultant images provided detailed views of bone surfaces and microarchitecture.  
Endosteal eroded surfaces were quantified using ImageJ. The percentage area of the inner cortex 
with evident resorption pits was calculated by using a grid of 200 crosses and identifying whether 
each cross overlayed an area of resorption.  Femurs were opened by Professor Alan Boyde.  Samples 
were mounted, imaged and analysed by the author. 
 
 
 
 
 
Figure 2.10 BSE-SEM images of the internal cortex of 
femurs 
Image A shows an endocortical surface with very little 
few resorption pits evident.  Image B shows an 
endocortical surface where several areas of resorption 
are evident (black arrows). 
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2.8.5 CONFOCAL MICROSCOPY 
PMMA embedded lumbar vertebrae were examined by confocal scanning light microscopy (CSLM) to 
determine the fraction of BS undergoing active bone formation (Doube et al., 2007).  Leica SP2 
reflection confocal was utilised, using 488 nm and 543nm excitation and 10x/1.0 and 40x/1.25 
objectives. Tissue layers immediately deep to the block surface were visualised to ensure that only 
fluorescently labelled bone forming surfaces that lie in orthogonal planes were analysed.  Montages 
of overlapping CSLM fields were constructed for each bone using Photoshop CSI 5 software and 
ImageJ.  
 
 
 
 
 
 
 
Figure 2.11 Montaged confocal image of a lumbar 
vertebra 
Cortical surfaces and primary spongiosa have been 
excluded.  Trabeculae are identified by their morphology 
and the presence of identifiable osteocytes.  Bright green 
calcein labelling can be clearly identified and double and 
single labelled surfaces can be easily defined when 
viewed in higher magnification. 
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BS was measured using ImageJ software.  All the BS, excluding the primary spongiosa just below the 
growth plate, in a single lumbar vertebra from each mouse were measured.  The length of double 
and single labels was quantified separately.  Finally, the multiple distances between all the double 
labels were measured taking the midpoint of one label and measuring to the midpoint of the label 
perpendicular to it.  Mineralising surface (MS) was determined by adding the length of double labels 
to half the length of the single labels.  MS/BS was calculated by dividing the MS by the total BS.  The 
MAR was determined by the mean separation between double labels. BFR was calculated from the 
product of MS/BS and MAR.  
QBSE-SEM, BSE-SEM and confocal microscopy were undertaken in collaboration with Professor Alan 
Boyde at QMUL and University College London.  Imaging of specimens, manipulation, measurement 
and analysis of images and parameters was performed by the author.   
 
Figure 2.12 Confocal images of double labelling 
Confocal image of trabeculae (A).  Bone morphology (dark areas with green labels 
and scattered orange osteocytes) and bone marrow (cellular areas) can be distinctly 
identified.  Calcein labels can be seen in green.  Double calcein labels (white arrows) 
and single calcein labels (blue arrows) can be clearly identified and measured.  
Mineral apposition is measured as the perpendicular distance between double 
labels as demonstrated by the white lines (B). 
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2.8.6 HISTOMORPHOMETRY 
Histomorphometric analysis of osteoclast parameters was performed on decalcified, stained sections 
of the humerus.  After sacrifice, upper limbs were fixed in 10% neutral buffered formalin for 18 
hours and then stored in 70% ethanol, following which they were decalcified in 10% EDTA (see 
Appendix) for three weeks.   EDTA was replaced with fresh EDTA once a week and decalcification 
was verified by faxitron X-ray imaging. Decalcified bones were embedded in paraffin and 3m 
sections mounted on slides ready for staining with aniline blue to delineate collagen and tartrate 
resistant acid phosphatase (TRAP) to identify osteoclasts. Paraffin was removed and then the 
sections rehydrated ready for staining.  
The slides were dipped in xylene for 10 mins two times and the samples rehydrated with sequential 
washes of ethanol at reducing concentrations: 100%, 100%, 80%, 70%, 50% and distilled water.  
Sections were first stained with TRAP (see Appendix) for 2 hours and the slides were subsequently 
stained with aniline blue (Aniline Blue 415049 + Phosphotungstic Acid Fluka 79690, both Sigma 
Aldrich, Dorset, UK) for 20 mins before being washed in water to remove excess stain.  The samples 
were mounted using DPX mountant (Promega, Southampton, UK) and imaged.  Sections were 
photographed using a Leica DM LB2 microscope and DFC320 digital camera and a montage of 
overlapping fields was constructed for each bone. Analysis was performed with custom software 
developed by Dr Rob J. van’t Hof using the Aphelion Image Analysis tool kit (Adcis SA, Herouvill-St 
Clair, France).  Using this software, the tissue area for measurement was first delineated, following 
which the BS was identified using thresholding of the blue areas.  The osteoclasts could then be 
defined by thresholding of the TRAP stained red areas.  Size and location of osteoclasts were 
individually checked by eye to ensure that those identified were osteoclasts.  The software then 
calculated tissue volume (TV), bone volume (BV), BS, Oc.N and surface (Oc.S).  Osteoclast indices 
could then be normalised to total BS (Oc.N/BS and Oc.S/BS) and compared.   
Embedding and sectioning of decalcified samples was performed by Dr Mahrokh Nohadani at 
Imperial College.  Staining, mounting, imaging and analysis all performed by the author.  All 
measurements were performed blind. 
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2.9 MECHANICAL LOADING AND BONE STRENGTH 
Destructive three-point bending tests were performed on tibias using an Instron 5543 load frame 
(Instron, UK).  A load perpendicular to the tibia, at a rate of displacement of 0.03 mm/sec, was 
applied in the mid diaphysis until fracture.  The force applied (load in Newtons) and displacement (in 
mm) were recorded.  Load displacement curves were then generated from the data and recorded on 
an excel spread sheet to determine yield load (direct measurement), maximum load (direct 
measurement), fracture load (direct measurement) and stiffness (gradient of the linear part of the 
graph) of the bone (see Figure 2.14).    It can be seen that the bone undergoes elastic deformation in 
the portion of the graph where there is a linear relationship between load and displacement.  The 
gradient of this section represents the stiffness of the bone - the steeper the gradient the greater 
the stiffness.  The bone undergoes plastic deformation where the relationship between load and 
displacement is no longer linear after the yield load.  The maximum load is the highest load which 
can be applied to the bone and the fracture load is the load at which the bone breaks. 
Figure 2.13 Osteoclast parameters analysis 
Osteoclast parameters analysis were calculated using custom software developed by Dr Rob J. 
van’t Hof using the Aphelion Image Analysis tool kit.  This image demonstrates identification of 
osteoclasts on the BS by red colour thresholding.  The identified osteoclasts were then checked 
and added or removed as necessary.  The software then calculated parameters which were 
exported onto an excel spread sheet (as seen at the bottom of the image). 
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Figure 2.14 Load displacement curves generated from three point 
bending of femur 
The yield load is the point at which the curve no longer shows a 
linear relationship between load and displacement.  The maximum 
load is the greatest load that can be applied through the bone and 
the fracture load is the force at which the bone fractures.   
These four parameters can be independent.  The second graph 
shows examples of the load displacement of tibias of mice from 
different genotypes (A-C).  Bone A is less stiff (gradient of graph is 
less steep) and has lower yield, max and fracture loads than that of 
bones B and C.  Bone C has the highest max load of all three bones 
but the fracture load of bone C is lower than that of bone B. 
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2.10 STATISTICS 
Normally distributed data was analysed using the Student’s t-test, or analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison post-hoc test. P values <0.05 were considered significant. 
Data expressed as mean ± standard error of mean (SEM). 
In Chapter 3, separate ANOVAs were performed in respect of:  
1) Thyroid status: comparison of hypothyroid (WT Hypo), euthyroid (WT Eu) and hyperthyroid 
(WT Hyper) groups. 
2) Genotype: comparison of TRα0/0, TRβ-/- and wild type (WT) groups. 
In Chapter 4, separate ANOVAs were performed to compare the effects of thyroid status in 1) TRα0/0 
and 2) TRβ-/- groups. 
Frequency distributions of bone mineralisation densities obtained by Faxitron and qBSE SEM were 
compared using the Kolmogorov-Smirnov test, in which P values for the D statistic in 1024 pixel data 
sets are D = >6.01 P<0.05, D = >7.20 P<0.01, and D = >8.62 P<0.001.   The Kolmogorov-Smirnov test 
is described by Demidenko (http://www.springerlink.com/content/wpc6c4aw8mpup66g/). 
The software used for statistical analysis was Graph Pad Prism version 4.0. 
2.10.1  TYPE I AND TYPE II ERRORS 
In Chapter 5, when analysing the different groups, I performed nine independent Student’s t-tests 
for each parameter.  Correction for multiple sampling is commonly used when performing several 
hundred t-tests at the same time; for example when analysing microarrays. Too stringent corrections 
for multiple testing lead to type II errors, where significant findings are not identified.  
I was concerned that any significance that I elicited could be due to chance leading to a type I error.  
I therefore initially applied two corrections independently, a Bonforroni and then a Sidak’s 
correction (1-(1-α)1/n where α is the significance level and n is the number of tests).  However, after 
applying either of these corrections, there were no significant differences in any of the groups 
tested.  Loss of bone mass has been well documented in mouse models undergoing ovariectomy and 
the results of my uncorrected Student’s t-tests are in line with this.  As the number of groups was 
relatively few at nine, I concluded that applying a correction for multiple testing resulted in a type II 
error with my analysis.  Thus the Student’s t-tests performed in Chapter 5 were not corrected for 
multiple testing.     
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Chapter 3  
Skeletal phenotyping of wild type mice with 
manipulated thyroid status in comparison 
to TRα0/0 and TRβ-/- mice 
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3 SKELETAL PHENOTYPING OF WILD TYPE MICE WITH MANIPULATED 
THYROID STATUS IN COMPARISON TO TRα0/0 and TRβ-/- MICE 
 
3.1 BACKGROUND 
Deletion or mutation of TRα during growth results in delayed endochondral ossification and 
transient growth retardation with reduced bone mineral deposition.  Adult TRα knockout and 
mutant mice are reported to have osteosclerosis characterised by increased trabecular bone mass, a 
skeletal remodelling defect and reduced osteoclast numbers and activity (Bassett et al., 2007b, 
Bassett and Williams, 2009).  The features in TRα mutant mice that have been described in the 
literature to date are characteristic of skeletal responses to hypothyroidism.  
By contrast, deletion or mutation of TRβ during growth results in accelerated intramembranous and 
endochondral ossification, with increased bone mineral deposition.  Adult TRβ knockout and mutant 
mice are reported to have osteoporosis with reduced bone volume and mineralisation and increased 
osteoclast numbers and activity (Bassett et al., 2007b, Bassett and Williams, 2009, Forrest et al., 
1996).  The features in TRβ mutant mice are characteristic of skeletal responses to thyrotoxicosis 
(O'Shea et al., 2003). 
Given the data available, it was proposed that the divergent skeletal phenotypes in TRα and TRβ 
mutant mice could be accounted for by consideration of the differing actions of TRα and TRβ in bone 
and on the hypothalamic-pituitary-thyroid axis.  TRα is the major TR isoform expressed in bone, 
whereas TRβ predominates in the hypothalamus and pituitary and mediates negative feedback 
regulation of TSH (Bookout et al., 2006, Forrest et al., 1996, Kaneshige et al., 2000, O'Shea et al., 
2003).  Consequently, TRβ knockout and mutant mice have central RTHs with elevated circulating 
thyroid hormone concentrations, which lead to increased activation of TRα in bone and a phenotype 
of increased T3 signalling in the skeleton.  By contrast, TRα knockout and mutant mice have absent 
TRα in bone, leading to reduced T3 signalling in the skeleton despite normal circulating thyroid 
hormone levels. 
The skeletal response to hyperthyroidism includes a reduced bone mass, resulting from both 
increased bone formation and bone resorption with a net negative balance, whereas the skeletal 
response to hypothyroidism includes low bone formation, decreased bone resorption and, in 
animals, an increased bone mass (Mosekilde and Melsen, 1978, Eriksen et al., 1986, Lanham et al., 
2011).  To date, experimental data which directly compares the skeleton of (i) hypothyroid mice with 
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TRα0/0 mice or (ii) hyperthyroid mice with TRβ-/- mice is lacking.  In particular, dynamic bone 
formation and biomechanical data in TRα0/0 and TRβ-/- mice, has not been reported in the literature. 
In this chapter, I describe the skeletal phenotype of adult wild type mice with manipulated thyroid 
status mice and compare them with untreated TRα0/0 and TRβ-/- mice. 
 It should be noted that “WT Eu” and “WT” were the same control group, but labelled differently to 
reflect the relevant comparison being made.     
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3.2 RESULTS 
3.2.1 CIRCULATING THYROID STATUS OF WILD TYPE, TRα0/0 AND TRβ-/- MICE 
The intended thyroid status of treated wild type mice (Table 2.1) was confirmed by analysis of serum 
total T4 and total T3 levels (Figure 3.1).  The hypothyroid group had serum T4 below the limits of 
detection for the assay and those treated with supplementation of T4 in the drinking water resulted 
in a 4 fold elevation of serum T4 level.  T3 levels in the wild type groups also reflected this trend.   
TRα0/0 mice were euthyroid, whilst both T3 and T4 were significantly elevated in TRβ-/- mice, to 
concentrations similar to hyperthyroid wild type mice (T4 concentration 40.8±10.3pm/l in 
hyperthyroid wild type mice compared to 43.2±3.8pm/l in TRβ-/-). 
 
 
 
 
 
 
Figure 3.1 Serum free T4 and free T3 levels 
Serum free T4 and free T3 concentrations (pmol/litre) at P112 in wild type control mice (WT 
Eu), wild type mice treated with 1.2μg/l of T4 in drinking water for 6 weeks (WT Hyper), wild 
type mice treated with a low iodine diet containing PTU for 6 weeks (WT Hypo),  TRα0/0  and  
TRβ-/- mice. Data expressed as mean ± SEM, n=6 per group and analysed by ANOVA and Tukey’s 
Multiple Comparison post hoc test: *, p<0.05; ***, p<0.001 versus euthyroid wild type (WT 
Eu/WT).  Serum free T4 levels for WT Hypo were below lower limit of detection by assay. 
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3.2.2 ANALYSIS OF BODY WEIGHT AND TAIL LENGTH MEASUREMENTS 
There was no difference in body weight or tail length in hypothyroid, euthyroid or hyperthyroid wild 
type mice.  Since both hyperthyroidism and hypothyroidism during development impair growth, this 
data suggests that the majority of growth was complete upon commencement of thyroid 
manipulation.  TRα0/0 mice had similar body weight and tail length to wild type mice whereas TRβ-/- 
mice were smaller with a lower body weight and shorter tail length (see Figure 3.2).   
 
 
 
 
 
 
  
Figure 3.2 Growth parameters 
Weight and tail length of P112 mice. Data expressed as mean ± SEM, n=6 per 
group. Analysis by ANOVA and Tukey’s Multiple Comparison post hoc test: *, 
p<0.05; **, p<0.005 versus WT. 
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3.2.3 STRUCTURAL PARAMETERS 
3.2.3.1 Analysis of bone length and cortical thickness measurements 
Manipulation of thyroid status in adult wild type mice did not alter femur and tibia length or cortical 
thickness.  The femoral and tibial bone lengths, cortical bone diameters and cortical thickness of 
TRα0/0 mice were similar to those of wild type mice.  In contrast, TRβ-/- mice had smaller bones with 
reduced bone size (femoral and tibial length), cortical bone diameter and cortical thickness when 
compared with wild type mice (see Figure 3.3).   
 
 
 
 
 
  
Figure 3.3 Gross structural parameters 
Femur length and cortical thickness of P112 mice.  Data expressed as mean ± SEM, 
n=6 per group and analysed by ANOVA and Tukey’s Multiple Comparison post hoc 
test: *, p<0.05; **, p<0.01; ***, p<0.001 versus WT. 
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3.2.3.2 Analysis of bone microarchitecture: BSE-SEM and Micro CT 
 
The effect of altered thyroid status on the microarchitecture of bone was investigated with low and 
high magnification BSE-SEM images and micro CT.  Low power BSE-SEM views of distal femurs clearly 
demonstrate a gain in trabecular bone mass in hypothyroid animals with the trabecular 
compartment extending up the femoral shaft.  Higher magnification images show increased 
thickness and connectivity of the trabeculae (see Figure 3.4).  Similarly, micro CT showed that BV/TV 
increased by 43% compared to euthyroid mice with significantly increased Tb.Th (see Table 3.1).  
Hypothyroid and euthyroid mice had similar Tb.Sp, Tb.N and structure module index (SMI) - a 
measure of how plate-like (score 0) or rod-like (score 3) the trabeculae are. 
Conversely, thyrotoxic mice had a loss in trabecular bone mass in the distal femur with a smaller 
extension up the femoral shaft.  High magnification images showed gracile, rod-like trabeculae with 
low connectivity (see Figure 3.4).  Micro CT demonstrated a 42% decrease in BV/TV with significantly 
increased Tb.Sp, similar Tb.Th and decreased Tb.N.  Thyrotoxic mice had a lower mean SMI than 
euthyroid mice and although this did not reach significance (p=0.059), the results suggests that the 
trabeculae were more rod-like, as in the BSE-SEM images.   
TRα0/0 mice have substantially increased trabecular bone mass with notable extension of trabeculae 
up the femoral shaft.  High power BSE-SEM images reveal thicker, plate-like trabeculae, with 
increased connectivity; accordingly, BV/TV was 20% greater than wild type mice and SMI was 
significantly decreased.   Despite a highly significantly increased BV/TV, Tb.Th, spacing and number 
were not significantly different from wild type mice.  This suggests that micro CT is insufficiently 
precise to determine parameters such as Tb.Th, spacing and number. 
In contrast to TRα0/0, TRβ-/- mice have gracile, rod-like trabeculae with low connectivity largely 
confined to around the growth plate.  BV/TV in TRβ-/- mice was reduced by 22% with increased 
Tb.Sp.  There was no difference in Tb.Th, number or SMI.  
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  BV/TV (%) Tb.Th (mm) Tb.Sp (mm) Tb.N (mm2) SMI 
WT hypo 15.6±1.3** 0.05±0.002*** 0.20±0.016 3.05±0.15 1.71±0.04 
WT Eu 10.9±1.1 0.04±0.003 0.19±0.016 2.74±0.23 1.74±0.09 
WT hyper 6.3±0.8* 0.04±0.001 0.25±0.023** 1.68±0.17** 1.99±0.07 
TRα0/0 13.1±0.4* 0.04±0.001 0.19±0.006 3.11±0.1 1.64±0.02 
TRβ-/-    7.1±0.5* 0.04±0.001 0.23±0.009* 3.24±0.15 1.91±0.05 
       
 
 
 
 
 
 
3.2.4 BONE MINERAL DENSITY 
3.2.4.1 Analysis of bone mineral content 
In order to determine bone mineralisation, X-ray microradiography faxitron analysis was utilised to 
quantify bone mineral content (BMC) in femurs (largely cortical bone) and caudal vertebrae (largely 
trabecular bone).    
In hypothyroid animals, there was a site specific increase in BMC.  There was a significantly increased 
BMC (p<0.001) in femurs whereas the BMC in caudal vertebrae remained unchanged.  Thyrotoxic 
animals were osteopenic with decreased BMC in both femurs (p<0.05) and caudal vertebrae 
(p<0.001), although the decrease in BMC was more pronounced in the caudal vertebrae, compared 
to the femurs.  TRα0/0 mice had increased BMC both in the femurs and in the caudal vertebrae, whilst 
TRβ-/- mice had reduced BMC in both bone types (see Figures 3.5 and 3.6).   
 
Table 3.1 Analysis of micro CT data 
Quantitative analysis of bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular spacing 
(Tb.Sp), trabecular number (Tb.N), and structure model index (SMI) determined by micro-CT 
analysis of distal femur (n=5-6). ANOVA and Tukey’s post hoc test. *, p<0.05; **, p<0.01; ***, 
p<0.001 when compared to euthyroid wild type bones.  
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Figure 3.5 Bone mineral content of femurs 
Faxitron images of femurs (A) of P112 mice from euthyroid wild type control mice (WT 
Eu), hyperthyroid wild type mice (WT Hyper), hypothyroid wild type mice (WT Hypo),  
TRα0/0  and  TRβ-/- mice.  Scale bar 1mm.  (B) Cumulative frequency and relative 
histograms of bone mineral content for whole femurs.  Kolmogorov-Smirnov test; *, 
p<0.05; **, p<0.001 versus WT Eu/WT . 
  
 
124 
 
 
  Figure 3.6 Bone mineral content of caudal vertebrae 
Faxitron images of caudal vertebrae (A) images of P112 mice from euthyroid wild type control 
mice (WT Eu), hyperthyroid wild type mice (WT Hyper), hypothyroid wild type mice (WT Hypo),  
TRα0/0  and  TRβ-/- mice.  (Scale bar 1mm).  (B) Cumulative frequency and relative histograms of 
mineralisation densities for whole femurs.  Kolmogorov-Smirnov test; ***, p<0.001 versus WT 
Eu/WT. 
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3.2.4.2 Analysis of qBSE-SEM 
Bone micro-mineralisation density was quantified by qBSE-SEM and was assessed in three places: 
the trabeculae of the lumbar vertebrae; the trabeculae of the proximal tibia and the cortices of the 
tibia.  Hypothyroid and TRα0/0 animals had increased micro-mineralisation at all sites.   The micro-
mineralisation of thyrotoxic mice was similar to wild type mice at all sites assessed.  The micro-
mineralisation of bone from TRβ-/- mice was increased in lumbar trabeculae, decreased in the 
trabeculae of the tibia and similar to wild type controls in the cortical bones (see Figures 3.7-9).     
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3.2.5 BONE FORMATION: P1NP AND BFR 
The activity of osteoblasts was assessed by quantifying dynamic bone formation parameters and 
serum bone formation marker P1NP.   
Hypothyroid wild type mice had a significantly reduced BFR when compared to euthyroid controls 
(Figure 3.10).  The decreased BFR was due to a reduction in both MA and MS/BS.  Calcein labelling in 
these hypothyroid mice was almost absent as shown in Figure 3.11.  
Mean serum P1NP levels in hypothyroid mice, although lower than controls, did not reach 
significance on statistical analysis.  This is likely to be due to the wide variation in P1NP levels in the 
WT controls.   
In hyperthyroid wild type mice, dynamic histomorphometric analysis demonstrated an increased BFR 
when compared to euthyroid controls.  This was predominantly due to an increased MS/BS as the 
MAR was similar to controls.  Analysis of mean serum P1NP levels in hyperthyroid compared to 
euthyroid controls did not show any statistical difference (see Figure 3.12).  
Measurements of dynamic bone formation and serum P1NP parameters were similar in TRα0/0 and 
TRβ-/- wild type mice, suggesting that changes in bone mass may result from differences in bone 
resorption. 
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Figure 3.10 Dynamic bone formation parameters 
Bone formation in lumbar vertebrae of P112 euthyroid wild type control mice (WT 
Eu), hyperthyroid wild type mice (WT Hyper), hypothyroid wild type mice (WT Hypo), 
TRα0/0 and TRβ-/- mice.  CSLM views of trabecular bone (scale bar 10 µm).  Trabecular 
bone mineralising surface, MAR and BFR determined by dual calcein labelling.  Data 
expressed as mean ± SEM, n=4 per group and analysed by ANOVA and Tukey’s 
Multiple Comparison post hoc test: **, p<0.01; ***, p<0.001 versus euthyroid wild 
type. 
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Figure 3.12 Serum P1NP concentrations 
Serum samples were obtained from mice at sacrifice and stored at -80oC.  N-
terminal P1NP was determined by enzyme immunoassay (Immunodiagnostic 
systems kit AC-33 F1).  Data expressed as mean ± SEM, n=3-4 per group and 
analysed by ANOVA and Tukey’s Multiple Comparison post hoc test did not 
show significant differences between groups compared to wild type. 
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3.2.6 BONE RESORPTION: CTX, CORTICAL RESORPTION, OSTEOCLAST PARAMETERS 
Bone resorption was quantified by serum CTX (which is released into the serum when bone is 
resorbed and so is an indication of overall resorption), osteoclast histomorphometric parameters 
and by assessing evidence of bone resorption on the internal (endocortical) cortical surfaces (see 
Figures 3.13-1.16).    
In hypothyroid mice, decreased resorption parameters would be expected in light of an increased 
bone mass alongside a decreased BFR; this was indeed the case.  Decreased osteoclast activity in 
hypothyroid mice compared to euthyroid controls was evidenced by a serum CTX at the lower limits 
of the detection range and significantly decreased osteoclast (decreased Oc.N/BS and Oc.N per bone 
perimeter).  Analysis of endocortical resorption pits did not show any significant difference and this 
is may be due to the presence of resorption pits that remained from before the induction of 
hypothyroidism.  
In hyperthyroid, TRα0/0 and TRβ-/- mice, no difference in serum CTX, endosteal resorption or 
histomorphometric parameters compared to euthyroid controls was detected.   
 
 
 
 
 
Figure 3.13 Serum bone resorption markers 
Serum samples were obtained from mice at sacrifice and stored at -80oC.  C-
terminal cross-linked telopeptide of type I collagen (CTX) concentrations were 
determined by enzyme immunoassay.  Data expressed as mean ± SEM, n=3-4 
per group and analysed by ANOVA and Tukey’s Multiple Comparison post hoc 
test.   
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Figure 3.14 Endosteal resorption parameters 
Quantitative analysis of endosteal osteoclast resorption surfaces 
(% of total BS) from P112 euthyroid wild type control mice (WT 
Eu), hyperthyroid wild type mice (WT Hyper), hypothyroid wild 
type mice (WT Hypo), TRα0/0 and TRβ-/- mice. Data expressed as 
mean ± SEM, n=4 per group and analysed by ANOVA.  Images of 
endosteal surfaces with minimal resorption (A) and with active 
resorption (B).  White arrows illustrate resorption pits. 
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Figure 3.16 Analysis of histomorphometric osteoclast parameters    
Bone and osteoclast indices in proximal humerus of P112 euthyroid wild 
type control mice (Eu), hyperthyroid wild type mice (Hyper), hypothyroid 
wild type mice (Hypo), TRα0/0 and TRβ-/- mice.   BV/TV of the area of 
analysis is shown.  Oc.S/BS and Oc.N/BS graphs are shown.  Data expressed 
as mean ± SEM, n=4 per group and analysed by ANOVA and Tukey’s 
Multiple Comparison post hoc test: *, p<0.05; **, p<0.001 versus 
euthyroid wild type mice. 
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3.2.7 BIOMECHANICAL TESTING 
The effects of thyroid status manipulation during adulthood on bone did not significantly alter the 
mechanical properties of the bones when assessed by three point bending.  The TRα0/0 mice had 
similar biomechanical properties as wild type but the long bones of TRβ-/- mice were weaker with 
lower stiffness and lower yield, maximum and fracture load (see Figure 3.17). 
 
 
 
 
 
 
  
Figure 3.17 Biomechanical properties 
Graphs showing yield load, maximum load, fracture load and stiffness in tibias of P112 
euthyroid wild type control mice (WT Eu), hyperthyroid wild type mice (WT Hyper), 
hypothyroid wild type mice (WT Hypo),  TRα0/0  and  TRβ-/- mice. Data expressed as mean ± 
SEM, n=4-6 per group and analysed by ANOVA and Tukey’s Multiple Comparison post hoc; 
*, p<0.05, ***, p<0.001 versus euthyroid wild type mice. 
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3.3 SUMMARY OF RESULTS 
 
 
 
 
 
  
 WT Hypo vs. WT  TRα0/0 vs. 
WT 
 WT Hyper vs. WT  TRβ-/- vs. WT 
Weight → →  → ↓↓ 
Tail length → →  → ↓ 
Femur length → →  → ↓ 
Tibial length → →  → ↓↓ 
Cortical  diameter → →  → ↓↓↓ 
Cortical thickness → →  → ↓↓ 
µCT BV/TV ↑↑↑ ↑  ↓ ↓ 
Femoral BMC ↑↑↑ ↑↑↑  ↓ ↓↓↓ 
Caudal Vert BMC → ↑↑↑  ↓↓↓ ↓↓↓ 
qBSE SEM 
Lumbar trabeculae 
↑↑↑ ↑↑↑  → ↑↑↑ 
qBSE SEM 
Tibial trabeculae 
↑↑↑ ↑↑↑  ↑↑↑ ↓↓ 
qBSE SEM 
Tibial cortices 
↑↑↑ ↑↑↑  ↑↑↑ → 
BFR ↓↓ →  → → 
MAR 
BS/BS 
↓↓↓ 
↓↓↓ 
→ 
→ 
 → 
↑↑↑ 
→ 
→ 
P1NP → →  → → 
CTX → →  → → 
Oc.S/BS ↓ →  → → 
N.Oc/B.Pm ↓↓ →  → → 
Resorption  → →  → → 
Yield Load → →  → ↓↓↓ 
Max Load → →  → ↓↓↓ 
Fracture Load → →  → ↓ 
Stiffness → →  → ↓ 
Table 3.2 Summary of skeletal phenotyping 
Results of skeletal phenotyping parameters of hypothyroid (WT hypo), TRα0/0, hyperthyroid (WT hyper) 
and TRβ-/- mice as compared to (vs) wild type mice controls (WT eu).  The level of significant difference of 
parameters compared to wild type controls are indicated by numbers of arrows: 1 arrow p<0.05, 2 
arrows p<0.01, 3 arrows p<0.001 and direction of arrow: up indicates greater than and down indicates 
lower than control data. → indicates no significant difference. 
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3.4 DISCUSSION 
To date, the published literature has shown that the skeletal phenotypes of TRα0/0 and TRβ-/- mice 
are similar to those of mice with hypothyroidism and hyperthyroidism respectively. This has led to 
the hypothesis that TRα0/0 mice have decreased skeletal T3 signalling due to a lack of TRα in skeletal 
tissue and TRβ-/- mice have increased skeletal T3 signalling due to the increase in circulating thyroid 
hormones and intact TRα.  The results of my experiments suggest that this may only be partially 
correct. 
The skeletal phenotype of TRα0/0 mice analysed in the experiments presented in this chapter, is in 
agreement with the published literature.  However, in addition to what is known, the novel data 
presented in this chapter provides evidence that TRα0/0  mice, unlike hypothyroid mice, have similar 
osteoblastic BFRs to those of wild type controls. 
This observation suggests that the increased bone mass in TRα0/0  mice is secondary to decreased 
osteoclast resorption and that there is an uncoupling of bone resorption and formation.  
Unfortunately, the parameters used, for assessment of bone resorption in these experiments were 
not sufficiently sensitive to detect any changes in TRα0/0  mice.  
TRβ-/- mice have skeletal phenotyping similar to that of mice with thyrotoxicosis, with reduced BMC 
as a consequence of increased resorption and formation (a high bone turnover osteoporosis) 
(Bassett and Williams, 2009).   
 
3.4.1 Changes in growth and gross structural parameters may be related to duration of disruption 
of tissue thyroid status 
Serum concentrations of fT4 and fT3 confirmed that manipulation of thyroid status in wild type mice 
had the desired effect (see Table 2.1).  Treatment with T4 in wild type mice was intended to induce 
hyperthyroidism without extreme thyrotoxicosis and accordingly did not result in a reduction in 
weight as would be expected in thyrotoxicosis.   
During early life and puberty, the skeleton undergoes a period of rapid expansion and remodelling 
before reaching peak bone mass, after which the skeleton remains in a relatively stable state.  In 
mice, the majority of growth is usually complete by around 10 weeks of age, which is the age at 
which thyroid status manipulation was commenced in the hypo and thyrotoxic groups.  
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Both hypothyroid and TRα0/0 mice were not growth impaired, and had similar gross structural bone 
parameters, including femur and tibial length and cortical bone diameter and thickness, when 
compared with euthyroid controls.  Whilst hyperthyroid mice also had similar growth and gross 
structural parameters as controls, TRβ-/- mice were lighter, with a shorter tail length, diminished 
cortical bone diameter and thickness and shorter long bones compared to euthyroid controls.   
The differences in growth and gross structural parameters between hyperthyroid and TRβ-/- mice 
could have been as a result of either a lack of TRβ or the length of time that the mice had been 
thyrotoxic.  TRβ-/- mice have been thyrotoxic throughout development and normal bone 
development is already impaired.  These mice therefore have a more pronounced phenotype when 
compared to the wild type mice used in this experiment that have undergone a relatively short 
duration (6 weeks) of thyroid status manipulation.   Further studies that could clarify this hypothesis 
include skeletal phenotyping of an inducible knockout model where the TR has been knocked out in 
adult mice for the same amount of time as the wild type mice have been rendered hyper and 
hypothyroid.  
 
3.4.2 Micro architecture in TRα0/0 mice is similar to hypothyroid mice and microarchitecture in 
TRβ-/- mice is similar to thyrotoxic mice 
Despite the lack of change in bone length and cortical diameter and thickness in wild type 
hypothyroid and hyperthyroid mice, micro CT and BSE-SEM analysis demonstrate substantial 
changes in bone microarchitecture.  TRα0/0 mice are similar to hypothyroid mice, with increased 
BV/TV and coarse, plate-like trabeculae, whilst TRβ-/- mice are similar to thyrotoxic mice and show 
decreased BV/TV with gracile trabeculae.    
The micro CT data in TRα0/0 mice showed a 20% greater BV/TV than controls but incongruously, no 
difference in Tb.Th, Tb.Sp or Tb.N.  Inconsistencies in micro CT data are also seen in the hypothyroid 
group, where the data shows a 43% greater BV/TV, with a significantly elevated Tb.Th but with no 
difference in Tb.N or Tb.Sp.  These results are incongruous because an increased Tb.Th with no 
difference in Tb.N should result in a decrease in Tb.Sp.  Alternatively, an increased Tb.Th with no 
difference in Tb.Sp should result in a decrease in Tb.N.  These anomalies suggest that some of the 
micro CT data may not be of sufficient precision and are likely to have arisen due to insufficient 
resolution.  Micro CT is reported to have a detection pixel size of 4.3µm3, which may not be a high 
enough resolution to detect differences in these parameters.  Another possibility is that the real 
resolution of imaging used for deriving the results is lower than reported.  In both cases, the 
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accuracy of the smaller measures such as Tb.N, Tb.Sp, Tb.N and SMI could have been compromised.  
The limitations of micro CT, as demonstrated by the data, highlight the importance of using a 
number of complementary techniques in assessing the skeleton.  In this way, an overall picture can 
be built up that provides a more accurate reflection of the skeletal phenotype. 
 
3.4.3 Changes in bone mineralisation are site specific  
Comparisons were further investigated by assessing and comparing bone mineralisation.    
Hypothyroid animals had an increased BMC, which was highly significant in the femurs but not in the 
caudal vertebrae.  This site specific difference in BMC can be attributed to femurs consisting 
predominantly of cortical bone whereas caudal vertebrae consist predominantly of cancellous bone.  
Although the increases in BMC in the femurs are likely to be due to cortical changes, cortical 
thickness and cortical bone width in hypothyroid mice and euthyroid mice were similar.  This 
suggests that the increase in femoral BMC in the hypothyroid group is likely to be a consequence of 
increased micro-mineralisation.  This was confirmed by qBSE-SEM analysis which showed that micro-
mineralisation was significantly increased in all hypothyroid bones assessed.  TRα0/0 mice showed 
similar but more pronounced changes in BMD with increased BMC and micro-mineralisation at all 
skeletal sites evaluated.   
The significant increase in micro-mineralisation in hypothyroid mice suggests that thyroid hormone 
is important in the normal regulation of mineralisation.  A potential mechanism for this may be the 
effects of hypothyroidism on the osteocytes, although this would need further investigation. 
Whilst hypothyroidism seems to affect cortical bone predominantly, the effect of hyperthyroidism 
on BMC is more pronounced in the caudal vertebrae.  The decrease in bone mass is a consequence 
of decreased trabecular volume as shown by the micro CT data rather than a decrease in micro-
mineralisation.  TRβ-/- mice having been thyrotoxic throughout development, have a more 
pronounced phenotype and therefore have lower BMC at both the femur and caudal vertebrae.   
Micro-mineralisation in TRβ-/- mice was higher than controls in the lumbar trabeculae, lower at the 
tibial trabeculae and no difference in the cortices.  These inconsistencies may be as a result of site 
specific differences in micro-mineralisation, but to draw meaningful conclusions from this data, this 
finding would ideally be repeated. 
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3.4.4 Bone formation in TRα0/0 mice is similar to controls 
To further assess the mechanism of skeletal changes, bone formation and resorption parameters 
were evaluated.  Bone formation in hypothyroid mice was almost completely absent, however, 
rather unexpectedly, TRα0/0 mice had bone formation similar to controls.  Bone formation in 
euthyroid TRα0/0 mice has not previously been described in the literature and a divergence in bone 
formation when compared to hypothyroid animals was unexpected.  This indicates that the presence 
of TRα is not essential for normal bone formation and that in the absence of TRα, thyroid signalling 
can occur via TRβ.  This was verified by the results in Chapter 4 which show that when TRα0/0 mice 
are rendered hypothyroid, the BFR becomes similar to hypothyroid animals, indicating that T3 
dependent BFR signalling is occurring via TRβ in the absence of TRα.  Interestingly, in light of normal 
bone formation in TRα0/0 mice, the increase in bone mass must therefore be secondary to decreased 
osteoclastic resorption and due to an uncoupling of the remodelling cycle.  These results also 
indicate that TRα is needed for normal osteoclastic resorption for which TRβ cannot be adequately 
substituted.  The role of TRα in osteoclastic resorption is unclear and whether this has a direct or 
secondary effect on osteoclasts.       
BFRs in hyperthyroid and TRβ-/- mice were similar to controls. Unfortunately, there was a wide 
variation in the measurements of these groups and although the mean BFR in both groups was 
higher, this was not significantly different from the controls. Hyperthyroid mice, however, did have 
an elevated MS/BS.  Serum P1NP levels also showed a high variability and whilst hypothyroid mice 
had a serum P1NP at the lower limits of the assay, assessment of bone formation in the other groups 
did not satisfactorily reflect dynamic bone formation measurements.   
Circulating serum levels of bone turnover markers (both formation P1NP and breakdown CTX) 
exhibit diurnal variation as well as seasonal variation, which may account for the large variability of 
the results.   To minimise the variability of serum bone markers, the mice were fasted and morning 
blood samples taken.  However, there were often a few hours between obtaining the serum samples 
of the first of a batch of mice compared to the last and the samples were harvested over a period of 
around 15 months which may have led to some inconsistency in the results.  It is also difficult to 
make direct comparisons between the groups because the bone mass between groups varied 
widely.  Although there is a wide variation in results, hypothyroid mice consistently had a P1NP at 
the lower limit of detection, whilst P1NP levels in TRα0/0 mice was much higher and similar to 
dynamic bone formation findings. 
  
 
143 
 
3.4.5 Bone resorption 
Hypothyroid and TRα0/0 mice have increased bone mass with low or normal BFRs.  This indicates that 
the increase in bone mass is likely to be as a result of relatively decreased osteoclast resorption.  
Conversely, hyperthyroid and TRβ-/- mice have decreased bone mass with a normal BFR, which 
indicates that there is likely to be relatively increased bone resorption. 
I chose to determine osteoclast activity by assessing three different parameters: serum 
concentration of bone breakdown marker CTX, percentage of endosteal erosion surfaces and 
osteoclast histomorphometric parameters (Oc.S/BS (%) and Oc.N/BS).  Unlike bone formation 
assessment by double labelling, there is no method of directly assessing bone resorption and the 
surrogate measures discriminates differences poorly.  
3.4.6 Resorption parameters in hypothyroid and TRα0/0 mice 
Hypothyroid mice have CTX at the lower limits of the assay and osteoclast surface and number were 
decreased.  The endosteal resorption surfaces were reduced in all but one outlier, which had 
residual erosion surfaces which were not filled after bone formation was switched off after the 
induction of hypothyroidism.  All these parameters indicate that hypothyroid mice have decreased 
bone resorption. 
Resorption parameters in TRα0/0 mice are similar to those in wild type mice but it is important to 
interpret serum CTX in light of the fact that TRα0/0 bones have increased bone volume, so direct 
comparisons to wild type mice cannot be made.  Histomorphometric osteoclast parameters such as 
Oc.S/BS and N.Oc/B.Pm are not different to controls.  CTX and histomorphometric osteoclast 
parameters are clearly higher than in hypothyroid wild type animals but this data does not indicate 
whether the osteopetrosis is secondary to dysfunction of osteoclast cells or due to osteoclast 
inactivity. It is likely that in TRα0/0 mice, resorption is impaired but still able to occur as evidenced by 
adequate modelling of the bones during growth.   
 
3.4.7 Resorption parameters in hyperthyroid and TRβ-/- mice 
Serum CTX, osteoclast parameters and endosteal resorption surfaces were not different compared 
to controls.   Previous studies in rats have shown that thyrotoxicosis results in an increase in 
resorption and osteoclast parameters but in those studies, the rats had been treated for a longer 
period and with higher doses of T4 (Ongphiphadhanakul et al., 1992).  As seen previously with the 
densitometry data, the sensitivity of bone to hyperthyroidism is also site specific and thus serum 
breakdown markers may be more likely to provide a more accurate picture of overall resorption. 
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TRβ-/- mice have a lower bone mass and although the CTX and mean Oc.N per bone perimeter were 
higher than controls, they did not reach statistical significance. 
 
3.4.8 Mechanical bone strength 
Fracture data shows that changing thyroid status does not impact mechanical bone strength in adult 
wild type mice.  This is likely to be because the thyroid status was manipulated in adult animals and 
only for a relatively short period of time (6 weeks).  TRα0/0 bones have similar mechanical properties 
to wild type controls, but TRβ-/- bones are less stiff and less strong than wild type controls.   
 
3.4.9 Summary and salient points 
In summary, TRα0/0 mice have some similar features to hypothyroid mice, such as increased bone 
mass and decreased bone resorption.   However, unlike in hypothyroidism, TRα0/0 mice have a BFR 
similar to that of wild type controls, suggesting that there is an uncoupling of bone formation and 
resorption.   
These results suggest that in the absence of TRα, T3 dependent bone formation can continue, 
compensated for by TRβ signalling.  Bone resorption, however, is more specifically dependent on T3 
signalling through TRα and is impaired in the absence of TRα.  It is not clear if TRα dependent 
osteoclast resorption is a direct or indirect effect of the action of T3 and the molecular mechanism 
for this process is a potential area of future research.  TRβ-/- mice have features of skeletal 
hyperthyroidism with a high turnover osteoporosis, but, the skeletal phenotype is more pronounced 
than that of the adult thyrotoxic mice because skeletal hyperthyroidism has been present 
throughout development.  The experiments in this chapter demonstrate that bone remodelling is 
not dependent on the presence of TRβ but the skeletal phenotype is likely to be due to elevated 
circulating levels of thyroid hormone, signalling through an intact TRα. 
The lack of discriminatory osteoclastic resorption parameters is a major short coming of these 
experiments.  The novel findings presented in this chapter highlight the importance of assessing the 
skeleton using multiple complementary phenotyping techniques (in particular, dynamic bone 
formation parameters) before determining physiological mechanisms.  
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Chapter 4 
The effects of differing thyroid status on the 
skeletal phenotype of TRα0/0 and TRβ-/- 
mice 
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4 THE EFFECTS OF DIFFERING THYROID STATUS ON THE SKELETAL PHENOTYPE 
OF TRα0/0 AND TRβ-/- MICE 
4.1 BACKGROUND 
The effects of excess thyroid hormone on the developing skeleton are anabolic, stimulating bone 
formation and resulting in increased linear growth and bone mass. In adults, the effects of excess 
thyroid hormone are catabolic, stimulating bone turnover (particularly by increasing osteoclastic 
bone resorption and bone loss) and resulting in osteoporosis (Mosekilde and Melsen, 1978).  
Conversely, insufficient thyroid hormone during development results in delayed bone maturation, 
lower bone mass and decreased linear growth.  In adults, one of the primary effects of 
hypothyroidism is decreased bone turnover, particularly due to decreased osteoclastic bone 
resorption (Eriksen et al., 1986).  The skeletal phenotyping of wild type hypo and hyperthyroid mice 
presented in Chapter 3 is in line with what is currently known in the literature.   
The role of TRα and TRβ in mediating the effects of thyroid hormone in skeletal tissue remains 
unclear.   
Previous studies of TRα0/0 and TRβ-/- mice from Professor Graham Williams’ lab, led to the proposal 
that differences in bone phenotype are accounted for by the differences in action of TRα and TRβ in 
the skeleton and in the HPT axis (Bassett and Williams, 2009).  It was hypothesised that TRα0/0 mice, 
despite having normal circulating thyroid hormone levels, have reduced skeletal T3 signalling due to 
the absence of TRα, the predominant receptor in bone.  TRβ-/- mice have RTH and have elevated 
circulating thyroid hormone levels, which result in increased T3 signalling in the skeleton through an 
intact TRα.   
The normal BFR in TRα0/0 mice, as shown in Chapter 3, suggests that thyroid hormone signalling is 
not reduced in the osteoblasts of these mice and that in the absence of TRα, TRβ is able to 
compensate.  The elevated bone mass in TRα0/0 mice, however, suggests that bone osteoclastic 
resorption is impaired and therefore TRα dependent. 
Another group, Monfoulet et al, proposed that the acute effects of changes in thyroid status were 
mediated by TRβ and that the long term chronic effects were mediated by TRα (Monfoulet et al., 
2011).  This group reached this conclusion after comparing the skeletal effects of hypothyroidism 
and thyrotoxicosis in TRα0/0 and TRβ-/- mice.  They found that after two weeks of thyroid 
manipulation, hypothyroid TRα0/0 mice had an increased BV/TV and bone density, and reduced 
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serum osteocalcin and CTX levels when compared to thyrotoxic TRα0/0 mice.  Conversely, after two 
weeks of treatment, hypothyroid TRβ-/- mice showed no differences in BV/TV, bone density or serum 
turnover parameters when compared to hyperthyroid mice.  They then extended thyroid status 
manipulation in TRβ-/- mice to five weeks and found a significantly higher BV/TV and lower MS/BS 
and Oc.S/BS in hypothyroid TRβ-/- mice.  The data presented by Monfoulet et al, however, has a 
number of limitations.  For example, data for the skeletal phenotypes of euthyroid TRα0/0 and TRβ-/- 
mice was not provided, so the individual effects of hyperthyroidism versus hypothyroidism on the 
skeleton are not clear.  Micro CT with a resolution of 16µm was used to measure differences in 
trabecular parameters such as Tb.N and thickness.  However, given the scan resolution, the reported 
significant differences in Tb.Th of less than 10 µm are unlikely to be accurate. Additionally, the 
authors were surprised to find that double labelling in T4 treated mice was 54% lower than in 
untreated mice.  They then also noted that there was considerable fragmentation of the double 
labels and therefore surmised that MAR and BFR could not be reliably measured.   Despite the 
observation that double labelling measurements were unreliable, they continued to use MS/BS data 
to support their conclusions.  These limitations in data analysis have led to controversies in the 
interpretation of the data.    
In this chapter, I describe the effects of hypothyroid, euthyroid and hyperthyroid status on the 
skeletal phenotype of adult TRα0/0 and TRβ-/- mice in order to clarify the role of liganded and 
unliganded TRα and TRβ in the skeleton.  I have used a number of techniques to verify the skeletal 
phenotype.  Of particular note, micro CT analysis was performed on images with 4.3 µm resolutions 
giving greater accuracy to measurement and calcein double labels were administered intravenously 
with a short interlabel interval to increase accuracy of measurements. The data obtained and 
presented in this chapter provides important new information about the effects of increased thyroid 
hormone signalling through each receptor and the effects of unliganded receptors on the skeleton. 
 
4.2 RESULTS 
4.2.1 CIRCULATING THYROID HORMONE STATUS 
Thyroid manipulation to induce hypothyroidism with low iodine diet and PTU was effective with 
serum levels of fT4 below the limits of detection in all groups of treated mice (Figure 4.1).  For 
hyperthyroid groups, TRα0/0 mice were treated with 1.2 ml/l of T4 which resulted in a significantly 
elevated serum T4, whilst TRβ-/- mice remained untreated but had significantly elevated circulating 
T3 and T4 compared to euthyroid wild type mice (see data in Chapter 3). For the euthyroid group, 
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TRα0/0 mice remained untreated and had a normal circulating thyroid hormone status, whilst TRβ-/- 
mice were rendered euthyroid by administering a low iodine diet with PTU alongside physiological 
concentrations of T3 (block and replace).  T3, and not T4, was required to render the mice euthyroid 
because PTU has actions to block deiodinase 1 activity and so prevents the conversion of 
prohormone T4 to T3.  Serum T3 levels in treated TRβ-/- mice were not significantly different to 
euthyroid wild type mice, confirming euthyroid circulating thyroid hormone status (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.1 Circulating thyroid hormone status 
Serum free T4 and free T3 concentrations (pmol/litre) in P112 mice.  
Data expressed as mean ± SEM, n=6 per group and analysed by ANOVA and Tukey’s 
Multiple Comparison post hoc test: ***, p<0.001 versus euthyroid animals in the same 
groups.   Serum free T4 levels for Hypo groups were below the lower limit of detection of 
the assay. 
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4.2.2 GROWTH 
4.2.2.1 Body weight and tail length measurements 
Manipulation of thyroid status in adult TRα0/0 and TRβ-/- mice did not have a significant impact on 
weight or tail length.  This is likely to be because the majority of growth was complete at the onset 
of thyroid status manipulation and so change in thyroid status was predominantly affecting 
remodelling and not modelling (see Figure 4.2). 
 
 
   
 
 
 
 
  
Figure 4.2 Growth parameters 
Weight and tail length of P112 mice. Data expressed as mean ± 
SEM, n=6 per group and analysed by ANOVA and Tukey’s Multiple 
Comparison post hoc test: no significant difference in any group 
when compared to euthyroid mice. 
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4.2.3 STRUCTURAL PARAMETERS 
4.2.3.1 Bone length and cortical measurements 
There was no difference in femur or tibial length in adult TRα0/0 and TRβ-/- mice as a result of change 
in thyroid status (Figure 4.3).  However, rendering TRα0/0 mice thyrotoxic resulted in a reduction in 
cortical thickness without any change in cortical bone diameter (Figure 4.3).  Alterations in thyroid 
status did not result in changes in bone length or cortical measurements in TRβ-/- mice.    
 
 
 
 
  
Figure 4.3 Gross structural parameters 
Femur length and cortical thickness of P112 mice.  Data expressed as mean 
± SEM, n=6 per group and analysed by ANOVA and Tukey’s Multiple 
Comparison post hoc test: *, p<0.05; versus euthyroid group. 
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4.2.3.2 Bone microarchitecture: BSE-SEM and micro CT 
Micro CT measurements of trabecular bone were analysed in the region above the growth plate of 
the distal femur.  The results for adult TRα0/0 and TRβ-/- mice with differing thyroid status are set out 
in Table 4.1.  BV/TV was similar in hypothyroid and euthyroid TRα0/0 mice (14.7±1.9% versus 
13.1±0.4% respectively).  Trabeculae of hypothyroid and euthyroid TRα0/0 femurs looked very similar 
in SEM images (see Figure 4.4).  SEM images of distal femoral trabeculae in hyperthyroid TRα0/0 mice 
appear similar to those of euthyroid TRα0/0 mice near the growth plate but are less coarse and less 
closely spaced further up the shaft of the femur (Figure 4.4).  The micro CT BV/TV parameters in 
hyperthyroid TRα0/0 mice are lower but not significantly different to euthyroid and hypothyroid 
TRα0/0 mice (ANOVA and Tukey’s post hoc test not significant). 
In TRβ-/- mice, there was a 63% increase in BV/TV in hypothyroid versus euthyroid groups (Table 4.1), 
which may be the result of an apoTRα effect.  There was no difference in BV/TV when hyperthyroid 
TRβ-/- mice were rendered euthyroid.  SEM images of the distal femurs also reflected the micro CT 
indices, suggesting more plate-like and coarse trabeculae in the hypothyroid TRβ-/- femur and scanty, 
gracile trabeculae in the euthyroid and hyperthyroid bones (Figure 4.4). 
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  BV/TV (%) Tb.Th(mm) Tb.Sp (mm) Tb.N (mm2) SMI 
TRα0/0 Hypo 14.7±1.9 0.05±0.001 0.18±0.009 3.16±0.29 0.83±0.08 
TRα0/0 Eu 13.1±0.4 0.04±0.001 0.19±0.006 3.11±0.1 1.64±0.02 
TRα0/0 Hyper 11.8±0.4 0.04±0.001 0.18±0.005 2.96±0.22 1.75±0.09 
  
     TRβ-/- Hypo 12.6±1.1** 0.05±0.002** 0.21±0.006 2.59±0.17* 1.87±0.06 
TRβ-/- Eu 7.7±0.8 0.04±0.001 0.22±0.005 1.96±0.16 2.06±0.07 
TRβ-/- Hyper 7.1±0.5 0.04±0.001 0.23±0.009 3.24±0.15*** 1.91±0.05 
       
 
 
 
 
 
4.2.4 BONE MINERAL DENSITY 
4.2.4.1 BMC: Faxitron Analysis 
Cumulative and relative histograms of mineralisation density for femurs and caudal vertebrae are 
shown in Figures 4.5 and 4.6.  BMC is unchanged in both the femur and the caudal vertebrae in 
hypothyroid TRα0/0 mice compared to the euthyroid group, but significantly reduced BMC when the 
mice are rendered hyperthyroid.  Conversely, TRβ-/- mice have significantly increased BMC in both 
the femur and caudal vertebrae when rendered hypothyroid but similar BMC when euthyroid and 
hyperthyroid groups are compared (Figures 4.5 and 4.6).  Unlike wild type mice, the changes to BMC 
are similar in both the femur and caudal vertebrae (see Chapter 3).     
 
 
Table 4.1 Analysis of micro CT data 
Quantitative analysis of bone volume (BV/TV), Trabecular thickness (Tb.Th), 
trabecular spacing (Tb.Sp), trabecular number (Tb.N), and structure model index 
(SMI) determined by micro CT analysis of distal femur (n=5-6). ANOVA and Tukey’s 
post hoc test. *, P<0.05; **, P<0.01; ***, P<0.001 when compared to euthyroid 
bones of the same genotype. 
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 Figure 4.5 Bone mineral content of femurs 
Faxitron images of femurs of P112 mice.  Grey scale images were 
pseudocoloured with a 16 colour palette where low mineralisation 
density is black and high density is white.  (Scale bar 1mm).  
Cumulative frequency histograms of mineralisation densities for 
whole femurs.  Kolmogorov-Smirnov test ***, p<0.001 versus 
euthyroid wild type mice. 
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Figure 4.6 Bone mineral content of caudal vertebrae 
Faxitron images of caudal vertebrae (A) of P112 mice.  Grey 
scale images were pseudocoloured with a 16 colour palette 
where low mineralisation density is black and high density is 
white.  (Scale bar 1mm).  Cumulative frequency histograms 
(B) of mineralisation densities for whole femurs.  
Kolmogorov-Smirnov test; **, p<0.01; ***, p<0.001 versus 
euthyroid wild type mice. 
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4.2.4.2 Micro-mineralisation: qBSE-SEM 
Cumulative and relative histograms of micro-mineralisation of the lumbar vertebrae are shown in 
Figure 4.7.  Micro-mineralisation is increased in hypothyroid and decreased in hyperthyroid TRα0/0 
mice at the lumbar vertebrae, when compared to euthyroid TRα0/0 mice.    Unexpectedly, micro-
mineralisation in the lumbar vertebrae of TRβ-/- mice was highest in the euthyroid group when 
compared to either hypothyroid or hyperthyroid TRβ-/- mice.  To verify this finding, micro-
mineralisation was repeated in the tibia (Figure 4.8).  There was decreased micro-mineralisation in 
the hyperthyroid mice and increased micro-mineralisation in hypothyroid TRβ-/- mice at the tibial 
trabeculae. The results of micro-mineralisation analysis in the cortices showed a similar pattern of 
results as the lumbar vertebrae, with increased micro-mineralisation in both the hyper and 
hypothyroid TRβ-/- mice, when compared to euthyroid mice.     
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Figure 4.7 Micro-mineralisation of lumbar vertebrae 
qBSE-SEM images of lumbar vertebrae P112 mice of TRα0/0 and TRβ-/- mice.  
Grey scale images were pseudocoloured to an eight colour palette; low 
mineralisation is blue and high density is grey.  Cumulative frequency 
histograms of mineralisation densities.  Kolmogorov-Smirnov test; ***, p<0.001 
versus euthyroid wild type mice. 
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Figure 4.8 Micro-mineralisation of tibial trabeculae and cortical bone 
qBSE-SEM images of trabeculae and cortices of  P112 TRβ-/- mice with 
manipulated thyroid status.  Grey scale images were pseudocoloured with an 
eight colour palette; low mineralisation density is blue and high density is 
grey.  Cumulative frequency histograms of mineralisation densities.  
Kolmogorov-Smirnov test; **, p<0.01; ***, p<0.001 versus euthyroid wild type 
mice. 
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4.2.5 BONE FORMATION: P1NP AND BFR 
Bone formation was assessed by both serum markers for P1NP (Figure 4.9) and dynamic bone 
formation (Figure 4.10).  In hypothyroid TRα0/0 mice, serum P1NP and BFR are significantly lower 
than in euthyroid TRα0/0 mice.  This indicates that thyroid hormone is important in bone formation in 
TRα0/0 mice.  Hypothyroid TRβ-/- mice also have reduced MS/BS and BFR compared to the euthyroid 
group but P1NP was not different between the groups.  Of particular note, when comparing the 
bone formation of hypothyroid wild type (results in Chapter 3), hypothyroid TRα0/0 and hypothyroid 
TRβ-/- mice, bone formation is fourfold greater in hypothyroid TRα0/0 mice and significantly higher 
(p<0.05, ANOVA and Tukey’s Multiple Comparison post hoc test) when compared to hypothyroid 
wild type or hypothyroid TRβ-/- mice.  Hyperthyroid TRα0/0 mice had similar serum P1NP and dynamic 
bone formation indices to euthyroid TRα0/0 mice.  Hyperthyroid TRβ-/- mice had significantly higher 
BS/MS and BFR compared to euthyroid TRβ-/- mice, although serum P1NP was not significantly 
different.  
      
 
Figure 4.9 Serum P1NP concentrations 
Serum samples were obtained from mice at sacrifice and stored at -80oC.  P1NP 
concentrations were determined by enzyme immunoassay (Immunodiagnostic systems kit 
AC-33 F1).  Data expressed as mean ± SEM, n=3-4 per group and analysed by ANOVA and 
Tukey’s Multiple Comparison post hoc test: **, p<0.005; versus euthyroid wild type mice. 
  
 
160 
 
 
Fi
gu
re
 4
.1
0 
D
yn
am
ic
 b
o
n
e 
fo
rm
at
io
n
 p
ar
am
e
te
rs
 
B
o
n
e 
fo
rm
at
io
n
 i
n
 l
u
m
b
ar
 v
er
te
b
ra
e 
o
f 
P
1
1
2
. 
 C
SL
M
 v
ie
w
s 
o
f 
tr
ab
ec
u
la
r 
b
o
n
e 
(s
ca
le
 b
ar
 1
0
 µ
m
).
  
Tr
ab
ec
u
la
r 
b
o
n
e 
m
in
er
al
is
in
g 
su
rf
ac
e,
 M
A
R
 a
n
d
 B
FR
 d
et
er
m
in
ed
 b
y 
d
u
al
 c
al
ce
in
 l
ab
el
lin
g.
  
D
at
a 
ex
p
re
ss
ed
 a
s 
m
ea
n
 ±
 S
EM
, 
n
=4
 p
er
 g
ro
u
p
 
an
d
 a
n
al
ys
ed
 b
y 
A
N
O
V
A
 a
n
d
 T
u
ke
y’
s 
M
u
lt
ip
le
 C
o
m
p
ar
is
o
n
 p
o
st
 h
o
c 
te
st
: 
*,
 p
<0
.0
5
; 
**
, 
p
<0
.0
0
5
; 
**
*,
 p
<0
.0
0
1
 v
er
su
s 
eu
th
yr
o
id
 w
ild
 t
yp
e 
m
ic
e.
 
 
  
 
161 
 
4.2.6 BONE RESORPTION: CTX AND ENDOCORTICAL RESORPTION 
Serum levels of bone resorption marker CTX (Figure 4.11) and endocortical resorption (Figure 4.12), 
as assessed by percentage of surface covered with resorption pits, was higher in hyperthyroid TRα0/0 
mice when compared to euthyroid controls.    
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Serum bone resorption markers 
Serum samples were obtained from mice at sacrifice and 
stored at -80oC.  C-terminal cross-linked telopeptide of type I 
collagen (CTX) concentrations were determined by enzyme 
immunoassay (AC06F1).  Data expressed as mean ± SEM, 
n=3-4 per group and analysed by ANOVA and Tukey’s 
Multiple Comparison post hoc test: *, p<0.05 versus 
euthyroid type mice in respective genotypes. 
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Figure 4.12 Bone resorption parameters 
Quantitative analysis of endosteal osteoclast resorption 
surfaces from BSE-SEM images (% of total BS) of P112 
mice. Data expressed as mean ± SEM, n=3-4 per group 
and analysed by ANOVA and Tukey’s Multiple 
Comparison post hoc test: no groups were significantly 
different. 
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4.2.7 BIOMECHANICAL TESTING 
Mechanical testing of tibias by three point bending assessed for differences in yield load, fracture 
load, maximum load and stiffness.  Although there was no significant change in the mechanical 
properties that could be statistically detected (Figure 4.13), TRβ-/- mice showed an inverse non-
significant trend in all parameters to thyroid hormone levels. 
  
Figure 4.13 Mechanical properties 
Graphs showing yield load, maximum load, fracture load and 
stiffness in tibias of P112 mice. Data expressed as mean ± 
SEM, n=4-6 per group and analysed by ANOVA and Tukey’s 
Multiple Comparison post hoc test: in no groups did altering 
thyroid status significantly affect mechanical properties. 
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4.3 SUMMARY OF RESULTS 
 WT 
Hypo 
 
Hyper 
 
 
TRα0/0 
Hypo 
 
Hyper 
 
 
TRβ-/- 
Hypo 
 
Hyper 
Weight → →  → →  → → 
Tail length → →  → →  → → 
Femur length → →  → →  → → 
Tibial length → →  → →  → → 
Cortical  diameter → →  → →  → → 
Cortical thickness → →  → ↓  → → 
µCT BV/TV ↑↑ ↓  → →  ↑↑ → 
Femoral BMC ↑↑↑ →  → ↓↓↓  ↑↑↑ → 
Vert BMC → ↓↓↓  → ↓↓↓  ↑↑↑ → 
qBSE SEM Lumbar 
vertebral trabeculae 
↑↑↑ →  ↑↑↑ ↓↓↓  ↑↑↑ ↑↑↑ 
qBSE SEM 
Tibial trabeculae 
      ↑↑↑ ↓↓ 
qBSE SEM 
Tibial cortices 
      ↑↑↑ ↑↑↑ 
BFR ↓↓ →  ↓↓↓ →  ↓ ↑↑ 
MAR 
BS/BS 
↓↓↓ 
↓↓↓ 
→ 
↑↑ 
 → 
↓↓ 
→ 
→ 
 → 
↓↓↓ 
→ 
↑↑ 
P1NP → →  ↓↓ →  → → 
CTX → →  ↑ →  → → 
Oc.S/BS ↓ →       
N.Oc/B.Pm ↓↓ →       
% Resorption  ↓ →  → →  → → 
 
 
 
 
 
 
 
 
 
 
  
Table 4.2 Summary of effects of alteration in thyroid status in TRα0/0 and TRβ-/- 
mice compared to euthyroid status in respective genotype 
 → No significant difference, ↑ significant increase, ↓ significant decrease.  Number 
of arrows indicates significance level: 1 arrow p<0.05, 2 arrows p<0.01, 3 arrows 
p<0.001. 
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4.4 DISCUSSION 
During development, thyroid hormones stimulate bone formation, mineral deposition and linear 
growth.  These effects are anabolic.  By contrast, in adults, thyroid hormones stimulate bone 
turnover, particularly increasing osteoclastic bone resorption and bone loss, resulting in 
osteoporosis.  These effects are catabolic.  The age at which changes in thyroid hormone status 
occurs can therefore result in either anabolic effects or catabolic effects.  The severity to which 
circulating thyroid hormone status is altered is likely to be important to the degree of effect on bone 
and as to whether such effects can be detected by phenotyping. 
Changes to the skeleton are influenced by the pre-existing bone structure – in the case of TRα0/0 and 
TRβ-/- mice, changes to the skeleton have been present throughout growth.  
To be able to understand to the effects of thyroid status manipulation on the skeleton, it is therefore 
critically important to consider three points: 
1. The age at which thyroid status is being manipulated. 
2. The degree and length of thyroid manipulation prior to skeletal phenotyping.  
3. Whether the skeletal phenotype was affected during growth and development prior to 
manipulation of thyroid status. 
The experiments in this thesis were performed when the mice were adults (P70-P112).  
Manipulation of thyroid hormone in these experiments rendered mice severely hypothyroid but only 
mildly hyperthyroid.  This was demonstrated by the very low serum thyroid hormone levels in all the 
hypothyroid groups and only mildly elevated thyroid hormone levels in hyperthyroid TRα0/0 and wild 
type mice (untreated TRβ-/- mice are very thyrotoxic).   
It is important to note that untreated skeletal phenotypes of TRα0/0 and TRβ-/- mice are significantly 
different from those of wild type mice both during development and in adulthood.  Therefore, 
comparisons need to be made to the euthyroid skeleton of the corresponding genotype, rather than 
against wild type mice, in order to elicit any changes to the skeletal phenotype resulting from altered 
thyroid status.  
Type 2 deiodinase in target cells is regulated by the concentration of T4, which maintains a constant 
supply of T3 to the nucleus over a range of circulating hormone concentrations.  This regulatory 
mechanism is only overridden at the extremes of hypothyroidism, as was the case in the mice used 
in the experiments presented in this thesis.  The manipulation of thyroid hormone status in mice 
lacking TRα and TRβ provides important information regarding the roles of liganded and unliganded 
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thyroid hormone receptors in bone.  The presence of liganded or unliganded receptors is 
summarised in Table 4.3. 
 
  Wild Type TRα0/0 TRβ-/- 
Hyperthyroid 
TRα Liganded Absent Liganded 
TRβ Liganded Liganded Absent 
Euthyroid 
TRα Liganded Absent Liganded 
TRβ Liganded Liganded Absent 
Hypothyroid 
TRα Unliganded Absent Unliganded 
TRβ Unliganded Unliganded Absent 
 
 
 
 
4.4.1 Skeletal effects of thyroid status in TRα0/0 mice 
Euthyroid TRα0/0 mice have similar bone formation to wild type mice but have increased BMC as a 
result of decreased osteoclast resorption (see results Chapter 3).  Rendering TRα0/0 mice hypothyroid 
decreases bone formation, suggesting that thyroid hormone is important in bone formation but also 
demonstrates that bone formation is not dependent on the presence of TRα, and that in its absence, 
TRβ can compensate.   
Rendering adult TRα0/0 mice hypothyroid had no effect on bone length, cortical measures, BMC or 
femoral BV/TV when compared to euthyroid TRα0/0 mice.  This is likely to be because TRα0/0 mice 
may already have decreased osteoclast resorption which could account for most of the acute 
changes in bone structure (as seen in the comparison between TRα0/0 and wild type skeletal 
phenotypes – see results Chapter 3).  Reduction in bone formation probably has a smaller role in 
changing the aforementioned elements of the adult skeletal phenotype. 
Table 4.3  Table showing the presence of liganded or unliganded TRα and TRβ in the 
different treatment groups 
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Low turnover bone which is not removed quickly has more time for secondary or passive 
mineralisation to occur, which results in increased micro-mineralisation (Boivin and Meunier, 2002).   
Hypothyroid TRα0/0 mice had decreased bone formation and resorption and in line with this, had 
elevated micro-mineralisation.   
When TRα0/0 mice were rendered hyperthyroid, there was a decrease in cortical thickness, lower 
BMC at both the femur and caudal vertebrae and a decrease in micro-mineralisation.  These effects 
are due to an uncoupling of bone formation and resorption, with BFR being unaffected by higher 
circulating thyroid hormone levels but resorption being elevated, resulting in a net negative balance 
and significant bone loss. 
As TRα0/0 mice lack all TRα receptors, the observed effects of hypothyroidism are likely to be due to 
a loss of liganded TRβ mediated action.  Thus, although TRα is the predominant receptor found in 
bone, it appears that TRβ also can have a compensatory role in the absence of TRα.  Unexpectedly, 
there was no increase in BFR in hyperthyroid mice compared to euthyroid TRα0/0 mice.  Reasons for 
this may include: (i) increases in osteoblastic bone formation are a TRα dependent process, (ii) 
thyroid hormone signalling in the skeleton is maximal in euthyroid animals (i.e. all the available TRβ 
are saturated - see Table 4.3) so increased amounts of free hormone should have no effect and (iii) 
that the because the hyperthyroidism was mild, small changes in BFR were not detected.   
The data in this chapter corroborates previous data showing that BV/TV decreases (Bassett and 
Williams, 2009, Monfoulet et al., 2011) upon rendering TRα0/0 mice hyperthyroid and concurs with a 
significant increase in resorption parameters.  MS/BS is significantly higher in hyperthyroid 
compared to hypothyroid TRα0/0 mice, which is in contrast to the data from Monfoulet et al showing 
a decrease in MS/BS in hyperthyroid compared to hypothyroid TRα0/0 mice (Monfoulet et al., 2011). 
It is not clear why this is, however the bone formation data in the Monfoulet paper, as previously 
discussed was suboptimal. 
4.4.2 Skeletal effects of thyroid status in TRβ-/- mice 
The response to hypothyroidism is similar in TRβ-/- mice and wild type mice.  Hypothyroid TRβ-/- mice 
have significantly greater BMC (both in femurs and caudal vertebrae), BV/TV and micro-
mineralisation when compared to euthyroid TRβ-/- mice.  Bone formation is nearly completely absent 
with a BFR similar to that of hypothyroid wild type mice.   As the increase in bone volume and BMC is 
not secondary to increased bone formation, it must therefore be as a result of decreased bone 
resorption.  Unfortunately, the parameters used to assess bone resorption in this thesis were not 
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able to detect this decrease as there was a large variation in the measurements.  Future work could 
include assessment of osteoclast parameters by quantitative histomorphometry. 
The lack of difference between euthyroid and hyperthyroid TRβ-/- mice in cortical parameters, BMC 
and BV/TV was unexpected, but it is important to consider that these mice were hyperthyroid 
throughout development and therefore both smaller and osteoporotic as adults before intervention 
was commenced.  To render them euthyroid, they were made hypothyroid and given physiological 
replacement T3 (block and replace).  To observe an increase in bone mass, there would need to be 
either increased bone formation and/or decreased bone resorption.  As the TRβ-/- mice are 
osteoporotic, the surface area (scaffold) upon which osteoblasts can lay down new bone is small, 
making it more difficult initially to accrue bone mass.  Six weeks of treatment may not have been 
insufficient time to observe a difference in the aforementioned parameters.      
Analysis of qBSE-SEM results showed lower micro-mineralisation in euthyroid TRβ-/- mice when 
compared to the hyperthyroid or hypothyroid groups.  Previous published data (Bassett et al., 
2007b) has shown that T4 treatment in TRβ-/- mice did not alter micro-mineralisation in the 
trabeculae or cortices of proximal femurs.   Lower micro-mineralisation in euthyroid compared to 
hyperthyroid mice was surprising and to try to rule out any technical or processing factors, the 
assessment of micro-mineralisation was repeated in the tibia, where both cortical and trabecular 
bone were analysed.   
Micro-mineralisation of the tibial cortices was similar to that in lumbar vertebrae, with the euthyroid 
mice having reduced micro-mineralisation when compared to either hyperthyroid or hypothyroid 
mice. However, the tibial trabeculae showed a significantly increased micro-mineralisation in 
hypothyroid TRβ-/- mice and decreased micro-mineralisation in hyperthyroid TRβ-/- mice.   As the 
cortices and the trabecular bone were embedded in the same block and processed in exactly the 
same manner, it suggests that an artefact of processing was unlikely to be responsible for affecting 
results and that there may be a real site specific difference in micro-mineralisation.  Physiologically, 
micro-mineralisation is affected by both the age of the bone (secondary mineralisation) and 
controlled by embedded osteocytes.  The mechanism for control of micro-mineralisation is likely to 
be different in the cortices compared to the trabeculae due to the different strains put on the 
compartments as well as the differing osteocyte alignment.  Trabeculae in the lumbar vertebrae are 
derived from both cortical bone and from the growth plate; hence, the osteocytic control of micro-
mineralisation in the lumbar vertebrae may be a combination of the mechanisms in the two 
different types of bone. 
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4.4.3 Changes in BMC in response to alteration in thyroid status in different genotypes 
The increase in BMC upon rendering mice hypothyroid compared to euthyroid mice was most 
pronounced in TRβ-/- mice, with changes in both the femurs and caudal vertebrae, intermediate in 
wild type mice (see Chapter3), where the BMC was only increased in the femurs but not the caudal 
vertebrae and least in TRα0/0 mice where BMC remained unchanged at both sites.    
Conversely, the decrease in BMC upon rendering mice hyperthyroid was most pronounced in TRα0/0 
mice, with changes in both the femurs and caudal vertebrae, intermediate in wild type mice where 
the BMC was only decreased in the caudal vertebrae but not the femurs (see Chapter 3) and least in 
TRβ-/- mice, where BMC remained unchanged at both sites.    
 
 
WT TRα0/0 TRβ-/- 
    Hypo Hyper Hypo Hyper Hypo Hyper 
FAXITRON               
BMC Femur ↑↑↑ ↓ → ↓↓↓ ↑↑↑ → 
                
  
Caudal 
Vert → ↓↓↓ → ↓↓ ↑↑↑ → 
                
         
 
 
The reason for these responses may not just be a thyroid receptor specific response but could also 
be explained by the different genotypes having a different setpoint at which changes in BMD occur.   
TRα0/0 mice are osteosclerotic so to increase their BMC would need a relatively large change in bone 
remodelling.  However, to render them osteoporotic should be relatively simple.  TRβ-/- mice are 
thyrotoxic and osteoporotic, so when rendering them euthyroid, the changes in BMC may not 
initially be great.  However, when rendering them hypothyroid, the changes are much more 
pronounced.  This is demonstrated in a model where thyroid status and BMC are correlated in 
sigmoid curve distribution which is shifted in TRα0/0 and TRβ-/- mice  (see Figure 4.14). 
      
Table 4.4 Summary of changes in BMC in femurs and 
caudal vertebrae of wild type, TRα0/0 and TRβ-/- mice with 
differing thyroid status 
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Thyroid status appeared to have a direct relationship with bone formation in wild type and TRβ-/- 
mice, but was blunted in TRα0/0 mice.  It is likely that thyroid hormone directly regulates bone 
formation by osteoblasts via TRα a mechanism which can be partially compensated for by TRβ in its 
absence.  
Hypothyroid wild type and TRβ-/- mice have an almost complete absence of bone formation but by 
comparison, hypothyroid TRα0/0 mice have four-fold greater BFR (Table 4.6).  This suggests that 
although bone formation is decreased in the absence of thyroid hormone, a basal rate of bone 
formation remains, which is inhibited by unliganded TRα (apo TRα). Evidence for this includes the 
growth retarded but viable skeleton of double knock out TRαβ mice, despite the absence of both 
thyroid hormone receptors (Gothe et al., 1999).    
Figure 4.14 Proposed model of thyroid hormone induced bone changes in 
differing genotypes  
Graph illustrating changes in BMC in response to differing circulating thyroid 
hormone levels in wild type, TRα0/0 and TRβ-/- mice.  Levels of hypothyroidism 
(Hypo) and hyperthyroidism (Hyper) are suggested on the graph alongside when 
such bones are osteoporotic or osteosclerotic.  Each genotype has a different 
setpoint around which changes in BMC occur. 
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  Wild Type TRα0/0 TRβ-/- 
BFR µm3/µm2/d  0.03 0.18*## 0.04 
Hypothyroid 
TRα Unliganded Absent Unliganded 
TRβ Unliganded Unliganded Absent 
 
 
 
 
 
 
 
4.4.4 Summary and salient points 
Manipulation of thyroid status in TRα0/0 and TRβ-/- mice has provided important insights into the 
individual roles of TRs in bone.  Whilst TRβ-/- mice are thyrotoxic due to central RTH, they respond to 
hypothyroidism in a similar way to wild type mice.  TRα0/0 mice, however, are euthyroid but are 
osteopetrotic and whilst they have features of hypothyroidism during development, the picture is 
mixed, and such mice have uncoupled bone remodelling with normal bone formation and reduced 
bone resorption.  Hypothyroid wild type, TRα0/0 and TRβ-/- mice all have decreased bone formation, 
indicating that normal thyroid status is essential for normal bone development.  The decrease in 
bone formation in hypothyroid TRα0/0 mice indicates that TRβ can play a compensatory role in the 
skeleton in the absence of TRα.  The data showing wild type and TRβ-/- mice having an almost 
complete absence of bone formation in contrast to TRα0/0 mice, which have a fourfold greater BFR, 
suggests that unliganded TRα has a repressive role on bone formation in the skeleton. 
  
Table 4.5  Table summarising the BFR in each genotype which are hypothyroid 
and whether each TR is liganded or not 
BFR of hypothyroid TRα0/0 is significantly higher than wild type * (p<0.05) or TRβ-/- 
## (p<0.01) analysed by ANOVA and Tukey’s Multiple Comparison post hoc test. 
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Chapter 5 
Effects of oestrogen and thyroid hormone 
interactions in the regulation of bone mass 
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5 EFFECTS OF OESTROGEN AND THYROID HORMONE INTERACTIONS IN THE 
REGULATION OF BONE MASS 
5.1 BACKGROUND 
Thyroid hormone and oestrogen both which act via intranuclear receptors to activate response 
elements and stimulate gene transcription.  However, oestrogen and thyroid hormone have 
opposing actions on adult bone and I hypothesise that accelerated bone loss at the menopause is 
due to unopposed actions of thyroid hormone on the skeleton.  To date, no in vivo experiments have 
investigated interactions between the two hormones in the skeleton.  In the previous two results 
chapters, I have described, in detail, the effects of thyroid status on the skeleton of wild type, TRα0/0 
and TRβ-/- mice.  In this chapter I now describe the effects of oestrogen deficiency on the skeleton in 
each group. 
5.2 RESULTS 
5.2.1 GROWTH 
5.2.1.1 Body weight and bone length parameters 
To evaluate the effects of oestrogen deficiency on growth in each group, detailed weight and bone 
measurements were taken.  Ovariectomy resulted in a 10 and 13.5% weight gain in euthyroid wild 
type and hyperthyroid TRβ-/- mice, respectively, but tail length remained similar in all groups (Figure 
5.1).   
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5.2.3 STRUCTURAL PARAMETERS 
5.2.3.1 Bone length and cortical measurements 
Femur lengths were significantly longer in the hyperthyroid TRβ-/- group only post ovariectomy. Tibial 
bone lengths were longer in hyperthyroid TRβ-/-, hyperthyroid wild type and hypothyroid TRα0/0 
groups post ovariectomy (Figure 5.2).  The results of the bone length measurements seem to 
indicate that the tibia is more sensitive to changes in oestrogen status than the femur.   
Cortical bone diameter is an indirect measure of periosteal apposition on the external cortical 
surface.  Cortical thickness results from the net balance between external cortical periosteal 
apposition by osteoblasts and internal cortical resorption by osteoclasts. 
 
Oestrogen deficiency did not result in changes to cortical bone diameter in any of the groups (Figure 
5.3).  There was a decrease in cortical thickness in euthyroid wild type mice and euthyroid and 
hyperthyroid TRα0/0 mice post ovariectomy, indicating increased endocortical resorption in these 
groups. 
 
The data suggests that TRβ-/- mice may be protected from oestrogen deficient endocortical bone loss 
(by the presence of TRα) and there is even an increase in cortical thickness in hypothyroid TRβ-/- mice 
(8% increase) post ovariectomy. 
 
Thyroid hormone replete TRα0/0 mice have the most significant decrease in cortical thickness in 
response to oestrogen deficiency (Figure 5.3, 8.2% decrease in Eu TRα0/0 and 13.7% decrease in 
Hyper TRα0/0 post ovariectomy) which also suggests that TRα has an osteoprotective effect against 
oestrogen deficiency bone loss. 
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5.2.3.2 Bone microarchitecture: BSE-SEM and micro CT 
 
In almost all of the femur BSE-SEM images, the trabecular compartments in the ovariectomised 
groups occupy a smaller endocortical area than the sham operated groups. The trabeculae appeared 
more gracile and less numerous (see Figure 5.5). 
 
Micro CT analysis showed that wild type mice have decreased BV/TV post ovariectomy in 
hypothyroid but not euthyroid or hyperthyroid groups (Figure 5.4 and Table 5.1).    TRα0/0 mice were 
found to have a 40-60% reduction in BV/TV in response to oestrogen deficiency, regardless of 
thyroid status. BV/TV in hypothyroid and hyperthyroid TRβ-/- mice was unaffected by ovariectomy, 
but there was a 20% decrease in BV/TV in the euthyroid group.  These results suggest that genotype 
is important (with TRα being osteoprotective) in determining trabecular bone loss in response to 
oestrogen deficiency. 
 
The micro CT data suggests that trabecular bone loss due to oestrogen deficiency (BV/TV) at the 
distal femur is largely secondary to a decrease in Tb.N (and correspondingly to an increase in Tb.Sp) 
and, to a lesser degree, to the thickness of the trabeculae (see Table 5.1).  This is the case in all of 
the TRα0/0 groups, regardless of thyroid status, and also in euthyroid TRβ-/- mice.  The SMI (trabecular 
morphology is graded into 0=plate-like and 3=rod-like) was highly significantly elevated in all TRα0/0 
groups (p<0.001), indicating that the trabeculae were more gracile and rod-like post ovariectomy. 
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Figure 5.4 Micro CT assessment of BV/TV 
Bone volume (BV/TV), determined by micro CT analysis of distal femur (n=5-6). Data 
expressed as mean ± SEM, n=6 per group and analysed by Student’s t-test:*, p<0.05, **, 
p<0.01, ***, p<0.001; versus non ovariectomised group of the same genotype and 
thyroid status. 
 
  
 
180 
 
 
  BV/TV (%) Tb.Th(mm) Tb.Sp (mm) Tb.N (mm2) SMI 
WT Hypo 15.6±1.3 0.051±0.002 0.20±0.006 3.05±0.15 1.71±0.04 
WT Hypo OVX 11.4±1.2* 0.045±0.001 0.21±0.008 2.53± 0.23 1.83± 0.09 
WT Eu 10.9±1.1 0.040±0.003 0.19±0.006 2.74±0.23 1.74±0.09 
WT Eu OVX 8.8±0.6 0.040±0.001 0.23±0.010* 2.18±0.17 1.88 ± 0.08 
WT Hyper 6.3±0.8 0.037±0.001 0.25±0.010 1.68±0.17 1.99±0.07 
WT Hyper OVX 5.3±0.8 0.043±0.001** 0.29±0.018 1.23±0.20 2.30±0.09* 
  
     TRα0/0 Hypo 14.7±1.9 0.046±0.001 0.18±0.009 3.16±0.29 0.83±0.08 
TRα0/0 Hypo OVX 7.1±0.7** 0.040±0.001** 0.23±0.073** 1.68±0.15** 2.20± 0.07** 
TRα0/0 Eu  13.1±0.4 0.042±0.001 0.19±0.006 3.11±0.10 1.64±0.02 
TRα0/0 Eu OVX 7.4±0.9*** 0.040±0.001 0.23±0.009** 1.85 ± 0.18*** 2.10 ± 0.06*** 
TRα0/0 Hyper 11.8±0.4 0.039±0.001 0.18±0.005 2.96±0.22 1.75±0.09 
TRα0/0 Hyper OVX 6.7±0.5** 0.039±0.0005 0.24±0.008*** 1.73 ± 0.13** 2.12± 0.07* 
  
     TRβ-/- Hypo 12.6±1.1 0.048±0.002 0.21±0.006 2.59±0.17 1.87±0.06 
TRβ-/- Hypo OVX 9.3±1.7 0.045±0.002 0.22±0.012 2.27± 0.32 1.96± 0.10 
TRβ-/- Eu 7.7±0.8 0.040±0.001 0.22±0.005 1.96±0.16 2.06±0.07 
TRβ-/- Eu OVX 5.4±1.0* 0.038±0.001 0.26±0.022** 1.40 ± 0.14* 2.11± 0.07 
TRβ-/- Hyper 7.1±0.5 0.036±0.004 0.23±0.009 3.24±0.15 1.91±0.05 
TRβ-/- Hyper OVX 5.7±0.6 0.038±0.001 0.28±0.019* 1.50±0.17*** 2.04± 0.063 
       
 
 
 
Table 5.1 Analysis of micro CT data. Quantitative analysis of bone volume (BV/TV), trabecular 
thickness (Tb.Th), trabecular spacing (Tb.Sp), trabecular number (Tb.N), and structure model index 
(SMI) determined by micro CT analysis of distal femur (n=5-6). Data expressed as mean ± SEM, 
analysed by Student’s t-test:*, p<0.05, **, p<0.0,1***, p<0.001; versus non ovariectomised group 
of the same genotype and thyroid status. 
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Figure 5.5 SEM images showing bone micro architecture  
BSE-SEM images of distal femurs from hypothyroid, euthyroid 
and hyperthyroid wild type (WT), TRα0/0 and TRβ-/- genotypes.  
Images of femurs from sham operated and ovariectomised mice 
from all groups are demonstrated.  
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5.2.4 BONE MINERAL DENSITY 
5.2.4.1 BMC  
The effects of oestrogen and thyroid hormone interaction on BMC were assessed by faxitron analysis 
of femurs and caudal vertebrae (Figures 5.6 and 5.7).   
In wild type mice, femurs were more sensitive to oestrogen deficiency bone loss than the caudal 
vertebrae (Figures 5.6 and 5.7).  There was a significant decrease in femoral BMC in hypothyroid and 
euthyroid, but not hyperthyroid wild type mice, post ovariectomy. No change in BMC was observed 
in the caudal vertebrae of wild type mice post ovariectomy, regardless of the thyroid hormone 
status.     
There were highly significant decreases in BMC post ovariectomy, in both femurs and caudal 
vertebrae of euthyroid and hyperthyroid TRα0/0 mice, but in contrast to wild type mice, no difference 
in BMC in the hypothyroid group (Figures 5.6 and 5.7).   
TRβ-/- mice showed no change in femoral or caudal BMC in response to ovariectomy, regardless of 
thyroid status.   
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 Figure 5.6 Bone mineral content of femurs 
Faxitron images of femurs of P112 mice.  Grey scale images were pseudocoloured with a 16 colour 
palette where low mineralisation density is black and high density is white.  Images of femurs from 
sham operated groups are on top whilst the bone from ovariectomised group is shown underneath 
(scale bar 1mm).  Cumulative and relative frequency histograms of mineralisation densities for 
whole femurs.  Kolmogorov-Smirnov test; *, p<0.05; ***, p<0.001 Sham operated versus OVX. 
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Figure 5.7 Bone mineral content of caudal vertebrae 
Faxitron images of caudal vertebrae of P112 mice.  Grey scale images were pseudocoloured with 
a 16 colour palette where low mineralisation density is black and high density is white (scale bar 
1mm).  Images of caudal vertebrae of sham operated mice shown on left with ovariectomy 
group on right.  Cumulative and relative frequency histograms of mineralisation densities for 
vertebrae shown.  Kolmogorov-Smirnov test; ***, p<0.001 Sham operated versus OVX. 
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5.2.3.2 Micro-mineralisation: qBSE-SEM  
QBSE-SEM analysis (Figure 5.8) demonstrated that oestrogen deficiency resulted in significantly 
decreased micro-mineralisation in all groups of wild type mice, regardless of thyroid status. These 
findings are in line with a high turnover osteoporosis with decreased mineralisation resulting from 
removal of older, more mineralised, bone and deposition of newer, less mineralised bone.   
The TRα0/0 mice had a significant reduction in micro-mineralisation post ovariectomy in all groups.  
This was particularly pronounced in the hypothyroid group but also highly significant in the 
euthyroid and hyperthyroid groups.  This suggests that the deletion of TRα increases susceptibility to 
oestrogen deficient bone loss and increases its magnitude. 
The TRβ-/- mice showed a reduction in micro-mineralisation in the hypothyroid group post 
ovariectomy but not in the euthyroid or hyperthyroid groups.   This suggests that the presence of 
liganded TRα mitigates the effect of ovariectomy on bone.  
Of particular note, the qBSE-SEM and BMC results show that hypothyroidism does not protect 
against oestrogen deficiency bone changes in any of the genotypes tested in these experiments, 
disproving my original hypothesis. 
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Figure 5.8 Micro-mineralisation of lumbar vertebrae 
qBSE-SEM images of lumbar vertebrae  from wild type,  TRα0/0  and  TRβ-/- 
mice with differing thyroid status. (scale bar 100µm).  Grey scale images 
were pseudocoloured with an eight colour palette; low mineralisation 
density is blue and high density is grey.  Cumulative frequency histograms 
of mineralisation densities.  Kolmogorov-Smirnov test; *, p<0.05; ***, 
p<0.001 for sham versus ovariectomy. 
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5.2.5 BONE FORMATION: P1NP AND BFR 
Bone formation was assessed by histomorphometry (Table 5.2) and serum formation marker P1NP 
concentrations (Figure 5.9).  There was a significant decrease in P1NP concentrations post 
ovariectomy in euthyroid and hyperthyroid   TRα0/0 mice compared to sham operated mice.   
 
 
 
 
 
 
 
Dynamic BFRs in lumbar vertebrae were assessed and compared in each group and the results are 
summarised in Figure 5.10.  
In wild type mice, BFR post ovariectomy was elevated (secondary to an increase in MA) in the 
euthyroid group as expected, but remained unchanged in hypothyroid or hyperthyroid groups.   
Hypothyroid TRα0/0 mice had a 2.6 fold greater BFR (as a result of increased MS/BS – Table 5.2) in 
ovariectomised mice when compared to sham operated mice.  There was no change in BFR in 
euthyroid or hyperthyroid   TRα0/0 mice.   
This data suggests that a reduction of bone formation, which is secondary to hypothyroidism, can be 
overcome by oestrogen deficiency.   
Hypothyroid TRα0/0 mice had similar BMC post ovariectomy versus sham (Figure 5.5), but in light of 
the data showing an increased BFR, it can be concluded that this was as a result of equal and 
Figure 5.9 Serum P1NP from wild type, TRα0/0 and TRβ-/- mice with differing 
thyroid status 
N=3 per group and analysed by Student’s t-test. No groups were significantly 
different when ovariectomised and sham operated comparisons were made. 
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balanced increases in bone resorption and formation.  This conclusion is also supported by the qBSE-
SEM data which showed a decreased micro-mineralisation in hypothyroid TRα0/0 mice post 
ovariectomy (Figure 5.9). 
Hypo and euthyroid TRβ-/- mice had increased BFRs with elevated MS/BS in the ovariectomised 
group. Ovariectomy had no effect on bone formation in the hyperthyroid animals of all three 
genotypes, suggesting that the increase in bone formation following oestrogen deficiency is 
attenuated by hyperthyroidism.  This may be due to the fact that bone formation is already at a 
maximal rate in hyperthyroidism. 
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  BFR MA MS/BS 
WT Hypo 0.04 ± 0.03 0.63 ± 0.24 4.62 ± 1.83 
WT Hypo OVX 0.11 ± 0.02 0.93 ± 0.11 11.49 ± 2.46 
WT Eu 0.44 ± 0.04 2.09 ± 0.15 21.50 ± 1.98 
WT Eu OVX 1.06 ± 0.22* 2.98 ± 0.31* 35.56 ± 5.84 
WT Hyper 0.71 ± 0.09 2.29 ± 0.06 30.70 ± 3.40 
WT Hyper OVX 0.85 ± 0.07 2.35 ± 0.12 36.10 ± 1.86 
     
TRα0/0 Hypo 0.18 ± 0.04  1.43 ± 0.04 12.59 ± 2.58 
TRα0/0 Hypo OVX 0.54 ± 0.08** 1.80 ± 0.16 29.07 ± 2.07** 
TRα0/0 Eu  0.53 ± 0.04  1.80 ± 0.06 29.52 ± 2.59 
TRα0/0 Eu OVX 0.70 ± 0.09  1.91 ± 0.16 36.94 ± 3.45 
TRα0/0 Hyper 0.55 ± 0.04 1.86 ± 0.20 30.02 ± 1.64 
TRα0/0 Hyper OVX 0.47± 0.06 1.71 ± 0.14 27.68 ± 3.17 
     
TRβ-/- Hypo 0.03 ± 0.01  0.68 ± 0.29 2.76 ± 1.26 
TRβ-/- Hypo OVX 0.11 ± 0.03* 1.23 ± 0.18 8.14 ± 1.63* 
TRβ-/- Eu 0.33 ± 0.06 1.49 ± 0.19 20.25 ± 1.60 
TRβ-/- Eu OVX 0.57 ± 0.05*  1.58 ± 0.03 35.83 ± 3.49** 
TRβ-/- Hyper 0.66 ± 0.08 2.20 ± 0.11 29.70 ± 2.27 
TRβ-/- Hyper OVX 0.61± 0.09 1.70 ± 0.21 35.38 ± 2.00 
     
 
 
 
 
Table 5.2 Analysis of dynamic bone formation parameters 
BFR, Mineral MA and mineralising surface per BS (MS/BS).  Data expressed as 
mean ± SEM, n=4 per group and analysed by Student’s t-test:*, p<0.05, **, p<0.01, 
***, p<0.001 versus non ovariectomised group of the same genotype and thyroid 
status. 
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Figure 5.10 Graphical representation of BFR 
Data expressed as mean ± SEM, n=4 per group and analysed by Student’s 
t-test:*, p<0.05, **, p<0.01, versus non ovariectomised group of the 
same genotype and thyroid status. 
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5.2.6 BONE RESORPTION: CTX AND CORTICAL RESORPTION 
Serum bone resorption markers CTX and endocortical surface resorption analysis (shown in Figure 
5.11) show a wide variation in measurements and therefore do not provide discriminatory 
information.  Given that oestrogen deficiency results in increased bone formation and has not been 
documented to decrease bone formation, it can be concluded that groups which have a decreased 
bone mass (BMC or BV/TV) probably have increased osteoclastic resorption.  This derived result 
would include hypothyroid and euthyroid wild type mice, all TRα0/0 mice and hypothyroid and 
euthyroid TRβ-/- mice which have undergone ovariectomy. 
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5.2.7 BIOMECHANICAL TESTING 
Mechanical properties of strength and load bearing were studied using destructive three point 
bending.  Yield, maximum and fracture loads as well as stiffness, were measured and compared in 
ovariectomised and sham operated mice. 
Figure 5.12 shows that in wild type mice, ovariectomy did not significantly alter the yield load, 
maximal load or the fracture load, regardless of the thyroid status.  
Despite a quite significant reduction in cortical thickness, BV/TV and BMC in euthyroid and 
hyperthyroid TRα0/0 mice post ovariectomy, there was no difference in the mechanical properties 
tested for any of the compared groups.   
Oestrogen deficiency for a six week time period made little difference to the mechanical properties 
of the tibia of adult mice.  Only euthyroid TRβ-/- mice had a decrease in fracture load in mice with 
oestrogen deficiency compared to controls.  There was no difference in yield load, maximum load or 
stiffness.   
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5.3 SUMMARY OF RESULTS 
  
Figure 5.12 Mechanical properties 
Graphs showing yield, maximum and fracture load and stiffness in tibias of P112 
wild type, TRα0/0 and TRβ-/- mice with differing oestrogen and thyroid status. Data 
expressed as mean ± SEM, n=4-6 per group and analysed by Student’s t-test. 
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5.3 SUMMARY OF RESULTS 
 
 
 
 
  
 Wild type TRα0/0 TRβ-/- 
 Hypo Eu Hyper Hypo Eu Hyper Hypo Eu Hyper 
Weight → ↑ → → → → → → ↑ 
Tail  
length 
→ → → → → → → → → 
Femoral  
length 
→ → → → → → → → ↑↑ 
Tibial 
length 
→ → ↑ ↑ → → → → ↑↑↑ 
Cortical  
diameter 
→ → → → → → → → → 
Cortical 
thickness 
→ ↓ → → ↓↓ ↓↓↓ ↑ → → 
µCT BV/TV ↓ → → ↓↓ ↓↓↓ ↓↓ → ↓ → 
Femoral 
BMC 
↓↓↓ ↓ → → ↓↓↓ ↓↓↓ → → → 
Vert 
BMC 
→ → → → ↓↓↓ ↓↓↓ → → → 
qBSE SEM 
Lumbar 
Vertebrae 
↓ ↓ ↓ ↓ ↓ ↓ ↓ → → 
BFR → ↑ → ↑↑ → → ↑ ↑ → 
MAR 
BS/BS 
→ 
→ 
↑ 
→ 
→ 
→ 
→ 
↑↑ 
→ 
→ 
→ 
→ 
→ 
↑ 
→ 
↑↑ 
→ 
→ 
P1NP → → → → ↓ ↓ → → → 
CTX → → → → → → → → → 
Resorption  → → → → → → → → → 
Table 5.3 Summary of effects of ovariectomy on the skeletal phenotype of wild 
type, TRα0/0 and  TRβ-/- mice with differing thyroid status 
Table is grouped according to genotype. → No significant difference, ↑ significant 
increase, ↓ significant decrease.  Number of arrows indicates significance level: 1 
arrow p<0.05, 2 arrows p<0.005, 3 arrows p<0.001. 
 
 
  
 
196 
 
 
 
 
 
 
  
 Hypothyroid Euthyroid Hyperthyroid 
 Wild 
type 
TRα0/0 TRβ-/- Wild 
type 
TRα0/0 TRβ-/- Wild 
type 
TRα0/0 TRβ-/- 
Weight → → → ↑ → → → → ↑ 
Tail  
length 
→ → → → → → → → → 
Femoral  
length 
→ → → → → → → → ↑↑ 
Tibial 
Length 
→ ↑ → → → → ↑ → ↑↑↑ 
Cortical  
diameter 
→ → → → → → → → → 
Cortical 
thickness 
→ → ↑ ↓ ↓↓ → → ↓↓↓ → 
µCT BV/TV ↓ ↓↓ → → ↓↓↓ ↓ → ↓↓ → 
Femoral 
BMC 
↓↓↓ → → ↓ ↓↓↓ → → ↓↓↓ → 
Vert 
BMC 
→ → → → ↓↓↓ → → ↓↓↓ → 
qBSE SEM 
Lumbar 
vertebrae 
↓ ↓ ↓ ↓ ↓ → ↓ ↓ → 
BFR → ↑↑ ↑ ↑ → ↑ → → → 
MAR 
BS/BS 
→ 
→ 
→ 
↑↑ 
→ 
↑ 
↑ 
→ 
→ 
→ 
→ 
↑↑ 
→ 
→ 
→ 
→ 
→ 
→ 
P1NP → → → → ↓ → → ↓ → 
CTX → → → → → → → → → 
Resorption  → → → → → → → → → 
Table 5.4 Summary of effects of ovariectomy on the skeletal phenotype of hypo, eu and 
hyperthyroid mice in different genotypes 
Table is grouped according to thyroid status. → No significant difference, ↑ significant 
increase, ↓ significant decrease.  Number of arrows indicates significance level: 1 arrow 
p<0.05, 2 arrows p<0.005, 3 arrows p<0.001. 
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5.4 DISCUSSION 
These studies demonstrate that oestrogen deficiency bone loss was greater in hypothyroid 
compared to hyperthyroid mice.  This indicates that accelerated bone loss following oestrogen 
withdrawal cannot result from the unopposed actions of thyroid hormones and thus disproves my 
hypothesis.  These studies also demonstrate the complex oestrogen and thyroid hormone receptor 
interactions in the regulation of bone mass. 
5.4.1 TRα has an osteoprotective effect on oestrogen deficiency bone loss 
The most prominent finding of the experiments in this chapter is that TRα has an osteoprotective 
effect against oestrogen deficiency bone loss.  This is apparent because in the absence of TRα (i.e. in 
TRα0/0 mice), there is a greater susceptibility to ovariectomy induced bone loss, which is mitigated in 
wild type and TRβ-/- mice. 
The results of multiple techniques used in evaluating the various skeletal phenotypes supported this 
finding and are listed: 
1 There was a highly significant reduction in cortical thickness in euthyroid and 
hyperthyroid TRα0/0 mice, in response to ovariectomy. 
2 Micro CT analysis showed that TRα0/0 mice had a 40-60% reduction in BV/TV in response 
to ovariectomy, regardless of thyroid status, with these changes in bone 
microarchitecture also being clearly visible on BSE-SEM images. 
3 Ovariectomy resulted in highly significantly decreased BMC at the femur and vertebrae 
in euthyroid and hyperthyroid TRα0/0 mice.  Although ovariectomised hypothyroid TRα0/0 
mice had a similar BMC to sham operated mice, there was a significantly elevated BFR in 
this group, suggesting that to maintain normal BMC, there was also likely to have been 
an increase in bone resorption. 
4 Analysis of qBSE-SEM results showed a significant reduction in micro-mineralisation in all 
TRα0/0 mice in response to ovariectomy, regardless of thyroid status. 
Unfortunately, parameters used to assess bone resorption were not sufficiently spensitive to detect 
any changes.  However, a decrease in bone mass in conjunction with normal or raised bone 
formation in TRα0/0 mice, suggests that ovariectomy induced bone loss is secondary to increased 
bone resorption. 
Ovariectomy induced bone loss in TRα0/0 mice is reduced or mitigated in the presence of TRα and this 
is demonstrated in the skeletal response of TRβ-/- and wild type mice to ovariectomy. 
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The finding that TRα is osteoprotective against ovariectomy induced bone loss is novel and contrary 
to my initial hypothesis that in the absence of oestrogen, bone loss results from the unopposed 
actions of thyroid hormone.  The molecular signalling pathways responsible for this finding are an 
area for possible future research. 
5.4.2 Oestrogen withdrawal associated with increased weight and bone length 
Oestrogen deficiency has been associated with increased central fat distribution in postmenopausal 
women when compared to premenopausal women (Toth et al., 2000).  Likewise, in oestrogen 
deficient mice, increased weight is found in euthyroid wild type and hyperthyroid TRβ-/- groups. 
Hyperthyroid TRβ-/- mice, which had the greatest increase in weight, also had a highly significant 
increase in femoral and tibial length.  This was unexpected, as hyperthyroid TRβ-/- mice have 
advanced growth plate maturation with diminished final height and would have reached skeletal 
maturity before the other groups (Bassett et al., 2007a).  The growth plates in these mice at P70 
would have been quiescent before manipulation of oestrogen and thyroid status and must have 
undergone reactivation, resulting in increased bone length.  It would appear that tibias are more 
sensitive to changes in bone length than femurs after oestrogen deficiency growth plate 
reactivation.  This may be because the reactivated growth plates of the tibia and femur have 
different sensitivities to thyroid hormone induced growth.  This observation is in line with findings in 
patients with TRα mutations have rhizomelia (Bochukova et al., 2012).  There is a small increase in 
tibial, but not femoral length, in hyperthyroid wild type and hypothyroid TRα0/0 mice.  Unlike 
humans, mice continue to grow slowly and their growth plates do not completely fuse.  This data 
suggests that in the presence of TRα and excess thyroid hormone, oestrogen withdrawal reactivates 
the growth plate, resulting in an increase in long bone length.  An increase in bone length and 
growth plate thickness post ovariectomy has been described in rats (Gevers et al., 1995) (van der 
Eerden et al., 2003).  This effect has been attributed to the direct action of oestrogen on 
chondrocytes (van der Eerden et al., 2002) or to the secondary action of oestrogen on GH/IGF and 
vascular endothelial growth factor (VEGF) (Borjesson et al., 2010, Juul, 2001, Emons et al., 2010).  It 
would be interesting to investigate this further by assessing growth plate width and evaluating GH 
and IGF1 levels in the serum and at the growth plate. 
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5.4.3 Oestrogen withdrawal in hypothyroid mice is associated with increased resorption on 
cancellous surfaces but not endocortical surfaces 
Oestrogen withdrawal does not result in any change in cortical diameter in any group, so any 
changes in cortical thickness must result from an increase in endocortical resorption.  Although there 
is a significant reduction in cortical thickness in wild type and euthyroid and hyperthyroid TRα0/0 
groups, there is no decrease in cortical thickness in any of the hypothyroid groups in response to 
oestrogen deficiency.  There is even an increase in cortical thickness in hypothyroid TRβ-/- mice, all of 
which suggests that hypothyroidism is associated with reduced endocortical resorption in response 
to oestrogen deficiency.  This is particularly evident in the TRα0/0 group, where there is a highly 
significant decrease in cortical thickness in euthyroid and hyperthyroid groups but none in the 
hypothyroid group. 
It was surprising that the measurements of percentage of endocortical resorption pits (Figure 5.11) 
did not confirm these findings.  This is likely to be because evaluation of endocortical resorption pits, 
in mice rendered hypothyroid, still reflects the resorption that was occurring at the time of being 
rendered hypothyroid and not at the time of sacrifice. 
Despite the lack of endocortical resorption, there is evidence for active resorption of the trabeculae.  
Hypothyroid mice have a significant decrease in BV/TV in response to oestrogen deficiency, as 
measured by micro CT, in wild type and TRα0/0 groups.  There is also a highly significant decrease in 
femoral BMC in hypothyroid wild type mice in response to ovariectomy. 
 
5.4.4 Hyperthyroid mice do not demonstrate oestrogen deficiency elevation in bone formation  
Hyperthyroid mice in all genotypes do not respond to oestrogen deficiency by an increase in BFR.  
This data may indicate that a similar mechanism of action or pathway to increase osteoblastic bone 
formation may be shared by thyroid excess and oestrogen deficiency.  This pathway may be 
saturated in hyperthyroid mice and so no further increases in BFR are detected on oestrogen 
withdrawal. 
 
5.4.5 Decreased bone formation associated with presence of oestrogen and unliganded TRα 
The presence of oestrogen decreases osteoblastic bone formation and data in Chapter 4 also 
suggests that unliganded TRα has a similar effect.  Thus, in hypothyroid ovariectomised TRα0/0 mice, 
where there is an absence of oestrogen and no apoTRαs, the BFR is significantly higher when 
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compared to sham operated mice.  The BFR of these mice is similar to euthyroid wild type mice.  
Interestingly, in ovariectomised TRα0/0 mice, only the hypothyroid group had a BFR comparable to 
euthyroid wild type mice, which suggests that hypothyroid induced suppression of bone resorption 
can be overcome with oestrogen deficiency. 
 
5.4.6 Bone remodelling uncoupled in ovariectomised TRα0/0 mice 
In Chapter 3, euthyroid TRα0/0 mice were shown to have uncoupled remodelling, with normal bone 
formation and reduced bone resorption, resulting in increased bone mass. Resorption increased 
when the TRα0/0 mice were rendered hyperthyroid and increased further in response to oestrogen 
deficiency.  Although both hyperthyroidism and oestrogen withdrawal increase resorption, there is 
no corresponding increase in BFR, evidencing uncoupling of remodelling in euthyroid and 
hyperthyroid TRα0/0 mice.  This data suggests that thyroid hormone may play an important role in 
osteoblast-osteoclast coupling.  The presence of TRα seems to be osteoprotective, but in its 
absence, the effects of thyroid hormone and oestrogen deficiency on osteoclast function appear to 
be independent. 
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Chapter 6 
General discussion 
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6 DISCUSSIONS AND CONCLUSIONS 
 
The novel findings presented in this thesis provide further insight into how thyroid hormone and its 
receptors affect the skeleton and also suggest complex interactions between oestrogen and thyroid 
hormone in the regulation of bone mass. 
6.1 Effects on the skeleton of oestrogen and thyroid hormone interactions 
The bone phenotype of TRα0/0 mice is very similar to that of hypothyroid mice (both show increased 
bone mass and decreased resorption compared with controls) but dynamic bone formation 
measurements uncover a divergence between these two groups when comparing bone formation.  
Hypothyroid wild type mice have almost absent bone formation whereas TRα0/0 mice have a BFR 
similar to that of wild type controls.  Thus, although it has previously been hypothesised that TRα0/0 
mice have decreased thyroid hormone signalling in the skeleton, the picture is likely to be more 
heterogeneous than one would expect.  It is possible that a lack of T3 liganded TRα action impairs 
chondrocyte and osteoclast function but there is no evidence of a similar effect on osteoblast 
function. 
The role of TRα in the skeleton is very evident when comparisons are made between the effects of 
hypothyroidism on wild type TRα0/0 and TRβ-/- mice.  Bone formation is radically reduced as a 
response to a lack of thyroid hormone but in the absence of unliganded TRα, bone formation is 
partially rescued with four times the BFR, suggesting that unliganded TRα, but not TRβ, has a 
repressive effect on bone formation.  This finding is in agreement with data from Flamant 2002, who 
generated congenitally hypothyroid pax8-/- mice, which were lethal, but could be rescued by crossing 
them with TRα0/0 mice to generate double knockout pax8-/- TRα0/0 mice.  Double knockout pax8-/- 
TRβ-/- mice, however, were similar to pax8-/- mice, resulting in early lethality before weaning.  From 
this data, the authors noted that TRα was the predominant receptor in bone and that unliganded 
TRα had a repressive effect on bone development.  My data adds to these findings by showing that 
apo TRα has a repressive effect specifically on osteoblastic bone formation.  The data from my 
experiments suggests that thyroid hormone has a direct incremental effect on bone formation via 
TRα, and additionally, that in the absence of TRα, TRβ has an important compensatory role in bone 
formation, as evidenced by the highly significant decrease in BFR when TRα0/0 mice are rendered 
hypothyroid. 
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Comparing the effects of thyroid hormones and oestrogen deficiency on different genotypes is 
highly complex and these experiments have demonstrated that it is important to assess the skeleton 
via a number of methods before conclusions can be drawn.  It is particularly difficult to assess 
responses to thyroid or oestrogen status across genotypes where bone development has been 
compromised.  Monfoulet et al assessed the response of thyroid status in wild type, TRα0/0 and TRβ-/- 
mice and found that TRα0/0 mice had a significant response to elevated thyroid hormone (much like 
with my data) but that TRβ-/- mice only had a significant response after prolonged exposure to excess 
thyroid hormone.  They concluded that TRβ mediates the acute effects of thyroid hormone, whilst 
TRα mediates the long term effects.  However, as discussed in Chapter 4, the data from that study 
did not include adequate bone formation parameters and no data for the euthyroid groups was 
given, making it difficult to assess the full picture. 
The skeletal phenotyping in this thesis has provided a more comprehensive picture.  Rather than TRβ 
mediating the acute effects of thyroid hormone and TRα mediating the long term effects, it is more 
likely that TRβ-/- mice (which are osteoporotic at baseline) are more resistant to excess thyroid 
hormone and TRα0/0 mice (which have a higher bone mass at baseline) are more sensitive to the 
effects of excess thyroid hormone. 
The skeletal response to oestrogen withdrawal differs not only with thyroid status and the presence 
of TRα, but is also dependent on which skeletal site is being assessed.  Intramedullary cortical 
resorption appears to be highly sensitive to hypothyroidism, in contrast to resorption in the 
cancellous compartment, which is less sensitive. 
The most significant ovariectomy induced decrease in bone resorption, regardless of thyroid status, 
was in the TRα0/0 group, which suggests that the presence of TRα has an osteoprotective effect 
against oestrogen deficiency bone loss.  The molecular mechanism behind this osteoprotective 
effect, is a potential area for future research. 
 
6.2 Bone biology 
As a result of the observations made in this thesis, I also now hypothesise that bone response differs 
according to pre-existing bone mass setpoints.  These sepoints may have been determined during 
growth or according to mutation.  This hypothesis would account for the differing responses of bone 
mass in wild type, TRα0/0 and TRβ-/- mice to changes in thyroid status.  Adult TRβ-/- mice are 
osteoporotic and a pre-existing low bone mass setpoint would account for the minimal differences 
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between euthyroid and hyperthyroid bone mass in these mice, a factor which can be overcome 
when the mice are rendered hypothyroid.  Adult TRα0/0 mice are osteosclerotic with a higher bone 
mass setpoint, so when rendered hyperthyroid, they showed a significant reduction in bone mass, 
but conversely, there was minimal change in bone mass when these mice were rendered 
hypothyroid. 
Surprisingly, given the literature, TRα0/0 mice had normal bone formation but decreased resorption, 
resulting in a net positive balance and a greatly increased bone mass.  Osteoblast and osteoclast 
function are usually highly coupled and the one directly affects the other.  For example, in 
bisphosphonate therapy, which renders osteoclasts apoptotic or dysfunctional (Russell, 2011), 
osteoblast function is also impaired, as evidenced by decreased bone formation rate and a reduction 
in other osteoblast indices (Munns et al., 2005).  Very few therapeutic interventions are able to 
uncouple bone formation and resorption and the finding in this thesis that uncoupling occurs in 
TRα0/0 mice is therefore of significance.  Further comprehension of the molecular mechanisms 
regulating bone formation in the skeleton of TRα0/0 mice could assist in developing therapeutic 
interventions for osteoporosis. 
 
6.3 Future research and ongoing experiments 
The experiments in this thesis contribute novel data to the published literature on both the role of 
thyroid receptors in bone and the interactions between thyroid hormone and oestrogen. 
Additional work for these experiments 
Bones from each mouse used in these experiments have been snap frozen and maintained in liquid 
Nitrogen for RNA extraction at a later date.  These samples could be used to assess the relative 
expression of RANK/RANKL/OPG, mRNAs or other important bone signalling pathways in the 
different mouse groups.  These experiments are due to be undertaken by other members of the 
laboratory, who will continue the work started in this thesis. 
Future experiments 
As with much research, the results of the experiments presented in this thesis lead to further 
questions, some of which have already started to be addressed in the laboratory. 
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1. In vivo studies addressing cell specific effects of thyroid hormone 
The role of thyroid hormone signalling in specific bone cells has begun to be investigated 
using mice which harbour floxed constructs for the conditional overexpression of the Dio3 
enzyme.  These mice can be crossed with lines that selectively express cre recombinase.  
This results in mice with conditional overexpression of Dio3, resulting in cell specific 
hypothyroidism.  Thyroid hormone regulation of bone is currently being investigated in 
chondrocytes, osteoblasts and osteoclasts using this technique.  The results of these further 
experiments should provide insight into whether the effects of hypothyroidism on decreased 
osteoclast activity are direct or indirect, and which other bone cell types may be involved in 
this process. 
2. In vitro osteoclast studies 
It is clear from my experiments that osteoclast function is TRα dependent.  To investigate if 
the action of T3 in osteoclasts is direct or mediated via TRα in another cell type, in vitro 
studies could be used.  The direct effects of T3 on osteoclasts can be assessed using cultures 
of wild type, TRα0/0 and TRβ-/- osteoclasts to study osteoclast survival and activity.  Cell co-
culture studies could then be used to assess the effect of T3 on the interactions between 
osteoblasts, or another cell type, and osteoclasts from wild type, TRα0/0 and TRβ-/- mice. 
3. Investigation of cellular mechanism to establish why TRα is osteoprotective against 
oestrogen deficiency bone loss 
Further research in respect of molecular signalling would include looking at the downstream 
signalling pathways involved in the changes seen in the skeleton as a result of oestrogen and 
thyroid hormone interactions.  Key pathways that could be investigated include the 
RANK/RANKL/OPG and Wnt pathways using techniques such as qRT-PCR, Western blots and 
immunoprecipitation.  Understanding the molecular mechanisms behind the 
osteoprotective nature of TRα could lead to potential therapies for osteoporosis. 
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APPENDIX 
Solutions used in this thesis 
T4: Sigma T1775    
Stock solution: 60mg to 10ml of dH2O 
Working solution: 20ul stock to 100mls of drinking water (final concentration of 1.2ug/ml) 
 
T3: Sigma T2877 
Stock solution: 5mg of T3 in 0.25ml of 1M NaOH and made up to 5ml with dH2O to make stock 
concentration of 1mg/ml 
Working solution: 12.5μl of stock to 250ml water to make final concentration of 0.05mg/ml 
 
Calcein: Sigma CO875 
Working solution: 5mg dissolved in 10mls of warmed pbs and administered at 5mls/kg iv  
 
Cacodylate: Agar R1103 
Stock solution:  Dissolve 21.4gm sodium cacodylate in dH2O and adjust pH to 7.4 by adding 9.5ml of 
1M HCl.  Make up to 500mls with distilled H2O to make 0.2M sodium cacodylate solution 
 
2.5% Glutaraldehyde Fixative: Agar R1012 
1ml of 25% glutaraldehyde 
1.5ml dH2O 
7.5mls of 0.2M sodium cacodylate buffer 
 
Histology staining 
 
Aniline Blue and Phosphotungstic Acid: Sigma 415049 and Fluka 79690:   
0.166g  Aniline Blue  
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3g Phosphotungstic Acid  
500ml H2O 
 
Acetate Buffer: 0.82g Sodium Acetate Anhydrous 
100ml dH2O 
pH adjusted to 5.2 using 100% Glacial Acetic Acid 
 
TRAP stain:  
350mg Napthol AS-TR Phosphate 
1250μl N-NDimethyl formanide 
250ml 0.2M Sodium Acetate Buffer  
575mg Sodium Tartrate dehydrate  
350mg Fast Red Salt TR 
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Calcineurin-nuclear factor of activated T cells signaling controls the differentiation and function
of osteoclasts and osteoblasts, and regulator of calcineurin-2 (Rcan2) is a physiological inhibitor of
this pathway. Rcan2 expression is regulated by T3, which also has a central role in skeletal devel-
opment and bone turnover. To investigate the role of Rcan2 in bone development and mainte-
nance, we characterized Rcan2/mice and determined its skeletal expression in T3 receptor (TR)
knockout and thyroid-manipulated mice. Rcan2/mice had normal linear growth but displayed
delayed intramembranous ossification, impaired cortical bone formation, and reduced bonemin-
eral accrual during development as well as increased mineralization of adult bone. These abnor-
malities resulted from an isolated defect in osteoblast function and are similar to skeletal pheno-
types ofmice lacking the type 2 deiodinase thyroid hormone activating enzymeorwith dominant-
negative mutations of TR, the predominant TR isoform in bone. Rcan2 mRNA was expressed in
primary osteoclasts and osteoblasts, and its expression in bone was differentially regulated in TR
and TR knockout and thyroid-manipulated mice. However, in primary osteoblast cultures, T3
treatment did not affectRcan2mRNAexpressionor nuclear factor of activated T cells c1 expression
andphosphorylation. Overall, these studies establish that Rcan2 regulates osteoblast function and
its expression in bone is regulated by thyroid status in vivo. (Endocrinology 153: 3537–3548, 2012)
Regulator of calcineurin (RCAN)-2 belongs to a familyof conserved proteins (RCAN1, RCAN2, and
RCAN3) that inhibit calcineurin (1, 2). Calcineurin is a
Ca2- and calmodulin-activated serine-threonine protein
phosphatase that consists of a calmodulin-binding cata-
lytic subunit andCa2-binding regulatory subunit (3).Ac-
tivation of calcineurin results in dephosphorylation of nu-
clear factor of activated T cells (NFAT), enabling it to
enter the nucleus and regulate gene expression in associ-
ation with other transcription factors, including activator
protein 1 (1, 2, 4, 5). Interaction of RCAN2 with the cat-
alytic subunit of calcineurin blocks NFAT-regulated gene
expression (6, 7), indicating RCAN2 is a physiological
inhibitor of calcineurin-NFAT signaling.
Calcineurin and NFAT are essential for osteoclast dif-
ferentiation and bone resorption. NFAT is a master tran-
scription factor for osteoclast differentiation, functioning
as a point of convergence for the receptor activator of
nuclear factor-B ligand, TNF receptor-associated factor
6 and c-Fos signaling pathways required for osteoclasto-
genesis (8). In addition to its important role in osteoclasts,
NFATalso regulates bonemass by acting in osteoblasts, in
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.
Copyright © 2012 by The Endocrine Society
doi: 10.1210/en.2011-1814 Received September 28, 2011. Accepted April 26, 2012.
First Published Online May 16, 2012
Abbreviations: BFR, Bone formation rate; BS, bone surface; BSE, backscattered electron;
CT, computed tomography; DIO2, type 2 deiodinase enzyme; MAR, mineral apposition
rate; MS, mineralizing surface; NFAT, nuclear factor of activated T cells; nt, nucleotide;
Oc.N, osteoclast numbers; Oc.S, osteoclast surface; P, postnatal day; qBSE-SEM, quanti-
tative BSE-SEM; RCAN, regulator of calcineurin; SEM, scanning electronmicroscopy; TR, T3
receptor; TRAP, tartrate-resistant acid phosphatase; WT, wild type.
T H Y R O I D - T R H - T S H
Endocrinology, July 2012, 153(7):3537–3548 endo.endojournals.org 3537
which its functions are more controversial. Initial studies
inmicewith global disruptionor activationof calcineurin-
NFAT signaling suggested the pathway stimulates osteo-
blast differentiation and bone formation in vivo and in
vitro (9–11), whereas recent studies specifically targeting
osteoblasts suggest the calcineurin-NFAT pathway is a
negative regulator of osteoblast differentiation and bone
formation that also inhibits osteoclastogenesis indirectly
via its effects on osteoprotegerin and receptor activator of
nuclear factor-B ligand in osteoblasts (12). The negative
effects on bone formation are supported by findings that
low doses of the calcineurin antagonist cyclosporin A in-
crease osteoblast differentiation and bonemass (13).Nev-
ertheless, cyclosporinAhas biphasic effects on osteoblasts
(12), and treatment of organ transplant patients with cal-
cineurin inhibitors is associated with high bone turnover
osteoporosis (14). Taken together, these data indicate the
regulatory effects of the calcineurin-NFAT pathway on
bone turnover are complex and involve direct actions in
osteoblasts and osteoclasts as well as indirect osteoblast-
mediated effects on osteoclastogenesis.
The human homolog of RCAN2 (previously named
ZAKI-4) was originally identified as a thyroid hormone
(T3)-responsive gene in skin fibroblasts by differential dis-
play (15), and ZAKI-4 and - mRNA isoforms were
identified subsequently (16). RCAN2–3 expression (pre-
viouslynamedZAKI-4) is restricted tobrainandencodes
a 197-amino acid short protein isoform RCAN2-S. By
contrast, RCAN2–1 (previously named ZAKI-4) is dis-
tributed widely, with the highest levels of expression in
brain, heart, skeletal muscle, and kidney, and encodes a
243-amino acid long protein isoform RCAN2-L (2, 16)
(Fig. 1). Although the two isoforms display tissue-specific
differences in expression, it is unknown whether they are
functionally distinct. Nevertheless, only RCAN2–3
(ZAKI-4) mRNA was found to be T3 responsive in fi-
broblasts (16), and this response was mediated by a non-
genomic signaling cascade involving T3 receptor (TR)-,
phosphatidylinositol 3-kinase-Akt/protein kinase B, and
mammalian target of rapamycin (17). T3 treatment also
resulted in reduced endogenous calcineurin activity, and
RCAN2 proteins were shown to interact directly with cal-
cineurin and inhibit calcineurin-NFAT signaling, indicat-
ingRCAN2 is aT3-responsive endogenous inhibitor of the
calcineurin-NFAT pathway (16).
In developing brain, Rcan2 mRNA was expressed
widely, increased with age, and colocalized with the ex-
pression of calcineurin in some regions. The temporal in-
crease in Rcan2 expression during brain maturation was
blunted in hypothyroid animals (18, 19). In particular,
Rcan2–3 mRNA expression was reduced in cerebral cor-
tex in hypothyroid mice, but levels in other brain regions
were not affected by thyroid status (19). Thus, Rcan2-
modulated calcineurin activity was suggested to influence
brain development leading to the hypothesis that reduced
Rcan2 expression could account for some of the adverse
consequences of hypothyroidism during brain develop-
ment (18, 19). In additional studies, the expression of
Rcan2–1 in the heart was increased after T3 administra-
tion (19, 20), but no effects were observed in other tissues
in response tohyperthyroidism(19).Taken together, these
findings indicate that T3 regulation of Rcan2–3 and
Rcan2–1 expression in vivo is isoform and tissue specific
and suggest that Rcan2maymediate some of the effects of
thyroid hormones in T3-target tissues (18–20).
Although Rcan2 functions as an endogenous inhibitor
of the calcineurin-NFAT signaling, it is not known
whether Rcan2 is also expressed in bone. To investigate
and determine the physiological importance of Rcan2 in
bone, we generated Rcan2/ knockout mice and char-
acterized their skeletal phenotype. We further hypothe-
sized thatRcan2may be a T3-responsive target gene in the
skeleton because both T3 and the calcineurin-NFAT path-
way regulate bone mass via actions in osteoblasts and os-
teoclasts (8, 12, 21). Thus,we also investigated expression
of Rcan2 in skeletal cells and in T3 receptor mutant and
thyroid manipulated mice. The effect of T3 on Rcan2 ex-
pression and downstream signaling was investigated in
primary osteoblast cultures.
Materials and Methods
Rcan2/ and Rcan2/ mice
Rcan2 knockout mice (Rcan2/) were generated by replac-
ing exon 4, common to both Rcan2–1 (ZAKI-4) and Rcan2–3
(ZAKI-4), with a LacZ/Neo cassette, and Northern blot anal-
ysis confirmed the absence of both transcripts inRcan2/mice
(22) (Fig. 1). Heterozygous Rcan2/ mice were backcrossed
and established in a C57B/6J genetic background in the animal
facility at theResearch Institute ofEnvironmentalMedicine (Na-
goya University, Nagoya, Japan) using protocols approved by
the institutional review board. The adult mice were given two ip
FIG. 1. Mouse Rcan2 gene. Genomic organization of the mouse
Rcan2 gene showing the alternative splicing events that lead to
expression of Rcan2–1 and Rcan2–3 isoforms. The locations of RT-PCR
primers are also shown.
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injections of calcein (15 mg/kg in saline with 2% NaHCO3) 7
and 4 d before the animals were killed at postnatal day (P) 112.
Manipulation of thyroid status in wild-type (WT)
mice
Hypothyroid mice were fed a low iodine diet containing
0.15% (wt/vol) of the antithyroid drug propylthiouracil from
P70 for 6 wk. Hyperthyroid mice were treated with TSH-sup-
pressive doses of T4 (1.2 g/ml in drinking water) from P70 for
6 wk. Manipulation of thyroid status was performed under li-
cense in compliancewith theAnimals (Scientific Procedures) Act
1986, and the studies were approved by the local Imperial Col-
lege London Biological Services Unit ethical review process.
Skeletal preparations and histology
P1mice and limbs from older animals were stained with aliz-
arin red and alcian blue (23, 24) and photographed using a Leica
MZ75 binocular microscope, KL1500 light source, DFC320
digital camera, and IM50Digital ImageManager (all fromLeica
AG, Heerbrugg, Switzerland). The angle of the clavicle, skull
dimensions, and open fontanelle and suture areas were calcu-
latedusing ImageJ1.43n (http://rsb.info.nih.gov/ij/). Limbswere
fixed in 10% neutral buffered formalin and decalcified in 10%
EDTA. Sections were stained with van Gieson and alcian blue.
Proliferative and hypertrophic zones in growth plate sections
were identifiedasdescribed (25–27).Measurements fromat least
four separate positions across the width of tibial growth plates
were obtained using a Leica DM LB2 microscope and Leica
DFC320 digital camera to calculate mean values for the heights
of the reserve, proliferative, and hypertrophic zones and total
growth plate. Results from two levels of sectioning were com-
pared with ensure consistency.
Faxitron digital x-ray microradiography
Digital x-ray imageswere recorded at 10mresolution using
a FaxitronMX20 variable kilovolt point projection x-ray source
and digital image system operating at 26 kV and5 magnifica-
tion (Qados; Cross Technologies PLC, Berkshire, UK). Images
were calibrated with a digital micrometer and bone lengths and
caudal vertebra heights determined using ImageJ [National In-
stitutes of Health (NIH)]. Cortical bone thickness and diameter
were determined at 10 locations in the middiaphysis. Relative
FIG. 2. Skeletal development and growth in Rcan2/ mice. A, Upper and lower limbs show detail of the upper limb paws and rib cages from P1
WT, Rcan2/, and Rcan2/ mice stained with alcian blue (cartilage) and alizarin red (bone). B, Proximal tibia growth plates from P28 WT,
Rcan2/, and Rcan2/ mice stained with alcian blue and van Gieson (osteoid) (50 and 200). E, Epiphysis; GP, growth plate; RZ, reserve zone;
PZ, proliferative zone; HZ, hypertrophic zone. Bars, 200 m. C, Growth plate and chondrocyte zone heights in P28 mice (n  3 per genotype) and
linear growth analysis from birth to P112 (n  3–4 per genotype). No statistical differences, ANOVA, Rcan2/, and Rcan2/ vs. WT. Humerus
middiaphysis cortical bone thickness at P28 (n  4 per genotype), ANOVA, Rcan2/, and Rcan2/ vs. WT. *, P  0.05, Tukey’s post hoc test. D,
Skulls and clavicles from P1 WT, Rcan2/, and Rcan2/ mice. Bars, 1000 m. E, Area of skull fontanelles, clavicle angle, and length in P1 WT,
Rcan2/, and Rcan2/ mice (n  4 per genotype), ANOVA, Rcan2/, and Rcan2/ vs. WT. *, P  0.05, Tukey’s post hoc test.
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mineral content was determined by comparison with steel, alu-
minum wire, and polyester fiber standards. The 2368  2340
16-bit DICOM images were converted to 8-bit Tiff images using
ImageJ (NIH), and the histogram stretched
between polyester (gray level 0) and steel
(gray level 255) standards. Gradations of
mineralizationdensitywere represented in 16
equal intervals by a pseudocolor scheme (28).
Biomechanical testing
Boneswere storedand tested in70%eth-
anol. Destructive three-point bend tests
were performed using an Instron 5543 load
frame and 100 N load cell (Instron Ltd.,
High Wycombe, Buckinghamshire, UK).
Bones were positioned horizontally and
centered on custom supports, and the load
was applied vertically to the midshaft with
a constant rate of displacement of 0.03mm/
sec until fracture. A span of 5.6 mm was
used. Biomechanical variables were derived
from the load displacement curves as de-
scribed previously (28–31).
Destructive compression tests were also
performedon caudal vertebrae6 and7 (Ca6
and Ca7) using a 500 N load cell. Vertebral
height and diameter was determined using
ImageJ (NIH). Parallel surfaces were cut
through adjacent intervertebral discs, and
vertebrae were fixed to the center of the
lower compression anvil with cyanoacry-
late glue. The load was applied vertically
with a constant rate of displacement of 0.03
mm/sec until failurewith load displacement
data acquired at 100 Hz. Load-displace-
ment curves were plotted and yield load,
displacement at yield, maximum load, dis-
placement at maximum load, and stiffness
were determined. Work energy was calcu-
lated from the area under the load displace-
ment curve atmaximum load. Elastic stored
energyatmaximumloadwasdeterminedby
calculating the area of a right-angled trian-
gle with the vertex at the point ofmaximum
load and a hypotenuse with a slope equal to
that of the linear phase of the load-displace-
ment curve. Energy dissipated at maximum
load was calculated by subtracting the elas-
tic stored energy from the work energy at
maximum load.
Backscattered electron (BSE)
scanning electron microscopy
(SEM)
Long bones were fixed in 70% ethanol
and opened longitudinally along anatomi-
cal curvatures as described (28). Samples
were coated with carbon and imaged using
backscattered electrons at 20 kV beam po-
tential in a Zeiss DSM962 digital scanning
electron microscope equipped with an an-
nular solid state BSE detector (KE Electronics, Toft, Cam-
bridgeshire, UK). The images provide detailed views of bone
FIG. 3. Faxitron and biomechanical analysis in Rcan2/ mice during growth. A, Images of
humerus and vertebrae from P28 WT, Rcan2/, and Rcan2/ mice. Gray-scale images were
pseudocolored according to a 16-color palette in which low mineral content is black and high
mineral content is white. Bars, 1000 m. No statistical differences in humerus length or
caudal vertebra height, ANOVA, Rcan2/, and Rcan2/ vs. WT were seen. B, Relative and
cumulative frequency histograms of bone mineralization densities (n  3 per genotype).
Kolmogorov-Smirnov test, Rcan2/, or Rcan2/ vs. WT. **, P  0.01; ***, P  0.001. C,
Representative load-displacement curves from destructive three-point bend testing of P28
WT, Rcan2/, and Rcan2/ humeri showing yield load, maximum load, fracture load, and
the gradient of the linear elastic phase (stiffness). Load-displacement curves from compression
testing of P28 WT, Rcan2/, and Rcan2/ caudal vertebrae show yield load, maximum
load, and stiffness. D, Graphs showing yield, maximum, and fracture loads and stiffness of
WT, Rcan2/, and Rcan2/ humeri. No statistical differences, ANOVA (n  4 per
genotype), were seen. Graphs showing yield and maximum loads and stiffness of WT,
Rcan2/, and Rcan2/ vertebrae. No statistical differences, ANOVA (n  4 per genotype),
were seen.
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surfaces andmicroarchitecture fromwhich surface activity states
(forming, resting, resorbing, resorbed) can be investigated (32,
33). The fraction of the trabecular and endosteal surfaces that
displayed osteoclastic bone resorption was quantified using Im-
ageJ (NIH).
Quantitative BSE-SEM (qBSE-SEM)
Bone micromineralization density was determined at cubic
micron resolution by qBSE-SEM. Block faces were cut through
polymethylmethacrylate-embedded specimens and analyzed in
the SEM operated at 20 kV and 0.5 nA at a working distance of
17 mm (11 mm sample to detector). Gradations of micromin-
eralization density were represented in eight equal intervals by a
pseudocolor scheme as described (28, 34–36).
Microcomputed tomography(CT) analysis
Humeri were analyzed by micro-CT (Skyscan 1172a; Kon-
tich, Belgium) at 50 kV and 200 A using a 0.5-mm aluminum
filter and a detection pixel size of 4.3m2. Scanned images were
reconstructed using Skyscan NRecon software (28). One cubic
millimeter of area, 0.2 mm from the growth plate, was selected
as the region of interest. Trabecular bone volume as proportion
of tissue volume (percentage), trabecular thickness (millimeters),
trabecular number (millimeters1), and structure model index
were analyzed in the region of interest using the Skyscan CT
analysis software. Cortical bone volume (cubic millimeters) was
also determined in the region of interest.
Osteoclastic bone resorption
Osteoclast numberswere determined in samples fixed in10%
neutral buffered formalin and decalcified in 10% EDTA (pH
7.4). Sections were stained for tartrate-resistant acid phospha-
tase (TRAP) using a Sigma TRAP kit (386A-1KT; Sigma, Poole,
Dorset, UK) and photographed at 200 magnification using a
Leica DM LB2 microscope and DFC320 digital camera and a
montage of nine overlapping fields constructed for each bone,
representing an area of approximately 1 mm2. Osteoclast num-
bers (Oc.N) and surface (Oc.S) were determined in trabecular
bone and normalized to total bone surface (BS). Measurements
commenced 0.2 mm below the growth plate (25, 26).
Osteoblastic bone formation
Midline longitudinal and midcoronal block faces were cut
through methacrylate embedded specimens and examined using
a Leica SP2 reflection confocal microscope with 488 nm excita-
tion and10/1.0 and40/1.25 objectives to determine the frac-
tion of bone surface undergoing active bone formation as de-
scribed (28, 37). Mineral apposition rate (MAR) was calculated
by determining calcein separation at between 10 and 20 loca-
tions per specimen using ImageJ (NIH). Montages of trabecular
bone were generated and the BS and mineralizing surface (MS)
measured using ImageJ. Bone formation rate (BFR) was calcu-
lated from the product of MS and MAR. Measurements com-
menced 0.2 mm below the growth plate.
Semiquantitative RT-PCR
cDNA was synthesized from total RNA (2.5 g), and 1 l
cDNA was used for PCR amplification of Rcan2–1, Rcan2–3,
and Gapdh (38). The nucleotide (nt) positions indicate the lo-
cations of PCR primers within the GenBank reference sequence:
Rcan2–1 forward primer, Rcan2–1 F (nt 294–313), reverse
primer Rcan2–1R (nt 530–511) (GenBank NM_207649);
Rcan2–3 forward primer, Rcan2–3 F (nt 205–224), reverse
primer, Rcan2–3R (nt 423–404) (NM_030598); Gapdh for-
wardprimer,GapdhF (nt658–677), reverseprimer,GapdhR(nt
881–863) (NM_008084) (Fig. 1). PCRwere performed with an
initial denaturation step at 94 C for 2 min, cycles of 30 sec at 94
C, 30 sec at an annealing temperature of 55 C, and 30 sec at 72
C, followed by a termination step at 72 C for 3 min. Semiquan-
titative RT-PCR was optimized as described (39) and cDNA
amplified using the optimized number of PCR cycles for each
gene (25 cycles forGapdh; 28 cycles forRcan2–1 andRcan2–3).
Osteoblast cultures
Calvaria were removed from 2-d-old mice and osteoblasts
isolated by sequential collagenase digestion. Osteoblasts were
cultured in 75-cm2 flasks in modified Eagle’s medium supple-
mented with 10% fetal calf serum, L-glutamine, penicillin, and
streptomycin for 72 h. Cells were replated in six-well plates
(250,000 cells/well) and maintained for 48 h before culture in
serum-free medium overnight. Cells were treated with vehicle or
T3 (100 nM) for 6 h before RNA extraction with Trizol or iso-
lation of nuclear and cytoplasmic protein fractions using anNE-
PER kit (Thermo Scientific, Waltham, MA).
TABLE 1. 3 point bend and compression testing
Yield load
(N)
Maximum Load
(N)
Fracture Load
(N)
Stiffness
(N/mm)
Energy dissipated
at max load (%)
Energy dissipated
at fracture
load (%)
WT P28 Humerus 4.3  0.6 5.1  0.7 3.4  0.5 26  4 43  4 90  2
Rcan2/ P28 Humerus 3.6  0.2 4.7  0.3 3.6  0.4 28  3 58  5 89  3
Rcan2/ P28 Humerus 3.4  0.3 4.1  0.5 3.2  0.2 22  6 51  11 88  2
WT P28 Ca6Ca7 13.9  2.2 17.2  2.2 51  6.2 35  2
Rcan2/ P28 Ca6Ca7 10.5  0.3 15.4  0.8 54  5.4 52  3
Rcan2/ P28 Ca6Ca7 9.8  1.4 13.9  1.8 56  11.5 52  10
WT P112 Humerus 8.2  0.1 13.2  1.9 11.6  1.5 61  2 33  5 46  11
Rcan2/ P112 Humerus 8.3  0.5 10.9  1.5 12.3  0.6 54  7 29  10 35  8
WT P112 Ca6Ca7 88  9 97  8 321  20 17  2
Rcan2/ P112 Ca6Ca7 77  6 86  6 329  12 18  1
P28: WT, Rcan2/, and Rcan2/ mice (n  3 per genotype); P112: WT and Rcan2/ mice (n  3 per genotype).
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Real-time RT-PCR
Total RNA was extracted from calvarial osteoblasts and
whole bones, and 1 g was reverse transcribed (QunatiTect re-
verse transcriptase kit; QIAGEN,Hilden, Germany). cDNAwas
amplified usingRcan2–1 andRcan2–3 primers described above
and -actin and 18s rRNA primers as follows: -actin forward
primer, -ActinF (nt 1035–1058), reverse primer, -ActinR (nt
1234–1209) (NM_007393); 18s rRNA forward primer, 18sF
(nt 1443–1461), reverse primer, 18sR (nt 1549–1530)
(NM_003278). RT-PCR was performed using a 7900HT Fast
real-time machine (Applied Biosystems, Foster City, CA) and
analyzed with SDS2.3 software (Applied Biosystems). PCRs
were performed with an initial denaturation step at 95 C for 10
min followed by 40 cycles of 95 C for 15sec, 30 sec at an an-
nealing temperature of 60 C, and 30 sec at 72 C, followed by a
dissociation stage to allow melt curve analysis.
Immunoprecipitation
Nuclear and cytoplasmic protein fractionswere isolated from
primary calvarial osteoblasts using a NE-PER kit (Thermo Sci-
entific). 20 g of each fraction was pre-cleared using protein
G-Sepharose beads (GE Healthcare, Hatfield, Hertfordshire,
UK) for 1 h. Cleared lysates were incubated overnight with 5 g
of anti-NFATc1 monoclonal antibody (Santa Cruz Biotechnol-
ogy, SantaCruz,CA)before the additionofprotein-G-Sepharose
beads for 1 h and collection of immunoprecipitates by centrifu-
gation. Samples were washed four times in PBS and eluted in
protein sample buffer. SDS-PAGE and Western blotting were
thenperformedusing anti-NFATc1monoclonal antibody (Santa
Cruz Biotechnology) or an antiphosphoserine antibody (Abcam,
Cambridge UK).
Statistics
Normally distributed data were analyzed by ANOVA fol-
lowed by Tukey’s multiple comparison post hoc test. P 0.05
was considered significant. Frequency distributions of bone mi-
cromineralization densities obtained by Faxitron and qBSEwere
comparedusing theKolmogorov-Smirnov test, inwhichP values
for theD statistic in 1024 pixel data sets wereD greater than
6.01,P0.05;D greater than7.20,P0.01, andD greater
than 8.62 P  0.001.
Results
Bone development in Rcan2/ mice
To determine whether deletion of Rcan2 affects bone
formation, endochondral and intramembranous ossifica-
tion was analyzed in neonatal P1 mice, and linear growth
was characterized between P1 and P112 (Fig. 2, A–E).
There were no differences in endochondral bone forma-
tion or linear growth between WT and mutant mice (Fig.
2, A–C). Consistent with these findings, histological anal-
ysis of the growth plate revealed no differences between
WT and Rcan2 mutant mice at P28 (Fig. 2, B and C). By
contrast, intramembranous ossificationwas delayed in P1
Rcan2/ mice, in which wider skull sutures and fonta-
FIG. 4. Bone microarchitecture and micromineralization in adult
Rcan2/ mice. A and B, Low-power BSE-SEM views of proximal tibia
and high-power views of distal femur from P112 WT, Rcan2/, and
Rcan2/ mice (n  3 per genotype). Bars, 200 m. C, qBSE-SEM
images of trabecular bone from proximal humerus of P112 WT,
Rcan2/, and Rcan2/ mice (n  2–4 per genotype). Gray-scale
images were pseudocolored according to an eight-color palette in
which the low mineralization density is blue and the high density is
gray. Bar, 200 m. D, Relative and cumulative frequency histograms of
trabecular bone micromineralization densities. *, P  0.05, Rcan2/
or Rcan2/ vs. WT, Kolmogorov-Smirnov test, WT (n  4), Rcan2/
(n  2), and Rcan2/ (n  4). E, qBSE-SEM images of cortical bone
from the midshaft of the humerus in WT, Rcan2/, or Rcan2/ mice.
Bar, 200 m. F, Frequency histograms of cortical bone
micromineralization densities. ***, P  0.001, Rcan2/ or Rcan2/
vs. WT, Kolmogorov-Smirnov test, WT (n  4), Rcan2/ (n  2), and
Rcan2/ (n  4).
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nelleswere present comparedwithWTmice andheterozy-
gotes, although claviclemorphologywasnormal (Fig. 2,D
and E). Cortical bone thickness was also reduced by 17%
in Rcan2/ mice in the middiaphysis of the humerus at
P28 (Fig. 2C), although this difference in cortical thickness
was not maintained at P112 (data not shown). Thus, dur-
ing skeletal development Rcan2-deficient mice display
normal endochondral ossification in the growth plate but
impaired intramembranous ossification and cortical bone
formation.
Bone mineralization and strength in juvenile
Rcan2/ mice
To determine whether deletion of Rcan2 affects bone
mineralization, bone mineral content in P28mice was an-
alyzed by Faxitron digital x-ray microradiography. Rela-
tive and cumulative frequency histograms revealed re-
duced bone mineral content in Rcan2/ mice and
reduced vertebral bone mineral content in bothRcan2/
and Rcan2/ mice (Fig. 3, A and B). To determine
whether reduced bone mineral content and cortical bone
thickness in juvenile Rcan2/mice was accompanied by
impaired bone strength, destructive three-point bend test-
ing was performed on humeri and compression testing on
caudal vertebrae from P28mice. Although biomechanical
analysis demonstrated a trend to suggest that bone
strength is impaired in Rcan2/ mice, the data did not
reach statistical significance (Fig. 3,CandD, andTable 1).
Bone microarchitecture in adult Rcan2/ mice
To investigate the structure of adult bone in Rcan2/
mice, bone microarchitecture was analyzed. Low-power
BSE-SEM views of proximal tibia revealed no differences
in cortical or trabecular bone between mutant and WT
mice at P112 (Fig. 4A). In higher-power views, the thick-
ness and connectivity of individual trabeculae was similar
among Rcan2/ and Rcan2/ and WT mice (Fig. 4B).
Accordingly, trabecular and cortical bone parameters de-
termined by micro-CT (Table 2), and cortical thickness
determined by Faxitron (data not shown), did not differ
betweenmutant andWTmice. Thus, adultRcan2mutant
mice have normal bone microarchitecture.
Bone mineralization and strength in adult Rcan2/
 mice
Detailed studies of bone mineralization were per-
formed using qBSE-SEM (Fig. 4, C–F). Frequency histo-
grams of micromineralization densities from trabecular
(Fig. 4D) and cortical bone (Fig. 4F) demonstrated in-
creased mineralization in Rcan2/ and Rcan2/ mice.
Thus, in contrast to the reduced bone mineral content
identified in juveniles, adult Rcan2 mutant mice display
increased bonemineralization. To determine whether this
increased bone mineralization was accompanied by al-
tered bone strength three-point bend and compression
testing was performed. Despite the observed changes in
mineralization, biomechanical parameters did not differ
between Rcan2/ and WT mice (Table 1).
Bone resorption and bone formation in Rcan2/
mice
To investigate whether changes in osteoclastic bone re-
sorption also occur in Rcan2 mutant mice, histomor-
phometry and BSE-SEM analyses were performed. Sec-
tions were stained for TRAP to determine the Oc.N and
quantify Oc.S in relation to the total trabecular BS (Fig. 5,
A andB), but nodifferences in these parameterswere iden-
tified between mutant and WT mice. The areas of oste-
oclastic bone resorption on trabecular and endosteal bone
surfaces were quantified in higher resolution BSE-SEM
images (Fig. 5,CandD), andnodifferenceswere identified
in the resorption surface relative to total BS between mu-
tant and WT mice.
To investigate osteoblast function and bone formation
parameters, mineralizing surfaces, MAR, and BFR were
quantified in bones from the calcein-labeled mice (Fig. 5,
E and F).Mineralizing surfaces were reduced by 54% and
MARby 29% inRcan2-deficient mice, and consequently,
bone formation rate was reduced by 67% in Rcan2/
mice. Thus, Rcan2-deficient mice exhibit an isolated de-
fect in osteoblast function but have normal osteoclast
function.
Rcan2 expression in bone
Expression of Rcan2 in the skeleton and its regulation
by thyroid hormones were investigated in primary bone
TABLE 2. Micro-CT analysis
BV/TV (%) Tb.Th (mm) Tb.N (mm1) SMI Cortical BV (mm3)
WT P112 Humerus 8.1%  0.7 0.038  0.001 2.1  0.18 1.91  0.07 0.59  0.02
Rcan2/ P112 Humerus 8.8%  2.7 0.038  0.001 2.3  0.71 1.94  0.28 0.53  0.05
WT and Rcan2/ mice (n  3 per genotype). BV/TV, Trabecular bone volume as proportion of tissue volume; Tb.Th, trabecular thickness; Tb.N,
trabecular number; SMI, structure model index; Cortical BV, Cortical bone volume.
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cell cultures from WT mice and in
bones obtained from TR knockout and
thyroid-manipulated mice. In primary
osteoclast cultures, bone marrow
monocytes and osteoclast precursors
expressed Rcan2–1 but not Rcan2–3,
whereas mature osteoclasts expressed
only Rcan2–3. By contrast, primary
osteoblasts expressed both isoforms
(Fig. 6).
Mice lacking TR (TR0/0) have im-
paired T3 signaling in bone because
they lack expression of TR, the pre-
dominant functional TR isoform in the
skeleton (26, 40). By contrast, mice
lacking TR (TR/) have increased
thyroid hormone signaling in bone due
to activation of the normal TR iso-
form by elevated circulating thyroid
hormones (25, 26). The level of
Rcan2–1 expression was similar in ju-
venile and adult TR0/0, TR/, and
WT mice, whereas expression of
Rcan2–3 was reduced by 50% in juve-
nile TR0/0 mice (Fig. 7). Consistent
with these findings, skeletal Rcan2–3
mRNA expression was increased by
more than 2-fold in thyrotoxic WT
mice compared with hypothyroid ani-
mals (Fig. 8A).
In vitro studies in primary
osteoblasts
In primary cultures of WT calvarial
osteoblasts, T3 treatment did not affect
the levels of Rcan2–1 or Rcan2–3
mRNA expression (Fig. 8B). Further-
more, T3 treatment did not alter levels
ofNFATc1 protein expression or phos-
phorylation and did not affect its rela-
tive distribution between nuclear and
cytoplasmic compartments (Fig. 8C).
Discussion
These studies demonstrate that, despite
normal endochondral ossification and
linear growth, juvenile Rcan2/ mice
display delayed intramembranous ossi-
fication, impaired cortical bone forma-
tion, and reducedbonemineral accrual.
FIG. 5. Bone turnover in Rcan2/ mice. A, TRAP-stained sections of tibia trabecular bone
from P112 WT, Rcan2/, and Rcan2/ mice. Black arrows indicate TRAP-stained
osteoclasts. Bar, 200 m. B, Quantitative analysis of Oc.S and the Oc.N relative to BS. No
statistical differences, ANOVA, WT (n  4), Rcan2/ (n  2), and Rcan2/ (n  4), were
seen. C, Endosteal bone surfaces from P112 WT, Rcan2/, and Rcan2/ mice imaged by
BSE-SEM. White arrows indicate roughened osteoclast resorption surfaces. Bar, 200 m. D,
Quantitative analysis of trabecular and endosteal osteoclast resorption surfaces (percentage of
total bone surface). No statistical differences, ANOVA, WT (n  4), Rcan2/ (n  2) and
Rcan2/ (n  4), were seen. E, Calcein labeling of trabecular bone from WT, Rcan2/, and
Rcan2/ mice. Bar, 10 m. F, Trabecular bone MS, MAR, and BFR determined by dual-
calcein labeling. ANOVA, Rcan2/ (n  2) and Rcan2/ (n  4) vs. WT (n  4), *, P  0.05
and **, P  0.01, Tukey’s post hoc test.
3544 Bassett et al. Rcan2 and Osteoblast Function Endocrinology, July 2012, 153(7):3537–3548
Adult Rcan2/mice exhibit normal bone microarchitec-
ture but increased mineralization. Heterozygous
Rcan2/micehavean intermediatephenotype consistent
with a gene dosage effect. The skeletal abnormalities in
Rcan2/micewere accompaniedbynormalbone resorp-
tion but reduced bone formation, indicating an isolated
defect in osteoblast function. The resulting reduction in
mineral apposition rate leads to an extended bone forma-
tion phase and prolongation of the bone remodeling cycle.
This protracted phase of osteoblastic bone formation is
accompanied by a longer period of secondary mineraliza-
tion (41, 42), which results in the observed increase in
bone mineralization in adult Rcan2/ mice.
Thyroid hormones have major effects on skeletal de-
velopment and adult bone maintenance (43, 44). Hypo-
thyroidism delays bone formation and linear growth,
whereas thyrotoxicosis accelerates skeletal development
and is an important risk factor for osteoporosis. In previ-
ous studies we characterized mice with mutation or dele-
tion of TR and TR in several genetic backgrounds (21,
23–27). Juvenile TRmutants exhibit delayed endochon-
dral ossification and impaired growth, whereas juvenile
TR mutants have advanced ossification. By contrast,
adult TR mutants have increased bone mass resulting
from disrupted T3 action in bone, whereas adult TRmu-
tants are osteoporotic due to increased T3 signaling in the
skeleton as a consequence of elevated circulating thyroid
hormone concentrations (23, 40). Taken together, these
studies indicate TR mediates T3 action in bone (21).
In studies to investigate the role of TR in skeletal de-
velopment, we characterized a series of TRmutant mice
(23, 25, 26). Mice lacking TR (TR0/0) had delayed en-
dochondral ossification but normal intramembranous os-
sification and normal adult bone mineralization. By con-
trast, mice harboring a dominant-negative mutation of
TR (TR1PV/ and TR1R384C/) had delayed endo-
chondral and intramembranous ossification accompanied
by increased adult bone mineralization (23, 25, 26). In
further studies we showed that expression of the type 2
deiodinase enzyme (DIO2), which generates T3 in thyroid
hormone-responsive target cells, is restricted to differen-
tiated osteoblasts in the skeleton (45). Accordingly,Dio2
knockout mice (Dio2/) exhibited a discrete defect of
osteoblast function, resulting in increased adult bonemin-
FIG. 6. Rcan2 mRNA expression in primary osteoblasts and
osteoclasts. A, Rcan2–1, Rcan2–3, and Gapdh mRNA expression in
primary osteoblasts (M; size marker). Ob, Osteoblasts; Br, brain; Ht,
heart; and C, no template control. B, Rcan2–1 and Rcan2–3 expression
in primary osteoclasts (Mo; bone marrow monocytes). Oc D1,
Osteoclast precursors (d 1 of culture); and Oc D5, mature osteoclasts
(d 5 of culture).
FIG. 7. Rcan2 mRNA expression in bone from TR knockout mice. A,
Rcan2–1 and Rcan2–3 mRNA expression in juvenile WT, TR0/0, and
TR/ bone at age P21. B, Rcan2–1 and Rcan2–3 mRNA expression in
adult WT, TR0/0, and TR/ bone at age P70. C, Graphs showing
Rcan2–1 and Rcan2–3 mRNA expression, normalized to Gapdh, in
bone from juvenile TR0/0 and TR/ mice compared with WT.
ANOVA, Rcan2// and Rcan2/ vs. WT. *, P  0.05, Tukey’s post
hoc test, n  4 per genotype. D, Graphs showing Rcan2–1 and Rcan2–
3 mRNA expression, normalized to Gapdh, in bone from adult TR0/0
and TR/ mice compared with WT. No significant difference,
ANOVA, n  4 per genotype, was seen.
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eralization (28). Thus, the findings of delayed intramem-
branous ossification and increased adult bonemineraliza-
tion identified in Rcan2/ mice are similar to those in
micewithosteoblast defects due todominant negativemu-
tations of TR or deletion of Dio2.
Cell-specific gene targeting has demonstrated that the
calcineurin-NFAT pathway is a negative regulator of os-
teoblast differentiation (12). Thus, deletion of the endog-
enous calcineurin inhibitor RCAN2would be expected to
inhibit osteoblast activity further by removal of tonal in-
hibition of calcineurin activity in osteoblasts. The findings
of delayed intramembranous ossification, impaired corti-
cal bone formation, and reduced bone mineral accrual
during development, together with increased bone min-
eralization in adultRcan2/, mice are all consistent with
this hypothesis. Together with the previous similar find-
ings in TR and Dio2 mutant mice (23, 25, 26, 28), the
skeletal phenotype ofRcan2/mice suggests that Rcan2
may lie downstream of T3 signaling in osteoblasts.
We therefore investigated thyroid hormone regulation
of Rcan2 expression in skeletal cells in vivo and in vitro.
Both Rcan2–1 and Rcan2–3 mRNA were expressed in
bone in vivo and, consistent with previous studies in fi-
broblasts (16), only theRcan2–3 isoformwas regulatedby
thyroid status or deletion of TR. In vitro studies dem-
onstrated that expression of Rcan2–1 and Rcan2–3 was
bone cell lineage specific anddependent on the stage of cell
differentiation.Osteoblasts expressed bothRcan2mRNA
isoforms and immature osteoclast precursor cells ex-
pressed only Rcan2–1, whereas mature differentiated os-
teoclasts expressed only Rcan2–3. The absence of an os-
teoclast phenotype in Rcan2/mice suggests the actions
ofRcan2 are dispensable in the osteoclast lineage, and this
may reflect redundancy in regulationof calcineurin/NFAT
signaling. Expression of both Rcan2 transcripts in osteo-
blasts suggests that Rcan2 may mediate some of the ac-
tions of T3 in osteoblasts.
To address this, primary osteoblasts were treated with
T3. Even though skeletal Rcan2–3 expression was in-
creased in thyrotoxic animals, T3 treatment did not affect
Rcan2–3 or Rcan2–1 expression in primary osteoblasts.
Furthermore, immunoprecipitation studies to investigate
expression of the calcineurin target gene NFATc1 and its
phosphorylation in cytoplasmic and nuclear compart-
ments also revealed no response to T3. These in vitro stud-
ies suggest that, even though skeletal expression ofRcan2
is regulated by thyroid status in vivo, the phenotype iden-
tified in Rcan2/ mice is unlikely to result directly from
disruption of T3 signaling in osteoblasts.
Nevertheless, the current studies establish that Rcan2
regulates osteoblast activity during growth and mainte-
nance of bone mineralization in adults.
FIG. 8. Rcan2 mRNA expression in whole bone and primary
osteoblasts from WT mice and expression and phosphorylation of
NFATc1 in WT osteoblasts treated with T3. A, Rcan2–1 and Rcan2–3
mRNA expression in whole bone from hypothyroid and thyrotoxic
P112 WT mice. Unpaired Student’s t test, hypothyroid vs. thyrotoxic. *,
P  0.05, n  3 per group. B, Rcan2–1 and Rcan2–3 mRNA expression
in primary calvarial osteoblasts obtained from WT mice. No significant
difference, unpaired Student’s t test, hypothyroid vs. thyrotoxic, n  3
per group, was seen. C, Immunoprecipitation and Western blot
analysis of total and phosphorylated NFATc1 in nuclear and
cytoplasmic protein fractions from cultured primary calvarial
osteoblasts treated with vehicle or T3 (100 nM). No significant
difference, unpaired Student’s t test, vehicle vs. T3, n  3 per group,
was seen.
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 4.8 
 Introduction 
 Osteoporosis is deﬁ ned as a bone mineral density (BMD) of 2.5 or more 
standard deviations below that of a young adult (T score  ≤  − 2.5). It 
is characterized by reduced bone mass, low BMD, deterioration of 
bone microarchitecture, and an increased susceptibility to fragility 
fracture. The prevalence of postmenopausal osteoporosis increases 
with age from 6 % at 50 years of age to over 50 % at age 80 and the 
lifetime incidence of fracture for a 50 year old in the UK is 40 % for 
women and 13 % for men. Osteoporosis is a worldwide public 
health burden that costs an estimated £1.7 billion in the UK, $15 
billion in the USA, and £32 billion in Europe per annum (see 
Chapter 4.7). 
 Low BMD, a prior or parental history of fracture, low body mass 
index, use of glucocorticoids, smoking, excessive alcohol con-
sumption, untreated thyrotoxicosis, and other risk factors increase 
susceptibility to osteoporosis and fracture. Even subclinical hyper-
thyroidism, deﬁ ned by a suppressed thyroid stimulating hormone 
(TSH) level in the presence of normal thyroid hormone concen-
trations, is associated with fracture while treatment with thyroxine 
(T 4 ) at doses that suppress TSH is associated with increased bone 
turnover and low BMD in postmenopausal women ( 1 ). 
 Thyroid disease occurs 10-fold more frequently in women and 
its prevalence increases with age. Hypothyroidism is a common 
disorder with a prevalence of 0.5 % in women between the ages of 
40 and 60 and greater than 2 % over the age of 70. Thyrotoxicosis 
has a prevalence of 0.45 % in women between the ages of 40 and 
60 and 1.4 % over the age of 60. As a result, 3 % of women over 
50 receive T 4 replacement for either primary hypothyroidism or 
the consequences of surgical or radio-iodine treatment for thyro-
toxicosis, and at least 20 % of them are overtreated ( 2 ). Moreover, 
subclinical hyperthyroidism affects an additional 1.5 % of women 
over 60 and its prevalence also increases with age. Nevertheless, the 
role of thyroid hormone in the pathogenesis of osteoporosis has 
been under-recognized and the extent of its contribution remains 
uncertain. 
 Bone strength and fracture susceptibility are determined by 
the acquisition of peak bone mass and the rate of bone loss in 
adulthood ( 3 ). In children, congenital hypothyroidism is the most 
common congenital endocrine disorder with an incidence of 1 
in 1800. Hypothyroidism in children results in delayed bone age 
and growth arrest and treatment with T 4 reverses these changes by 
inducing rapid ‘catch-up’ growth. Although juvenile Graves’ dis-
ease is rare, it remains the commonest cause of thyrotoxicosis in 
children, being characterized by advanced bone age and acceler-
ated growth that results in short stature due to premature fusion of 
the growth plates ( 4 ). In adults, histomorphometry studies reveal 
that hypothyroidism results in reduced bone turnover but a net 
gain in bone mass per remodelling cycle, whereas thyrotoxicosis 
increases bone resorption and bone formation but induces a net 
10 % loss of bone per remodelling cycle ( 5 ,  6 ). Taken together, 
these studies indicate the juvenile and adult skeleton is exquisitely 
sensitive to thyroid hormones. Thus, euthyroid status is essential 
for skeletal development, bone mineralization, and acquisition of 
peak bone mass, and the regulation of bone maintenance in adults. 
Importantly, recent large population studies have shown that 
both hypothyroidism and thyrotoxicosis are associated with an 
increased risk of fracture, demonstrating the physiological impor-
tance of euthyroid status for optimization of skeletal integrity and 
bone strength ( 7 – 11 ). 
 In this chapter we provide an up to date analysis of the role of 
thyroid hormone in skeletal development and adult bone mainte-
nance by discussing evidence from animal models and basic science 
in relation to a detailed review of the current clinical literature. 
 Thyroid hormone action 
 Circulating thyroid hormone levels are maintained in the euthy-
roid range by a classical endocrine negative feedback loop. 
Thyrotropin-releasing hormone is synthesized in the paraventricu-
lar nucleus of the hypothalamus and stimulates synthesis and 
secretion of TSH from thyrotrophs in the anterior pituitary gland. 
TSH, acting via the G-protein coupled TSH receptor (TSHR), 
stimulates growth of thyroid follicular cells and the synthesis and 
release of thyroid hormones. Thyroid hormones act via thyroid 
hormone receptors in the hypothalamus and pituitary to inhibit 
thyrotropin-releasing hormone and TSH synthesis and secretion. 
This negative feedback loop maintains circulating thyroid hormones 
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and TSH in a physiological inverse relationship, which deﬁ nes the 
hypothalamic–pituitary–thyroid (HPT) axis set point ( 4 ). 
 The thyroid gland secretes the prohormone T 4 and a small amount 
of the physiologically active hormone 3,5,3 ′ - l -triiodothyronine 
(T 3 ). The majority of circulating T 3 , however, is thought to be gen-
erated via 5 ′ -deiodination of T 4 by the type 1 iodothyronine deio-
dinase enzyme (D1) in liver and kidney. Circulating free T 4 levels 
are maintained at approximately three to fourfold higher concen-
trations than free T 3 . Intracellular availability of T 3 is determined 
by active uptake of the free hormones by speciﬁ c cell membrane 
transporters, including monocarboxylate transporter-8 and -10, 
and organic acid transporter protein-1c1, and by the activities of 
the type 2 and 3 deiodinase enzymes (D2 and D3). D2 converts 
T 4 to the active hormone T 3 by catalysing removal of a 5 ′ -iodine 
atom. By contrast, D3 prevents activation of T 4 and inactivates T 3 
by removal of a 5-iodine atom to generate the metabolites 3,3 ′ ,5 ′ -
 l -triiodothyronine (reverse T 3 ) and 3,3 ′ -diiodothyronine (T 2 ), 
respectively. Thus, the relative levels of D2 and D3 ultimately deter-
mine the concentration of intracellular T 3 available to the nuclear 
T 3 receptors (TRs) ( 12 ). 
 TRs act as hormone-inducible transcription factors that regulate 
expression of T 3 -responsive target genes. The  THRA and  THRB 
genes encode three functional TRs: TR α 1, TR β 1, and TR β 2. TR α 1 
and TR β 1 are expressed widely but their relative levels differ during 
development and in adulthood due to tissue-speciﬁ c and tempo-
rospatial regulation. Expression of TR β 2, however, is restricted. In 
the hypothalamus and pituitary it mediates inhibition of thyrotro-
pin-releasing hormone and TSH expression whilst in the cochlea 
and retina it has a key role to control the timing of sensory organ 
development ( 13 ). 
 Skeletal development and 
bone maintenance 
 The skeleton develops via two distinct processes. Endochondral 
ossiﬁ cation is the process by which long bones form and linear 
growth occurs. A cartilage anlage forms from mesenchyme con-
densations to form a scaffold for subsequent bone formation. 
Mesenchyme progenitor cells differentiate into chondrocyte pre-
cursors, which undergo a tightly regulated sequence of clonal 
expansion, proliferation, hypertrophic differentiation, and apop-
tosis. Chondrocytes secrete a cartilage matrix that mineralizes and 
is subsequently remodelled by the activities of bone resorbing oste-
oclasts and bone forming osteoblasts, resulting in formation of the 
diaphysis. Linear growth continues throughout development by a 
similar process within the epiphyseal growth plates, which are 
located at the proximal and distal ends of long bones. By contrast, 
the skull vertex forms by intramembranous ossiﬁ cation, in which 
mesenchymal cells differentiate directly into osteoblasts, resulting 
in bone formation in the absence of a cartilage scaffold. Linear 
growth continues until fusion of the growth plates during puberty 
but bone mineralization and consolidation of bone mass accrual 
continues into early adulthood so that peak bone mass is achieved 
during the third to fourth decade ( 14 ,  15 ). 
 Functional integrity and strength of the skeleton is maintained by 
the process of bone remodelling, which is achieved by the integrated 
and coupled activities of osteocytes, osteoclasts, and osteoblasts. 
Osteocytes comprise 90–95 % of all adult bone cells. They derive 
from osteoblasts that have become embedded in bone matrix. The 
osteocyte network is thought to sense changes in mechanical load 
and regulate local initiation of bone remodelling by the release of 
cytokines and chemotactic signals or by osteocyte apoptosis. Bone 
remodelling begins with the recruitment of mature osteoclasts 
and their precursors to sites of altered mechanical load or micro-
damage. Osteoclasts excavate a resorption cavity over a period of 
3–5 weeks until this process is terminated by apoptosis and followed 
by recruitment of osteoblast precursors. Subsequently, osteoblasts 
undergo a programme of maturation during which they secrete 
and mineralize osteoid to replace the resorbed bone over a period 
of approximately 3 months. Coupling of osteoclast and osteoblast 
activities via signalling between the two cell lineages regulates the 
bone remodelling cycle and results in skeletal homoeostasis with 
preservation of bone strength. In summary, the bone remodelling 
cycle is initiated and orchestrated by osteocytes, and regulated by 
coupled crosstalk between osteoblasts and osteoclasts. 
 Thyroid hormone action in bone 
 TR α 1 and TR β 1 are expressed in growth plate chondrocytes, bone 
marrow stromal cells, and osteoblasts but it is uncertain whether 
they are present in osteoclasts ( 4 ,  16 ). 
 In vivo  and in vitro studies have shown that T 3 acts via the Indian 
hedgehog/ parathyroid hormone-related peptide feedback loop, 
growth hormone/ insulin-like growth factor-1, and ﬁ broblast 
growth factor receptor-3 (FGFR3) signalling pathways to inhibit 
growth plate chondrocyte proliferation and stimulate hypertrophic 
chondrocyte differentiation. In childhood hypothyroidism, growth 
arrest and delayed bone formation are consequences of gross dis-
ruption of growth plate architecture (epiphyseal dysgenesis), which 
results from disorganization of the growth plates and a failure of 
hypertrophic chondrocyte differentiation. By contrast, thyroid 
hormone excess accelerates hypertrophic chondrocyte differentia-
tion resulting in advanced bone formation ( 4 ,  16 ). 
 Studies of bone marrow stromal cells suggest that many of the 
actions of T 3 involve complex cytokine and growth factor signal-
ling pathways that regulate communication between osteoblast and 
osteoclast cell lineages within the bone marrow microenvironment. 
 In vivo  and  in vitro studies have further shown that T 3 regulates 
osteoblast differentiation and activity at least in part via the FGFR1 
signalling pathway. Activating mutations of  FGFR1 cause Pfeiffer’s 
craniosynostosis syndrome and, consistent with this, craniosynos-
tosis is a recognized manifestation of severe juvenile thyrotoxicosis 
in which FGFR1 activity is increased in osteoblasts. 
 The regulation of adult bone turnover by thyroid hormones 
has been investigated by bone histomorphometry ( 5 ,  6 ). The skel-
etal manifestations of hypothyroidism include reduced osteoblast 
activity, impaired osteoid apposition, and a prolonged period of 
secondary bone mineralization. Consistent with a state of low bone 
turnover, osteoclast activity and bone resorption are also reduced. 
The effect of the low bone turnover state in hypothyroidism is a net 
increase in mineralization without a change in bone volume. By 
contrast, thyrotoxicosis results in a state of high bone turnover. The 
frequency of initiation of bone remodelling is markedly increased 
and the duration of the bone remodelling cycle is reduced. The net 
result is that the duration of bone formation and mineralization 
is reduced to a greater extent than the reduction in duration of 
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bone resorption. This leads to a net 10 % loss of bone per remodel-
ling cycle, resulting in high bone turnover osteoporosis. 
 Studies in genetically modiﬁ ed mice 
 In vivo studies in mutant mice have demonstrated that TR α 1 medi-
ates T 3 action in bone ( 17 ). Mutation or deletion of TR α results in 
transient growth retardation, impaired ossiﬁ cation, and reduced 
bone mineralization during growth (Table  4.8.1 ). In adults, there is 
a defect in bone remodelling, a marked increase in bone mass, and 
increased bone mineralization. By contrast, mutation or deletion 
of TR β results in an opposite phenotype of accelerated growth, 
advanced ossiﬁ cation with increased mineralization during growth 
but short stature, which results from premature quiescence of the 
growth plates (Table  4.8.1 ). In adults, increased bone remodelling 
results in osteoporosis and reduced bone mineralization. Taken 
together, these features indicate that thyroid hormones exert ana-
bolic actions during skeletal growth but catabolic responses in 
adult bone ( 17 ). Mutation of TR α disrupts T 3 action in bone cells 
resulting in skeletal hypothyroidism, whereas mutation of TR β 
disrupts the HPT axis, leading to elevated levels of circulating thy-
roid hormones which activate TR α in bone cells, resulting in skel-
etal hyperthyroidism. Consistent with these phenotypes, levels of 
TR α mRNA expression are 10- to 100-fold greater than TR β in 
adult bone. 
 Recently, a direct role for TSH as a negative regulator of bone 
turnover has also been proposed ( 4 ). Osteoblasts and osteoclasts 
were shown to express the TSHR, and congenitally hypothyroid 
TSHR knockout mice treated with thyroid hormone displayed a 
phenotype of high bone turnover osteoporosis. As a result of these 
ﬁ ndings, it was suggested that bone loss was a consequence of TSH 
deﬁ ciency. However, the susceptibility of patients with Graves’ dis-
ease to osteoporosis and fracture is inconsistent with the hypothesis 
that TSH negatively regulates bone turnover because the presence 
of TSHR-stimulating antibodies would be predicted to protect 
patients from osteoporosis. Thus, the skeletal consequences of 
thyrotoxicosis are most likely to result primarily from thyroid 
hormone excess although TSH deﬁ ciency cannot be excluded as a 
contributing factor ( 4 ). 
 These two possibilities cannot be differentiated readily because 
the HPT axis maintains thyroid hormones and TSH in a physiolog-
ical reciprocal relationship. Nevertheless, studies in mutant mice 
have enabled the issue to be addressed  in vivo . Thus, the skeletal 
phenotypes of two different mouse models of congenital hypothy-
roidism were compared. Pax8 knockout mice lack a transcription 
factor that is essential for thyroid follicular cell development and 
have undetectable thyroid hormone levels, a 2000-fold elevation of 
TSH, and a fully functional TSHR. By contrast, hyt/hyt mice have 
gross congenital hypothyroidism also accompanied by a 2000-fold 
increase in TSH but they harbour a point mutation in the  Tshr 
gene, leading to complete loss of TSHR protein function. Both 
mutants exhibited a similar phenotype of growth retardation and 
delayed ossiﬁ cation typical of hypothyroidism despite the divergence 
in TSH signalling ( 4 ). 
 In summary, the skeleton is exquisitely sensitive to thyroid status 
during growth and in adulthood. T 3 exerts important anabolic 
responses during skeletal growth and has signiﬁ cant catabolic 
effects on adult bone. Both of these actions are mediated by TR α 1. 
 Skeletal consequences of altered thyroid 
status in humans 
 Studies in children 
 Childhood hypothyroidism 
 Congenital hypothyroidism results in growth arrest, epiphyseal dys-
genesis, delayed bone age, and short stature. Thyroxine replacement 
therapy induces rapid catch-up growth and as a result children that 
are treated early ultimately reach their predicted adult height and 
achieve normal BMD after 8.5 years’ follow-up. Nevertheless, a sin-
gle study has suggested that adult BMD may be reduced despite 
treatment from the neonatal period. Children with juvenile acquired 
hypothyroidism also display growth arrest, delayed bone matura-
tion, and short stature. T 4 replacement again induces rapid catch-up 
growth, but these individuals may fail to achieve ﬁ nal predicted 
height and the resulting permanent height deﬁ cit is related to the 
duration of thyroid hormone deﬁ ciency prior to replacement ( 18 ). 
 Childhood hyperthyroidism 
 Juvenile thyrotoxicosis results in accelerated growth, advanced 
bone age, and short stature, which is a consequence of the premature 
fusion of the epiphyseal growth plates due to accelerated skeletal 
maturation. In severe cases in young children, early closure of the 
cranial sutures may result in craniosynostosis ( 19 ). To date, there 
 Table 4.8.1 Skeletal phenotypes of thyroid hormone receptor mutant mice 
  TR α mutant mice  TR β mutant mice 
 Systemic thyroid status  Euthyroid  Elevated T 4 , T 3 and TSH 
 Skeletal thyroid status  Hypothyroid  Thyrotoxic 
 Juvenile skeleton  Transient growth delay 
 Delayed endochondral and intramembranous ossiﬁ cation 
 Impaired chondrocyte differentiation 
 Reduced calciﬁ ed bone 
 Persistent short stature 
 Advanced endochondral and intramembranous ossiﬁ cation 
 Enhanced chondrocyte differentiation 
 Increased calciﬁ ed bone 
 Adult skeleton  Osteosclerosis 
 Increased bone volume 
 Increased mineralization 
 Reduced osteoclastic bone resorption 
 Osteoporosis 
 Reduced bone volume 
 Reduced mineralization 
 Increased osteoclastic bone resorption 
 See review ( 17 ). 
 TR, 3,5,3 ′ - L -triiodothyronine receptor. 
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are no data relating to the effects of childhood thyrotoxicosis on 
BMD. 
 Resistance to thyroid hormone 
 Resistance to thyroid hormone is an autosomal dominant condi-
tion resulting from a dominant negative mutation of TR β ( 20 ). 
The mutant TR β protein disrupts negative feedback in the HPT 
axis, leading to increased circulating thyroid hormone concentra-
tions in the presence of inappropriately normal or elevated TSH 
levels. The syndrome results in a complex mixed phenotype of 
hyperthyroidism and hypothyroidism depending on the target tis-
sue studied and the speciﬁ c mutation present in TR β . Thus, an 
individual patient can have symptoms of both thyroid hormone 
deﬁ ciency and excess. A broad range of skeletal abnormalities have 
been described in association with resistance to thyroid hormone. 
These include craniofacial abnormalities, craniosynostosis, delayed 
or advanced bone age, short stature, increased bone turnover, oste-
oporosis, and fracture, although only a few patients have been 
studied in detail. 
 Studies in adults 
 A large number of studies have attempted to characterize the skel-
etal consequences of altered thyroid function in adults. 
Unfortunately, many of these studies have been confounded by 
inclusion of patients with a variety of thyroid diseases and by com-
parison of mixed cohorts of patients, which have included pre- and 
postmenopausal women or men. Furthermore, many studies have 
lacked sufﬁ cient statistical power because of the inclusion of small 
numbers of patients and the absence of long-term follow-up. In 
addition, in many studies there has been inadequate control for 
other confounding factors that inﬂ uence bone mass and fracture 
susceptibility, including: age, prior or family history of fracture, 
body mass index, physical activity, use of oestrogens, glucocorti-
coids, bisphosphonates, and vitamin D, prior history of thyroid 
disease or use of thyroxine, and smoking or alcohol intake. For these 
reasons, the literature in this ﬁ eld has been difﬁ cult to investigate by 
meta-analysis and conclusions can only be uncertain ( 1 ). 
 Studies of normal individuals 
 Bone turnover markers 
 Few studies have determined bone turnover markers in euthyroid 
populations. Zofkova  et al. in a study of bone turnover markers in 
a population of 60 healthy postmenopausal women reported that 
high circulating TSH levels correlated with low urinary deoxypy-
ridinoline concentrations but not with serum procollagen type I C 
propeptide levels ( 21 ). This study illustrates difﬁ culties with inter-
pretation of thyroid hormone effects on bone turnover as only a 
small number of subjects were investigated and individuals with 
treated hypothyroidism, subclinical hyperthyroidism, and secondary 
hyperparathyroidism were not excluded. 
 Bone mineral density and fracture 
 Four large population studies have investigated the relationship 
between thyroid status and BMD (Table  4.8.2 ). van der Deure  et al. 
studied a population of 1151 euthyroid men and women over 55 
from Rotterdam ( 22 ). BMD at the femoral neck was positively cor-
related with TSH levels and inversely correlated with free T 4 , and 
the association with free T 4 was much stronger than the association 
with TSH. No relationships between free T 4 or TSH and fracture were 
identiﬁ ed in this study. Kim  et al. studied 959 Korean postmenopausal 
women and showed that individuals with low-normal TSH levels 
between 0.5 and1.1 mU/l had lower lumbar spine and femoral neck 
BMD than women with high-normal TSH between 2.8 and 
5.0 mU/l, although no fracture data were reported ( 23 ). Morris 
studied 581 postmenopausal American women and showed that 
subjects with a low-normal TSH were nearly ﬁ ve times more likely 
to have osteoporosis than women with a high-normal TSH ( 24 ). 
Grimnes  et al . studied a population of 993 postmenopausal women 
and 968 men from Tromso. This study revealed that individuals 
with TSH below the 2.5th percentile had a low forearm BMD 
whereas those with TSH above the 97.5th percentile had a high 
femoral neck BMD compared with the rest of the population ( 25 ). 
Neither of these studies investigated the incidence of fracture. 
Finally, the incidence of fracture in 367 UK women over 50 was pro-
spectively studied for 10 years by Finigan  et al. and no associations 
between free T 3 , free T 4 , or TSH and incident vertebral fracture were 
identiﬁ ed ( 26 ). 
 In summary, these studies suggest the hypothesis that thyroid 
status in the upper normal range is associated with reduced BMD 
whereas thyroid status in the lower normal range is associated with 
increased BMD. A deﬁ nitive conclusion, however, is not possible 
as these studies unfortunately did not account for a number of 
confounding variables. Prospective population studies of sufﬁ cient 
size and duration will be required to determine the relationship 
between thyroid status and fracture risk. 
 Studies of patients with hypothyroidism 
 Bone turnover markers and BMD 
 Histomorphometric analyses have demonstrated that bone turno-
ver is decreased in hypothyroidism ( 5 ,  6 ) but studies of the effect of 
 Table 4.8.2 Large studies of thyroid status and BMD 
 First author (reference)  Study design  Subjects (n)  Patient group  Fracture risk 
 Van der Deure ( 22 )  Prospective 
cohort 
 479 men 
 672 women 
 Men and women  > 55 
years of age 
 Free T 4 negatively associated with spine and hip BMD 
 Grimnes ( 25 )  Cross-sectional  968 men 
 993 women 
 Men and women  > 55 
years of age 
 Decreased forearm BMD associated with low-normal TSH 
 Morris ( 24 )  Cross-sectional  581 women  Postmenopausal  women  Decreased spine BMD associated with low-normal TSH 
 Kim ( 23 )  Cross-sectional  959 women  Postmenopausal  women  Decreased spine and hip BMD associated with low-normal 
TSH 
 Jamal ( 9 )  Cross-sectional  15 316 women  Postmenopausal  women  Decreased hip BMD associated with abnormally low TSH 
 Abbreviations: BMD, bone mineral density; TSH, thyroid stimulating hormone. 
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hypothyroidism on bone turnover markers have included only 
very small numbers of patients and were inconclusive. Consistent 
with histomorphometric data showing normal bone volume in 
hypothyroid patients, Vestergaard and Mosekilde, and Stamato 
 et al . have reported that BMD is normal in patients newly diag-
nosed with hypothyroidism ( 10 ,  27 ). 
 Fracture 
 Large population studies, however, have demonstrated an associa-
tion between hypothyroidism and fracture. Patients with a prior 
history of hypothyroidism had a two to three-fold increased rela-
tive risk of fracture, which persisted for up to 10 years following 
initial diagnosis ( 7 ,  10 ,  11 ,  28 ) (Table  4.8.3 ).
In summary, hypothyroidism results in low bone turnover and 
an increased risk of fracture. 
 Studies of patients with thyrotoxicosis 
 The severe bone disease associated with overt uncontrolled thyro-
toxicosis in now rare because of early diagnosis and treatment, 
although several studies have investigated the skeleton in thyrotoxic 
patients prior to treatment. 
 Bone turnover markers and BMD 
 The effect of thyrotoxicosis on bone turnover markers is consistent 
with histomorphometric data reported by Eriksen  et al. ( 5 ). Thus, 
levels of bone resorption markers such as urinary pyridinoline and 
deoxypyridinoline are increased. Bone formation markers, includ-
ing bone-speciﬁ c alkaline phosphatase and osteocalcin, are also 
elevated. A meta-analysis of 20 eligible studies by Vestergaard and 
Mosekilde ( 37 ) calculated that BMD at the time of diagnosis of 
thyrotoxicosis was reduced compared to age-matched controls 
(Table  4.8.4 ). 
 Fracture 
 Two cross-sectional case–controlled ( 11 ,  43 ) and four population 
studies ( 7 ,  8 ,  29 ,  30 ) have identiﬁ ed an association between frac-
ture and a prior history of thyrotoxicosis (Table  4.8.3 ). Similarly, a 
meta-analysis of patients with thyrotoxicosis revealed an increased 
relative risk of hip fracture ( 37 ). The majority of these studies did 
not determine whether the increased fracture risk could be accounted 
for by reduced BMD, although one prospective study ( 29 ) showed 
that a prior history of thyroid disease is associated with hip fracture 
even after adjustment for BMD. Furthermore, Bauer  et al. ( 8 ,  44 ) 
 Table 4.8.3 Large studies of thyroid status and fracture risk 
 Reference  Study design  Subjects (n)  Patient group  Fracture risk 
 Positive studies  
 Ahmed ( 7 )  Cross-sectional  27 159 men and women  Nonvertebral 
 fractures 
 Increased risk of fractures with both thyrotoxicosis 
and  hypothyroidism 
 Vestergaard ( 11 )  Cross-sectional 
case–control 
 124 655 men and women 
 373 962 controls 
 All fractures  Fracture risk increased for 5 years after 
thyrotoxicosis and 10 years after hypothyroidism 
 Jamal ( 9 )  Cross-sectional  15 316 women  Postmenopausal 
 women 
 Increased risk of vertebral fracture with low TSH 
 Vestergaard ( 10 )  Cross-sectional  11 776 thyrotoxic 
 4473 hypothyroid 
 48 710 controls 
 National register  Increased risk of femur fracture with thyrotoxicosis 
and hypothyroidism 
 Sheppard ( 35 )  Cross-sectional  23 183 men and women  T 4 replacement  Increase risk of femur fracture in males 
 Bauer ( 8 )  Prospective 
longitudinal 
 686 women  Women  > 65 years 
 of age 
 Increased risk of hip and vertebral fracture with 
suppressed TSH 
 Lau ( 36 )  Cross-sectional  1176 Asian men and women 
 1162 controls 
 > 50 years with hip 
fracture 
 Increase risk of hip fracture with T 4 treatment 
 Franklyn ( 31 )  Retrospective 
 cohort 
 1226 men 
 5983 women 
 Radio-iodine treated 
thyrotoxicosis 
 Increase risk of death from hip fracture 
 Seeley ( 30 )  Longitudinal  9704 women  Women  > 65 years 
 of age 
 Increased risk of foot fractures if prior thyrotoxicosis 
 Cummings ( 29 )  Longitudinal  9516 women  Women  > 65 years 
 of age 
 Increased fracture risk with prior thyrotoxicosis 
 Negative studies  
 Van der Deure ( 22 )  Prospective 
cohort 
 479 men 
 672 women 
 > 55 years of age  Free T 4 and TSH not associated with fracture 
 Van den Eeden ( 34 )  Cross-sectional 
case–controlled 
 501 women 
 533 controls 
 Hip fracture  No association with T 4 replacement 
 Melton ( 33 )  Retrospective 
cohort 
 630 men and women  Thyroidectomy  No association with fracture 
 Leese ( 32 )  Cross-sectional  1180 men and women  Thyroid register  No association between fracture risk and TSH 
 TSH, thyroid stimulating hormone. 
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demonstrated that low TSH was associated with a three to fourfold 
increased risk of fracture even though a relationship between TSH 
and BMD was not identiﬁ ed. In agreement with these observations, 
Franklyn  et al. showed an increased standardized mortality ratio 
due to fractured femur in a follow-up register of thyrotoxic patients 
treated with radio-iodine ( 31 ). Nevertheless, several studies have 
failed to demonstrate an association between thyrotoxicosis and 
fracture ( 32 – 34 ). 
 In summary, a prior history of thyrotoxicosis may be associated 
with reduced bone density and a long-term increased risk of fracture, 
although data are conﬂ icting and limited by confounding factors. 
 Studies of individuals with subclinical hyperthyroidism 
 Bone turnover markers and BMD 
 Either elevated or normal levels of the bone resorption markers 
urinary deoxypyridinoline and hydroxyproline have been reported 
in patients with subclinical hyperthyroidism. Similarly, levels of 
the bone formation markers osteocalcin, alkaline phosphatase, and 
procollagen I C-terminal extension propeptide have been reported 
to be elevated or normal. Subclinical hyperthyroidism has also 
been associated with reduced BMD at the femoral neck and other 
sites, although other studies have not found such a relationship. 
Accordingly, a meta-analysis was inconclusive ( 38 ) (Table  4.8.4 ). 
 Fracture 
 Although no prospective studies of fracture risk in subclinical 
hyperthyroidism have been published, data from Bauer  et al. sug-
gest that suppressed TSH levels may be associated with an increased 
risk of fracture ( 8 ). Additionally, Jamal  et al . reported a subanalysis 
of the Fracture Intervention Trial and demonstrated that a TSH 
level suppressed below 0.5 mIU/l was associated with an increased 
risk of vertebral fracture ( 9 ). Unfortunately, there was insufﬁ cient 
information provided to determine whether patients in this study 
had subclinical hyperthyroidism or untreated thyrotoxicosis. 
 In summary, subclinical hyperthyroidism may be associated 
with increased bone turnover, reduced BMD, and increased frac-
ture risk although again insufﬁ cient data are currently available to 
draw deﬁ nitive conclusions. 
 Studies in patients treated with suppressive doses of thyroxine 
 The long-term management of patients with differentiated thyroid 
cancer frequently involves treatment with doses of thyroxine that 
suppress circulating TSH concentrations and which may have 
detrimental effects on the skeleton. 
 Bone turnover markers 
 A number of small studies have investigated the effect of suppres-
sive doses of T 4 on bone turnover markers. Three studies reported 
increased levels of bone resorption markers in patients receiving T 4 
and two of these also demonstrated an increase in bone formation 
markers ( 45 ). Nevertheless, other studies reported no effect on 
markers of bone resorption or formation ( 46 ). 
 Bone mineral density
A large number of studies have investigated the effects of sup-
pressive doses of T 4 on BMD in pre- and postmenopausal women 
and in men at various anatomical locations.
Most studies showed no effect of TSH suppression therapy on 
BMD at the lumber spine, femur, or radius in premenopausal 
women. By contrast, three studies have reported reduced BMD at 
the femur in premenopausal women receiving suppressive doses of 
T 4 . Heemstra  et al. analysed 12 cross-sectional and four prospec-
tive studies of premenopausal women receiving suppressive doses 
of T 4 , but a meta-analysis could not be performed due to hetero-
geneity of the cohorts ( 39 ). The authors concluded that treatment 
 Table 4.8.4 Meta-analyses and literature reviews 
 First author (reference)  Population  Studies (n)  Type  Conclusions 
 Heemstra ( 39 )  Suppressive T 4  21 BMD  Literature 
review 
 Postmenopausal women at risk of reduced BMD; no effect in 
premenopausal women or men 
 Murphy ( 1 )  Suppressive T 4 
 T 4 replacement 
 Thyroid disease 
 19 BMD 
 9 BMD 
 15 Fracture 
 Literature 
review 
 Prior history of thyrotoxicosis is associated with increased fracture risk 
 Subclinical hyperthyroidism is associated with reduced BMD in 
postmenopausal women 
 A suppressed TSH from any cause is associated with an increased 
fracture risk in postmenopausal women 
 Appropriate T 4 replacement does not affected BMD or fracture risk 
 Suppressive T 4 treatment does not affect BMD in premenopausal 
women or men; the situation is less clear in postmenopausal women 
 Vestergaard ( 37 )  Thyrotoxicosis  20 BMD 
 5 Fracture 
 Meta-analysis  Spine and hip BMD reduced in untreated thyrotoxicosis 
 Fractures risk increases with age at diagnosis 
 Schneider ( 42 )  T 4 replacement  63 BMD  Literature 
review 
 Insufﬁ cient evidence to draw formal conclusion 
 Quan ( 40 )  Suppressive T 4  11 BMD  Literature 
review 
 Effect in postmenopausal women unclear 
 No effect in premenopausal women or men 
 Uzzan ( 41 )  T 4 replacement 
 Suppressive T 4 
 13 BMD 
 27 BMD 
 Meta-analysis  Suppressive doses of T 4 associated with reduced BMD at radius, spine, and 
hip in postmenopausal women but not in premenopausal women or men 
 Faber ( 38 )  Suppressive T 4  13 BMD  Meta-analysis  Suppressive T 4 associated with reduced BMD in postmenopausal 
women and an excess annual bone loss of 1 % per year 
 No effect in premenopausal women 
 BMD, bone mineral density; T 4 , thyroid hormone; TSH, thyroid stimulating hormone. 
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with suppressive doses of T 4 did not affect BMD in premenopausal 
women (Table  4.8.4 ). This ﬁ nding supported results of an earlier 
review of eight studies by Quan  et al. ( 40 ). 
 The effects of suppressive doses of T 4 on BMD in postmenopausal 
women are less clear as the two most rigorous cross-sectional studies 
reported conﬂ icting results ( 47 ,  48 ). Franklyn  et al. investigated 26 
UK postmenopausal women treated for 8 years and demonstrated no 
effect of TSH suppression on BMD ( 47 ), whereas Kung and Yeung 
studied 34 postmenopausal Asian women and found a decrease in 
total body, lumbar spine, and femoral BMD in patients treated with 
suppressive doses of T 4 ( 48 ). However, direct comparison between 
the two studies is difﬁ cult because in the study by Franklyn  et al. 
TSH was fully suppressed in only 80 % of patients, whilst mean 
calcium intake was low in the study by Kung  et al. Similar conﬂ ict-
ing results have been reported at various anatomical sites in less 
well-controlled cross-sectional and longitudinal studies. Eight 
cross-sectional studies also included investigation of male patients, 
but only Jodar  et al. reported a reduction in lumber spine and 
femur BMD in men receiving suppressive doses of T 4 ( 49 ). 
 A meta-analysis of 27 studies investigating the effect of suppres-
sive doses of T 4 on BMD ( 41 ) concluded there were no effects on 
BMD in premenopausal women or men, although such treatment in 
postmenopausal women for up to 10 years led to reductions in BMD 
at the distal radius, lumbar spine, and femoral neck of between 5 
and 7 % (Table  4.8.4 ). Although the long-term effects of suppressive 
doses of T 4 on BMD in postmenopausal women remain uncertain, 
further reviews of this topic support the ﬁ ndings of Uzzan  et al. and 
recommend monitoring of BMD in such patients ( 1 ,  39 ,  40 ). 
 Fracture 
 No studies with sufﬁ cient statistical power to determine the effect of 
treatment with suppressive dose of T 4 on fracture risk have been 
reported. 
 In summary, treatment with suppressive dose of T 4 does not 
affect BMD in premenopausal women or men but may lead to 
reduced BMD in postmenopausal women. Effects on bone turno-
ver are inconclusive and there are no data regarding fracture risk. 
 Studies of patients treated for hypothyroidism 
 Bone turnover markers, BMD, and fracture
 Histomorphometric studies have suggested an increase in bone 
turnover in response to T 4 replacement in hypothyroidism ( 5 ) but 
the effect on bone markers has not been reported. The majority of 
cross-sectional studies of pre- and postmenopausal women receiv-
ing long-term T 4 replacement for hypothyroidism have not identi-
ﬁ ed any signiﬁ cant effect on BMD. However, in premenopausal 
women Paul  et al. ( 50 ) reported a 10 % reduction BMD in the femur 
but no change at the lumbar spine following T 4 replacement, whilst 
Kung and Pun ( 51 ) reported reduced BMD at both lumbar spine 
and hip. There are no prospective studies investigating the effects 
of T 4 replacement in hypothyroid patients on fracture risk, 
although population studies have not identiﬁ ed an association 
between T 4 replacement therapy and fracture ( 29 ,  33 ,  34 ). 
 Studies of patients treated for thyrotoxicosis 
 Bone turnover markers, BMD, and fracture 
 Two prospective studies of patients with thyrotoxicosis have 
shown that elevated levels of bone resorption and bone formation 
markers return to normal levels within 1 month of initiation of 
treatment. A meta-analysis of 20 studies investigating the effect of 
treatment for thyrotoxicosis on BMD ( 37 ) demonstrated that the 
low BMD at diagnosis returned to normal after 5 years (Table  4.8.4 ). 
In a subsequent study, treatment for thyrotoxicosis was shown to 
result in a 4 % increase in BMD within 1 year ( 52 ). Nevertheless, in 
a large population study Vestergaard  et al . ( 11 ) reported that an 
increased relative risk of fracture risk persisted for 5 years following 
a diagnosis of thyrotoxicosis (Table  4.8.3 ). 
 In summary, treatment of patients with thyrotoxicosis results in 
normalization of bone turnover and BMD by 5 years, although the 
increased risk of fracture may persist for longer. 
 Human genetics 
 In healthy individuals free T 3 , free T 4 , and TSH levels ﬂ uctuate 
over a range that is less than 50 % of the normal reference range. 
Thus, variation in thyroid status within an individual is narrower 
than the broad interindividual variation seen in the population. 
Each person has a unique HPT axis set point that lies within the 
population reference range, indicating there is variation in tissue 
sensitivity to thyroid hormones between normal individuals ( 53 ). 
Data from the UK Adult Twin Registry estimate heritability for free 
T 3 concentration at 23 % , free T 4 at 39 % , and TSH at 65 % , whilst 
estimates from a Danish twin study were 64 % , 65 % , and 64 % , 
respectively ( 54 ,  55 ). A genome-wide screen identiﬁ ed eight quan-
titative trait loci linked to circulating free T 3 , free T 4 , and TSH lev-
els, indicating that thyroid status is inherited as a complex genetic 
trait ( 56 ). Similarly, unbiased genome-wide association studies and 
candidate gene approaches have shown that osteoporosis is a poly-
genic disorder in which many genes and signalling pathways exert 
small contributions that inﬂ uence bone size, BMD, and fracture 
susceptibility ( 57 ). 
 These observations raise the possibility that variations in bone 
turnover, BMD, and fracture susceptibility in normal individuals 
may be associated with differences in their HPT axis set points. 
Furthermore, genes that establish the HPT axis set point and thus 
regulate thyroid status may also inﬂ uence the acquisition of peak 
bone mass, skeletal growth, and bone turnover and thereby contrib-
ute to the genetic determination of fracture risk. This hypothesis is 
consistent with observations in other physiological complex traits 
including body mass index, blood pressure, heart rate, atheroscle-
rosis, serum cholesterol, and psychological well-being, in which 
variations have been associated with small alterations in thyroid 
function and with polymorphisms in thyroid pathway genes that 
are themselves associated with altered serum thyroid hormone and 
TSH concentrations ( 58 ). These new developments in our under-
standing the physiological regulation of the HPT axis and thyroid 
hormone action in target tissues have been extended recently to 
investigation of the skeleton and these studies suggest common 
genetic factors may be involved in the determination of thyroid 
status, bone turnover, and BMD ( 22 ,  59 ). 
 Future prospective studies investigating the relationships 
between variations in the HPT axis set point and genes regulat-
ing thyroid hormone transport, metabolism, and action with bone 
mass and fracture risk will need to be well designed and adequately 
powered. Stringent exclusion criteria will be required to deﬁ ne 
large populations of individuals which can be followed up prospec-
tively for prolonged periods. Nevertheless, such studies have the 
potential to individualize fracture risk prediction and inform the 
choice of preventative therapy ( 58 ). 
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 Conclusions 
 ◆ Bone strength and fracture susceptibility are determined by peak 
bone mass acquisition during growth and the rate of bone loss 
in adulthood. 
 ◆ Large population studies indicate that both hypothyroidism and 
thyrotoxicosis are associated with increased fracture susceptibil-
ity, demonstrating the importance of euthyroid status for optimal 
bone strength. 
 ◆ A negative feedback loop maintains circulating thyroid hor-
mones and TSH in an inverse relationship which deﬁ nes the 
HPT axis set point. 
 ◆ The skeleton is exquisitely sensitive to thyroid status during 
growth and in adulthood. T 3 exerts anabolic responses during 
skeletal growth and has catabolic effects on adult bone. 
 ◆ Many studies have investigated the consequences of altered thy-
roid function on bone. Unfortunately, many of these have been 
confounded by poor study design, lack of statistical power, and 
an absence of long-term follow-up analysis. Thus, deﬁ nitive 
conclusions cannot be obtained from the current literature. 
 ◆ Population studies suggest that reduced BMD is associated with 
thyroid status in the upper normal range whereas increased BMD 
is associated with thyroid status in the lower normal range. 
 ◆ Hypothyroidism results in low bone turnover and may be asso-
ciated with an increased risk of fracture. 
 ◆  Untreated hyperthyroidism results in increased bone turnover, 
reduced BMD, and an increased risk of fracture. A prior history 
of thyrotoxicosis may be associated with reduced BMD and a 
long-term increased risk of fracture. Subclinical hyperthyroidism 
may be associated with increased bone turnover, reduced BMD, 
and increased risk of fracture. Treatment with suppressive dose 
of T 4 may lead to reduced BMD in postmenopausal women. 
 ◆ Treatment of patients with thyrotoxicosis results in normaliza-
tion of bone turnover and BMD within 5 years, although the 
increased risk of fracture may persist for much longer. 
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Osteoporosis is characterized by reduced bone 
mineral density (BMD) and deterioration of the 
bone micro-architecture with increased suscep-
tibility to fragility fracture. Osteoporosis affects 
50% of women and 20% of men over the age 
of 50 years, accounting for over 9 million frac-
tures worldwide with an annual estimated cost 
of US$50 billion in Northern Europe and the 
USA [1,2]. Furthermore, osteoporotic fractures 
impair quality of life owing to chronic pain, 
skeletal deformities or disability and result in 
increased mortality [3]. Thus, the economic bur-
den of osteoporosis is already substantial and 
will continue to rise as the average age of the 
population increases.
Bone is a dynamic tissue that continu-
ally senses load and mechanical stresses, and 
responds by maintaining optimal bone struc-
ture, mineralization and strength in addi-
tion to repairing areas of microdamage. This 
homeostatic process is mediated by the bone 
remodeling cycle, which is characterized by 
focal bone resorption followed by new bone 
formation [4]. Current therapies for osteopo-
rosis manipulate this process to preserve bone 
mass and strength by either inhibiting bone 
resorption or stimulating bone formation. 
Nevertheless, current therapies are limited by 
patient compliance and efficacy, with 70% of 
individuals discontinuing treatment in the first 
year [5]. Recent advances in our understanding 
of the signaling pathways that regulate bone 
turnover have identified new and promising 
therapeutic targets for the prevention and 
treatment of osteoporosis.
Bone cell biology
Skeletal remodeling is mediated by the inte-
grated and tightly coupled actions of mechano-
sensing osteocytes, bone-resorbing osteoclasts 
and bone-forming osteoblasts (Figure 1).
Osteocytes
Osteocytes comprise 90–95% of all adult bone 
cells. They derive from osteoblasts that have 
become embedded in bone matrix. Osteocyte cell 
bodies lie within bone lacunae and their numer-
ous dendrititic processes ramify though networks 
of canaliculi that connect the periosteal and end-
osteal bone surfaces. Osteocytes sense fluid shear 
stresses within the canaliculi and communicate 
with each other via gap junctions at the tips of 
their dendritic processes [6,7]. Mechanical stresses 
and localized microdamage control osteocyte sig-
naling pathways that result in release of cytokines 
and chemotactic signals, or they may induce osteo-
cyte apoptosis. In general, increased mechanical 
stress stimulates local osteoblastic bone formation, 
whereas reduced loading or microdamage results 
in osteoclastic bone resorption [4,8].
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Osteoclasts
Osteoclasts comprise 1–2% of bone cells. They are polarized 
multinucleated cells derived from the monocyte–macrophage 
lineage that resorb bone matrix and minerals. Attachment of 
osteoclasts to bone is mediated by avb3 integrins expressed on 
the surface of filamentous actin-containing podosomes. avb3 
integrins interact with bone matrix proteins that include osteo-
pontin and vitronectin. These interactions lead to development of 
an actin ring and sealing zone with polarization of the osteoclast 
into functionally distinct ruffled border and basolateral mem-
brane regions [9]. Carbonic anhydrase II generates protons (H+) 
and bicarbonate (HCO
3
-) within the osteoclast cytoplasm [10] and 
the HCO
3
- is exchanged for extracellular chloride at the baso-
lateral membrane by a specific Cl-/HCO
3
- channel. An osteoclast-
specific proton pump (H+-ATPase) transports the protons across 
the ruffled border, while the CLCN7 chloride channel balances 
the ionic charge by transporting chloride simultaneously. Within 
the resorption lacuna, the resultant acidic environment facili-
tates dissolution of hydroxyapatite [Ca
10
(PO
4
)
6
(OH)
2
]
 
to release 
Ca2+ and HPO
4
2-, while a secreted cysteine protease, cathepsin 
K, digests the organic bone matrix [10]. The degradation prod-
ucts are endocytosed at the ruffled border, transported across the 
cytoplasm in tartrate-resistant acid phosphatase-rich vesicles and 
released at the basolateral membrane by exocytosis (Figure 2) [10].
Osteoblasts
Bone-forming osteoblasts comprise approximately 5% of bone 
cells and are derived from common multipotent mesenchymal 
stem cells that are capable of differentiation into chondrocytes, 
osteoblasts or adipocytes. Osteoblast maturation is a stepwise 
process comprising precursor cell commit-
ment to the osteoblast lineage, cell prolif-
eration, bone matrix deposition, matrix 
maturation and bone mineralization. 
Following the program of bone formation, 
osteoblasts may ultimately form bone lin-
ing cells, become embedded within matrix 
as osteocytes or undergo apoptosis [11].
Bone remodeling cycle
The continual process of adult bone 
remodeling is essential for the mainte-
nance of bone mass and skeletal micro-
architecture [4]. The basic multicellular 
unit of bone remodeling comprises osteo-
cytes, osteoclasts and osteoblasts [12]. Over 
95% of the surface of the normal adult 
skeleton is quiescent because osteocytes 
exert a resting inhibition of both osteoclas-
tic bone resorption and osteoblastic bone 
formation [11]. By contrast, when local skel-
etal microdamage occurs or when there is 
a reduction in mechanical loading, osteo-
cytes respond either by releasing cytokines 
and chemoattractants or by undergoing 
apoptosis. These responses result in local 
recruitment of osteoclast precursor cells and mature osteoclasts 
to initiate bone resorption [4]. Osteoclasts excavate a resorption 
cavity over a period of 3–5 weeks until this process is terminated 
by apoptosis and followed by recruitment of osteoblast precur-
sors. Subsequently, osteoblasts undergo a program of matura-
tion, during which they secrete and mineralize osteoid to replace 
the resorbed bone over a period of approximately 3 months [11]. 
Coupling of osteoclast and osteoblast activities via signaling 
between the two cell lineages regulates the bone remodeling 
cycle and results in skeletal homeostasis with preservation of 
bone strength [13]. In summary, the bone remodeling cycle is ini-
tiated and orchestrated by osteocytes, and regulated by coupled 
crosstalk between osteoblasts and osteoclasts.
Signaling pathways regulating osteoclast 
differentiation & bone resorption
Bone marrow stromal cells synthesize and secrete macrophage 
colony-stimulating factor (M-CSF), which promotes prolifera-
tion, survival and differentiation of osteoclast precursor cells 
that express RANK. The ligand that activates RANK (RANKL) 
is a key osteoclastogenic cytokine sufficient for mature osteo-
clast formation. RANKL acts via several downstream signaling 
molecules, including c-fos, NF-kB, MAPK and TNF receptor-
associated factor-6 [14–17]. RANKL also induces expression of 
the avb3 integrin in osteoclast precursor cells, which signals via 
c-src to induce the activation of small GTPases that are criti-
cal for formation of the actin ring sealing zone and osteoclast 
migration and survival. In addition to RANKL, osteoblasts 
and bone marrow stromal cells also express osteoprotegerin 
Figure 1. Bone remodeling. Bone remodeling occurs in the BMU. Osteocytes act as 
mechanosensors and respond to mechanical load and microdamage by recruiting osteoclasts 
to initiate bone resorption. Removal of bone by osteoclast resorption is followed by 
deposition of osteoid by osteoblasts, which subsequently mineralize the matrix to form new 
bone. During bone remodeling, osteoblasts may become embedded in newly formed bone 
as osteocytes and, following completion of the cycle, form lining cells or undergo apoptosis. 
BMU: Basic multicellular unit.
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(OPG). OPG is a secreted decoy receptor for RANKL and 
functions as the physiological inhibitor of RANK–RANKL 
signaling (Figure 3) [10,18]. Thus, the ratio of RANKL to OPG 
expressed by osteoblasts determines osteoclast differentiation 
and activity. This ratio is determined by systemic hormones and 
local cytokines that regulate bone remodeling, which include 
estrogen, parathyroid hormone (PTH), glucocorticoids, thyroid 
hormone, TNF-a, IL-1 and prostaglandin E
2
 [19]. 
Signaling pathways regulating osteoblast 
differentiation & bone formation
Osteoblast differentiation is predominantly regulated by Wnts, 
which are mammalian homologs of the Drosophila secreted morpho-
gen wingless, and bone morphogenetic proteins, which are members 
of the TGF-b superfamily. Although commitment of mesenchyme 
precursors to the osteochondrogenic lineages requires both Wnt 
and bone morphogenetic protein signaling, the canonical Wnt 
pathway subsequently acts as the master regulator of osteogenesis 
[13,20]. In the absence of Wnt, glycogen synthase kinase (GSK)-3b 
forms a stable complex with axin and adenomatous polyposis coli 
proteins and phosphorylates the transcription factor b-catenin in 
the cytoplasm. Phosphorylated b-catenin is targeted for ubiqui-
tination and degradation by the proteosome, thereby preventing 
its entry into the nucleus. Binding of Wnt to its receptor Frizzled 
(Fz) and co receptor low-density lipoprotein 
receptor-related protein (LRP) 5 or 6, results 
in inhibition and degradation of GSK-3b by 
the cytoplasmic phosphoprotein dishev-
elled (Dsh). Anchoring of axin to LRP5/6 
is also induced by Dsh and further disrupts 
the complex containing GSK-3b and APC. 
This results in accumulation of b-catenin 
and its subsequent nuclear translocation. In 
the nucleus, b-catenin interacts with T-cell 
factor-4 or lymphoid enhancer binding fac-
tor-1 to regulate transcription of Wnt target 
genes [13,20]. Physiological negative regulation 
of this critical pathway is mediated by soluble 
and membrane proteins that interfere with 
the interaction between Wnt and its recep-
tor and co receptor. Soluble Fz-related pro-
teins and Wnt inhibitory factor-1 are decoy 
receptors that bind Wnt and prevent its 
interaction with Fz. Alternatively, sclerostin 
and Dickkopf (Dkk) bind to LRP5 and 6 in 
association with Kremen, a transmembrane 
receptor for Dkk, resulting in internaliza-
tion and degradation of LRP5/6 and, thus, 
inhibition of Wnt signaling (Figure 4) [11,20].
Human genetic disorders of bone 
remodeling
Studies of patients with osteopetrosis, 
a condition characterized by increased 
bone mass and mineralization resulting 
from osteoclast dysfunction, have resulted in identification of 
many critical genes and signaling pathways and confirmed their 
requirement for osteoclast differentiation and activity in humans. 
Similarly, essential genes in the canonical Wnt signaling pathway 
that are required for osteoblast differentiation have been revealed 
by investigation of patients with skeletal dysplasias. Population 
studies have used polymorphisms in some of these important 
genes to identify associations with altered BMD and increased 
fracture risk.
Disruption of osteoclastic bone resorption
Homozygous loss-of-function mutations in RANKL (TNFSF11) 
have been identified in families with autosomal recessive osteope-
trosis, in which osteoclast numbers are depleted [21]. In addition, 
polymorphisms adjacent to TNFSF11 are associated with reduced 
BMD and increased fracture susceptibility [22]. Similarly, homo-
zygous or compound heterozygous loss-of-function mutations in 
RANK (TNFRSF11A) have been identified in patients with severe 
autosomal recessive osteoclast-poor osteopetrosis. Furthermore, 
homozygous loss-of-function mutations in OPG (TNFRSF11B) 
have been found in patients with juvenile Paget’s disease, a condi-
tion characterized by osteopenia, fractures and progressive skeletal 
deformity resulting from abnormal and rapid bone remodeling 
[23,24]. Polymorphisms adjacent to TNFRSF11B are also associated 
Figure 2. The osteoclast. Osteoclasts attach to bone via podosomes containing 
filamentous actin and avb3 integrin. CAII generates H+ and HCO
3
 from CO
2
 and H
2
O. 
Protons and chloride ions are transported across the ruffled border into resorption
lacunae by an osteoclast-specific H+-ATPase pump and the CLCN7 chloride channel.
The chloride–bicarbonate exchanger facilitates the balance of ionic charge across 
the basolateral cell membrane. The acidic environment facilitates dissolution of bone 
mineral to release Ca2+, HPO
4
3- and H
2
O. Organic matrix is degraded by cathepsin K and 
degradation products are transported across the cytoplasm in TRAP-containing vesicles
and exocytosed at the basolateral membrane.  
CAII: Carbonic anhydrase II; TRAP: Tartrate-resistant acid phosphatase.
Expert Rev. Endocrinol. Metab. 4(6), (2009)642
Review
Proliferation and 
differentiation
Hemopoietic 
precursor
Proliferation and 
differentiation Bone resorption
TRAF-6
MAPK
NF-κB
c-src
OB
OB
OC
RANKL
RANK
OPG
Denosumab
Recombinant 
human OPG-Fc Expert Rev. Endocrinol. Metab. © Future Science Group (2009)
Gogakos, Cheung, Bassett & Williams
with altered BMD and fracture risk [22,25]. Together, these studies 
have confirmed the critical role of the RANKL/OPG/RANK 
pathway in osteoclastogenesis and control of bone turnover.
Similar investigations of patients with osteopetrosis but normal 
osteoclast numbers have resulted in identification of critical genes 
required for osteoclast function. Homozygous or compound het-
erozygous loss-of-function mutations of CAII (CA2) have been 
identified in patients with autosomal recessive osteopetrosis and 
renal tubular acidosis [26]. In addition to the impaired generation 
of protons resulting from CA2 inactivation, mutations result-
ing in disruption of H+ and Cl- ion transport have also been 
described in patients with osteopetrosis. Thus, homozygous and 
compound heterozygous loss-of-function mutations of CLCN7 
encoding the osteoclast chloride channel cause the rare autoso-
mal recessive infantile malignant osteopetrosis [27], while het-
erozygous dominant negative mutations result in the more com-
mon Albers–Schönberg autosomal dominant osteopetrosis [28]. 
Furthermore, homozygous mutations of osteopetrosis-associated 
trans membrane protein 1 (OSTM1) also cause a syndrome of 
autosomal recessive infantile malignant osteopetrosis. OSTM1 
localizes to late endosomes, lysosomes and the osteoclast ruffled 
border, and interacts with CLCN7 facilitating acidification of 
the osteoclast resorption lacuna [29]. Homozygous or compound 
heterozygous loss-of-function mutations in the osteoclast-specific 
H+-ATPase (TCIRG1) also cause autosomal 
recessive infantile malignant osteopetrosis 
in which osteoclast numbers are normal or 
elevated [30,31] but resorption lacuna acidifica-
tion is impaired. Finally, a homozygous loss-
of-function mutation in pleckstrin homology 
domain-containing protein, family M, mem-
ber 1 (PLEKHM1) resulted in a less severe 
recessive adult osteopetrosis syndrome, in 
which osteoclast numbers were again normal. 
PLEKHM1 is a prenylated protein thought 
to be important in vesicle acidification and 
exocytosis of tartrate-resistant acid phospha-
tase in osteoclasts [32]. An additional hetero-
zygous missense mutation in PLEKHM1 has 
been described in a patient with low BMD 
but areas of focal osteosclerosis [33], further 
confirming the critical importance of acidi-
fication and endosomal transport pathways 
in the function of mature osteoclasts and 
regulation of bone mass.
Disruption of osteoblastic 
bone formation
The central role of the canonical Wnt 
pathway in osteoblast function in humans 
was first shown following identification of 
homozygous loss-of-function mutations 
of LRP5 in osteoporosis–pseudoglioma 
syndrome, in which patients have reduced 
BMD, skeletal fragility and congenital 
blindness [34]. By contrast, a heterozygous G171V point muta-
tion in LRP5 causes an autosomal dominant high bone mass 
trait [35,36]. The mutant LRP5 protein has impaired binding 
to Dkk1, sclerostin and other soluble inhibitors of Wnt sig-
naling, and this mechanism is thought to result in increased 
osteoblastic bone formation [37,38]. Other missense mutations 
in the N-terminal of LRP5 are associated with increased BMD, 
mainly affecting long bones and the skull [39]. Polymorphisms 
in LRP5 have also been associated with BMD and fracture 
risk in population studies [40]. Consistent with these find-
ings, homozygous loss-of-function mutations in the SOST 
gene encoding sclerostin result in the sclerosteosis syndrome, 
which is characterized by cortical hyperostosis and syndactyly 
[41]. Furthermore, homozygous genomic deletions adjacent to 
SOST reduce its expression and cause van Buchem disease, 
which is similarly characterized by cortical hyperostosis [42]. 
Polymorphisms within SOST are also associated with altered 
BMD, although no effects on fracture risk were observed in 
prospective studies [43].
Prevention & treatment of osteoporosis
The recent advances in understanding of the molecular mecha-
nisms underlying homeostatic control of bone mass, together 
with characterization of the genetic basis of human skeletal 
Figure 3. Therapeutic targeting of RANKL/OPG/RANK signaling. Osteoclasts 
express RANK, while osteoblasts express the RANKL and also secrete a decoy receptor 
and physiological inhibitor of the RANKL/RANK interaction, OPG. RANKL/RANK signaling
stimulates osteoclastogenesis and the ratio of RANKL to OPG expressed by osteoblasts
determines the level of osteoclast differentiation and activity. Denosumab, an anti-RANKL 
fully humanized monoclonal antibody acts like OPG to inhibit RANKL/RANK signaling and
decrease bone resorption. A recombinant human OPG–Fc fusion protein was also used
to inhibit RANKL/RANK signaling, but its clinical use was limited by the development of 
antibodies resulting in loss of efficacy.  
c-src: c-src tyrosine kinase; NF-kB: Nuclear factor-kB; OB: Osteoblast; OC: Osteoclast; 
OPG: Osteoprotegerin; OPG-Fc: Osteoprotegerin fused to the Fc portion of human IgG1;
TRAF: TNF receptor-associated factor.
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disorders, has identified novel therapeu-
tic targets for the prevention and treat-
ment of osteoporosis. In addition, these 
advances have clarified the under lying 
mechanisms by which currently available 
drugs act to inhibit bone resorption or 
promote bone formation. 
Drugs that inhibit bone resorption: 
currently available drugs
Bisphosphonates
Nitrogen-containing bisphosphonates, 
including alendronate, risedronate, iban-
dronate and zoledronic acid, are the most 
widely used drugs for the primary and 
secondary prevention of osteoporosis. The 
skeletal selectivity of nitrogen-containing 
bisphosphonates is a consequence of their 
avid binding to calcium hydroxyapatite, 
and this property also accounts for their 
extended biological half-life in bone. The 
nitrogen-containing bisphosphonates 
inhibit farnesyl diphosphate synthase 
within the mevalonate pathway. Inhibition 
of farnesyl diphosphate synthase results in 
disruption of prenylation of small GTPases, 
including Ras, Rho, Rac and Rab. These 
GTPases are essential for osteoclast cyto-
skeletal organization, formation of the 
sealing zone and ruffled border, vesicle 
transport and osteoclast survival. Thus, the 
bisphosphonates inhibit osteoclast func-
tion and promote cellular apoptosis [44,45]. 
Inhibition of osteoclastic bone resorption 
by bisphosphonates results in reduced bone 
turnover and a concomitant reduction in osteoblastic bone forma-
tion. Although long-term studies of up to 10 years have shown 
a persistent reduction in fracture risk with alendronate treat-
ment [46], there remain concerns that prolonged suppression of 
bone remodeling may result in increased bone fragility. Indeed, 
a number of studies have reported atraumatic atypical subtro-
chanteric fractures of the femoral cortex in patients treated with 
alendronate for up to 8 years [47,48]. An additional problem that 
has been highlighted recently is osteonecrosis of the jaw, which 
is characterized by persistent exposure of necrotic mandibular 
or maxillary bone. Its association with high-dose intravenous 
bisphosphonate therapy was initially identified in patients treated 
for malignant disease. However, osteonecrosis of the jaw is rare 
in osteoporotic patients treated with bisphosphonates, its inci-
dence being estimated at less than 1:100,000 patient years [49]. 
In summary, nitrogen-containing bisphosphonates are widely and 
safely used in the vast majority of patients and they are effective, 
with a 35–65% reduction in vertebral fracture risk and 25–50% 
reduction in hip fractures [50,51]. Despite this, the clinical effec-
tiveness of oral bisphosphonates is limited by compliance and 
patient intolerance of gastro intestinal side-effects; up to 70% of 
patients have been reported to discontinue treatment during the 
first year of therapy [5].
Selective estrogen-receptor modulators
Estrogen acts via ligand-inducible nuclear receptors (estrogen 
receptors [ERs]) to regulate expression of target genes in skeletal 
cells. Estrogens act directly in monocytes, bone marrow stromal 
cells and osteoblasts, which respond by reducing the expression 
and secretion of cytokines, including IL-1, IL-6, TNF-a, granulo-
cyte–monocyte colony-stimulating factor, M-CSF and RANKL, 
while increasing expression and secretion of OPG and TGF-b. 
The overall effect is that estrogen reduces osteoclast number and 
activity, and thus inhibits bone resorption and turnover [52–54]. 
Conversely, estrogen deficiency results in high bone turnover with 
accelerated bone loss leading to an increased risk of fragility frac-
ture. While estrogen-replacement therapy reverses these skeletal 
effects, its detrimental actions in other tissues result in unaccept-
able side effects that now preclude its use in osteo porosis preven-
tion and treatment; these include an increased risk of coronary 
Figure 4. Therapeutic targeting of canonical Wnt signaling. (A) The canonical Wnt 
pathway acts as the master regulator of osteogenesis. Wnt signaling is physiologically 
inhibited by sFRP1, Dkk1 and SOST, which bind soluble Wnt or bind to the Wnt coreceptor
LRP5/6 and target its degradation. In the absence of Wnt, b-catenin is phosphorylated by 
GSK-3b in a complex containing axin and APC, thus targeting its ubiquitination and
degradation by the proteasome. Neutralizing humanized antibodies that target either 
Dkk1 or SOST relieve the physiological inhibition of Wnt signaling resulting in increased 
osteoblastic bone formation. (B) Binding of Wnt to its receptor Fz and coreceptor LRP5/6
causes Dsh-mediated degradation of GSK-3b and anchoring of axin to LRP5/6, thus
resulting in inhibition of b-catenin phosphorylation. Unphosphorylated b-catenin 
accumulates and translocates to the nucleus where it activates Wnt target genes following 
interaction with the transcription factors TCF-4 or LEF-1. Li+ and other small-molecule 
inhibitors of GSK-3b enhance Wnt signaling by interfering with phosphorylation of 
b-catenin and facilitating its accumulation and translocation to the nucleus. 
APC: Adenomatous polyposis coli; Dkk: Dickkopf; Dsh: Dishevelled; Fz: Frizzled;
GSK:Glycogen synthase kinase; LEF: Lymphoid enhancer factor; sFRP: Secreted frizzled
related protein; SOST: Sclerostin; TCF: T-cell factor.
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heart disease, breast cancer and thromboembolic disease [55–58]. 
Selective ER modulators (SERMs) are ligands that exhibit vary-
ing degrees of ER agonist activity leading to tissue selectivity. 
The ideal SERM would have ER agonist activity in bone, brain 
and the urogenital tract, while having no detrimental effects in 
the breast, endometrium or cardiovascular system. The second-
generation SERM raloxifene is used as a second-line treatment for 
osteoporosis and reduces vertebral fracture risk, but is not effective 
at nonvertebral sites. Although raloxifene may have a protective 
effect against breast cancer, it has a similar risk of thromboem-
bolic disease to estrogen. Furthermore, the frequent occurrence of 
menopausal vasomotor symptoms with raloxifene treatment limits 
patient tolerability and results in poor compliance [59].
Novel antiresorptive agents 
Cathepsin K inhibitors
Cathepsin K is a key osteoclast-specific enzyme required for 
bone resorption and thus represents a potential drug target to 
inhibit bone loss [60]. A 12-month oral treatment with balicatib, 
a non selective cathepsin inhibitor, resulted in a 2–4% increase 
in lumbar spine and hip BMD accompanied by a reduction in 
bone turnover [61]. Unfortunately, use of this agent was lim-
ited by adverse skin reactions and the drug was withdrawn. 
Subsequently, a 2-year randomized Phase IIB trial of odanacatib, 
a well-tolerated selective inhibitor of cathepsin K, revealed a 50% 
reduction in bone resorption and 10% reduction in bone forma-
tion accompanied by 3 and 6% gains in BMD at the femoral 
neck and lumbar spine, respectively [62]. The effect of odanacatib 
on vertebral, hip and nonvertebral fractures is currently being 
investigated in a worldwide Phase III study [31].
Inhibitors of RANKL/RANK signaling 
RANKL is the key regulator of osteoclast function and sur-
vival, mediating crosstalk between osteoblasts and osteoclasts 
[14]. OPG is the physiologically negative regulator of RANKL 
and three different approaches have been adopted to pharma-
cologically inhibit RANKL signaling. Initially, subcutaneous 
injection of a recombinant human OPG–Fc fusion protein, 
a chimera comprising mature soluble OPG and the Fc frag-
ment of IgG
1
, was demonstrated to be an effective and potent 
inhibitor of bone resorption [63,64]. However, its clinical use 
was limited by the development of antibodies that resulted in a 
reduced effective half-life and the necessity for increasing doses 
and frequency of administration [65]. As a result, denosumab, 
a human monoclonal IgG
2
 RANKL antibody, was developed 
as a direct inhibitor of RANKL/RANK signaling [66]. In six 
reported Phase II and III clinical trials, 3–6 monthly subcu-
taneous injections of denosumab administered for between 1 
and 3 years have been demonstrated to reduce differentiation, 
activation and survival of osteoclasts, inhibit bone resorption 
and increase BMD [67–72]. Fracture risk was also reduced by 
68% at the lumbar spine, 40% at the hip and 20% at other 
nonvertebral sites [72]. Despite these promising results, since 
RANKL/RANK signaling is also involved in regulation of the 
immune system there are concerns that general inhibition of 
this pathway may result in significant side effects that will need 
to be addressed in long-term clinical trials [68,73]. Nevertheless, 
the recent identification of an intra cellular motif of RANK 
that might be specifically involved in osteoclast differentiation 
may provide an opportunity for inhibition of RANK signaling 
specifically in osteoclasts. A cell permeable RANK receptor 
inhibitor peptide has been developed to target this motif and 
it was shown to protect against ovariectomy-induced bone loss 
in mice by inhibiting osteoclast maturation and activity [74].
C-src kinase inhibitors
C-src, a nonreceptor tyrosine kinase, is a key regulator of osteo-
clast cytoskeletal organization required for sealing zone forma-
tion. It is an important secondary messenger signaling molecule 
involved in mediating the actions of M-CSF and RANKL. Initial 
studies showed that inhibition of c-src reduces bone resorption 
in vitro and decreases bone loss in ovariectomized rodents [75], 
although preliminary results in humans have been less promising 
and this target has not been pursued further. 
avb3 integrin inhibitors
The avb3 integrin is essential for formation of the osteoclast 
sealing zone and is, therefore, a potential therapeutic target for 
inhibition of osteoclast function. The orally active avb3 integrin 
antagonist, SB265123, prevented ovariectomy-induced bone loss 
in rodents [76], while in a multicenter, randomized, double-blind, 
placebo-controlled, 12-month study the avb3 integrin antago-
nist L-000845704 resulted in reduced bone turnover and a small 
increase in BMD at the hip and femoral neck [77]. However, avb3 
integrin antagonists have not been pursued further as potential 
drugs for the treatment of osteoporosis because of limited efficacy 
and nonselective actions.
Drugs that promote bone formation: currently 
available drugs
Recombinant PTH
In bone, PTH activates the G- protein-coupled PTH receptor 
PTH receptor in cells of the osteoblast lineage. Continuous 
activation of the PTHR results in bone loss, whereas intermit-
tent stimulation results in increased bone formation although 
the underlying molecular mechanisms are poorly understood. 
Continuous exposure of osteoblasts to PTH receptor increases 
expression of M-CSF and RANKL but reduces expression of 
OPG resulting in increased osteoclastogenesis and bone resorp-
tion. By contrast, intermittent PTH induces Runx-2 expres-
sion in osteoblasts, increases osteo blast cell number and delays 
cellular apoptosis. PTH augments differentiation of commit-
ted osteoblast precursors by stimulating exit of proliferating 
cells from the cell cycle. It is thought these effects sensitize 
osteoblasts to the actions of IGF-1, FGF2 and Wnts, thereby 
promoting an anabolic skeletal response to intermittent PTH 
administration [78].
Recombinant human PTH(1–34) fragment (teriparatide) is 
licensed for treatment of osteoporosis in Europe and the USA, 
whereas full-length intact PTH(1–84) is only licensed in Europe. 
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In an 18-month randomized double-blind study, treatment with 
teriparatide resulted in a twofold increase in bone formation and 
60% increase in resorption [79]. In a separate study, treatment of 
postmenopausal women with teriparatide resulted in 10 and 2.5% 
increases in BMD at the spine and hip, respectively, with reduc-
tions in vertebral fractures and nonvertebral fragility fractures of 
60 and 50% [80]. Similarly, treatment of postmenopausal women 
with PTH(1–84) in a double-blind, placebo-controlled study 
resulted in a 7% increase in BMD at the spine and 2% increase 
at the hip. These changes were accompanied by a relative risk 
reduction of 58% for vertebral fractures but no reduction in non-
vertebral fractures [81]. Even though transient and mild increases 
in serum calcium are common in the first 6 months of treatment, 
teriparatide is generally well tolerated. Although initial safety 
studies suggested that administration of high and prolonged doses 
of teriparatide was associated with osteosarcoma in rats, only one 
case has been reported in more than 600,000 patients treated 
with the drug [82]. Nevertheless, widespread use of teriparatide is 
limited by its subcutaneous route of administration and high cost. 
Novel anabolic agents
Modulators of calcium-sensing receptors to stimulate transient 
endogenous PTH release
Calcium-sensing receptors are G-protein coupled receptors 
expressed in the parathyroid glands that mediate inhibition of 
PTH synthesis and release in response to changes in serum cal-
cium concentration to maintain negative feedback control of cal-
cium homeostasis [83]. The success of subcutaneously and inter-
mittently administered PTH as an anabolic agent has resulted 
in investigation of short-acting orally active calcilytic drugs to 
inhibit the calcium-sensing receptors and induce transient release 
of PTH. The first agent to be investigated in Phase II clinical 
trials, ronacaleret, did not have sufficient efficacy to be pursued. 
New calcilytic compounds have been developed subsequently and 
additional studies are continuing because of the current lack of an 
orally active anabolic agent [84].
Agonists of the canonical Wnt signaling pathway
GSK-3b inhibitors
GSK-3b is a multifunctional serine/threonine kinase that is 
central to Wnt signaling but also involved in the regulation of 
numerous other signaling pathways [20]. Nevertheless, GSK-3b is 
amenable to pharmacological manipulation. Thus, treatment of 
ovariectomized rats with a nonspecific GSK-3a and -3b inhibitor 
(LY603281-31-8) increased bone mineral content and BMD and 
also improved bone strength [85]. Furthermore, treatment of mice 
with the selective GSK-3b inhibitors lithium chloride or 6-bromo-
indirubin-3 -´oxime resulted in enhanced bone formation and 
increased bone mass [86]. In addition, case–control studies have 
shown that long-term treatment of patients with bipolar disorder 
results in a reduced risk of fracture [87]. However, since GSK-3b 
has also been implicated in the pathogenesis of Alzheimer’s dis-
ease and noninsulin-dependent diabetes [20], clinical use of selec-
tive GSK-3b inhibitors in osteoporosis may be limited by their 
extraskeletal actions [88].
Inhibitors of physiological antagonists of canonical 
Wnt signaling
Inhibitors of the negative regulators of Wnt signaling are potential 
candidates for the prevention and treatment of bone loss. In mice, 
Dkk1 haploinsufficiency results in high bone mass, whereas its 
transgenic overexpression causes osteopenia [89,90]. Treatment of 
rats with antisense Dkk1 oligonucleotides prevents the detrimen-
tal effects of ovariectomy by improving bone mineral content, 
BMD and bone strength [91]. In multiple myeloma, Dkk1 lev-
els are associated with the extent of osteolysis [92] and treatment 
is accompanied by a reduction in serum Dkk1 levels [93]. Fully 
human monoclonal Dkk1-neutralizing antibodies enhanced bone 
formation, increased BMD and reduced osteolytic bone resorp-
tion, as well as reducing tumor burden in SCID-rab mice with 
multiple myeloma [94,95]. These promising preclinical data have 
resulted in further investigation of a human Dkk1 monoclonal 
antibody BHQ880 in current Phase Ib and Phase II clinical trials 
in patients with multiple myeloma [3].
Reduced expression of sclerostin or impairment of its interac-
tion with LRP5/6 results in sclerosteosis, van Buchem’s disease or 
high bone mass trait, suggesting that pharmacological inhibition 
of sclerostin may prevent bone loss [96,97]. This represents a par-
ticularly attractive strategy as sclerostin expression is restricted to 
osteocytes [98]. Following 1 year of estrogen deficiency, treatment 
of ovariectomized rats with a sclerostin-neutralizing monoclonal 
antibody enhanced bone formation, resulting in increased bone 
mass and bone strength to levels greater than those in nonovariec-
tomized controls [99]. As a result of these encouraging findings, the 
clinical efficacy of sclerostin neutralizing antibodies (AMG 785) 
is being tested in a Phase II clinical trial of postmenopausal 
women with low BMD [3].
Agents with dual actions on bone resorption & formation
Strontium ranelate
Strontium is a divalent cation with a molecular weight more than 
twice that of calcium. Strontium ranelate is currently used in 
Europe as a second-line agent for the treatment of osteo porosis, 
although it is not licensed in the USA [67]. Strontium ranelate is 
thought to inhibit osteoclast differentiation and activity directly, 
while also stimulating osteoblast proliferation and differentia-
tion, perhaps acting via the calcium- sensing receptor and pros-
taglandins [100]. Treatment results in an approximately 30–45% 
reduction in vertebral fracture risk and 15–30% reduction at 
nonvertebral sites [101,102]. Strontium ranelate has been associ-
ated with an increased risk of venous thromboembolism [103]. 
Importantly, interpretation of bone densitometry data is compli-
cated by the incorporation of x-ray dense strontium into bone; 
thus, any relative change in BMD following treatment must be 
corrected accordingly [104]. Furthermore, the requirement for 
daily administration of the drug limits patient compliance.
Expert commentary
Understanding of the molecular and genetic basis for regula-
tion of bone remodeling has advanced rapidly in the last decade. 
Nevertheless, the incidence and financial burden of osteoporosis 
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Key issues
• Osteoporosis results in over nine million fractures per year at a cost of more than US$50 billion.
• Bone mass and strength are maintained by the bone remodeling cycle involving the integrated actions of osteocytes, osteoclasts 
and osteoblasts.
• Current therapies for the prevention and treatment of osteoporosis are limited by efficacy and patient compliance.
• RANKL/osteoprotegerin/RANK signaling regulates bone resorption and is essential for osteoclastogenesis, osteoclast activity 
and survival.
• Canonical Wnt signaling regulates bone formation and is essential for osteoblast proliferation, differentiation, function and survival.
• Antiresorptive agents are the mainstay of current osteoporosis treatment and include bisphosphonates, Selective estrogen receptor 
modulators and strontium ranelate.
• Novel antiresorptive agents include cathepsin K inhibitors and fully humanized RANKL-neutralizing antibodies. 
• Teriparatide and parathyroid hormone(1–84) are the only currently available purely anabolic agents but require daily 
subcutaneous administration.
• Novel anabolic therapies include short-acting calcilytic agents and neutralizing antibodies to Dkk1 and sclerostin.
• Novel regulatory pathways linking fat mass, the CNS and the GI tract to the control of bone mass will offer many new therapeutic
opportunities for the prevention and treatment of osteoporosis in the future. 
is relentlessly increasing as the population progressively ages. 
Prevention and treatment of osteoporosis continues to rely on 
antiresorptive treatment with bisphosphonates, although a sin-
gle anabolic agent, teriparatide, has recently become available. 
Poor tolerability and compliance in the case of bisphosphonates, 
and problems relating to route of administration and cost in the 
case of teriparatide, clearly highlight the need for development 
of new drugs. Two key signaling pathways that control osteo-
clast and osteoblast function have now been identified. Targeting 
the RANKL/OPG/RANK pathway has led to development of 
novel antiresorptive compounds, while targeting Wnt signaling 
has resulted in the emergence of new anabolic agents. SERMs 
and other drug classes are continuously being refined to increase 
their efficacy. Ensuring skeletal specificity of these new agents is 
a significant challenge and their pharmacodynamics, long-term 
safety and compliance will also require optimization. A further 
area under intense current study is whether combination or sequen-
tial administration of antiresorptive and anabolic drugs should be 
used to maximize therapeutic benefit and minimize dose-related 
side effects.
Five-year view
Although great progress has been made in our understanding of 
skeletal homeostasis, fundamental new pathways that control bone 
mass have recently been discovered. Leptin is an adipokine and 
its serum concentrations are proportional to fat mass. Leptin sup-
presses appetite via actions in the hypothalamic arcuate nucleus 
resulting in homeostatic maintenance of bodyweight via a classical 
negative-feedback loop [105]. Recent studies have shown that leptin 
also regulates bone mass through a regulatory loop that involves 
the ventromedial hypothalamic nuclei [106,107]. Leptin regulates 
bone mass by its effects on both osteoblasts and osteoclasts. It regu-
lates bone formation by controlling the rate of osteoblast prolifera-
tion via two opposing pathways coordinated by the SNS [107–110]. 
Furthermore, leptin also regulates bone resorption via two oppos-
ing pathways. It promotes bone resorption by increasing osteoclast 
differentiation via its actions to induce RANKL expression in 
osteoblasts [111], but also inhibits resorption by unknown mecha-
nisms that involve the neurotransmitter cocaine- and amphet-
amine- regulated transcript [112]. Thus, leptin is a homeostatic 
hormone that links regulation of bodyweight by adipocytes to 
the control of bone mass. More recently, osteocalcin has been 
identified as a homeostatic regulator secreted by osteocytes that 
controls insulin sensitivity, glucose homeostasis and fat mass [113]. 
These landmark findings demonstrate communication between 
adipocytes, the hypothalamus and bone. In the coming years, 
detailed characterization of the cellular pathways involved in this 
regulatory loop will identify new therapeutic targets for treatment 
of obesity, diabetes and osteoporosis.
Of equal significance, the central role of the Wnt pathway 
in osteoblasts to regulate bone formation has been challenged. 
Analysis of mice with gut-specific deletion of the Wnt corecep-
tor LRP5 recapitulated the skeletal phenotype of low bone mass 
observed in Lrp5-/- mice, whereas mice with osteoblast-specific 
deletion of LRP5 did not [114,115]. Microarray studies in Lrp5-/- 
mice demonstrated greatly increased expression of Tph1 encoding 
tryptophan hydroxylase, the rate-limiting enzyme responsible for 
synthesis of serotonin [114]. Subsequently, duodenal LRP5 activity 
was shown to inhibit serotonin synthesis in enterochromaffin 
cells of the duodenum and circulating serotonin was demon-
strated to reduce bone formation by inhibiting osteoblast prolif-
eration directly [114,116]. These findings suggest that Wnts act in 
duodenal enterochromaffin cells to reduce circulating serotonin 
levels and thus increase bone formation. Identification of sero-
tonin as a new factor that contributes to the regulation of bone 
mass may offer further anabolic opportunities for the future. 
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with 
any organization or entity with a financial interest in or financial conflict 
with the subject matter or materials discussed in the manuscript. This 
includes employment, consultancies, honoraria, stock ownership or options, 
expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
www.expert-reviews.com 647
ReviewBone signaling pathways & treatment of osteoporosis
References
Papers of special note have been highlighted as:
• of interest
•• of considerable interest
1 Kanis JA; on behalf of the World Health 
Organization Scientific Group. Assessment 
of osteoporosis at the primary health-care 
level: technical report. World Health 
Organization Collaborating Centre for 
Metabolic Bone Diseases. University of 
Sheffield, Sheffield, UK (2007).
• Detailed review of osteoporosis
epidemiology and fracture risk assessment.
2 Sambrook P, Cooper C. Osteoporosis. 
Lancet 367(9527), 2010–2018 (2006).
3 Lewiecki ME. Emerging drugs for 
postmenopausal osteoporosis. Expert Opin. 
Emerg. Drugs 14(1), 129–144 (2009).
4 Seeman E, Delmas PD. Bone Quality – the 
material and structural basis of bone 
strength and fragility. N. Engl. J. Med. 354, 
2250–2261 (2006).
• Physiologyandpathophysiologyof
bonemetabolism.
5 Cotté FE, Fardellone P, Mercier F, Gaudin 
AF, Roux C. Adherence to monthly and 
weekly oral bisphosphonates in women 
with osteoporosis. Osteoporos Int.  DOI: 
10.1007/s00198-009-0930-1 (2009) (Epub 
ahead of print).
6 Bonewald LF, Johnson ML. Osteocytes, 
mechanosensing and Wnt signaling. Bone 
42, 606–615 (2008).
7 Bilezikian JP, Matsumoto T, Bellido T 
et al. Targeting bone remodeling for the 
treatment of osteoporosis: summary of the 
proceedings of an ASBMR workshop. 
J. Bone Miner. Res. 24(3), 373–385 (2009).
8 Han Y, Cowin SC, Schaffler MB, 
Weinbaum S. Mechanotransduction and 
strain amplification in osteocyte cell 
processes. Proc. Natl Acad. Sci. USA 101, 
16689–16694 (2004).
9 Vaananen HK, Zhao H, Mulari M, 
Halleen JM. The cell biology of osteoclast 
function. J. Cell. Sci. 113, 377–381 (2000).
10 Tolar J, Teitelbaum SL, Orchard PJ. 
Osteopetrosis. N. Engl. J. Med. 351, 
2839–2849 (2004).
11 Martin TJ, Sims NA, Ng KW. Regulatory 
pathways revealing new approaches to the 
development of anabolic drugs for 
osteoporosis. Osteoporos. Int. 19, 1125–1138 
(2008).
12 Koshla S, Westendorf JJ, Ousler MJ. 
Building bone to reverse osteoporosis and 
repair fractures. J. Clin. Invest. 118, 
421–428 (2008).
13 Canalis E, Giustina A, Bilezikian JP. 
Mechanisms of anabolic therapies for 
osteoporosis. N. Engl. J. Med. 357, 
905–916 (2007).
• Very good review of the biological basis
of many emerging anabolic agents.
14 Kearns AE et al. Receptor activator of 
nuclear factor kB ligand and 
osteoprotegerin regulation of bone 
remodeling in health and disease. Endocr. 
Rev. 29, 155–192 (2008).
• RANK/RANKL/osteoprotegerin
involvement in regulation of
bone remodeling.
15 Yasuda H, Shima N, Nakagawa N et al. 
Osteoclast differentiation factor is a 
ligandfor osteoprotegerin/
osteoclastogenesis-inhibitory factor and is 
identical to TRANCE/RANKL. Proc. 
Natl Acad. Sci. USA 95, 3597–3602 
(1998).
16 Burgess TL, Qian Y, Kaufman S et al. The 
ligand for osteoprotegerin (OPGL) directly 
activates mature osteoclasts. J. Cell. Biol. 
145, 527–538 (1999).
17 Lee ZH, Kim HH. Signal transduction by 
receptor activator of nuclear factor kB in 
osteoclasts. Biochem. Biophys. Res. 
Commun. 305, 211–214 (2003).
18 Lacey DL, Timms E, Tan HL et al. 
Osteoprotegerin ligand is a cytokine that 
regulates osteoclast differentiation and 
activation. Cell 93, 165–176 (1998).
19 Teitelbaum SL, Ross FP. Genetic 
regulation of osteoclast development and 
function. Nat. Rev. Genet. 4, 638–649 
(2003).
20 Baron R, Rawadi G. Minireview: targeting 
the Wnt/b-catenin pathway to regulate 
bone formation in the adult skeleton. 
Endocrinology 148(6), 2635–2643 (2007).
• Elucidation of Wnt signalling pathway
and its implication in regulation of
bone formation.
21 Sobacchi C, Frattini A, Guerrini MM 
et al. Osteoclast-poor human osteopetrosis 
due to mutations in the gene encoding 
RANKL. Nat. Genet. 39(8), 960–962 
(2007).
22 Styrkarsdottir U, Halldorsson BV, 
Gretarsdottir S et al. Multiple genetic loci 
for bone mineral density and fractures. 
N. Engl. J. Med. 358(22), 2355–2365 
(2008).
23 Whyte MP, Obrecht SE, Finnegan PM 
et al. Osteoprotegerin deficiency and 
juvenile Paget’s disease. N. Engl. J. Med. 
347(3), 175–184 (2002).
24 Cundy T, Hegde M, Naot D et al. A 
mutation in the gene TNFRSF11B encoding 
osteoprotegerin causes an idiopathic 
hyperphosphatasia phenotype. Hum. Mol. 
Genet. 11(18), 2119–2127 (2002).
25 Arko B, Prezelj J, Komel R, Kocijancic A, 
Hudler P, Marc J. Sequence variations in 
the osteoprotegerin gene promoter in 
patients with postmenopausal osteoporosis. 
J. Clin. Endocrinol. Metab. 87(9), 
4080–4084 (2002).
26 Venta PJ, Welty RJ, Johnson TM, Sly WS, 
Tashian RE. Carbonic anhydrase II 
deficiency syndrome in a Belgian family is 
caused by a point mutation at an invariant 
histidine residue (107 His–Tyr): complete 
structure of the normal human CA II gene. 
Am. J. Hum. Genet. 49(5), 1082–1090 
(1991).
27 Kornak U, Kasper D, Bösl MR et al. Loss of 
the ClC-7 chloride channel leads to 
osteopetrosis in mice and man. Cell 104(2), 
205–215 (2001).
28 Cleiren E, Bénichou O, Van Hul E et al. 
Albers-Schönberg disease (autosomal 
dominant osteopetrosis, type II) results 
from mutations in the ClCN7 chloride 
channel gene. Hum. Mol. Genet. 10(25), 
2861–2867 (2001).
29 Chalhoub N, Benachenhou N, 
Rajapurohitam V et al. Grey-lethal 
mutation induces severe malignant 
autosomal recessive osteopetrosis in mouse 
and human. Nat. Med. 9(4), 399–406 
(2003).
30 Frattini A, Orchard PJ, Sobacchi C et al. 
Defects in TCIRG1 subunit of the vacuolar 
proton pump are responsible for a subset of 
human autosomal recessive osteopetrosis. 
Nat. Genet. 25(3), 343–346 (2000).
31 Kornak U, Schulz A, Friedrich W et al. 
Mutations in the a3 subunit of the vacuolar 
H(+)-ATPase cause infantile malignant 
osteopetrosis. Hum. Mol. Genet. 9(13), 
2059–2063 (2000).
32 Van Wesenbeeck L, Odgren PR, Coxon FP 
et al. Involvement of PLEKHM1 in 
osteoclastic vesicular transport and 
osteopetrosis in incisors absent rats and 
humans. J. Clin. Invest. 117(4), 919–930 
(2007).
33 Del Fattore A, Fornari R, Van Wesenbeeck 
L et al. A new heterozygous mutation 
(R714C) of the osteopetrosis gene, 
pleckstrin homolog domain containing 
family M (with run domain) member 1 
(PLEKHM1), impairs vesicular acidification 
and increases TRACP secretion in 
osteoclasts. J. Bone Miner. Res. 23(3), 
380–391 (2008).
Expert Rev. Endocrinol. Metab. 4(6), (2009)648
Review Gogakos, Cheung, Bassett & Williams
34 Gong Y, Slee RB, Fukai N et al. LDL 
receptor-related protein 5 (LRP5) affects 
bone accrual and eye development. Cell 
107(4), 513–523 (2001).
35 Boyden LM, Mao J, Belsky J et al. High 
bone density due to a mutation in 
LDL-receptor-related protein 5. N. Engl. J. 
Med. 346, 1513–1521 (2002).
36 Little RD, Carulli JP, Del Mastro RG et al. 
A mutation in the LDL receptor-related 
protein 5 gene results in the autosomal 
dominant high-bone-mass trait. Am. J. 
Hum. Genet. 70, 11–19 (2002).
37 Zhang Y, Wang Y, Li X et al. The LRP5 
high-bone-mass G171V mutation disrupts 
LRP5 interaction with Mesd. Mol. Cell. 
Biol. 24(11), 4677–4684 (2004).
38 Ellies DL, Viviano B, McCarthy J et al. 
Bone density ligand, sclerostin, directly 
interacts with LRP5 but not LRP5G171V 
to modulate Wnt activity. J. Bone Miner. 
Res. 21(11), 1738–1749 (2006).
39 Ferrari SL, Deutsch S, Choudhury U et al. 
Polymorphisms in the low-density 
lipoprotein receptor-related protein 5 
(LRP5) gene are associated with variation 
in vertebral bone mass, vertebral bone size, 
and stature in whites. Am. J. Hum. Genet. 
74(5), 866–875 (2004).
40 Richards JB, Rivadeneira F, Inouye M et al. 
Bone mineral density, osteoporosis, and 
osteoporotic fractures: a genome-wide 
association study. Lancet 371(9623), 
1505–1512 (2008).
41 Brunkow ME, Gardner JC, Van Ness J 
et al. Bone dysplasia sclerosteosis results 
from loss of the SOST gene product, a 
novel cystine knot-containing protein. 
Am. J. Hum. Genet. 68(3), 577–589 
(2001).
42 Balemans W, Patel N, Ebeling M et al. 
Identification of a 52 kb deletion 
downstream of the SOST gene in patients 
with van Buchem disease. J. Med. Genet. 
39(2), 91–97 (2002).
43 Uitterlinden AG, Arp PP, Paeper BW et al. 
Polymorphisms in the sclerosteosis/van 
Buchem disease gene (SOST ) region are 
associated with bone-mineral density in 
elderly whites. Am. J. Hum. Genet. 75(6), 
1032–1045 (2004).
44 McClung MR. Bisphosphonates. 
Endocrinol. Metab. Clin. North Am. 32, 
253–271 (2003).
45 Russell RG, Xia Z, Dunford JE et al. 
Bisphosphonates: an update on 
mechanisms of action and how these relate 
to clinical efficacy. Ann. NY Acad. Sci. 
1117, 209–257 (2007).
46 Black DM, Schwartz AV, Ensrud KE et al. 
Effects of continuing or stopping 
alendronate after 5 years of treatment: the 
Fracture Intervention Trial Long-term 
Extension (FLEX): a randomized trial. 
JAMA 296(24), 2927–2938 (2006).
47 Goh SK, Yang KY, Koh JS et al. 
Subtrochanteric insufficiency fractures in 
patients on alendronate therapy: a caution. 
J. Bone Joint Surg. Br. 89(3), 394–353 
(2007).
48 Kwek EB, Goh SK, Koh JS, Png MA, 
Howe TS. An emerging pattern of 
subtrochanteric stress fractures: a long-term 
complication of alendronate therapy? Injury 
39(2), 224–231 (2008).
49 Khosla S, Burr D, Cauley J et al. 
Bisphosphonate-associated osteonecrosis of 
the jaw: report of a task force of the 
American society for bone and mineral 
research. J. Bone Miner. Res. 22(10), 
1479–1491 (2007).
50 Wells GA, Cranney A, Peterson J et al. 
Alendronate for the primary and secondary 
prevention of osteoporotic fractures in 
postmenopausal women. Cochrane 
Database Syst. Rev. 23(1), CD001155 
(2008).
51 Wells G, Cranney A, Peterson J et al. 
Risedronate for the primary and secondary 
prevention of osteoporotic fractures in 
postmenopausal women. Cochrane Database 
Syst. Rev. 23(1), CD004523 (2008).
52 Zallone A. Direct and indirect estrogen 
actions on osteoblasts and osteoclasts. Ann 
NY Acad. Sci. 1068, 173–179 (2006).
53 Nakamura T, Imai Y, Matsumoto T et al. 
Estrogen prevents bone loss via estrogen 
receptor alpha and induction of fas ligand 
in osteoclasts. Cell 130, 811–823 (2007).
54 Charatcharoenwitthaya N, Khosla S.
Atkinson EJ et al. Effect of blockade of 
TNF-a and interleukin-1 action on bone 
resorptionin early postmenopausal women. 
J. Bone Miner. Res. 22, 724–729 (2007).
55 Chlebowski RT, Hendrix SL, Langer RD 
et al. Influence of estrogen plus progestin 
on breast cancer and mammography in 
healthy postmenopausal women: the 
Women’s Health Initiative randomized 
trial. JAMA 289(24), 3243–3253 (2003).
56 Cauley JA, Robbins J, Chen Z et al. Effects 
of estrogen plus progestin on risk of 
fracture and bone mineral density: the 
Women’s Health Initiative randomized 
trial. JAMA 290(13), 1729–1738 (2003).
57 Rossouw JE, Anderson GL, Prentice RL 
et al. Risks and benefits of estrogen plus 
progestin in healthy postmenopausal 
women: principal results from the 
Women’s Health Initiative randomized 
controlled trial. JAMA 288(3), 321–333 
(2002).
58 Anderson GL, Limacher M, Assaf AR et al. 
Effects of conjugated equine estrogen in 
postmenopausal women with hysterectomy: 
the Women’s Health Initiative randomized 
controlled trial. JAMA 291(14), 1701–1712 
(2004).
59 Barrett-Conno E, Mosca L, Collins P et al. 
Effects of raloxifene on cardiovascular 
events and breast cancer in postmenopausal 
women. N. Engl. J. Med. 355(2), 125–137 
(2006). 
60 Vasiljeva O, Reinheckel T, Peters C, 
Turk D, Turk V, Turk B. Emerging roles of 
cysteine cathepsins in disease and their 
potential as drug targets. Curr. Pharm. Des. 
13, 387–403 (2007).
61 Adami S, Supronik J, Hala T et al. Effect of 
one year treatment with the cathepsin-K 
inhibitor, balicatib, on bone mineral 
density (BMD) in postmenopausal women 
with osteopenia/osteoporosis. J. Bone 
Miner. Res. 21, S24 (2006).
• EvidencethatcathepsinKinhibition
reducesboneresorption.
62 Deal C. Potential new drug targets for 
osteoporosis. Nat. Clin. Pract. Rheumatol. 
5(1), 20–27 (2009).
63 Bekker PJ, Holloway D, Nakanishi A, 
Arrighi M, Leese PT, Dunstan CR. The 
effect of a single dose of osteoprotegerin in 
postmenopausal women. J. Bone Miner. 
Res. 16(2), 348–360 (2001).
64 Body JJ, Greipp P, Coleman RE et al. 
A Phase I study of AMGN-0007, a 
recombinant osteoprotegerin construct, in 
patients with multiple myeloma or breast 
carcinoma related bone metastases. Cancer 
97(3 Suppl.), 887–892 (2003).
65 Boyce BF, Xing L,. Functions of 
RANKL/RANK/OPG in bone modeling 
and remodeling. Arch. Biochem. Biophys. 
473(2), 139–146 (2008).
66 Hamdy NA. Denosumab: RANKL 
inhibition in the management of bone loss. 
Drugs Today (Barc.) 44, 7–21 (2008).
67 Lewiecki EM, Miller PD, McClung MR 
et al. Two-year treatment with denosumab 
(AMG 162) in a randomized Phase 2 study 
of postmenopausal women with low BMD. 
J. Bone Miner. Res. 22(12), 1832–1841 
(2007).
68 McClung MR, Lewiecki EM, Cohen SB 
et al. Denosumab in postmenopausal 
women with low bone mineral density. 
N. Engl. J. Med. 354(8), 821–831 (2006).
www.expert-reviews.com 649
ReviewBone signaling pathways & treatment of osteoporosis
69 Brown JP, Prince RL, Deal C et al. 
Comparison of the effect of denosumab 
and alendronate on BMD and biochemical 
markers of bone turnover in 
postmenopausal women with low bone 
mass: a randomized, blinded, Phase 3 trial. 
J. Bone Miner. Res. 24(1), 153–161 (2009).
•• PhaseIIIstudyoftheskeletaleffectsof
RANKLinhibitionwithamonoclonal
antibody(denosumab)–comparison
withbisphosphonates.
70 Miller PD, Bolognese MA, Lewiecki EM 
et al. Effect of denosumab on bone density 
and turnover in postmenopausal women 
with low bone mass after long-term 
continued, discontinued, and restarting of 
therapy: a randomized blinded Phase 2 
clinical trial. Bone 43(2), 222–229 (2008).
71 Kendler DL, Benhamou CL, Brown JP 
et al. Effects of denosumab vs alendronate 
on bone mineral density (BMD), bone 
turnover markers (BTM), and safety in 
women previously treated with alendronate. 
J. Bone Miner. Res. 23(Suppl.), S473 
(2008).
72 Cummings S, McClung MR, 
Christiansen C et al. A Phase III study of 
the effects of denosumab on vertebral, 
nonvertebral, and hip fracture in women 
with osteoporosis: results from the 
FREEDOM trial. J. Bone Miner. Res. 23, 
(2008) (Abstract 1286).
73 Whyte MP. The long and the short of bone 
therapy. N. Engl. J. Med. 354(8), 860–863 
(2006).
74 Kim H, Choi HK, Shin JH et al. Selective 
inhibition of RANK blocks osteoclast 
maturation and function and prevents bone 
loss in mice. J. Clin. Invest. 119(4), 
813–825 (2009).
75 Missbach M, Jeschke M, Feyen J et al. 
A novel inhibitor of the tyrosine kinase Src 
suppresses phosphorylation of its major 
cellular substrates and reduces bone 
resorption in vitro and in rodent models 
in vivo. Bone 24(5), 437–449 (1999).
76 Lark MW, Stroup GB, Hwang SM et al. 
Design and characterization of orally active 
Arg–Gly–Asp peptidomimetic vitronectin 
receptor antagonist SB 265123 for 
prevention of bone loss in osteoporosis. 
J. Pharmacol. Exp. Ther. 291(2), 612–617 
(1999).
77 Murphy MG, Cerchio K, Stoch SA et al. 
Effect of L-000845704, an avb3 integrin 
antagonist, on markers of bone turnover 
and bone mineral density in 
postmenopausal osteoporotic women. 
J. Clin. Endocrinol. Metab. 90(4), 
2022–2028 (2005).
78 Jilka RL. Molecular and cellular mechanisms 
of the anabolic effect of intermittent PTH. 
Bone 40(6), 1434–1446 (2007).
79 McClung MR, San Martin J, Miller PD 
et al. Opposite bone remodeling effects of 
teriparatide and alendronate in increasing 
bone mass. Arch. Intern. Med. 165(15), 
1762–1768 (2005).
80 Neer RM, Arnaud CD, Zanchetta JR et al. 
Effect of parathyroid hormone (1–34) on 
fractures and bone mineral density in 
postmenopausal women with osteoporosis. 
N. Engl. J. Med. 344(19), 1434–1441 
(2001).
81 Greenspan SL, Bone HG, Ettinger MP et al. 
Effect of recombinant human parathyroid 
hormone (1–84) on vertebral fracture and 
bone mineral density in postmenopausal 
women with osteoporosis: a randomized 
trial. Ann. Intern. Med. 146(5), 326–339 
(2007).
82 Harper KD, Krege JH, Marcus R, Mitlak 
BH. Osteosarcoma and teriparatide? J. Bone 
Miner. Res. 22(2), 334 (2007).
83 Brown M. The calcium-sensing receptor: 
physiology, pathophysiology and CaR-based 
therapeutics. Subcell. Biochem. 45, 139–167 
(2007).
84 Balan G, Bauman J, Bhattacharya S et al. 
The discovery of novel calcium sensing 
receptor negative allosteric modulators. 
Bioorg. Med. Chem. Lett. 19(12), 3328–3332 
(2009).
85 Kulkarni NH, Onyia JE, Zeng Q et al. 
Orally bioavailable GSK-3a/b dual inhibitor 
increases markers of cellular differentiation 
in vitro and bone mass in vivo. J. Bone Miner. 
Res. 21, 910–920 (2006).
86 Clement-Lacroix P, Ai M, Morvan F et al. 
Lrp5-independent activation of Wnt 
signaling by lithium chloride increases bone 
formation and bone mass in mice. Proc. Natl 
Acad. Sci. USA 102, 17406–17411 (2005).
87 Vestergaard P, Rejnmark L, Mosekilde L. 
Reduced relative risk of fractures among 
users of lithium. Calcif. Tissue Int. 77, 1–8 
(2005).
88 Wilting I, de Vries F, Thio BM et al. 
Lithium use and the risk of fractures. Bone 
40, 1252–1258 (2007).
89 Morvan F, Boulukos K, Clement-Lacroix P 
et al. Deletion of a single allele of the Dkk1 
gene leads to an increase in bone formation 
and bone mass. J. Bone Miner. Res. 21, 
934–945 (2006).
90 Li J, Sarosi I, Cattley RC et al. Dkk1-
mediated inhibition of Wnt signaling in 
bone results in osteopenia. Bone 39, 
754–766 (2006).
91 Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, 
Tai PJ. Knocking down dickkopf-1 alleviates 
estrogen deficiency induction of bone loss. A 
histomorphological study in ovariectomized 
rats. Bone 40(2), 485–492 (2007).
92 Tian E, Zhan F, Walker R et al. The role of 
the Wnt-signaling antagonist DKK1 in the 
development of osteolytic lesions in multiple 
myeloma. N. Engl. J. Med. 349, 2483–2494 
(2003).
93 Heider U, Kaiser M, Mieth M et al. Serum 
concentrations of DKK-1 decrease in 
patients with multiple myeloma responding 
to anti-myeloma treatment. Eur. J. 
Haematol. 82(1) 31–38 (2009).
94 Yaccoby S, Ling W, Zhan F, Walker R, 
Barlogie B, Shaughnessy JD Jr. Antibody-
based inhibition of DKK1 suppresses 
tumor-induced bone resorption and multiple 
myeloma growth in vivo. Blood 109(5), 
2106–2111 (2007).
95 Fulciniti M, Tassone P, Hideshima T et al. 
Anti-DKK1 mAb (BHQ880) as a potential 
therapeutic agent for multiple myeloma. 
Blood 114(2), 371–379 (2009).
96 Robling AG, Bellido T, Turner CH. 
Mechanical stimulation in vivo reduces 
osteocyte expression of sclerostin. 
J. Musculoskelet. Neuronal Interact. 6, 354 
(2006).
97 Ominsky M, Warmongton KS, Asuncion FJ 
et al. Sclerostin monoclonal antibody 
treatment increases bone strength in aged 
osteopenic ovariectomized rats. J. Bone 
Miner. Res. 21, S44 (2006).
98 Poole KE, van Bezooijen RL, Loveridge N 
et al. Sclerostin is a delayed secreted product 
of osteocytes that inhibits bone formation. 
FASEB J. 19, 1842–1844 (2005).
99 Li X, Ominsky MS, Warmington KS et al. 
Sclerostin antibody treatment increases 
bone formation, bone mass and bone 
strength in a rat model of postmenopausal 
osteoporosis. J. Bone Miner. Res. 24(4), 
578–588 (2009).
• Evidence suggestive that sclerostin
antagonism has anabolic effects on bone.
100 Reginster JY, Sarlet N, Lejeune E, Leonori 
L. Strontium ranelate: a new treatment for 
postmenopausal osteoporosis with a dual 
mode of action. Curr. Osteoporos. Rep. 3(1), 
30–34 (2005).
101 Meunier PJ, Roux C, Seeman E et al. The 
effects of strontium ranelate on the risk of 
vertebral fracture in women with 
postmenopausal osteoporosis. N. Engl. J. 
Med. 350(5), 459–468 (2004).
• Evidencethatstrondiumranelate
decreasesfractureriskinvertebralsites.
Expert Rev. Endocrinol. Metab. 4(6), (2009)650
Review Gogakos, Cheung, Bassett & Williams
102 Reginster JY, Seeman E, De Vernejoul MC 
et al. Strontium ranelate reduces the risk of 
nonvertebral fractures in postmenopausal 
women with osteoporosis: Treatment of 
Peripheral Osteoporosis (TROPOS) study. J. 
Clin. Endocrinol. Metab. 90(5), 2816–2822 
(2005).
103 Stevenson M, Davis S, Lloyd-Jones M, 
Beverley C. The clinical effectiveness and 
cost-effectiveness of strontium ranelate for 
the prevention of osteoporotic fragility 
fractures in postmenopausal women. Health 
Technol. Assess. 11(4), 1–134 (2007). 
104 Blake GM, Lewiecki EM, Kendler DL et al. 
A review of strontium ranelate and its effect 
on DXA scans. J. Clin. Densitom. 10(2), 
113–119 (2007).
105 Spiegelman BM, Flier JS. Obesity and the 
regulation of energy balance. Cell 104(4), 
531–543 (2001).
106 Ducy P, Amling M, Takeda S et al. Leptin 
inhibits bone formation through a 
hypothalamic relay: a central control of bone 
mass. Cell 100(2) 197–207 (2000).
107 Karsenty G. Convergence between bone and 
energy homeostases: leptin regulation of 
bone mass. Cell Metab. 4(5), 341–348 
(2006).
108 Fu L, Patel MS, Bradley A, Wagner EF, 
Karsenty G. The molecular clock mediates 
leptin-regulated bone formation. Cell 122(5), 
803–815 (2005).
109 Rosen CJ. Bone remodeling, energy 
metabolism, and the molecular clock. Cell 
Metab. 7(1), 7–10 (2008).
•• Excellentreviewofthecentralcontrolof
boneremodeling.Adetailedviewintothe
interactionsbetweenbonephysiologyand
energymetabolism,centralneuronal
pathways,osteocalcinandserotonin.
110 Sato S, Hanada R, Kimura A et al. 
Central control of bone remodeling by 
neuromedin U. Nat. Med. 13(10), 
1234–1240 (2007).
111 Elefteriou F, Ahn JD, Takeda S et al. 
Leptin regulation of bone resorption by 
the sympathetic nervous system and 
CART. Nature 434(7032), 514–520 
(2005).
112 Ahn JD, Dubern B, Lubrano-Berthelier 
C, Clement K, Karsenty G. Cart 
overexpression is the only identifiable 
cause of high bone mass in melanocortin 
4 receptor deficiency. Endocrinology 
147(7), 3196–3202 (2006).
113 Lee NK, Sowa H, Hinoi E et al. 
Endocrine regulation of energy 
metabolism by the skeleton. Cell 130(3), 
456–469 (2007).
114 Yadav VK, Ryu JH, Suda N et al. Lrp5 
controls bone formation by inhibiting 
serotonin synthesis in the duodenum. Cell 
135(5), 825–837 (2008).
115 Collet C, Schiltz C, Geoffroy V, 
Maroteaux L, Launay JM, de Vernejoul 
MC. The serotonin 5-HT2B receptor 
controls bone mass via osteoblast 
recruitment and proliferation. FASEB J. 
22, 418–427 (2008).
116 Rosen CJ. Serotonin rising – the bone, 
brain, bowel connection. N. Engl. J. Med. 
360(10), 957–959 (2009).
Affiliations
• Apostolos I Gogakos 
Molecular Endocrinology Group, Imperial 
College London, MRC Clinical Sciences 
Centre, Room 7N2, 7th Floor 
Commonwealth Building, Hammersmith 
Hospital, Du Cane Road, London, 
W12 0NN, UK 
Tel.: +44 208 383 4326 
a.gogakos@imperial.ac.uk
• Moira S Cheung 
Molecular Endocrinology Group, Imperial 
College London, MRC Clinical Sciences 
Centre, Room 7N2, 7th Floor 
Commonwealth Building, Hammersmith 
Hospital, Du Cane Road, London, 
W12 0NN, UK 
Tel.: +44 208 383 4326 
m.cheung@imperial.ac.uk
• JH Duncan Bassett 
Molecular Endocrinology Group, Imperial 
College London, MRC Clinical Sciences 
Centre, Room 7N2b, 7th Floor 
Commonwealth Building, Hammersmith 
Hospital, Du Cane Road, London, 
W12 0NN, UK 
Tel.: +44 (0) 208 383 4613 
d.bassett@imperial.ac.uk
• Graham R Williams 
Molecular Endocrinology Group, Imperial 
College London, MRC Clinical Sciences 
Centre,Room 7N2a, 7th Floor 
Commonwealth Building,Hammersmith 
Hospital, Du Cane Road, London, 
W12 0NN, UK 
Tel.: +44 208 383 1383 
Fax: +44208 383 8306 
graham.williams@imperial.ac.uk
